Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6088752,si,"Consequently the sieving coefficients of salicylic acid and antipyrine in one rat are not significantly different from one but in the other are significantly smaller than one, resulting in 0.6-0.7 in average.",Solvent drag in jejunal absorption of salicylic acid and antipyrine obtained by in situ single-pass perfusion method in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6088752/),,0.6-0.7,1987,DB01435,Antipyrine
excess,1587055,t 1/2 beta,Amlodipine is an exception with a t 1/2 beta in excess of 30h.,Clinical pharmacokinetics of calcium antagonists. An update. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587055/),h,30,2483,DB01435,Antipyrine
,2723115,total clearance,"The elimination of midazolam was significantly retarded in the patients as indicated by its lower total clearance (3.34 vs. 5.63 ml/min/kg), lower total elimination rate constant (0.400 vs. 0.721 h-1), and longer elimination half-life (7.36 vs. 3.80 h).",Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),[ml] / [kg·min],3.34,3045,DB01435,Antipyrine
,2723115,total clearance,"The elimination of midazolam was significantly retarded in the patients as indicated by its lower total clearance (3.34 vs. 5.63 ml/min/kg), lower total elimination rate constant (0.400 vs. 0.721 h-1), and longer elimination half-life (7.36 vs. 3.80 h).",Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),[ml] / [kg·min],5.63,3046,DB01435,Antipyrine
,2723115,total elimination rate constant,"The elimination of midazolam was significantly retarded in the patients as indicated by its lower total clearance (3.34 vs. 5.63 ml/min/kg), lower total elimination rate constant (0.400 vs. 0.721 h-1), and longer elimination half-life (7.36 vs. 3.80 h).",Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),1/[h],0.400,3047,DB01435,Antipyrine
,2723115,total elimination rate constant,"The elimination of midazolam was significantly retarded in the patients as indicated by its lower total clearance (3.34 vs. 5.63 ml/min/kg), lower total elimination rate constant (0.400 vs. 0.721 h-1), and longer elimination half-life (7.36 vs. 3.80 h).",Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),1/[h],0.721,3048,DB01435,Antipyrine
,2723115,elimination half-life,"The elimination of midazolam was significantly retarded in the patients as indicated by its lower total clearance (3.34 vs. 5.63 ml/min/kg), lower total elimination rate constant (0.400 vs. 0.721 h-1), and longer elimination half-life (7.36 vs. 3.80 h).",Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),h,7.36,3049,DB01435,Antipyrine
,2723115,elimination half-life,"The elimination of midazolam was significantly retarded in the patients as indicated by its lower total clearance (3.34 vs. 5.63 ml/min/kg), lower total elimination rate constant (0.400 vs. 0.721 h-1), and longer elimination half-life (7.36 vs. 3.80 h).",Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),h,3.80,3050,DB01435,Antipyrine
,2723115,bioavailability,The bioavailability of oral midazolam was significantly (P less than 0.05) higher in patients than controls (76% vs. 38%).,Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),%,76,3051,DB01435,Antipyrine
,2723115,bioavailability,The bioavailability of oral midazolam was significantly (P less than 0.05) higher in patients than controls (76% vs. 38%).,Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),%,38,3052,DB01435,Antipyrine
,2723115,-,The antipyrine-half-life was 32.4 h in the patients and 11.8 h in the controls.,Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),h,32.4,3053,DB01435,Antipyrine
,2723115,-,The antipyrine-half-life was 32.4 h in the patients and 11.8 h in the controls.,Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),h,11.8,3054,DB01435,Antipyrine
,2723115,half-life,The antipyrine-half-life was 32.4 h in the patients and 11.8 h in the controls.,Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),h,32.4,3055,DB01435,Antipyrine
,2723115,half-life,The antipyrine-half-life was 32.4 h in the patients and 11.8 h in the controls.,Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723115/),h,11.8,3056,DB01435,Antipyrine
,2655682,elimination half-life,The mean elimination half-life was 23 h (CBZ-C) and 25 h (CBZ-CR) after dose 29 compared with a base-line value of 37 h (both P less than 0.02).,A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655682/),h,23,3281,DB01435,Antipyrine
,2655682,elimination half-life,The mean elimination half-life was 23 h (CBZ-C) and 25 h (CBZ-CR) after dose 29 compared with a base-line value of 37 h (both P less than 0.02).,A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655682/),h,25,3282,DB01435,Antipyrine
,2655682,elimination half-life,The mean elimination half-life was 23 h (CBZ-C) and 25 h (CBZ-CR) after dose 29 compared with a base-line value of 37 h (both P less than 0.02).,A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655682/),h,37,3283,DB01435,Antipyrine
,3947503,half-life,Administration of rifapentine (600 mg 48 h-1) for 10 days resulted in a significant reduction in antipyrine half-life (from 13.2 +/- 1.0 h to 7.7 +/- 0.4 h) and a corresponding increase in its total body clearance (from 41.8 +/- 5.5 ml min-1 to 67.4 +/- 5.6 ml min-1).,"Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3947503/),h,13.2,3495,DB01435,Antipyrine
,3947503,half-life,Administration of rifapentine (600 mg 48 h-1) for 10 days resulted in a significant reduction in antipyrine half-life (from 13.2 +/- 1.0 h to 7.7 +/- 0.4 h) and a corresponding increase in its total body clearance (from 41.8 +/- 5.5 ml min-1 to 67.4 +/- 5.6 ml min-1).,"Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3947503/),h,7.7,3496,DB01435,Antipyrine
,3947503,total body clearance,Administration of rifapentine (600 mg 48 h-1) for 10 days resulted in a significant reduction in antipyrine half-life (from 13.2 +/- 1.0 h to 7.7 +/- 0.4 h) and a corresponding increase in its total body clearance (from 41.8 +/- 5.5 ml min-1 to 67.4 +/- 5.6 ml min-1).,"Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3947503/),[ml] / [min],41.8,3497,DB01435,Antipyrine
,3947503,total body clearance,Administration of rifapentine (600 mg 48 h-1) for 10 days resulted in a significant reduction in antipyrine half-life (from 13.2 +/- 1.0 h to 7.7 +/- 0.4 h) and a corresponding increase in its total body clearance (from 41.8 +/- 5.5 ml min-1 to 67.4 +/- 5.6 ml min-1).,"Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3947503/),[ml] / [min],67.4,3498,DB01435,Antipyrine
,1403775,total plasma,"After i.v. administration, total plasma clearance of L-689,502 in rats decreased with increasing dose; the clearance decreased from 181 ml/min/kg at 1 mg/kg to 86 ml/min/kg at 20 mg/kg.","Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],181,4261,DB01435,Antipyrine
,1403775,clearance,"After i.v. administration, total plasma clearance of L-689,502 in rats decreased with increasing dose; the clearance decreased from 181 ml/min/kg at 1 mg/kg to 86 ml/min/kg at 20 mg/kg.","Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],181,4262,DB01435,Antipyrine
,1403775,clearance,"After i.v. administration, total plasma clearance of L-689,502 in rats decreased with increasing dose; the clearance decreased from 181 ml/min/kg at 1 mg/kg to 86 ml/min/kg at 20 mg/kg.","Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],86,4263,DB01435,Antipyrine
,1403775,clearance,Similar results were observed in dogs; clearance fell from 29 ml/min/kg at 0.5 mg/kg to 17 ml/min/kg at 10 mg/kg.,"Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],29,4264,DB01435,Antipyrine
,1403775,clearance,Similar results were observed in dogs; clearance fell from 29 ml/min/kg at 0.5 mg/kg to 17 ml/min/kg at 10 mg/kg.,"Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],17,4265,DB01435,Antipyrine
,17312018,influx clearances,"The developed model could adequately explain the concentration profiles of salicylic acid in the effluents with influx clearances from maternal and fetal perfusates to placental tissue of 0.0407 and 0.0813 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates (k2 and k3) of 0.0238 and 0.176 min(-1), respectively.","Kinetic analysis of the transport of salicylic acid, a nonsteroidal anti-inflammatory drug, across human placenta. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312018/),[ml] / [g·min],0.0407,4518,DB01435,Antipyrine
,17312018,influx clearances,"The developed model could adequately explain the concentration profiles of salicylic acid in the effluents with influx clearances from maternal and fetal perfusates to placental tissue of 0.0407 and 0.0813 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates (k2 and k3) of 0.0238 and 0.176 min(-1), respectively.","Kinetic analysis of the transport of salicylic acid, a nonsteroidal anti-inflammatory drug, across human placenta. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312018/),[ml] / [g·min],0.0813,4519,DB01435,Antipyrine
,17312018,k2,"The developed model could adequately explain the concentration profiles of salicylic acid in the effluents with influx clearances from maternal and fetal perfusates to placental tissue of 0.0407 and 0.0813 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates (k2 and k3) of 0.0238 and 0.176 min(-1), respectively.","Kinetic analysis of the transport of salicylic acid, a nonsteroidal anti-inflammatory drug, across human placenta. ","λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312018/),1/[min],0.0238,4520,DB01435,Antipyrine
,17312018,k3,"The developed model could adequately explain the concentration profiles of salicylic acid in the effluents with influx clearances from maternal and fetal perfusates to placental tissue of 0.0407 and 0.0813 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates (k2 and k3) of 0.0238 and 0.176 min(-1), respectively.","Kinetic analysis of the transport of salicylic acid, a nonsteroidal anti-inflammatory drug, across human placenta. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312018/),1/[min],0.0238,4521,DB01435,Antipyrine
,17312018,k3,"The developed model could adequately explain the concentration profiles of salicylic acid in the effluents with influx clearances from maternal and fetal perfusates to placental tissue of 0.0407 and 0.0813 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates (k2 and k3) of 0.0238 and 0.176 min(-1), respectively.","Kinetic analysis of the transport of salicylic acid, a nonsteroidal anti-inflammatory drug, across human placenta. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312018/),1/[min],0.176,4522,DB01435,Antipyrine
,17312018,K''1/k2,The K''1/k2 value of salicylic acid was 1.07 ml/g cotyledon and was larger than that of antipyrine (0.642 ml/g cotyledon).,"Kinetic analysis of the transport of salicylic acid, a nonsteroidal anti-inflammatory drug, across human placenta. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312018/),[ml] / [g],1.07,4523,DB01435,Antipyrine
,17312018,K''1/k2,The K''1/k2 value of salicylic acid was 1.07 ml/g cotyledon and was larger than that of antipyrine (0.642 ml/g cotyledon).,"Kinetic analysis of the transport of salicylic acid, a nonsteroidal anti-inflammatory drug, across human placenta. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312018/),[ml] / [g],0.642,4524,DB01435,Antipyrine
,2714050,clearance,"2. The clearance of theophylline in the patients was faster than in 15 controls with a 'healthy lifestyle' [median 104 (range 18-320) ml h-1 kg-1 vs median 68 (range 50-97) ml h-1 kg-1, P less than 0.01].",Factors contributing to the accelerated clearance of theophylline and antipyrine in adults with exocrine pancreatic disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714050/),[ml] / [h·kg],104,4644,DB01435,Antipyrine
,2714050,clearance,"2. The clearance of theophylline in the patients was faster than in 15 controls with a 'healthy lifestyle' [median 104 (range 18-320) ml h-1 kg-1 vs median 68 (range 50-97) ml h-1 kg-1, P less than 0.01].",Factors contributing to the accelerated clearance of theophylline and antipyrine in adults with exocrine pancreatic disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714050/),[ml] / [h·kg],68,4645,DB01435,Antipyrine
,7904983,elimination half-life,"Surprisingly, a significantly shorter elimination half-life was found after 20 days on cimetidine (from 5.1 +/- 0.4 h to 4.4 +/- 0.5 h).",The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7904983/),h,5.1,4806,DB01435,Antipyrine
,7904983,elimination half-life,"Surprisingly, a significantly shorter elimination half-life was found after 20 days on cimetidine (from 5.1 +/- 0.4 h to 4.4 +/- 0.5 h).",The effect of cimetidine on the pharmacokinetics of single oral doses of alfuzosin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7904983/),h,4.4,4807,DB01435,Antipyrine
,3197750,elimination t1/2,"Between Trials 1 and 3, antipyrine elimination t1/2 (17.2 vs 17.4 h), clearance (0.44 vs 0.43 ml.min-1.kg-1) and 24-h recovery of antipyrine and metabolites (313 vs 293 mg) did not differ significantly.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,17.2,5484,DB01435,Antipyrine
,3197750,elimination t1/2,"Between Trials 1 and 3, antipyrine elimination t1/2 (17.2 vs 17.4 h), clearance (0.44 vs 0.43 ml.min-1.kg-1) and 24-h recovery of antipyrine and metabolites (313 vs 293 mg) did not differ significantly.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,17.4,5485,DB01435,Antipyrine
,3197750,clearance,"Between Trials 1 and 3, antipyrine elimination t1/2 (17.2 vs 17.4 h), clearance (0.44 vs 0.43 ml.min-1.kg-1) and 24-h recovery of antipyrine and metabolites (313 vs 293 mg) did not differ significantly.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],0.44,5486,DB01435,Antipyrine
,3197750,clearance,"Between Trials 1 and 3, antipyrine elimination t1/2 (17.2 vs 17.4 h), clearance (0.44 vs 0.43 ml.min-1.kg-1) and 24-h recovery of antipyrine and metabolites (313 vs 293 mg) did not differ significantly.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],0.43,5487,DB01435,Antipyrine
,3197750,clearance,"Between Trials 1 and 3, antipyrine elimination t1/2 (17.2 vs 17.4 h), clearance (0.44 vs 0.43 ml.min-1.kg-1) and 24-h recovery of antipyrine and metabolites (313 vs 293 mg) did not differ significantly.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),,24,5488,DB01435,Antipyrine
,3197750,VZ,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[l] / [kg],1.14,5489,DB01435,Antipyrine
,3197750,VZ,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[l] / [kg],1.00,5490,DB01435,Antipyrine
,3197750,t1/2,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,2.7,5491,DB01435,Antipyrine
,3197750,t1/2,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,3.3,5492,DB01435,Antipyrine
,3197750,clearance,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],4.8,5493,DB01435,Antipyrine
,3197750,clearance,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],3.6,5494,DB01435,Antipyrine
,3197750,VZ,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[l] / [kg],2.6,5495,DB01435,Antipyrine
,3197750,VZ,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[l] / [kg],2.7,5496,DB01435,Antipyrine
,3197750,t1/2,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,2.0,5497,DB01435,Antipyrine
,3197750,t1/2,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,2.4,5498,DB01435,Antipyrine
,3197750,clearance,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],15.0,5499,DB01435,Antipyrine
,3197750,clearance,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],13.5,5500,DB01435,Antipyrine
,3353439,elimination half-life,"Compared to young males, elderly men had significantly prolonged elimination half-life (17 vs. 11 h, p less than 0.025) and reduced clearance (32 vs. 54 ml/min, p less than 0.06).",Antipyrine absorption and disposition in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3353439/),h,17,5927,DB01435,Antipyrine
,3353439,elimination half-life,"Compared to young males, elderly men had significantly prolonged elimination half-life (17 vs. 11 h, p less than 0.025) and reduced clearance (32 vs. 54 ml/min, p less than 0.06).",Antipyrine absorption and disposition in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3353439/),h,11,5928,DB01435,Antipyrine
,3353439,clearance,"Compared to young males, elderly men had significantly prolonged elimination half-life (17 vs. 11 h, p less than 0.025) and reduced clearance (32 vs. 54 ml/min, p less than 0.06).",Antipyrine absorption and disposition in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3353439/),[ml] / [min],32,5929,DB01435,Antipyrine
,3353439,clearance,"Compared to young males, elderly men had significantly prolonged elimination half-life (17 vs. 11 h, p less than 0.025) and reduced clearance (32 vs. 54 ml/min, p less than 0.06).",Antipyrine absorption and disposition in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3353439/),[ml] / [min],54,5930,DB01435,Antipyrine
,3353439,half-life,"However, elderly and young women did not differ in half-life (12 vs. 11 h) or clearance (37 vs. 44 ml/min).",Antipyrine absorption and disposition in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3353439/),h,12,5931,DB01435,Antipyrine
,3353439,half-life,"However, elderly and young women did not differ in half-life (12 vs. 11 h) or clearance (37 vs. 44 ml/min).",Antipyrine absorption and disposition in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3353439/),h,11,5932,DB01435,Antipyrine
,3353439,clearance,"However, elderly and young women did not differ in half-life (12 vs. 11 h) or clearance (37 vs. 44 ml/min).",Antipyrine absorption and disposition in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3353439/),[ml] / [min],37,5933,DB01435,Antipyrine
,3353439,clearance,"However, elderly and young women did not differ in half-life (12 vs. 11 h) or clearance (37 vs. 44 ml/min).",Antipyrine absorption and disposition in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3353439/),[ml] / [min],44,5934,DB01435,Antipyrine
less,3353439,Absolute bioavailability,Absolute bioavailability was not significantly less than 100% and was not related to age.,Antipyrine absorption and disposition in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3353439/),%,100,5935,DB01435,Antipyrine
less,3353439,absolute bioavailability,"Postprandial oral dosage of antipyrine caused reduced Cmax and prolonged Tmax in all groups, but absolute bioavailability was not significantly less than 100%.",Antipyrine absorption and disposition in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3353439/),%,100,5936,DB01435,Antipyrine
,9535994,plasma steady-state concentration ratio,A fetal-maternal plasma steady-state concentration ratio of 0.76 +/- 0.06 suggested that the drug was transferred extensively to the fetal compartment.,In vivo maternal-fetal-amniotic fluid pharmacokinetics of zidovudine in the pigtailed macaque: comparison of steady-state and single-dose regimens. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9535994/),,0.76,6422,DB01435,Antipyrine
,9535994,plasma area under the curve (AUC) ratio,"Similarly, the mean fetal-maternal plasma area under the curve (AUC) ratio after administration of an i.v. bolus dose to the dam was 0.84 +/- 0. 09.",In vivo maternal-fetal-amniotic fluid pharmacokinetics of zidovudine in the pigtailed macaque: comparison of steady-state and single-dose regimens. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9535994/),,0.84,6423,DB01435,Antipyrine
,9535994,clearance,"The placental transfer of zidovudine was passive, with a clearance of approximately 2.0 ml/min/kg, about 35% of the rate of the placental blood flow marker antipyrine.",In vivo maternal-fetal-amniotic fluid pharmacokinetics of zidovudine in the pigtailed macaque: comparison of steady-state and single-dose regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9535994/),[ml] / [kg·min],2.0,6424,DB01435,Antipyrine
,9725468,surface area,"When the surface area of both barriers in man was recalculated to a unit of body weight, nearly identical values (2.71 and 2.86 m2/kg of body mass, respectively) were obtained.",Pharmacokinetic examination of antipyrine passage through the placenta and the small intestine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725468/),[m2] / [kg],2.71,6473,DB01435,Antipyrine
,9725468,surface area,"When the surface area of both barriers in man was recalculated to a unit of body weight, nearly identical values (2.71 and 2.86 m2/kg of body mass, respectively) were obtained.",Pharmacokinetic examination of antipyrine passage through the placenta and the small intestine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725468/),[m2] / [kg],2.86,6474,DB01435,Antipyrine
,9725468,k(tr),In placental studies AP showed that its rapid transfer through the placenta (k(tr) = 0.046 min(-1)) was governed by the mechanism of passive diffusion.,Pharmacokinetic examination of antipyrine passage through the placenta and the small intestine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725468/),1/[min],0.046,6475,DB01435,Antipyrine
,9725468,CR(eq),"In the closed circuit, FMCR(eq) was 1.085, t(eq) was 112.10 min and k(eq) was 0.020 min(-1).",Pharmacokinetic examination of antipyrine passage through the placenta and the small intestine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725468/),,1.085,6476,DB01435,Antipyrine
,9725468,t(eq),"In the closed circuit, FMCR(eq) was 1.085, t(eq) was 112.10 min and k(eq) was 0.020 min(-1).",Pharmacokinetic examination of antipyrine passage through the placenta and the small intestine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725468/),min,112.10,6477,DB01435,Antipyrine
,9725468,k(eq),"In the closed circuit, FMCR(eq) was 1.085, t(eq) was 112.10 min and k(eq) was 0.020 min(-1).",Pharmacokinetic examination of antipyrine passage through the placenta and the small intestine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725468/),1/[min],0.020,6478,DB01435,Antipyrine
,9725468,apparent first-order absorption rate constant,"The apparent first-order absorption rate constant of AP was 0.479 min(-1), and Tmax was 8.95 minutes.",Pharmacokinetic examination of antipyrine passage through the placenta and the small intestine in rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725468/),1/[min],0.479,6479,DB01435,Antipyrine
,9725468,Tmax,"The apparent first-order absorption rate constant of AP was 0.479 min(-1), and Tmax was 8.95 minutes.",Pharmacokinetic examination of antipyrine passage through the placenta and the small intestine in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725468/),min,8.95,6480,DB01435,Antipyrine
,9725468,t(1/2),"Differences in AP pharmacokinetics between pregnant and non-pregnant rats were significant during the distribution phase (t(1/2) = 3.78 and 5.87 min, respectively), whereas the elimination phase was unaffected.",Pharmacokinetic examination of antipyrine passage through the placenta and the small intestine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725468/),min,3.78,6481,DB01435,Antipyrine
,9725468,t(1/2),"Differences in AP pharmacokinetics between pregnant and non-pregnant rats were significant during the distribution phase (t(1/2) = 3.78 and 5.87 min, respectively), whereas the elimination phase was unaffected.",Pharmacokinetic examination of antipyrine passage through the placenta and the small intestine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725468/),min,5.87,6482,DB01435,Antipyrine
,1356725,Metabolic clearance,"Metabolic clearance of AP increased from 6.8 +/- 1.0 (mean +/- SD, N = 23) to 18.4 +/- 7.9 (N = 10) ml.min-1.kg-1, whereas the metabolic clearance of TH increased from 1.9 +/- 0.6 to 20.0 +/- 5.1 ml.min-1.kg-1.",Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356725/),[ml] / [kg·min],6.8,9624,DB01435,Antipyrine
,1356725,Metabolic clearance,"Metabolic clearance of AP increased from 6.8 +/- 1.0 (mean +/- SD, N = 23) to 18.4 +/- 7.9 (N = 10) ml.min-1.kg-1, whereas the metabolic clearance of TH increased from 1.9 +/- 0.6 to 20.0 +/- 5.1 ml.min-1.kg-1.",Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356725/),[ml] / [kg·min],18.4,9625,DB01435,Antipyrine
,1356725,metabolic clearance,"Metabolic clearance of AP increased from 6.8 +/- 1.0 (mean +/- SD, N = 23) to 18.4 +/- 7.9 (N = 10) ml.min-1.kg-1, whereas the metabolic clearance of TH increased from 1.9 +/- 0.6 to 20.0 +/- 5.1 ml.min-1.kg-1.",Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356725/),[ml] / [kg·min],1.9,9626,DB01435,Antipyrine
,1356725,metabolic clearance,"Metabolic clearance of AP increased from 6.8 +/- 1.0 (mean +/- SD, N = 23) to 18.4 +/- 7.9 (N = 10) ml.min-1.kg-1, whereas the metabolic clearance of TH increased from 1.9 +/- 0.6 to 20.0 +/- 5.1 ml.min-1.kg-1.",Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356725/),[ml] / [kg·min],20.0,9627,DB01435,Antipyrine
,1356725,Elimination half-life,"Elimination half-life in plasma decreased from 77 +/- 10 to 33 +/- 9 min for AP and from 171 +/- 36 to 25 +/- 7 min for TH, respectively.",Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356725/),min,77,9628,DB01435,Antipyrine
,1356725,Elimination half-life,"Elimination half-life in plasma decreased from 77 +/- 10 to 33 +/- 9 min for AP and from 171 +/- 36 to 25 +/- 7 min for TH, respectively.",Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356725/),min,33,9629,DB01435,Antipyrine
,1356725,Elimination half-life,"Elimination half-life in plasma decreased from 77 +/- 10 to 33 +/- 9 min for AP and from 171 +/- 36 to 25 +/- 7 min for TH, respectively.",Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356725/),min,171,9630,DB01435,Antipyrine
,1356725,Elimination half-life,"Elimination half-life in plasma decreased from 77 +/- 10 to 33 +/- 9 min for AP and from 171 +/- 36 to 25 +/- 7 min for TH, respectively.",Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1356725/),min,25,9631,DB01435,Antipyrine
,3802708,oral clearance,"Pretreatment with verapamil, 80 mg and 120 mg (every 8 hours for 3 days), reduced the oral clearance of quinidine from 17.0 L/hr to 11.6 and 11.3 L/hr, respectively (P less than 0.01).",The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802708/),[l] / [h],17.0,9894,DB01435,Antipyrine
,3802708,oral clearance,"Pretreatment with verapamil, 80 mg and 120 mg (every 8 hours for 3 days), reduced the oral clearance of quinidine from 17.0 L/hr to 11.6 and 11.3 L/hr, respectively (P less than 0.01).",The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802708/),[l] / [h],11.6,9895,DB01435,Antipyrine
,3802708,oral clearance,"Pretreatment with verapamil, 80 mg and 120 mg (every 8 hours for 3 days), reduced the oral clearance of quinidine from 17.0 L/hr to 11.6 and 11.3 L/hr, respectively (P less than 0.01).",The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802708/),[l] / [h],11.3,9896,DB01435,Antipyrine
,2737234,Total oxazepam clearance,Total oxazepam clearance was 1.04 ml.min-1.kg-1 and it decreased 0.88-fold after the diet.,Influence of a very low calorie diet on the clearance of oxazepam and antipyrine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737234/),[ml] / [kg·min],1.04,9944,DB01435,Antipyrine
,2737234,elimination half-life,"The elimination half-life increased to 1.22-times the control value, 7.9 h.",Influence of a very low calorie diet on the clearance of oxazepam and antipyrine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737234/),h,7.9,9945,DB01435,Antipyrine
,2737234,clearance,"Antipyrine clearance, estimated by the one-sample technique, was 52.4 and 51.8 ml.",Influence of a very low calorie diet on the clearance of oxazepam and antipyrine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737234/),ml,52.4,9946,DB01435,Antipyrine
,2737234,clearance,"Antipyrine clearance, estimated by the one-sample technique, was 52.4 and 51.8 ml.",Influence of a very low calorie diet on the clearance of oxazepam and antipyrine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737234/),ml,51.8,9947,DB01435,Antipyrine
,6105062,Total body clearance,Total body clearance falls significantly from 5.93 to 3.5 ml/min/kg in the pregnant rat whereas no significant increase in antipyrine volume of distribution occurs.,Antipyrine pharmacokinetics in the pregnant rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105062/),[ml] / [kg·min],5.93,10502,DB01435,Antipyrine
,6105062,Total body clearance,Total body clearance falls significantly from 5.93 to 3.5 ml/min/kg in the pregnant rat whereas no significant increase in antipyrine volume of distribution occurs.,Antipyrine pharmacokinetics in the pregnant rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105062/),[ml] / [kg·min],3.5,10503,DB01435,Antipyrine
,6105062,half-life,These changes result in an increase in antipyrine half-life from 109 to 223 min in the pregnant rat.,Antipyrine pharmacokinetics in the pregnant rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105062/),min,109,10504,DB01435,Antipyrine
,6105062,half-life,These changes result in an increase in antipyrine half-life from 109 to 223 min in the pregnant rat.,Antipyrine pharmacokinetics in the pregnant rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105062/),min,223,10505,DB01435,Antipyrine
,27199202,maximum concentrations,"The average maximum concentrations of MAA and AA were of 47.59 and 4.94 mg/mL, respectively.",Pharmacokinetic investigations of the marker active metabolites 4-methylamino-antipyrine and 4-amino-antipyrine after intramuscular injection of metamizole in healthy piglets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27199202/),[mg] / [ml],47.59,11106,DB01435,Antipyrine
,27199202,maximum concentrations,"The average maximum concentrations of MAA and AA were of 47.59 and 4.94 mg/mL, respectively.",Pharmacokinetic investigations of the marker active metabolites 4-methylamino-antipyrine and 4-amino-antipyrine after intramuscular injection of metamizole in healthy piglets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27199202/),[mg] / [ml],4.94,11107,DB01435,Antipyrine
,27199202,half-lives,"The average half-lives were 8.57 and 13.3 h for MAA and AA, respectively.",Pharmacokinetic investigations of the marker active metabolites 4-methylamino-antipyrine and 4-amino-antipyrine after intramuscular injection of metamizole in healthy piglets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27199202/),h,8.57,11108,DB01435,Antipyrine
,27199202,half-lives,"The average half-lives were 8.57 and 13.3 h for MAA and AA, respectively.",Pharmacokinetic investigations of the marker active metabolites 4-methylamino-antipyrine and 4-amino-antipyrine after intramuscular injection of metamizole in healthy piglets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27199202/),h,13.3,11109,DB01435,Antipyrine
,1133166,steady-state plasma concentration,"However, there was also a lower steady-state plasma concentration of diphenylhydantoin (2.9 plus or minus 0.6 vs.",Pharmacokinetics of drugs in patients with the nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133166/),,2.9,11292,DB01435,Antipyrine
,1133166,plasms clearance,"6.8 plus or minus 0.6 mug/ml, P smaller than 0.001) secondary to an increase in the plasms clearance (0.048 plus or minus 0.019 vs. 0.022 plus or minus 0.006 liter/kg.h, P smaller than 0.001) in the nephrotic patients.",Pharmacokinetics of drugs in patients with the nephrotic syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133166/),[l] / [h·kg],0.048,11293,DB01435,Antipyrine
,1133166,plasms clearance,"6.8 plus or minus 0.6 mug/ml, P smaller than 0.001) secondary to an increase in the plasms clearance (0.048 plus or minus 0.019 vs. 0.022 plus or minus 0.006 liter/kg.h, P smaller than 0.001) in the nephrotic patients.",Pharmacokinetics of drugs in patients with the nephrotic syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133166/),[l] / [h·kg],0.022,11294,DB01435,Antipyrine
,1133166,absolute concentration,The net effect is no difference in the absolute concentration of unbound diphenylhydantoin in healthy individuals (0.69 plus or minus 0.05 mug/ml) and patients with the nephrotic syndrome (0.59 plus or minus 0.06 mug/ml).,Pharmacokinetics of drugs in patients with the nephrotic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133166/),[μg] / [ml],0.69,11295,DB01435,Antipyrine
,1133166,absolute concentration,The net effect is no difference in the absolute concentration of unbound diphenylhydantoin in healthy individuals (0.69 plus or minus 0.05 mug/ml) and patients with the nephrotic syndrome (0.59 plus or minus 0.06 mug/ml).,Pharmacokinetics of drugs in patients with the nephrotic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133166/),[μg] / [ml],0.59,11296,DB01435,Antipyrine
,8478313,peak plasma concentration (Cmax),"In man, following an oral 500 mg dose of dirithromycin, a mean peak plasma concentration (Cmax) of 0.48 mg/L (range 0.1-1.97) was observed at 4 h.",Pharmacokinetics of dirithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478313/),[mg] / [l],0.48,11702,DB01435,Antipyrine
,8478313,area under the plasma concentration versus time curve (AUC0-24h),The mean area under the plasma concentration versus time curve (AUC0-24h) measured 3.37 mg.h/L (range 0.39-17.16).,Pharmacokinetics of dirithromycin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478313/),[h·mg] / [l],3.37,11703,DB01435,Antipyrine
,8478313,apparent volume of distribution,The extensive tissue penetration is reflected in a large mean apparent volume of distribution of 800 L (range 504-1041).,Pharmacokinetics of dirithromycin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478313/),l,800,11704,DB01435,Antipyrine
,8478313,Plasma protein binding,Plasma protein binding was determined to be 15-30% by ultracentrifugation.,Pharmacokinetics of dirithromycin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478313/),%,15-30,11705,DB01435,Antipyrine
,8478313,plasma elimination half-life,Dirithromycin is characterized by a plasma elimination half-life of 44 h (range 16-65 h) that permits once-daily administration.,Pharmacokinetics of dirithromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478313/),h,44,11706,DB01435,Antipyrine
,8478313,Total body clearance,Total body clearance was 226-1040 mL/min in the 14C-radiolabelled study.,Pharmacokinetics of dirithromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478313/),[ml] / [min],226-1040,11707,DB01435,Antipyrine
,8478313,absolute bioavailability,The absolute bioavailability calculated from dose-corrected urinary excretion data was 10% (6-14%).,Pharmacokinetics of dirithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478313/),%,10,11708,DB01435,Antipyrine
,8646824,Plasma clearance,Plasma clearance was significantly greater in patients with cystic fibrosis for both lorazepam (1.7 +/- 0.4 versus 1.2 +/- 0.5 ml/min/kg) and indocyanine green (14.2 +/- 6.1 versus 9.1 +/- 3.0 ml/min/kg).,Hepatic drug clearance in patients with mild cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646824/),[ml] / [kg·min],1.7,13549,DB01435,Antipyrine
,8646824,Plasma clearance,Plasma clearance was significantly greater in patients with cystic fibrosis for both lorazepam (1.7 +/- 0.4 versus 1.2 +/- 0.5 ml/min/kg) and indocyanine green (14.2 +/- 6.1 versus 9.1 +/- 3.0 ml/min/kg).,Hepatic drug clearance in patients with mild cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646824/),[ml] / [kg·min],1.2,13550,DB01435,Antipyrine
,8646824,Plasma clearance,Plasma clearance was significantly greater in patients with cystic fibrosis for both lorazepam (1.7 +/- 0.4 versus 1.2 +/- 0.5 ml/min/kg) and indocyanine green (14.2 +/- 6.1 versus 9.1 +/- 3.0 ml/min/kg).,Hepatic drug clearance in patients with mild cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646824/),[ml] / [kg·min],14.2,13551,DB01435,Antipyrine
,8646824,Plasma clearance,Plasma clearance was significantly greater in patients with cystic fibrosis for both lorazepam (1.7 +/- 0.4 versus 1.2 +/- 0.5 ml/min/kg) and indocyanine green (14.2 +/- 6.1 versus 9.1 +/- 3.0 ml/min/kg).,Hepatic drug clearance in patients with mild cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646824/),[ml] / [kg·min],9.1,13552,DB01435,Antipyrine
,8646824,clearance,"In contrast, the clearance of antipyrine was not significantly different (1.0 +/- 0.7 versus 0.8 +/- 0.3 ml/min/kg), but the formation clearance for 3-hydroxymethylantipyrine was significantly greater in patients with cystic fibrosis.",Hepatic drug clearance in patients with mild cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646824/),[ml] / [kg·min],1.0,13553,DB01435,Antipyrine
,8646824,clearance,"In contrast, the clearance of antipyrine was not significantly different (1.0 +/- 0.7 versus 0.8 +/- 0.3 ml/min/kg), but the formation clearance for 3-hydroxymethylantipyrine was significantly greater in patients with cystic fibrosis.",Hepatic drug clearance in patients with mild cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646824/),[ml] / [kg·min],0.8,13554,DB01435,Antipyrine
,10363621,half-life time,The mean phenazone half-life time was significantly shorter in patients with AML (8.79 (3.01) h) than in control group (11.08 (3.61) h) (p < 0.012).,Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),h,8.79,14193,DB01435,Antipyrine
,10363621,half-life time,The mean phenazone half-life time was significantly shorter in patients with AML (8.79 (3.01) h) than in control group (11.08 (3.61) h) (p < 0.012).,Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),h,11.08,14194,DB01435,Antipyrine
,10363621,half-life time,"The mean phenazone half-life time was significantly longer (18.08 (8.80) h) and the mean metabolic clearance rate was significantly smaller (33.92 (15.40) ml/min) after chemotherapy in comparison with the initial value, before treatment (10.22 (2.90) h), (p < 0.01) (50.33 (20.29) ml/min) (p < 0.008).",Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),h,18.08,14195,DB01435,Antipyrine
,10363621,metabolic clearance rate,"The mean phenazone half-life time was significantly longer (18.08 (8.80) h) and the mean metabolic clearance rate was significantly smaller (33.92 (15.40) ml/min) after chemotherapy in comparison with the initial value, before treatment (10.22 (2.90) h), (p < 0.01) (50.33 (20.29) ml/min) (p < 0.008).",Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),[ml] / [min],33.92,14196,DB01435,Antipyrine
,10363621,metabolic clearance rate,"The mean phenazone half-life time was significantly longer (18.08 (8.80) h) and the mean metabolic clearance rate was significantly smaller (33.92 (15.40) ml/min) after chemotherapy in comparison with the initial value, before treatment (10.22 (2.90) h), (p < 0.01) (50.33 (20.29) ml/min) (p < 0.008).",Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),h,10.22,14197,DB01435,Antipyrine
,10363621,metabolic clearance rate,"The mean phenazone half-life time was significantly longer (18.08 (8.80) h) and the mean metabolic clearance rate was significantly smaller (33.92 (15.40) ml/min) after chemotherapy in comparison with the initial value, before treatment (10.22 (2.90) h), (p < 0.01) (50.33 (20.29) ml/min) (p < 0.008).",Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),[ml] / [min],50.33,14198,DB01435,Antipyrine
,8169835,apparent first-order distribution (lambda 1),"The apparent first-order distribution (lambda 1) and elimination (lambda z) rate constants were 0.043 +/- 0.014 min-1 and 0.020 +/- 0.007 min-1, respectively.",Mefloquine transfer during in vitro human placenta perfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),1/[min],0.043,14426,DB01435,Antipyrine
,8169835,elimination (lambda z),"The apparent first-order distribution (lambda 1) and elimination (lambda z) rate constants were 0.043 +/- 0.014 min-1 and 0.020 +/- 0.007 min-1, respectively.",Mefloquine transfer during in vitro human placenta perfusion. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),1/[min],0.043,14427,DB01435,Antipyrine
,8169835,rate constants,"The apparent first-order distribution (lambda 1) and elimination (lambda z) rate constants were 0.043 +/- 0.014 min-1 and 0.020 +/- 0.007 min-1, respectively.",Mefloquine transfer during in vitro human placenta perfusion. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),1/[min],0.020,14428,DB01435,Antipyrine
,8169835,mass ratio,The fetomaternal mass ratio became constant (0.46 +/- 0.07) after 120 min of perfusion and the time needed to achieve equal concentrations on both sides of the placenta was 178 +/- 31 min.,Mefloquine transfer during in vitro human placenta perfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),,0.46,14429,DB01435,Antipyrine
,8169835,time needed to achieve,The fetomaternal mass ratio became constant (0.46 +/- 0.07) after 120 min of perfusion and the time needed to achieve equal concentrations on both sides of the placenta was 178 +/- 31 min.,Mefloquine transfer during in vitro human placenta perfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),min,178,14430,DB01435,Antipyrine
,8169835,clearance,MQ clearance was 3.36 +/- 0.38 ml/min.,Mefloquine transfer during in vitro human placenta perfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),[ml] / [min],3.36,14431,DB01435,Antipyrine
,9065170,clearance index,The clearance index of lamivudine at a maternal concentration of 1.39 micrograms/ml was 0.23 +/- 0.14.,The maternal-fetal transfer of lamivudine in the ex vivo human placenta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065170/),,0.23,14683,DB01435,Antipyrine
,9065170,peak concentration,At a peak concentration of 14.68 micrograms/ml the clearance index was 0.14 +/- 0.06.,The maternal-fetal transfer of lamivudine in the ex vivo human placenta. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065170/),[μg] / [ml],14.68,14684,DB01435,Antipyrine
,9065170,clearance index,At a peak concentration of 14.68 micrograms/ml the clearance index was 0.14 +/- 0.06.,The maternal-fetal transfer of lamivudine in the ex vivo human placenta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065170/),,0.14,14685,DB01435,Antipyrine
,1747507,extra energy expenditure,"We measured antipyrine clearance, using the one-sample, simplified procedure in a group of 50 young Italian army soldiers, while at rest and during a 6 hour march in the mountains (extra energy expenditure: 7.43 kjoule per min).",Effect of physical exercise on one-sample antipyrine clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1747507/),[kjoule] / [min],7.43,14805,DB01435,Antipyrine
,1747507,clearance,"Mean antipyrine clearance was on average 46.6 (SD 10.2) ml/min (range 30.5-65.4) while resting, and 46.2 (10.5) (range 25.5-64.8) while exercising (not different).",Effect of physical exercise on one-sample antipyrine clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1747507/),[ml] / [min],46.6,14806,DB01435,Antipyrine
,1747507,clearance,"Mean antipyrine clearance was on average 46.6 (SD 10.2) ml/min (range 30.5-65.4) while resting, and 46.2 (10.5) (range 25.5-64.8) while exercising (not different).",Effect of physical exercise on one-sample antipyrine clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1747507/),,46.2,14807,DB01435,Antipyrine
,11999127,fraction absorbed (f(abs)),"At pH 6.0 (0-100 min) the fraction absorbed (f(abs)) and effective permeability (P(eff)) of phenoxymethylpenicillin were 0.3% and 0.06 x 4 cm s(-1), respectively, and remained unaffected by the addition of sodium caprate.",The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999127/),%,0.3,15696,DB01435,Antipyrine
,11999127,effective permeability (P(eff)),"At pH 6.0 (0-100 min) the fraction absorbed (f(abs)) and effective permeability (P(eff)) of phenoxymethylpenicillin were 0.3% and 0.06 x 4 cm s(-1), respectively, and remained unaffected by the addition of sodium caprate.",The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999127/),[cm] / [s],0.06 x 4,15697,DB01435,Antipyrine
,11999127,f(abs),"When the same subjects were perfused at pH 7.4, the f(abs) and P(eff) of phenoxymethylpenicillin were 2.4% and 0.11 x 10(-4) cm s(-1) (0-100 min), respectively, also remaining unchanged by addition of sodium caprate (100-200 min).",The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999127/),%,2.4,15698,DB01435,Antipyrine
,11999127,P(eff),"When the same subjects were perfused at pH 7.4, the f(abs) and P(eff) of phenoxymethylpenicillin were 2.4% and 0.11 x 10(-4) cm s(-1) (0-100 min), respectively, also remaining unchanged by addition of sodium caprate (100-200 min).",The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999127/),[cm] / [s],0.11 x 10(-4),15699,DB01435,Antipyrine
,11999127,plasma AUC,"It was possible to determine the plasma AUC of phenoxymethylpenicillin after addition of sodium caprate in three subjects at both pHs; this was in the range of 14.0-62.8 and 56.4-231 (min micromol L(-1)) at pH 6.0 and 7.4, respectively.",The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999127/),[min·μM] / [l],14.0-62.8,15700,DB01435,Antipyrine
,11999127,plasma AUC,"It was possible to determine the plasma AUC of phenoxymethylpenicillin after addition of sodium caprate in three subjects at both pHs; this was in the range of 14.0-62.8 and 56.4-231 (min micromol L(-1)) at pH 6.0 and 7.4, respectively.",The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999127/),[min·μM] / [l],56.4-231,15701,DB01435,Antipyrine
,2229451,clearance,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),[l] / [h],20.3,15994,DB01435,Antipyrine
,2229451,clearance,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),[l] / [h],20.1,15995,DB01435,Antipyrine
,2229451,half-life,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),h,7.9,15996,DB01435,Antipyrine
,2229451,half-life,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),h,7.8,15997,DB01435,Antipyrine
,2229451,maximum concentration,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),[mg] / [l],1.4,15998,DB01435,Antipyrine
,2229451,maximum concentration,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),[mg] / [l],1.5,15999,DB01435,Antipyrine
,2229451,time to maximum concentration,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),h,1.5,16000,DB01435,Antipyrine
,2229451,time to maximum concentration,"There were no significant differences in clearance (20.3 +/- 3.3 L/hr vs 20.1 +/- 2.3 L/hr, P = .836), half-life (7.9 +/- 1 hr vs 7.8 +/- 0.8 hr, P = 0.8), maximum concentration (1.4 +/- 0.6 mg/L vs 1.5 +/- 0.6 mg/L, P = 0.613), or time to maximum concentration (1.5 +/- 0.2 hr vs 1.5 +/- 0.1 hr, P = 0.571) for quinidine between Phase A and Phase B, respectively.",The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229451/),h,1.5,16001,DB01435,Antipyrine
,9156376,volume of distribution,"Mean kinetic variables in the nonsmoking, non-oral contraceptive using control group were: volume of distribution, 37.7 L; elimination half-life, 13.2 hours; and clearance, 34.4 mL/min.","Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156376/),l,37.7,16356,DB01435,Antipyrine
,9156376,elimination half-life,"Mean kinetic variables in the nonsmoking, non-oral contraceptive using control group were: volume of distribution, 37.7 L; elimination half-life, 13.2 hours; and clearance, 34.4 mL/min.","Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156376/),h,13.2,16357,DB01435,Antipyrine
,9156376,clearance,"Mean kinetic variables in the nonsmoking, non-oral contraceptive using control group were: volume of distribution, 37.7 L; elimination half-life, 13.2 hours; and clearance, 34.4 mL/min.","Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156376/),[ml] / [min],34.4,16358,DB01435,Antipyrine
,9156376,elimination half-life,"In cigarette smoking, non-oral contraceptive users versus controls, elimination half-life was reduced (8.0 vs. 13.2 hours, P < 0.05) and clearance increased (56.0 vs. 34.4 mL/min, P < 0.05).","Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156376/),h,8.0,16359,DB01435,Antipyrine
,9156376,elimination half-life,"In cigarette smoking, non-oral contraceptive users versus controls, elimination half-life was reduced (8.0 vs. 13.2 hours, P < 0.05) and clearance increased (56.0 vs. 34.4 mL/min, P < 0.05).","Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156376/),h,13.2,16360,DB01435,Antipyrine
,9156376,clearance,"In cigarette smoking, non-oral contraceptive users versus controls, elimination half-life was reduced (8.0 vs. 13.2 hours, P < 0.05) and clearance increased (56.0 vs. 34.4 mL/min, P < 0.05).","Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156376/),[ml] / [min],56.0,16361,DB01435,Antipyrine
,9156376,clearance,"In cigarette smoking, non-oral contraceptive users versus controls, elimination half-life was reduced (8.0 vs. 13.2 hours, P < 0.05) and clearance increased (56.0 vs. 34.4 mL/min, P < 0.05).","Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156376/),[ml] / [min],34.4,16362,DB01435,Antipyrine
,9156376,elimination half-life,"In nonsmoker oral contraceptive users, the reverse was true (elimination half-life was significantly increased: 16.6 vs. 13.2 hours, P < 0.05; and clearance was significantly decreased: 24.8 vs. 34.4 mL/min, P < 0.05).","Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156376/),h,16.6,16363,DB01435,Antipyrine
,9156376,elimination half-life,"In nonsmoker oral contraceptive users, the reverse was true (elimination half-life was significantly increased: 16.6 vs. 13.2 hours, P < 0.05; and clearance was significantly decreased: 24.8 vs. 34.4 mL/min, P < 0.05).","Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156376/),h,13.2,16364,DB01435,Antipyrine
,9156376,clearance,"In nonsmoker oral contraceptive users, the reverse was true (elimination half-life was significantly increased: 16.6 vs. 13.2 hours, P < 0.05; and clearance was significantly decreased: 24.8 vs. 34.4 mL/min, P < 0.05).","Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156376/),[ml] / [min],24.8,16365,DB01435,Antipyrine
,9156376,clearance,"In nonsmoker oral contraceptive users, the reverse was true (elimination half-life was significantly increased: 16.6 vs. 13.2 hours, P < 0.05; and clearance was significantly decreased: 24.8 vs. 34.4 mL/min, P < 0.05).","Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156376/),[ml] / [min],34.4,16366,DB01435,Antipyrine
,9156376,elimination half-life,"In smokers who were using oral contraceptives, values were not significantly different from controls (elimination half-life, 11.2 hours; clearance, 39.5 mL/min).","Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156376/),h,11.2,16367,DB01435,Antipyrine
,9156376,clearance,"In smokers who were using oral contraceptives, values were not significantly different from controls (elimination half-life, 11.2 hours; clearance, 39.5 mL/min).","Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156376/),[ml] / [min],39.5,16368,DB01435,Antipyrine
,2369810,t1/2,"In group 1, ciprofloxacin administration resulted in a significant decrease in antipyrine elimination (t1/2, 9.45 +/- 3.74 vs. 14.92 +/- 3.32 hr).",Metabolic interactions of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),h,9.45,16811,DB01435,Antipyrine
,2369810,t1/2,"In group 1, ciprofloxacin administration resulted in a significant decrease in antipyrine elimination (t1/2, 9.45 +/- 3.74 vs. 14.92 +/- 3.32 hr).",Metabolic interactions of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),h,14.92,16812,DB01435,Antipyrine
,2369810,clearance,The average decrease in antipyrine clearance was 35% (0.85 +/- 0.45 vs. 0.52 +/- 0.24 ml/min/kg).,Metabolic interactions of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),[ml] / [kg·min],0.85,16813,DB01435,Antipyrine
,2369810,clearance,The average decrease in antipyrine clearance was 35% (0.85 +/- 0.45 vs. 0.52 +/- 0.24 ml/min/kg).,Metabolic interactions of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),[ml] / [kg·min],0.52,16814,DB01435,Antipyrine
,2369810,t1/2,"In group 2, the change in antipyrine kinetics was less pronounced (t1/2, 9.79 +/- 3.06 vs. 11.22 +/- 2.64 hr).",Metabolic interactions of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),h,9.79,16815,DB01435,Antipyrine
,2369810,t1/2,"In group 2, the change in antipyrine kinetics was less pronounced (t1/2, 9.79 +/- 3.06 vs. 11.22 +/- 2.64 hr).",Metabolic interactions of ciprofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),h,11.22,16816,DB01435,Antipyrine
,2369810,clearance,Antipyrine clearance was decreased by only 10% (0.77 +/- 0.13 vs. 0.70 +/- 0.14 ml/min/kg).,Metabolic interactions of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),[ml] / [kg·min],0.77,16817,DB01435,Antipyrine
,2369810,clearance,Antipyrine clearance was decreased by only 10% (0.77 +/- 0.13 vs. 0.70 +/- 0.14 ml/min/kg).,Metabolic interactions of ciprofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369810/),[ml] / [kg·min],0.70,16818,DB01435,Antipyrine
,2407090,apparent volume of distribution,"The drug has a large apparent volume of distribution (approximately 4 liters/kg), exhibits extensive plasma protein binding (approximately 95%) and produces at least 30 metabolites.",Clinical pharmacokinetics of moricizine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407090/),[l] / [kg],4,17631,DB01435,Antipyrine
,2407090,plasma protein binding,"The drug has a large apparent volume of distribution (approximately 4 liters/kg), exhibits extensive plasma protein binding (approximately 95%) and produces at least 30 metabolites.",Clinical pharmacokinetics of moricizine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407090/),%,95,17632,DB01435,Antipyrine
,2407090,elimination half-life,"The elimination half-life of moricizine is 2 to 6 hours, but its duration of antiarrhythmic action is much longer suggesting active metabolites.",Clinical pharmacokinetics of moricizine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407090/),h,2 to 6,17633,DB01435,Antipyrine
,8803524,apparent oral clearance,"Accordingly, apparent oral clearance was markedly reduced (from 9.1 to 4.5 and 4.1 ml.min-1.kg-1 in nonascitic and ascitic patients, respectively).",Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803524/),[ml] / [kg·min],9.1,17941,DB01435,Antipyrine
,8803524,apparent oral clearance,"Accordingly, apparent oral clearance was markedly reduced (from 9.1 to 4.5 and 4.1 ml.min-1.kg-1 in nonascitic and ascitic patients, respectively).",Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803524/),[ml] / [kg·min],4.5,17942,DB01435,Antipyrine
,8803524,apparent oral clearance,"Accordingly, apparent oral clearance was markedly reduced (from 9.1 to 4.5 and 4.1 ml.min-1.kg-1 in nonascitic and ascitic patients, respectively).",Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803524/),[ml] / [kg·min],4.1,17943,DB01435,Antipyrine
,8803524,Terminal half-life (t1/2),"Terminal half-life (t1/2), was significantly longer in nonascitic patients than in control subjects (32 vs 22 min).",Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803524/),min,32,17944,DB01435,Antipyrine
,8803524,Terminal half-life (t1/2),"Terminal half-life (t1/2), was significantly longer in nonascitic patients than in control subjects (32 vs 22 min).",Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803524/),min,22,17945,DB01435,Antipyrine
,8803524,t1/2,"A further significant prolongation of t1/2, most likely due to an increased distribution volume, was observed in patients with ascites (56 min).",Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803524/),min,56,17946,DB01435,Antipyrine
,8803524,time to Cmax,The time to Cmax increased from 30 to 45 min in both cirrhotic groups.,Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803524/),min,30,17947,DB01435,Antipyrine
,8803524,time to Cmax,The time to Cmax increased from 30 to 45 min in both cirrhotic groups.,Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803524/),min,45,17948,DB01435,Antipyrine
,7201837,Absolute bioavailability,Absolute bioavailability of an aqueous solution of antipyrine was on average 97%.,Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7201837/),%,97,18167,DB01435,Antipyrine
,7201837,half-life,Antipyrine half-life in smokers was significantly shorter (mean 9.7 h) as compared to non-smokers (mean 11.7 h).,Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7201837/),h,9.7,18168,DB01435,Antipyrine
,7201837,half-life,Antipyrine half-life in smokers was significantly shorter (mean 9.7 h) as compared to non-smokers (mean 11.7 h).,Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7201837/),h,11.7,18169,DB01435,Antipyrine
,7201837,cumulative urinary excretion,"In addition, cumulative urinary excretion of 4-hydroxy-antipyrine, norantipyrine and 3-hydroxymethyl-antipyrine was on average higher in smokers (77.1 +/- 5.0%) as compared to non-smokers (69.5 +/- 10.8%).",Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7201837/),%,77.1,18170,DB01435,Antipyrine
,7201837,cumulative urinary excretion,"In addition, cumulative urinary excretion of 4-hydroxy-antipyrine, norantipyrine and 3-hydroxymethyl-antipyrine was on average higher in smokers (77.1 +/- 5.0%) as compared to non-smokers (69.5 +/- 10.8%).",Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7201837/),%,69.5,18171,DB01435,Antipyrine
,37091,A.U.C.,Rifampicin caused a significant reduction in the A.U.C. of a single dose of 1 mg norethisterone from 37.8 +/- 13.1 to 21.9 +/- 5.9 ng/ml X h (p less than 0.01).,The effect of rifampicin on norethisterone pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/37091/),[ng] / [h·ml],37.8,19017,DB01435,Antipyrine
,37091,A.U.C.,Rifampicin caused a significant reduction in the A.U.C. of a single dose of 1 mg norethisterone from 37.8 +/- 13.1 to 21.9 +/- 5.9 ng/ml X h (p less than 0.01).,The effect of rifampicin on norethisterone pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/37091/),[ng] / [h·ml],21.9,19018,DB01435,Antipyrine
,37091,half life (beta-phase),The plasma norethisterone half life (beta-phase) was also reduced from 6.2 +/- 1.7 to 3.2 +/- 1.0 h (p less than 0.0025).,The effect of rifampicin on norethisterone pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/37091/),h,6.2,19019,DB01435,Antipyrine
,37091,half life (beta-phase),The plasma norethisterone half life (beta-phase) was also reduced from 6.2 +/- 1.7 to 3.2 +/- 1.0 h (p less than 0.0025).,The effect of rifampicin on norethisterone pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/37091/),h,3.2,19020,DB01435,Antipyrine
,2023880,minimum measurable concentration,The minimum measurable concentration was 0.2 microgram/ml.,Simplified determination of antipyrine clearance by liquid chromatography of a microsample of saliva or plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023880/),[μg] / [ml],0.2,20189,DB01435,Antipyrine
,2023880,clearance,"The antipyrine clearance in the healthy subjects ranged from 2.203 to 5.721 liters/hr, while in patients with chronic liver disease it was significantly (P less than 0.0027) less (range, 0.544 to 1.103 liter/hr).",Simplified determination of antipyrine clearance by liquid chromatography of a microsample of saliva or plasma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023880/),[l] / [h],2.203 to 5.721,20190,DB01435,Antipyrine
,8430058,blood clearance,From intravenous bolus studies it was established that BNF showed a high blood clearance (130 ml/min/kg) and no detectable excretion of unchanged compound in the urine.,Time-dependent disposition of beta-naphthoflavone in the rat. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430058/),[ml] / [kg·min],130,20741,DB01435,Antipyrine
,8430058,volume of distribution,"The volume of distribution for BNF was large (6 L/kg), and binding to plasma proteins extensive (96%).",Time-dependent disposition of beta-naphthoflavone in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430058/),[l] / [kg],6,20742,DB01435,Antipyrine
,8430058,half-life,In the short infusion studies the postinfusion half-life (27 min) was significantly shorter than the terminal half-life after bolus administration (40 min).,Time-dependent disposition of beta-naphthoflavone in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430058/),min,27,20743,DB01435,Antipyrine
,8430058,terminal half-life,In the short infusion studies the postinfusion half-life (27 min) was significantly shorter than the terminal half-life after bolus administration (40 min).,Time-dependent disposition of beta-naphthoflavone in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430058/),min,40,20744,DB01435,Antipyrine
,10440421,AUC ratio,"No significant change in the disposition of antipyrine was observed after the ingestion of clopidogrel over 10 days: mean AUC ratio (+/-SEM) for plasma antipyrine was 1.021+/-0.023 for the clopidogrel group versus 1.001+/-0.019 for the placebo group; mean day 10/day -2 t 1/2 ratios were 1.019+/-0.018 and 1.027+/-0.023, respectively.",Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440421/),,1.021,21263,DB01435,Antipyrine
,10440421,AUC ratio,"No significant change in the disposition of antipyrine was observed after the ingestion of clopidogrel over 10 days: mean AUC ratio (+/-SEM) for plasma antipyrine was 1.021+/-0.023 for the clopidogrel group versus 1.001+/-0.019 for the placebo group; mean day 10/day -2 t 1/2 ratios were 1.019+/-0.018 and 1.027+/-0.023, respectively.",Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440421/),,1.001,21264,DB01435,Antipyrine
,10440421,t 1/2 ratios,"No significant change in the disposition of antipyrine was observed after the ingestion of clopidogrel over 10 days: mean AUC ratio (+/-SEM) for plasma antipyrine was 1.021+/-0.023 for the clopidogrel group versus 1.001+/-0.019 for the placebo group; mean day 10/day -2 t 1/2 ratios were 1.019+/-0.018 and 1.027+/-0.023, respectively.",Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers. ,t1/2 ratio-Q58,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440421/),,1.019,21265,DB01435,Antipyrine
,10440421,t 1/2 ratios,"No significant change in the disposition of antipyrine was observed after the ingestion of clopidogrel over 10 days: mean AUC ratio (+/-SEM) for plasma antipyrine was 1.021+/-0.023 for the clopidogrel group versus 1.001+/-0.019 for the placebo group; mean day 10/day -2 t 1/2 ratios were 1.019+/-0.018 and 1.027+/-0.023, respectively.",Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers. ,t1/2 ratio-Q58,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440421/),,1.027,21266,DB01435,Antipyrine
,10499483,clearance,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[ml] / [min],27.2,24669,DB01435,Antipyrine
,10499483,ICG,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[ml] / [min],27.2,24670,DB01435,Antipyrine
,10499483,ICG,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[ml] / [min],46.2,24671,DB01435,Antipyrine
,10499483,ICG,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[ml] / [min],501,24672,DB01435,Antipyrine
,10499483,ICG,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[mu] / [min],4014601,24673,DB01435,Antipyrine
,10499483,ICG,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[mu] / [min],771,24674,DB01435,Antipyrine
,10499483,clearance,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[ml] / [min],46.2,24675,DB01435,Antipyrine
,10499483,clearance,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[ml] / [min],501,24676,DB01435,Antipyrine
,10499483,clearance,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[mu] / [min],4014601,24677,DB01435,Antipyrine
,10499483,clearance,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[mu] / [min],771,24678,DB01435,Antipyrine
,10499483,clearance,The oxazepam clearance did not differ significantly between the two groups (181 ml/min (145-217) versus 178 ml/min (152-204)).,"Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[ml] / [min],181,24679,DB01435,Antipyrine
,10499483,clearance,The oxazepam clearance did not differ significantly between the two groups (181 ml/min (145-217) versus 178 ml/min (152-204)).,"Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[ml] / [min],178,24680,DB01435,Antipyrine
,10499483,clearance ratios,"The model drug clearance ratios between the patient and control clearances showed decreased values for antipyrine and ICG compared with the oxazepam data (0.59 and 0.65 versus 1.02, respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),,0.59,24681,DB01435,Antipyrine
,10499483,clearance ratios,"The model drug clearance ratios between the patient and control clearances showed decreased values for antipyrine and ICG compared with the oxazepam data (0.59 and 0.65 versus 1.02, respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),,0.65,24682,DB01435,Antipyrine
,10499483,clearance ratios,"The model drug clearance ratios between the patient and control clearances showed decreased values for antipyrine and ICG compared with the oxazepam data (0.59 and 0.65 versus 1.02, respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),,1.02,24683,DB01435,Antipyrine
,3878153,concentrations,"After oral administration of 750 mg mefloquine to six volunteers, absorption, was apparently slow, with plasma mefloquine concentrations at 24 h (559 +/- 181 ng ml-1; mean +/- s.d.) higher than at 6 h (459 +/- 166 ng ml-1).",The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3878153/),[ng] / [ml],559,26083,DB01435,Antipyrine
,3878153,concentrations,"After oral administration of 750 mg mefloquine to six volunteers, absorption, was apparently slow, with plasma mefloquine concentrations at 24 h (559 +/- 181 ng ml-1; mean +/- s.d.) higher than at 6 h (459 +/- 166 ng ml-1).",The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3878153/),[ng] / [ml],459,26084,DB01435,Antipyrine
,3878153,elimination half-life,"The elimination half-life was 373 +/- 249 h, oral clearance was 5.09 +/- 2.7 1 h-1, and apparent volume of distribution was 35.7 +/- 30.7 l kg-1 (assuming 100% bioavailability).",The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3878153/),h,373,26085,DB01435,Antipyrine
,3878153,oral clearance,"The elimination half-life was 373 +/- 249 h, oral clearance was 5.09 +/- 2.7 1 h-1, and apparent volume of distribution was 35.7 +/- 30.7 l kg-1 (assuming 100% bioavailability).",The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3878153/),[1] / [h],5.09,26086,DB01435,Antipyrine
,3878153,apparent volume of distribution,"The elimination half-life was 373 +/- 249 h, oral clearance was 5.09 +/- 2.7 1 h-1, and apparent volume of distribution was 35.7 +/- 30.7 l kg-1 (assuming 100% bioavailability).",The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3878153/),[l] / [kg],35.7,26087,DB01435,Antipyrine
,8480081,elimination half lives,"The elimination half lives in serum, blood dialysate and hepatic dialysate were 2.24 +/- 0.09, 2.06 +/- 0.31 and 2.10 +/- 0.32 hrs, respectively; there were not significantly different statistically.",Antipyrine concentrations in liver and blood monitored by microdialysis of unrestrained conscious rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8480081/),h,2.24,26247,DB01435,Antipyrine
,8480081,elimination half lives,"The elimination half lives in serum, blood dialysate and hepatic dialysate were 2.24 +/- 0.09, 2.06 +/- 0.31 and 2.10 +/- 0.32 hrs, respectively; there were not significantly different statistically.",Antipyrine concentrations in liver and blood monitored by microdialysis of unrestrained conscious rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8480081/),h,2.06,26248,DB01435,Antipyrine
,8480081,elimination half lives,"The elimination half lives in serum, blood dialysate and hepatic dialysate were 2.24 +/- 0.09, 2.06 +/- 0.31 and 2.10 +/- 0.32 hrs, respectively; there were not significantly different statistically.",Antipyrine concentrations in liver and blood monitored by microdialysis of unrestrained conscious rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8480081/),h,2.10,26249,DB01435,Antipyrine
,2365292,clearance,The patients showed a severe reduction in the quantitative liver function as assessed by estimation of the clearance of antipyrine; the median value was 9 ml.,Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2365292/),ml,9,26433,DB01435,Antipyrine
,2365292,Apparent clearance,"Apparent clearance of oxazepam in cirrhotic patients was 0.55 ml.min-1.kg-1, with a range of 0.46 to 1.24 ml.min-1.kg-1, compared with 1.19 ml.min-1.kg-1 and a range of 0.80 to 1.66 ml.min-1.kg-1 in the controls (p less than 0.05).",Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2365292/),[ml] / [kg·min],0.55,26434,DB01435,Antipyrine
,2365292,Apparent clearance,"Apparent clearance of oxazepam in cirrhotic patients was 0.55 ml.min-1.kg-1, with a range of 0.46 to 1.24 ml.min-1.kg-1, compared with 1.19 ml.min-1.kg-1 and a range of 0.80 to 1.66 ml.min-1.kg-1 in the controls (p less than 0.05).",Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2365292/),[ml] / [kg·min],1.19,26435,DB01435,Antipyrine
,2365292,unbound clearance,"The unbound clearance of oxazepam in patients was 4.1 ml.min-1.kg-1, with a range of 3.4 to 5.5 ml.",Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2365292/),[ml] / [kg·min],4.1,26436,DB01435,Antipyrine
,3455371,steady state concentrations,"Infusion of aldosterone at a constant rate of 0.17 mg/h over 4.5 h produced steady state concentrations after 2 h, with no difference before and after rifampicin treatment (mean +/- SD, 1649 +/- 144 vs 1586 +/- 80 pg/ml, respectively).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[pg] / [ml],1649,26474,DB01435,Antipyrine
,3455371,steady state concentrations,"Infusion of aldosterone at a constant rate of 0.17 mg/h over 4.5 h produced steady state concentrations after 2 h, with no difference before and after rifampicin treatment (mean +/- SD, 1649 +/- 144 vs 1586 +/- 80 pg/ml, respectively).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[pg] / [ml],1586,26475,DB01435,Antipyrine
,3455371,alpha-phase,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),min,29,26476,DB01435,Antipyrine
,3455371,alpha-phase,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),min,30,26477,DB01435,Antipyrine
,3455371,beta-phase,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),min,129,26478,DB01435,Antipyrine
,3455371,beta-phase,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),min,126,26479,DB01435,Antipyrine
,3455371,MCR,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[l] / [h·kg],1.47,26480,DB01435,Antipyrine
,3455371,MCR,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[l] / [h·kg],1.46,26481,DB01435,Antipyrine
,3455371,volume of distribution,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),l,9.9,26482,DB01435,Antipyrine
,3455371,volume of distribution,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),l,10.2,26483,DB01435,Antipyrine
,3455371,half-life,The antipyrine half-life decreased significantly from 12.2 +/- 2.6 h to 7.6 +/- 0.9 h (P less than 0.05) with a rise in antipyrine clearance from 0.38 +/- 0.07 to 0.80 +/- 0.23 ml/min/kg (P less than 0.05) and no change in the volume of distribution.,Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),h,12.2,26484,DB01435,Antipyrine
,3455371,half-life,The antipyrine half-life decreased significantly from 12.2 +/- 2.6 h to 7.6 +/- 0.9 h (P less than 0.05) with a rise in antipyrine clearance from 0.38 +/- 0.07 to 0.80 +/- 0.23 ml/min/kg (P less than 0.05) and no change in the volume of distribution.,Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),h,7.6,26485,DB01435,Antipyrine
,3455371,clearance,The antipyrine half-life decreased significantly from 12.2 +/- 2.6 h to 7.6 +/- 0.9 h (P less than 0.05) with a rise in antipyrine clearance from 0.38 +/- 0.07 to 0.80 +/- 0.23 ml/min/kg (P less than 0.05) and no change in the volume of distribution.,Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[ml] / [kg·min],0.38,26486,DB01435,Antipyrine
,3455371,clearance,The antipyrine half-life decreased significantly from 12.2 +/- 2.6 h to 7.6 +/- 0.9 h (P less than 0.05) with a rise in antipyrine clearance from 0.38 +/- 0.07 to 0.80 +/- 0.23 ml/min/kg (P less than 0.05) and no change in the volume of distribution.,Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[ml] / [kg·min],0.80,26487,DB01435,Antipyrine
,4006370,clearance,Antipyrine clearance during the acute illness was 31.4 +/- 7.6 ml/min (X +/- SD).,Antipyrine clearance in pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006370/),[ml] / [min],31.4,26954,DB01435,Antipyrine
,4006370,clearance,"Fourteen and 28 days later during convalescence, clearance values were higher (47.8 +/- 18.9 and 49.2 +/- 15.0 ml/min, respectively).",Antipyrine clearance in pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006370/),[ml] / [min],47.8,26955,DB01435,Antipyrine
,4006370,clearance,"Fourteen and 28 days later during convalescence, clearance values were higher (47.8 +/- 18.9 and 49.2 +/- 15.0 ml/min, respectively).",Antipyrine clearance in pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006370/),[ml] / [min],49.2,26956,DB01435,Antipyrine
,2328554,terminal elimination half-life,"The terminal elimination half-life in this group varied from 0.8 to 60.2 hours (median, 11.7 hours), compared with 0.6 to 4.1 hours (median, 1.4 hours) in the group of eight subjects with normal liver function.",The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328554/),h,11.7,27555,DB01435,Antipyrine
,2328554,terminal elimination half-life,"The terminal elimination half-life in this group varied from 0.8 to 60.2 hours (median, 11.7 hours), compared with 0.6 to 4.1 hours (median, 1.4 hours) in the group of eight subjects with normal liver function.",The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328554/),h,0.6 to 4.1,27556,DB01435,Antipyrine
,2328554,terminal elimination half-life,"The terminal elimination half-life in this group varied from 0.8 to 60.2 hours (median, 11.7 hours), compared with 0.6 to 4.1 hours (median, 1.4 hours) in the group of eight subjects with normal liver function.",The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328554/),h,1.4,27557,DB01435,Antipyrine
,27789367,relative bioavailability,The oral pharmacokinetic study showed 571% relative bioavailability with NODS compared to EDR suspension.,Development of a novel oral delivery system of edaravone for enhancing bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27789367/),%,571,28355,DB01435,Antipyrine
,7341283,Clearance,"Clearance to 3-hydroxymethylantipyrine was increased from 7.8 +/- 0.9 ml/min to 13.3 +/- 1.3 ml/min, to norphenazone from 5.8 +/- 0.6 ml/min to 19.3 +/- 2.1 ml/min and to 4-hydroxyantipyrine from 14.3 +/- 2.2 ml/min to 21.9 +/- 3.9 ml/min.",Differential induction of antipyrine metabolism by rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341283/),[ml] / [min],7.8,29991,DB01435,Antipyrine
,7341283,Clearance,"Clearance to 3-hydroxymethylantipyrine was increased from 7.8 +/- 0.9 ml/min to 13.3 +/- 1.3 ml/min, to norphenazone from 5.8 +/- 0.6 ml/min to 19.3 +/- 2.1 ml/min and to 4-hydroxyantipyrine from 14.3 +/- 2.2 ml/min to 21.9 +/- 3.9 ml/min.",Differential induction of antipyrine metabolism by rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341283/),[ml] / [min],13.3,29992,DB01435,Antipyrine
,7341283,Clearance,"Clearance to 3-hydroxymethylantipyrine was increased from 7.8 +/- 0.9 ml/min to 13.3 +/- 1.3 ml/min, to norphenazone from 5.8 +/- 0.6 ml/min to 19.3 +/- 2.1 ml/min and to 4-hydroxyantipyrine from 14.3 +/- 2.2 ml/min to 21.9 +/- 3.9 ml/min.",Differential induction of antipyrine metabolism by rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341283/),[ml] / [min],5.8,29993,DB01435,Antipyrine
,7341283,Clearance,"Clearance to 3-hydroxymethylantipyrine was increased from 7.8 +/- 0.9 ml/min to 13.3 +/- 1.3 ml/min, to norphenazone from 5.8 +/- 0.6 ml/min to 19.3 +/- 2.1 ml/min and to 4-hydroxyantipyrine from 14.3 +/- 2.2 ml/min to 21.9 +/- 3.9 ml/min.",Differential induction of antipyrine metabolism by rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341283/),[ml] / [min],19.3,29994,DB01435,Antipyrine
,7341283,Clearance,"Clearance to 3-hydroxymethylantipyrine was increased from 7.8 +/- 0.9 ml/min to 13.3 +/- 1.3 ml/min, to norphenazone from 5.8 +/- 0.6 ml/min to 19.3 +/- 2.1 ml/min and to 4-hydroxyantipyrine from 14.3 +/- 2.2 ml/min to 21.9 +/- 3.9 ml/min.",Differential induction of antipyrine metabolism by rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341283/),[ml] / [min],14.3,29995,DB01435,Antipyrine
,7341283,Clearance,"Clearance to 3-hydroxymethylantipyrine was increased from 7.8 +/- 0.9 ml/min to 13.3 +/- 1.3 ml/min, to norphenazone from 5.8 +/- 0.6 ml/min to 19.3 +/- 2.1 ml/min and to 4-hydroxyantipyrine from 14.3 +/- 2.2 ml/min to 21.9 +/- 3.9 ml/min.",Differential induction of antipyrine metabolism by rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341283/),[ml] / [min],21.9,29996,DB01435,Antipyrine
,9300934,half-life,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,0.97,31295,DB01435,Antipyrine
,9300934,half-life,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,1.11,31296,DB01435,Antipyrine
,9300934,half-life,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,11.9,31297,DB01435,Antipyrine
,9300934,half-life,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,13.7,31298,DB01435,Antipyrine
,9300934,excretion,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),[μg] / [24·h],472.3,31299,DB01435,Antipyrine
,9300934,excretion,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),[μg] / [24·h],340.6,31300,DB01435,Antipyrine
,9300934,half-life,"Administration of zidovudine did, however, result in a significant reduction in antipyrine half-life (11.7 +/- 2.0 h before vs. 9.9 +/- 2.3h after ZDV) and a significant increase in 6-beta-hydroxycortisol excretion (438,7 +/- 138.2 microg/24 h before and 684.6 +/- 157.3 microg/24 h after ZDV).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,11.7,31301,DB01435,Antipyrine
,9300934,half-life,"Administration of zidovudine did, however, result in a significant reduction in antipyrine half-life (11.7 +/- 2.0 h before vs. 9.9 +/- 2.3h after ZDV) and a significant increase in 6-beta-hydroxycortisol excretion (438,7 +/- 138.2 microg/24 h before and 684.6 +/- 157.3 microg/24 h after ZDV).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,9.9,31302,DB01435,Antipyrine
,9300934,excretion,"Administration of zidovudine did, however, result in a significant reduction in antipyrine half-life (11.7 +/- 2.0 h before vs. 9.9 +/- 2.3h after ZDV) and a significant increase in 6-beta-hydroxycortisol excretion (438,7 +/- 138.2 microg/24 h before and 684.6 +/- 157.3 microg/24 h after ZDV).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),[μg] / [24·h],"438,7",31303,DB01435,Antipyrine
,9300934,excretion,"Administration of zidovudine did, however, result in a significant reduction in antipyrine half-life (11.7 +/- 2.0 h before vs. 9.9 +/- 2.3h after ZDV) and a significant increase in 6-beta-hydroxycortisol excretion (438,7 +/- 138.2 microg/24 h before and 684.6 +/- 157.3 microg/24 h after ZDV).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),[μg] / [24·h],684.6,31304,DB01435,Antipyrine
,6649682,blood clearance,Treatment with PB increased antipyrine blood clearance from 11.1 to 59.1 ml/min per kg.,Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6649682/),[ml] / [kg·min],11,31662,DB01435,Antipyrine
,6649682,blood clearance,Treatment with PB increased antipyrine blood clearance from 11.1 to 59.1 ml/min per kg.,Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6649682/),[ml] / [kg·min],59,31663,DB01435,Antipyrine
,6649682,clearance,Treatment with AIA resulted in a reduction of antipyrine clearance to 5.6 ml/min per kg.,Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6649682/),[ml] / [kg·min],5.6,31664,DB01435,Antipyrine
,6649682,Blood clearance,Blood clearance of antipyrine was reduced from 59.1 to 12.3 ml/min per kg.,Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6649682/),[ml] / [kg·min],59.1,31665,DB01435,Antipyrine
,6649682,Blood clearance,Blood clearance of antipyrine was reduced from 59.1 to 12.3 ml/min per kg.,Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6649682/),[ml] / [kg·min],12.3,31666,DB01435,Antipyrine
,19204082,influx clearances,"The transplacental pharmacokinetic model could adequately explain the transplacental transfer of diclofenac with influx clearances from maternal and fetal perfusates to placental tissue of 0.276 and 0.0345 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates of 0.406 and 0.0337 min(-1), respectively.",Transplacental pharmacokinetics of diclofenac in perfused human placenta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19204082/),[ml] / [g·min],0.276,32373,DB01435,Antipyrine
,19204082,influx clearances,"The transplacental pharmacokinetic model could adequately explain the transplacental transfer of diclofenac with influx clearances from maternal and fetal perfusates to placental tissue of 0.276 and 0.0345 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates of 0.406 and 0.0337 min(-1), respectively.",Transplacental pharmacokinetics of diclofenac in perfused human placenta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19204082/),[ml] / [g·min],0.0345,32374,DB01435,Antipyrine
,19204082,efflux rate constants,"The transplacental pharmacokinetic model could adequately explain the transplacental transfer of diclofenac with influx clearances from maternal and fetal perfusates to placental tissue of 0.276 and 0.0345 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates of 0.406 and 0.0337 min(-1), respectively.",Transplacental pharmacokinetics of diclofenac in perfused human placenta. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19204082/),1/[min],0.406,32375,DB01435,Antipyrine
,19204082,efflux rate constants,"The transplacental pharmacokinetic model could adequately explain the transplacental transfer of diclofenac with influx clearances from maternal and fetal perfusates to placental tissue of 0.276 and 0.0345 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates of 0.406 and 0.0337 min(-1), respectively.",Transplacental pharmacokinetics of diclofenac in perfused human placenta. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19204082/),1/[min],0.0337,32376,DB01435,Antipyrine
,19204082,placental tissue/plasma concentration ratio,"By taking into account protein binding, the placental tissue/plasma concentration ratio in humans for diclofenac was estimated to be 0.108 ml/g of cotyledon and was smaller than that of antipyrine.",Transplacental pharmacokinetics of diclofenac in perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19204082/),[ml] / [g],0.108,32377,DB01435,Antipyrine
,10440613,liver volume,The relation between liver volume and body weight increased from 19.9 (16.5-23.7) ml/kg to 21.4 (17.1-21.9) ml/kg (P = 0.11).,"Liver volume, portal vein flow, and clearance of indocyanine green and antipyrine in hyperthyroidism before and after antithyroid treatment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440613/),[ml] / [kg],19.9,33528,DB01435,Antipyrine
,10440613,liver volume,The relation between liver volume and body weight increased from 19.9 (16.5-23.7) ml/kg to 21.4 (17.1-21.9) ml/kg (P = 0.11).,"Liver volume, portal vein flow, and clearance of indocyanine green and antipyrine in hyperthyroidism before and after antithyroid treatment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440613/),[ml] / [kg],21.4,33529,DB01435,Antipyrine
,21439120,extraction recovery,"Mean extraction recovery from human plasma of caffeine and the IS was 91% and 86%, respectively.",Validated HPLC method for determination of caffeine level in human plasma using synthetic plasma: application to bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21439120/),%,91,34304,DB01435,Antipyrine
,21439120,extraction recovery,"Mean extraction recovery from human plasma of caffeine and the IS was 91% and 86%, respectively.",Validated HPLC method for determination of caffeine level in human plasma using synthetic plasma: application to bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21439120/),%,86,34305,DB01435,Antipyrine
,10771450,"AUC(0,12 h)","The mean AUC(0,12 h) for ziprasidone was statistically significantly greater in the hepatically impaired subjects compared with the normal subjects (590 ng ml(-1) h vs. 467 ng ml(-1) h, P = 0. 042).",The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771450/),[h·ng] / [ml],590,35535,DB01435,Antipyrine
,10771450,"AUC(0,12 h)","The mean AUC(0,12 h) for ziprasidone was statistically significantly greater in the hepatically impaired subjects compared with the normal subjects (590 ng ml(-1) h vs. 467 ng ml(-1) h, P = 0. 042).",The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771450/),[h·ng] / [ml],467,35536,DB01435,Antipyrine
,6508980,Liver volume,"Liver volume was also measured and was found to be larger in patients than in controls, mean values being 1.86 and 1.36 l respectively.",Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508980/),l,1.86,35584,DB01435,Antipyrine
,6508980,Liver volume,"Liver volume was also measured and was found to be larger in patients than in controls, mean values being 1.86 and 1.36 l respectively.",Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508980/),l,1.36,35585,DB01435,Antipyrine
,6508980,clearance,Mean clearance values (ranges) were 13.5 (9.3-22.8) ml/min in the patients and 49.3 (31.1-103) ml/min in healthy subjects.,Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508980/),[ml] / [min],13.5,35586,DB01435,Antipyrine
,6508980,clearance,Mean clearance values (ranges) were 13.5 (9.3-22.8) ml/min in the patients and 49.3 (31.1-103) ml/min in healthy subjects.,Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508980/),[ml] / [min],49.3,35587,DB01435,Antipyrine
,6508980,plasma clearance,"Normalization of antipyrine plasma clearance for liver volume resulted in an only slightly increased distinction between patients and healthy subjects, mean values (ranges) being 7.8 (3.3-13.0) ml min(-1) 1(-1) and 36.1 (21.9-35.9) ml min(-1) 1(-1) respectively.",Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508980/),[ml] / [1·min],7.8,35588,DB01435,Antipyrine
,6508980,plasma clearance,"Normalization of antipyrine plasma clearance for liver volume resulted in an only slightly increased distinction between patients and healthy subjects, mean values (ranges) being 7.8 (3.3-13.0) ml min(-1) 1(-1) and 36.1 (21.9-35.9) ml min(-1) 1(-1) respectively.",Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508980/),[ml] / [1·min],36.1,35589,DB01435,Antipyrine
,2146057,clearance,Mean +/- SD antipyrine clearance after diltiazem (0.0258 +/- 0.0065 L/hr/kg) was significantly lower than that observed after isradipine (0.0334 +/- 0.0098 L/hr/kg) or placebo (0.0329 +/- 0.0082 L/hr/kg).,Comparative evaluation of the effects of isradipine and diltiazem on antipyrine and indocyanine green clearances in elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146057/),[l] / [h·kg],0.0258,36949,DB01435,Antipyrine
,2146057,clearance,Mean +/- SD antipyrine clearance after diltiazem (0.0258 +/- 0.0065 L/hr/kg) was significantly lower than that observed after isradipine (0.0334 +/- 0.0098 L/hr/kg) or placebo (0.0329 +/- 0.0082 L/hr/kg).,Comparative evaluation of the effects of isradipine and diltiazem on antipyrine and indocyanine green clearances in elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146057/),[l] / [h·kg],0.0334,36950,DB01435,Antipyrine
,2146057,clearance,Mean +/- SD antipyrine clearance after diltiazem (0.0258 +/- 0.0065 L/hr/kg) was significantly lower than that observed after isradipine (0.0334 +/- 0.0098 L/hr/kg) or placebo (0.0329 +/- 0.0082 L/hr/kg).,Comparative evaluation of the effects of isradipine and diltiazem on antipyrine and indocyanine green clearances in elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146057/),[l] / [h·kg],0.0329,36951,DB01435,Antipyrine
,2146057,clearances,Mean +/- SD ICG clearances after diltiazem (9.17 +/- 1.35 ml/min/kg) or isradipine (9.57 +/- 1.82 ml/min/kg) were significantly higher than that observed after placebo (8.06 +/- 1.45 ml/min/kg).,Comparative evaluation of the effects of isradipine and diltiazem on antipyrine and indocyanine green clearances in elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146057/),[ml] / [kg·min],9.17,36952,DB01435,Antipyrine
,2146057,clearances,Mean +/- SD ICG clearances after diltiazem (9.17 +/- 1.35 ml/min/kg) or isradipine (9.57 +/- 1.82 ml/min/kg) were significantly higher than that observed after placebo (8.06 +/- 1.45 ml/min/kg).,Comparative evaluation of the effects of isradipine and diltiazem on antipyrine and indocyanine green clearances in elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146057/),[ml] / [kg·min],9.57,36953,DB01435,Antipyrine
,2146057,clearances,Mean +/- SD ICG clearances after diltiazem (9.17 +/- 1.35 ml/min/kg) or isradipine (9.57 +/- 1.82 ml/min/kg) were significantly higher than that observed after placebo (8.06 +/- 1.45 ml/min/kg).,Comparative evaluation of the effects of isradipine and diltiazem on antipyrine and indocyanine green clearances in elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146057/),[ml] / [kg·min],8.06,36954,DB01435,Antipyrine
,19012189,differential transport rate,"The differential transport rate of cisplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.49 +/- 0.02, 1.23 +/- 0.03, 2.41 +/- 0.04, 3.67 +/- 0.03, and 4.48 +/- 0.07 minutes in 12 perfusions, while corresponding rates for antipyrine, for above mentioned efflux fractions averaged 0.51 +/- 0.01, 1.26 +/- 0.05, 2.52 +/- 0.01, 3.78 +/- 0.01, and 4.52 +/- 0.01 minutes, respectively.",Transport kinetics of cisplatin in the perfused human placental lobule in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19012189/),min,0.49,37254,DB01435,Antipyrine
,19012189,differential transport rate,"The differential transport rate of cisplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.49 +/- 0.02, 1.23 +/- 0.03, 2.41 +/- 0.04, 3.67 +/- 0.03, and 4.48 +/- 0.07 minutes in 12 perfusions, while corresponding rates for antipyrine, for above mentioned efflux fractions averaged 0.51 +/- 0.01, 1.26 +/- 0.05, 2.52 +/- 0.01, 3.78 +/- 0.01, and 4.52 +/- 0.01 minutes, respectively.",Transport kinetics of cisplatin in the perfused human placental lobule in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19012189/),min,1.23,37255,DB01435,Antipyrine
,19012189,differential transport rate,"The differential transport rate of cisplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.49 +/- 0.02, 1.23 +/- 0.03, 2.41 +/- 0.04, 3.67 +/- 0.03, and 4.48 +/- 0.07 minutes in 12 perfusions, while corresponding rates for antipyrine, for above mentioned efflux fractions averaged 0.51 +/- 0.01, 1.26 +/- 0.05, 2.52 +/- 0.01, 3.78 +/- 0.01, and 4.52 +/- 0.01 minutes, respectively.",Transport kinetics of cisplatin in the perfused human placental lobule in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19012189/),min,2.41,37256,DB01435,Antipyrine
,19012189,differential transport rate,"The differential transport rate of cisplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.49 +/- 0.02, 1.23 +/- 0.03, 2.41 +/- 0.04, 3.67 +/- 0.03, and 4.48 +/- 0.07 minutes in 12 perfusions, while corresponding rates for antipyrine, for above mentioned efflux fractions averaged 0.51 +/- 0.01, 1.26 +/- 0.05, 2.52 +/- 0.01, 3.78 +/- 0.01, and 4.52 +/- 0.01 minutes, respectively.",Transport kinetics of cisplatin in the perfused human placental lobule in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19012189/),min,3.67,37257,DB01435,Antipyrine
,19012189,differential transport rate,"The differential transport rate of cisplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.49 +/- 0.02, 1.23 +/- 0.03, 2.41 +/- 0.04, 3.67 +/- 0.03, and 4.48 +/- 0.07 minutes in 12 perfusions, while corresponding rates for antipyrine, for above mentioned efflux fractions averaged 0.51 +/- 0.01, 1.26 +/- 0.05, 2.52 +/- 0.01, 3.78 +/- 0.01, and 4.52 +/- 0.01 minutes, respectively.",Transport kinetics of cisplatin in the perfused human placental lobule in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19012189/),min,4.48,37258,DB01435,Antipyrine
,19012189,differential transport rate,"The differential transport rate of cisplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.49 +/- 0.02, 1.23 +/- 0.03, 2.41 +/- 0.04, 3.67 +/- 0.03, and 4.48 +/- 0.07 minutes in 12 perfusions, while corresponding rates for antipyrine, for above mentioned efflux fractions averaged 0.51 +/- 0.01, 1.26 +/- 0.05, 2.52 +/- 0.01, 3.78 +/- 0.01, and 4.52 +/- 0.01 minutes, respectively.",Transport kinetics of cisplatin in the perfused human placental lobule in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19012189/),min,0.51,37259,DB01435,Antipyrine
,19012189,differential transport rate,"The differential transport rate of cisplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.49 +/- 0.02, 1.23 +/- 0.03, 2.41 +/- 0.04, 3.67 +/- 0.03, and 4.48 +/- 0.07 minutes in 12 perfusions, while corresponding rates for antipyrine, for above mentioned efflux fractions averaged 0.51 +/- 0.01, 1.26 +/- 0.05, 2.52 +/- 0.01, 3.78 +/- 0.01, and 4.52 +/- 0.01 minutes, respectively.",Transport kinetics of cisplatin in the perfused human placental lobule in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19012189/),min,1.26,37260,DB01435,Antipyrine
,19012189,differential transport rate,"The differential transport rate of cisplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.49 +/- 0.02, 1.23 +/- 0.03, 2.41 +/- 0.04, 3.67 +/- 0.03, and 4.48 +/- 0.07 minutes in 12 perfusions, while corresponding rates for antipyrine, for above mentioned efflux fractions averaged 0.51 +/- 0.01, 1.26 +/- 0.05, 2.52 +/- 0.01, 3.78 +/- 0.01, and 4.52 +/- 0.01 minutes, respectively.",Transport kinetics of cisplatin in the perfused human placental lobule in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19012189/),min,2.52,37261,DB01435,Antipyrine
,19012189,differential transport rate,"The differential transport rate of cisplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.49 +/- 0.02, 1.23 +/- 0.03, 2.41 +/- 0.04, 3.67 +/- 0.03, and 4.48 +/- 0.07 minutes in 12 perfusions, while corresponding rates for antipyrine, for above mentioned efflux fractions averaged 0.51 +/- 0.01, 1.26 +/- 0.05, 2.52 +/- 0.01, 3.78 +/- 0.01, and 4.52 +/- 0.01 minutes, respectively.",Transport kinetics of cisplatin in the perfused human placental lobule in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19012189/),min,3.78,37262,DB01435,Antipyrine
,19012189,differential transport rate,"The differential transport rate of cisplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.49 +/- 0.02, 1.23 +/- 0.03, 2.41 +/- 0.04, 3.67 +/- 0.03, and 4.48 +/- 0.07 minutes in 12 perfusions, while corresponding rates for antipyrine, for above mentioned efflux fractions averaged 0.51 +/- 0.01, 1.26 +/- 0.05, 2.52 +/- 0.01, 3.78 +/- 0.01, and 4.52 +/- 0.01 minutes, respectively.",Transport kinetics of cisplatin in the perfused human placental lobule in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19012189/),min,4.52,37263,DB01435,Antipyrine
,19012189,transport fraction (TF),"The transport fraction (TF) of cisplatin, expressed as a fraction of the drug appearing in the fetal vein during a study period of 5 minutes, averaged 9.00 +/- 0.52% of bolus dose, while antipyrine TF averaged 68.6 +/- 2.01% of injected bolus dose, representing 13.10% of reference marker value.",Transport kinetics of cisplatin in the perfused human placental lobule in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19012189/),%,9.00,37264,DB01435,Antipyrine
,19012189,TF,"The transport fraction (TF) of cisplatin, expressed as a fraction of the drug appearing in the fetal vein during a study period of 5 minutes, averaged 9.00 +/- 0.52% of bolus dose, while antipyrine TF averaged 68.6 +/- 2.01% of injected bolus dose, representing 13.10% of reference marker value.",Transport kinetics of cisplatin in the perfused human placental lobule in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19012189/),%,68,37265,DB01435,Antipyrine
,3718808,bioavailability,"Bioavailability was essentially complete (mean bioavailability 101.2% +/- 14.4 (s.d.] indicating that even in enzyme induced subjects, antipyrine behaves as a restrictively eliminated compound with negligible presystemic elimination in the gut or liver.",Pharmacokinetics of antipyrine in epileptic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718808/),%,101.2,37381,DB01435,Antipyrine
less,2613393,metabolic ratio (MR),"In PM on rifampicin, the debrisoquine metabolic ratio (MR) was significantly reduced, even reaching a value less than 12.6 in 2 subjects but on phenobarbital and cimetidine, the MR was not significantly modified.","Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2613393/),,12,39596,DB01435,Antipyrine
,21626050,f,"EBT parameters (N = 19) (mean, [CV%]): CO(2)f(10) (%/min) 0.051 (106), CO(2)f(20) 0.052 (82), k(CO2) (min(-1)) 0.007 (22), AUC(CO2,(0-∞)) 7.9 (85), AUC(CO2,(0-60)) 2.64 (81).",Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21626050/),[%] / [min],0.051,39655,DB01435,Antipyrine
,21626050,f,"EBT parameters (N = 19) (mean, [CV%]): CO(2)f(10) (%/min) 0.051 (106), CO(2)f(20) 0.052 (82), k(CO2) (min(-1)) 0.007 (22), AUC(CO2,(0-∞)) 7.9 (85), AUC(CO2,(0-60)) 2.64 (81).",Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21626050/),,0.052,39656,DB01435,Antipyrine
,21626050,k(CO2),"EBT parameters (N = 19) (mean, [CV%]): CO(2)f(10) (%/min) 0.051 (106), CO(2)f(20) 0.052 (82), k(CO2) (min(-1)) 0.007 (22), AUC(CO2,(0-∞)) 7.9 (85), AUC(CO2,(0-60)) 2.64 (81).",Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21626050/),1/[min],0.007,39657,DB01435,Antipyrine
,21626050,AUC,"EBT parameters (N = 19) (mean, [CV%]): CO(2)f(10) (%/min) 0.051 (106), CO(2)f(20) 0.052 (82), k(CO2) (min(-1)) 0.007 (22), AUC(CO2,(0-∞)) 7.9 (85), AUC(CO2,(0-60)) 2.64 (81).",Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21626050/),,7.9,39658,DB01435,Antipyrine
,21626050,AUC,"EBT parameters (N = 19) (mean, [CV%]): CO(2)f(10) (%/min) 0.051 (106), CO(2)f(20) 0.052 (82), k(CO2) (min(-1)) 0.007 (22), AUC(CO2,(0-∞)) 7.9 (85), AUC(CO2,(0-60)) 2.64 (81).",Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21626050/),,2.64,39659,DB01435,Antipyrine
,21626050,CL(Ant),CL(Ant) (N = 19) (ml/min); 35.8 (37).,Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21626050/),[ml] / [min],35.8,39660,DB01435,Antipyrine
,21626050,CL(Doc),"Docetaxel PK parameters (N = 19): CL(Doc) (l/h) = 57.2 (36), t(Doc1/2) (h) = 12.7 (33).",Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21626050/),[l] / [h],57.2,39661,DB01435,Antipyrine
,21626050,t(Doc1/2),"Docetaxel PK parameters (N = 19): CL(Doc) (l/h) = 57.2 (36), t(Doc1/2) (h) = 12.7 (33).",Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21626050/),h,12.7,39662,DB01435,Antipyrine
,3203041,clearance,"2. Mean clearance values for the complete study (48.0 ml min-1) were nearly identical to abbreviated approaches A, B, and C (49.1, 49.3, and 46.4 ml min-1), and were highly correlated (r = 0.99).",Simplified approaches to the determination of antipyrine pharmacokinetic parameters. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203041/),[ml] / [min],48.0,41470,DB01435,Antipyrine
,3203041,clearance,"2. Mean clearance values for the complete study (48.0 ml min-1) were nearly identical to abbreviated approaches A, B, and C (49.1, 49.3, and 46.4 ml min-1), and were highly correlated (r = 0.99).",Simplified approaches to the determination of antipyrine pharmacokinetic parameters. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203041/),[ml] / [min],49.1,41471,DB01435,Antipyrine
,3203041,clearance,"2. Mean clearance values for the complete study (48.0 ml min-1) were nearly identical to abbreviated approaches A, B, and C (49.1, 49.3, and 46.4 ml min-1), and were highly correlated (r = 0.99).",Simplified approaches to the determination of antipyrine pharmacokinetic parameters. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203041/),[ml] / [min],49.3,41472,DB01435,Antipyrine
,3203041,clearance,"2. Mean clearance values for the complete study (48.0 ml min-1) were nearly identical to abbreviated approaches A, B, and C (49.1, 49.3, and 46.4 ml min-1), and were highly correlated (r = 0.99).",Simplified approaches to the determination of antipyrine pharmacokinetic parameters. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203041/),[ml] / [min],46.4,41473,DB01435,Antipyrine
,3203041,elimination half-life,"Overall mean values of elimination half-life (11.9, 12.1, 12.0 and 12.5 h) and volume of distribution (43.7, 45.1, 45.2, and 44.71) were likewise very similar for complete A, B and C analyses respectively.",Simplified approaches to the determination of antipyrine pharmacokinetic parameters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203041/),h,11.9,41474,DB01435,Antipyrine
,3203041,elimination half-life,"Overall mean values of elimination half-life (11.9, 12.1, 12.0 and 12.5 h) and volume of distribution (43.7, 45.1, 45.2, and 44.71) were likewise very similar for complete A, B and C analyses respectively.",Simplified approaches to the determination of antipyrine pharmacokinetic parameters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203041/),h,12.1,41475,DB01435,Antipyrine
,3203041,elimination half-life,"Overall mean values of elimination half-life (11.9, 12.1, 12.0 and 12.5 h) and volume of distribution (43.7, 45.1, 45.2, and 44.71) were likewise very similar for complete A, B and C analyses respectively.",Simplified approaches to the determination of antipyrine pharmacokinetic parameters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203041/),h,12.0,41476,DB01435,Antipyrine
,3203041,elimination half-life,"Overall mean values of elimination half-life (11.9, 12.1, 12.0 and 12.5 h) and volume of distribution (43.7, 45.1, 45.2, and 44.71) were likewise very similar for complete A, B and C analyses respectively.",Simplified approaches to the determination of antipyrine pharmacokinetic parameters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203041/),h,12.5,41477,DB01435,Antipyrine
,3203041,volume of distribution,"Overall mean values of elimination half-life (11.9, 12.1, 12.0 and 12.5 h) and volume of distribution (43.7, 45.1, 45.2, and 44.71) were likewise very similar for complete A, B and C analyses respectively.",Simplified approaches to the determination of antipyrine pharmacokinetic parameters. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203041/),,43.7,41478,DB01435,Antipyrine
,3203041,volume of distribution,"Overall mean values of elimination half-life (11.9, 12.1, 12.0 and 12.5 h) and volume of distribution (43.7, 45.1, 45.2, and 44.71) were likewise very similar for complete A, B and C analyses respectively.",Simplified approaches to the determination of antipyrine pharmacokinetic parameters. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203041/),,45.1,41479,DB01435,Antipyrine
,3203041,volume of distribution,"Overall mean values of elimination half-life (11.9, 12.1, 12.0 and 12.5 h) and volume of distribution (43.7, 45.1, 45.2, and 44.71) were likewise very similar for complete A, B and C analyses respectively.",Simplified approaches to the determination of antipyrine pharmacokinetic parameters. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203041/),,45.2,41480,DB01435,Antipyrine
,3203041,volume of distribution,"Overall mean values of elimination half-life (11.9, 12.1, 12.0 and 12.5 h) and volume of distribution (43.7, 45.1, 45.2, and 44.71) were likewise very similar for complete A, B and C analyses respectively.",Simplified approaches to the determination of antipyrine pharmacokinetic parameters. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203041/),,44.71,41481,DB01435,Antipyrine
,6131657,Peak alprazolam levels,Peak alprazolam levels averaged 20.4 ng/mL and were reached a mean of 1.25 hours after dosage.,Alprazolam kinetics in the elderly. Relation to antipyrine disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6131657/),[ng] / [ml],20.4,42024,DB01435,Antipyrine
,284720,biological half-life,"The average biological half-life after oral administration of 1 g paracetamol was significantly prolonged in patients with hepatic cirrhosis compared to the controls (3.7 hr vs.2.1 hr) and, correspondingly, the average plasma clearance was significantly reduced from 337 ml x min-1 in the controls to 162 ml x min-1 in the patients with cirrhosis of the liver.",Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/284720/),h,3.7,44120,DB01435,Antipyrine
,284720,biological half-life,"The average biological half-life after oral administration of 1 g paracetamol was significantly prolonged in patients with hepatic cirrhosis compared to the controls (3.7 hr vs.2.1 hr) and, correspondingly, the average plasma clearance was significantly reduced from 337 ml x min-1 in the controls to 162 ml x min-1 in the patients with cirrhosis of the liver.",Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/284720/),h,2.1,44121,DB01435,Antipyrine
,284720,plasma clearance,"The average biological half-life after oral administration of 1 g paracetamol was significantly prolonged in patients with hepatic cirrhosis compared to the controls (3.7 hr vs.2.1 hr) and, correspondingly, the average plasma clearance was significantly reduced from 337 ml x min-1 in the controls to 162 ml x min-1 in the patients with cirrhosis of the liver.",Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/284720/),[ml] / [min],337,44122,DB01435,Antipyrine
,284720,plasma clearance,"The average biological half-life after oral administration of 1 g paracetamol was significantly prolonged in patients with hepatic cirrhosis compared to the controls (3.7 hr vs.2.1 hr) and, correspondingly, the average plasma clearance was significantly reduced from 337 ml x min-1 in the controls to 162 ml x min-1 in the patients with cirrhosis of the liver.",Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/284720/),[ml] / [min],162,44123,DB01435,Antipyrine
,3709636,total clearance,"The elimination of mexiletine was markedly retarded in the cirrhotics, as indicated by its lower total clearance (2.31 vs. 8.27 ml/kg/h,) lower total elimination rate constant (0.059 vs 0.353 h-1), and longer elimination half-life (28.7 vs 9.9 h).",Cirrhosis of the liver markedly impairs the elimination of mexiletine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709636/),[ml] / [h·kg],2.31,44187,DB01435,Antipyrine
,3709636,total clearance,"The elimination of mexiletine was markedly retarded in the cirrhotics, as indicated by its lower total clearance (2.31 vs. 8.27 ml/kg/h,) lower total elimination rate constant (0.059 vs 0.353 h-1), and longer elimination half-life (28.7 vs 9.9 h).",Cirrhosis of the liver markedly impairs the elimination of mexiletine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709636/),[ml] / [h·kg],8.27,44188,DB01435,Antipyrine
,3709636,total elimination rate constant,"The elimination of mexiletine was markedly retarded in the cirrhotics, as indicated by its lower total clearance (2.31 vs. 8.27 ml/kg/h,) lower total elimination rate constant (0.059 vs 0.353 h-1), and longer elimination half-life (28.7 vs 9.9 h).",Cirrhosis of the liver markedly impairs the elimination of mexiletine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709636/),1/[h],0.059,44189,DB01435,Antipyrine
,3709636,total elimination rate constant,"The elimination of mexiletine was markedly retarded in the cirrhotics, as indicated by its lower total clearance (2.31 vs. 8.27 ml/kg/h,) lower total elimination rate constant (0.059 vs 0.353 h-1), and longer elimination half-life (28.7 vs 9.9 h).",Cirrhosis of the liver markedly impairs the elimination of mexiletine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709636/),1/[h],0.353,44190,DB01435,Antipyrine
,3709636,elimination half-life,"The elimination of mexiletine was markedly retarded in the cirrhotics, as indicated by its lower total clearance (2.31 vs. 8.27 ml/kg/h,) lower total elimination rate constant (0.059 vs 0.353 h-1), and longer elimination half-life (28.7 vs 9.9 h).",Cirrhosis of the liver markedly impairs the elimination of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709636/),h,28.7,44191,DB01435,Antipyrine
,3709636,elimination half-life,"The elimination of mexiletine was markedly retarded in the cirrhotics, as indicated by its lower total clearance (2.31 vs. 8.27 ml/kg/h,) lower total elimination rate constant (0.059 vs 0.353 h-1), and longer elimination half-life (28.7 vs 9.9 h).",Cirrhosis of the liver markedly impairs the elimination of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709636/),h,9.9,44192,DB01435,Antipyrine
,3709636,half-life,The antipyrine half-life was 38.3 h in the patients and 14.7 h in the controls.,Cirrhosis of the liver markedly impairs the elimination of mexiletine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709636/),h,38.3,44193,DB01435,Antipyrine
,3709636,half-life,The antipyrine half-life was 38.3 h in the patients and 14.7 h in the controls.,Cirrhosis of the liver markedly impairs the elimination of mexiletine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709636/),h,14.7,44194,DB01435,Antipyrine
,7370981,initial plasma t1/2,"After i.v. administration of HAQ at 15 mg/kg (300 mg/sq m), the initial plasma t1/2 of the agent was 9.4 min, and the terminal t1/2 was 115.2 min.","Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370981/),min,9.4,46535,DB01435,Antipyrine
,7370981,terminal t1/2,"After i.v. administration of HAQ at 15 mg/kg (300 mg/sq m), the initial plasma t1/2 of the agent was 9.4 min, and the terminal t1/2 was 115.2 min.","Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370981/),min,115.2,46536,DB01435,Antipyrine
,7370981,maximal plasma concentration,A maximal plasma concentration of 24.9 mg of HAQ per liter was attained.,"Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370981/),mg,24.9,46537,DB01435,Antipyrine
,7370981,plasma clearance,A high plasma clearance of 23.5 ml/kg/min was observed in these animals.,"Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370981/),[ml] / [kg·min],23.5,46538,DB01435,Antipyrine
,7370981,apparent volume of distribution,"The extrapolated apparent volume of distribution was 693.7 ml/kg, comparable to that of antipyrine in the dog.","Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7370981/),[ml] / [kg],693.7,46539,DB01435,Antipyrine
,7656504,plasma elimination half-life (t1/2),Mean plasma elimination half-life (t1/2) is between 1.3 and 2.1 hours in healthy volunteers.,Clinical pharmacokinetics of lansoprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7656504/),h,1.3 and 2.1,47682,DB01435,Antipyrine
,20110753,bioavailability,"On the other hand, bioavailability of oral mucosal, rectal and oral administration was about 100, 63.5 and 26.6%, respectively.",A novel administration route of edaravone--II: mucosal absorption of edaravone from edaravone/hydroxypropyl-beta-cyclodextrin complex solution including L-cysteine and sodium hydrogen sulfite. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110753/),%,100,49846,DB01435,Antipyrine
,20110753,bioavailability,"On the other hand, bioavailability of oral mucosal, rectal and oral administration was about 100, 63.5 and 26.6%, respectively.",A novel administration route of edaravone--II: mucosal absorption of edaravone from edaravone/hydroxypropyl-beta-cyclodextrin complex solution including L-cysteine and sodium hydrogen sulfite. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110753/),%,63.5,49847,DB01435,Antipyrine
,20110753,bioavailability,"On the other hand, bioavailability of oral mucosal, rectal and oral administration was about 100, 63.5 and 26.6%, respectively.",A novel administration route of edaravone--II: mucosal absorption of edaravone from edaravone/hydroxypropyl-beta-cyclodextrin complex solution including L-cysteine and sodium hydrogen sulfite. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110753/),%,26.6,49848,DB01435,Antipyrine
,1195128,systemic availability,"The systemic availability of antipyrine was not altered significantly by the surgical procedure whereas the availability of lidocaine and salicylamide, drugs with a marked first-pass effect, was increased from 14.8 +/- 2.8 to 81.3 +/- 5.2% and from 21.8 +/- 7.8 to 57.5 +/- 2.5%, respectively.",Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1195128/),%,14.8,51039,DB01435,Antipyrine
,1195128,availability,"The systemic availability of antipyrine was not altered significantly by the surgical procedure whereas the availability of lidocaine and salicylamide, drugs with a marked first-pass effect, was increased from 14.8 +/- 2.8 to 81.3 +/- 5.2% and from 21.8 +/- 7.8 to 57.5 +/- 2.5%, respectively.",Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1195128/),%,14.8,51040,DB01435,Antipyrine
,1195128,availability,"The systemic availability of antipyrine was not altered significantly by the surgical procedure whereas the availability of lidocaine and salicylamide, drugs with a marked first-pass effect, was increased from 14.8 +/- 2.8 to 81.3 +/- 5.2% and from 21.8 +/- 7.8 to 57.5 +/- 2.5%, respectively.",Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1195128/),%,81.3,51041,DB01435,Antipyrine
,1195128,availability,"The systemic availability of antipyrine was not altered significantly by the surgical procedure whereas the availability of lidocaine and salicylamide, drugs with a marked first-pass effect, was increased from 14.8 +/- 2.8 to 81.3 +/- 5.2% and from 21.8 +/- 7.8 to 57.5 +/- 2.5%, respectively.",Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1195128/),%,21.8,51042,DB01435,Antipyrine
,1195128,availability,"The systemic availability of antipyrine was not altered significantly by the surgical procedure whereas the availability of lidocaine and salicylamide, drugs with a marked first-pass effect, was increased from 14.8 +/- 2.8 to 81.3 +/- 5.2% and from 21.8 +/- 7.8 to 57.5 +/- 2.5%, respectively.",Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1195128/),%,57.5,51043,DB01435,Antipyrine
,3988389,half-life (t1/2),A prolongation in antipyrine half-life (t1/2) was observed in 108 patients with liver disease (24.59 +/- 1.72 h) as compared to 12 controls (11.63 +/- 0.86 h).,Impairment of drug elimination in patients with liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988389/),h,24.59,53228,DB01435,Antipyrine
,3988389,half-life (t1/2),A prolongation in antipyrine half-life (t1/2) was observed in 108 patients with liver disease (24.59 +/- 1.72 h) as compared to 12 controls (11.63 +/- 0.86 h).,Impairment of drug elimination in patients with liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988389/),h,11.63,53229,DB01435,Antipyrine
,27271368,mean residence time,The duration of ABT in mice was very short (mean residence time = 1.7 hours) after subcutaneous bolus administration.,Application of Osmotic Pumps for Sustained Release of 1-Aminobenzotriazole and Inhibition of Cytochrome P450 Enzymes in Mice: Model Comparison with the Hepatic P450 Reductase Null Mouse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27271368/),h,1.7,53302,DB01435,Antipyrine
,2612061,Ratios of clearance,"2. Ratios of clearance of PHT, p-OH-PHT and p-OH-PHT-glucuronide to clearance of antipyrine were 1.08 +/- 0.03, 0.52 +/- 0.02 and 0.12 +/- 0.01 (mean and s.e.m.), respectively.","Maternofetal transfer of phenytoin, p-hydroxy-phenytoin and p-hydroxy-phenytoin-glucuronide in the perfused human placenta. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612061/),,1.08,53357,DB01435,Antipyrine
,2612061,Ratios of clearance,"2. Ratios of clearance of PHT, p-OH-PHT and p-OH-PHT-glucuronide to clearance of antipyrine were 1.08 +/- 0.03, 0.52 +/- 0.02 and 0.12 +/- 0.01 (mean and s.e.m.), respectively.","Maternofetal transfer of phenytoin, p-hydroxy-phenytoin and p-hydroxy-phenytoin-glucuronide in the perfused human placenta. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612061/),,0.52,53358,DB01435,Antipyrine
,2612061,Ratios of clearance,"2. Ratios of clearance of PHT, p-OH-PHT and p-OH-PHT-glucuronide to clearance of antipyrine were 1.08 +/- 0.03, 0.52 +/- 0.02 and 0.12 +/- 0.01 (mean and s.e.m.), respectively.","Maternofetal transfer of phenytoin, p-hydroxy-phenytoin and p-hydroxy-phenytoin-glucuronide in the perfused human placenta. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612061/),,0.12,53359,DB01435,Antipyrine
,3402522,half-life,"In Type I diabetics, the half-life of AP was significantly reduced from 12.0 (controls) to 7.9 h, and the volume of distribution (V) was lowered from 733 to 569 ml.kg-1.",Differential effect of type I and type II diabetes on antipyrine disposition in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402522/),h,12.0,53585,DB01435,Antipyrine
,3402522,half-life,"In Type I diabetics, the half-life of AP was significantly reduced from 12.0 (controls) to 7.9 h, and the volume of distribution (V) was lowered from 733 to 569 ml.kg-1.",Differential effect of type I and type II diabetes on antipyrine disposition in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402522/),h,7.9,53586,DB01435,Antipyrine
,3402522,volume of distribution (V),"In Type I diabetics, the half-life of AP was significantly reduced from 12.0 (controls) to 7.9 h, and the volume of distribution (V) was lowered from 733 to 569 ml.kg-1.",Differential effect of type I and type II diabetes on antipyrine disposition in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402522/),[ml] / [kg],73,53587,DB01435,Antipyrine
,3402522,volume of distribution (V),"In Type I diabetics, the half-life of AP was significantly reduced from 12.0 (controls) to 7.9 h, and the volume of distribution (V) was lowered from 733 to 569 ml.kg-1.",Differential effect of type I and type II diabetes on antipyrine disposition in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402522/),[ml] / [kg],56,53588,DB01435,Antipyrine
,3402522,half-life,"In Type II diabetics, the AP half-life (14.5 h) and V (568 ml.kg-1) did not differ from their age- and sex-matched controls (11.1 h and 643 ml.kg-1, respectively), but the plasma clearance of AP was significantly reduced by 30%, and urinary excretion was significantly reduced to 44% of controls.",Differential effect of type I and type II diabetes on antipyrine disposition in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402522/),h,14.5,53589,DB01435,Antipyrine
,3402522,V,"In Type II diabetics, the AP half-life (14.5 h) and V (568 ml.kg-1) did not differ from their age- and sex-matched controls (11.1 h and 643 ml.kg-1, respectively), but the plasma clearance of AP was significantly reduced by 30%, and urinary excretion was significantly reduced to 44% of controls.",Differential effect of type I and type II diabetes on antipyrine disposition in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402522/),[ml] / [kg],568,53590,DB01435,Antipyrine
,3402522,V,"In Type II diabetics, the AP half-life (14.5 h) and V (568 ml.kg-1) did not differ from their age- and sex-matched controls (11.1 h and 643 ml.kg-1, respectively), but the plasma clearance of AP was significantly reduced by 30%, and urinary excretion was significantly reduced to 44% of controls.",Differential effect of type I and type II diabetes on antipyrine disposition in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402522/),h,11.1,53591,DB01435,Antipyrine
,3402522,V,"In Type II diabetics, the AP half-life (14.5 h) and V (568 ml.kg-1) did not differ from their age- and sex-matched controls (11.1 h and 643 ml.kg-1, respectively), but the plasma clearance of AP was significantly reduced by 30%, and urinary excretion was significantly reduced to 44% of controls.",Differential effect of type I and type II diabetes on antipyrine disposition in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402522/),[ml] / [kg],643,53592,DB01435,Antipyrine
,2312782,apparent oral clearance,"Mean serum concentrations, apparent oral clearance (1.93 +/- 0.86 vs 2.06 +/- 1.06 L/hr with quinidine) and half-life (13.5 +/- 3.3 vs 12.4 +/- 3.6 hr with quinidine) were not significantly different between the two treatments.",Quinidine does not alter antipyrine metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312782/),[l] / [h],1.93,55170,DB01435,Antipyrine
,2312782,apparent oral clearance,"Mean serum concentrations, apparent oral clearance (1.93 +/- 0.86 vs 2.06 +/- 1.06 L/hr with quinidine) and half-life (13.5 +/- 3.3 vs 12.4 +/- 3.6 hr with quinidine) were not significantly different between the two treatments.",Quinidine does not alter antipyrine metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312782/),[l] / [h],2.06,55171,DB01435,Antipyrine
,2312782,half-life,"Mean serum concentrations, apparent oral clearance (1.93 +/- 0.86 vs 2.06 +/- 1.06 L/hr with quinidine) and half-life (13.5 +/- 3.3 vs 12.4 +/- 3.6 hr with quinidine) were not significantly different between the two treatments.",Quinidine does not alter antipyrine metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312782/),h,13.5,55172,DB01435,Antipyrine
,2312782,half-life,"Mean serum concentrations, apparent oral clearance (1.93 +/- 0.86 vs 2.06 +/- 1.06 L/hr with quinidine) and half-life (13.5 +/- 3.3 vs 12.4 +/- 3.6 hr with quinidine) were not significantly different between the two treatments.",Quinidine does not alter antipyrine metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312782/),h,12.4,55173,DB01435,Antipyrine
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),min,0.52,55195,DB01435,Antipyrine
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),min,1.30,55196,DB01435,Antipyrine
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),min,2.37,55197,DB01435,Antipyrine
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),min,3.57,55198,DB01435,Antipyrine
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),min,4.43,55199,DB01435,Antipyrine
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),,1.01,55200,DB01435,Antipyrine
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),,1.03,55201,DB01435,Antipyrine
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),,0.95,55202,DB01435,Antipyrine
,17674247,Differential transport rate,"Differential transport rate of methotrexate for 10, 25, 50, 75 and 90% efflux fractions in fetal venous effluent averaged 0.52, 1.30, 2.37, 3.57 and 4.43 minutes in 12 perfusions, representing 1.01 + 0.08, 1.03 + 0.06, 0.95 + 0.03, 0.93 + 0.03, 0.93 + 0.03 respectively times antipyrine reference value.",Maternal-fetal transport kinetics of methotrexate in perfused human placenta: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674247/),,0.93,55203,DB01435,Antipyrine
higher,18570312,Recovery rates,Recovery rates were higher than 95% and the quantification limit was 2.5-ng/ml plasma for both enantiomers.,Determination of cyclophosphamide enantiomers in plasma by LC-MS/MS: Application to pharmacokinetics in breast cancer and lupus nephritis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18570312/),%,95,55287,DB01435,Antipyrine
,18570312,Clearance,"Clearance values of 2.63 and 2.93 l/h and of 3.36 and 3.61 l/h for (-)-(S) and (+)-(R)-CPA were obtained for the breast cancer and lupus nephritis patient, respectively.",Determination of cyclophosphamide enantiomers in plasma by LC-MS/MS: Application to pharmacokinetics in breast cancer and lupus nephritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18570312/),[l] / [h],2.63,55288,DB01435,Antipyrine
,18570312,Clearance,"Clearance values of 2.63 and 2.93 l/h and of 3.36 and 3.61 l/h for (-)-(S) and (+)-(R)-CPA were obtained for the breast cancer and lupus nephritis patient, respectively.",Determination of cyclophosphamide enantiomers in plasma by LC-MS/MS: Application to pharmacokinetics in breast cancer and lupus nephritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18570312/),[l] / [h],2.93,55289,DB01435,Antipyrine
,18570312,Clearance,"Clearance values of 2.63 and 2.93 l/h and of 3.36 and 3.61 l/h for (-)-(S) and (+)-(R)-CPA were obtained for the breast cancer and lupus nephritis patient, respectively.",Determination of cyclophosphamide enantiomers in plasma by LC-MS/MS: Application to pharmacokinetics in breast cancer and lupus nephritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18570312/),[l] / [h],3.36,55290,DB01435,Antipyrine
,18570312,Clearance,"Clearance values of 2.63 and 2.93 l/h and of 3.36 and 3.61 l/h for (-)-(S) and (+)-(R)-CPA were obtained for the breast cancer and lupus nephritis patient, respectively.",Determination of cyclophosphamide enantiomers in plasma by LC-MS/MS: Application to pharmacokinetics in breast cancer and lupus nephritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18570312/),[l] / [h],3.61,55291,DB01435,Antipyrine
,2868864,t1/2,The second rate constant did not represent the accumulation or persistence of rifampin (t1/2 = 4.4 hr).,The kinetics of induction by rifampin of alpha 1-acid glycoprotein and antipyrine clearance in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2868864/),h,4.4,55477,DB01435,Antipyrine
,3568541,half life,"Propylene glycol had no effect on antipyrine half life (11.7 hours control vs. 12.1 hours treatment), clearance (42.6 vs. 39.2 ml/min), or volume of distribution (42.1 vs 41.9 L).",The effect of propylene glycol on antipyrine clearance in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3568541/),h,11.7,56260,DB01435,Antipyrine
,3568541,half life,"Propylene glycol had no effect on antipyrine half life (11.7 hours control vs. 12.1 hours treatment), clearance (42.6 vs. 39.2 ml/min), or volume of distribution (42.1 vs 41.9 L).",The effect of propylene glycol on antipyrine clearance in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3568541/),h,12.1,56261,DB01435,Antipyrine
,3568541,clearance,"Propylene glycol had no effect on antipyrine half life (11.7 hours control vs. 12.1 hours treatment), clearance (42.6 vs. 39.2 ml/min), or volume of distribution (42.1 vs 41.9 L).",The effect of propylene glycol on antipyrine clearance in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3568541/),[ml] / [min],42.6,56262,DB01435,Antipyrine
,3568541,clearance,"Propylene glycol had no effect on antipyrine half life (11.7 hours control vs. 12.1 hours treatment), clearance (42.6 vs. 39.2 ml/min), or volume of distribution (42.1 vs 41.9 L).",The effect of propylene glycol on antipyrine clearance in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3568541/),[ml] / [min],39.2,56263,DB01435,Antipyrine
,3568541,volume of distribution,"Propylene glycol had no effect on antipyrine half life (11.7 hours control vs. 12.1 hours treatment), clearance (42.6 vs. 39.2 ml/min), or volume of distribution (42.1 vs 41.9 L).",The effect of propylene glycol on antipyrine clearance in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3568541/),l,42.1,56264,DB01435,Antipyrine
,3568541,volume of distribution,"Propylene glycol had no effect on antipyrine half life (11.7 hours control vs. 12.1 hours treatment), clearance (42.6 vs. 39.2 ml/min), or volume of distribution (42.1 vs 41.9 L).",The effect of propylene glycol on antipyrine clearance in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3568541/),l,41.9,56265,DB01435,Antipyrine
,3392245,volume of distribution,"Mean +/- SE pharmacokinetic variables in control and conjugated-estrogen groups were volume of distribution, 0.57 +/- 0.02 versus 0.56 +/- 0.02 L/kg; elimination half-life, 11.0 +/- 0.82 versus 12.6 +/- 0.89 hours; and clearance, 0.63 +/- 0.06 versus 0.54 +/- 0.03 mL/min/kg.",Antipyrine pharmacokinetics in women receiving conjugated estrogens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392245/),[l] / [kg],0.57,56321,DB01435,Antipyrine
,3392245,volume of distribution,"Mean +/- SE pharmacokinetic variables in control and conjugated-estrogen groups were volume of distribution, 0.57 +/- 0.02 versus 0.56 +/- 0.02 L/kg; elimination half-life, 11.0 +/- 0.82 versus 12.6 +/- 0.89 hours; and clearance, 0.63 +/- 0.06 versus 0.54 +/- 0.03 mL/min/kg.",Antipyrine pharmacokinetics in women receiving conjugated estrogens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392245/),[l] / [kg],0.56,56322,DB01435,Antipyrine
,3392245,elimination half-life,"Mean +/- SE pharmacokinetic variables in control and conjugated-estrogen groups were volume of distribution, 0.57 +/- 0.02 versus 0.56 +/- 0.02 L/kg; elimination half-life, 11.0 +/- 0.82 versus 12.6 +/- 0.89 hours; and clearance, 0.63 +/- 0.06 versus 0.54 +/- 0.03 mL/min/kg.",Antipyrine pharmacokinetics in women receiving conjugated estrogens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392245/),h,11.0,56323,DB01435,Antipyrine
,3392245,elimination half-life,"Mean +/- SE pharmacokinetic variables in control and conjugated-estrogen groups were volume of distribution, 0.57 +/- 0.02 versus 0.56 +/- 0.02 L/kg; elimination half-life, 11.0 +/- 0.82 versus 12.6 +/- 0.89 hours; and clearance, 0.63 +/- 0.06 versus 0.54 +/- 0.03 mL/min/kg.",Antipyrine pharmacokinetics in women receiving conjugated estrogens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392245/),h,12.6,56324,DB01435,Antipyrine
,3392245,clearance,"Mean +/- SE pharmacokinetic variables in control and conjugated-estrogen groups were volume of distribution, 0.57 +/- 0.02 versus 0.56 +/- 0.02 L/kg; elimination half-life, 11.0 +/- 0.82 versus 12.6 +/- 0.89 hours; and clearance, 0.63 +/- 0.06 versus 0.54 +/- 0.03 mL/min/kg.",Antipyrine pharmacokinetics in women receiving conjugated estrogens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392245/),[ml] / [kg·min],0.63,56325,DB01435,Antipyrine
,3392245,clearance,"Mean +/- SE pharmacokinetic variables in control and conjugated-estrogen groups were volume of distribution, 0.57 +/- 0.02 versus 0.56 +/- 0.02 L/kg; elimination half-life, 11.0 +/- 0.82 versus 12.6 +/- 0.89 hours; and clearance, 0.63 +/- 0.06 versus 0.54 +/- 0.03 mL/min/kg.",Antipyrine pharmacokinetics in women receiving conjugated estrogens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392245/),[ml] / [kg·min],0.54,56326,DB01435,Antipyrine
,4205524,total hepatic blood flow,Phenobarbital significantly increased total hepatic blood flow from 179+/-15 to 239+/-27 ml/min.,Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4205524/),[ml] / [min],179,56651,DB01435,Antipyrine
,4205524,total hepatic blood flow,Phenobarbital significantly increased total hepatic blood flow from 179+/-15 to 239+/-27 ml/min.,Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4205524/),[ml] / [min],239,56652,DB01435,Antipyrine
,9091249,Cytochrome P450 content,Cytochrome P450 content in subjects from 20 to 29 years of age was 7.2 +/- 2.6 nmol.,Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9091249/),nM,7.2,56892,DB01435,Antipyrine
,9091249,clearance rate,"The antipyrine (phenazone) clearance rate in young subjects was 46.4 +/- 18.5 ml.min-1, remained unaltered during the fourth decade, and declined after 40 years by a rate of 0.34 ml.min-1 per year toward old age (-29%, p < 0.001).",Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9091249/),[ml] / [min],46.4,56893,DB01435,Antipyrine
,9091249,half-life,"The half-life in young subjects was 9.5 +/- 2.0 hours and increased after 30 years toward old age (+26%, p < 0.001).",Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9091249/),h,9.5,56894,DB01435,Antipyrine
,9091249,volume of anti,"The volume of antipyrine distribution, 0.46 +/- 0.12 L.kg-1 in young subjects, decreased after 30 years (-11%).",Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9091249/),[l] / [kg],0.46,56895,DB01435,Antipyrine
,2824523,t1/2term,"Unlike adriamycin and antipyrine, adriamycinol was found to have a significantly longer t1/2term (60.5 vs 28.3 h, P less than 0.001), an increased AUC (3.00 vs 1.43 h/ug per ml, P less than 0.02), and a higher AUCadriamycinol/AUCadriamycin ratio (0.94 vs 0.52, P less than 0.02) in patients with moderate tumor involvement of the liver.","Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2824523/),h,60.5,57138,DB01435,Antipyrine
,2824523,t1/2term,"Unlike adriamycin and antipyrine, adriamycinol was found to have a significantly longer t1/2term (60.5 vs 28.3 h, P less than 0.001), an increased AUC (3.00 vs 1.43 h/ug per ml, P less than 0.02), and a higher AUCadriamycinol/AUCadriamycin ratio (0.94 vs 0.52, P less than 0.02) in patients with moderate tumor involvement of the liver.","Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2824523/),h,28.3,57139,DB01435,Antipyrine
,2824523,AUC,"Unlike adriamycin and antipyrine, adriamycinol was found to have a significantly longer t1/2term (60.5 vs 28.3 h, P less than 0.001), an increased AUC (3.00 vs 1.43 h/ug per ml, P less than 0.02), and a higher AUCadriamycinol/AUCadriamycin ratio (0.94 vs 0.52, P less than 0.02) in patients with moderate tumor involvement of the liver.","Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2824523/),[h] / [ml·ug],3.00,57140,DB01435,Antipyrine
,2824523,AUC,"Unlike adriamycin and antipyrine, adriamycinol was found to have a significantly longer t1/2term (60.5 vs 28.3 h, P less than 0.001), an increased AUC (3.00 vs 1.43 h/ug per ml, P less than 0.02), and a higher AUCadriamycinol/AUCadriamycin ratio (0.94 vs 0.52, P less than 0.02) in patients with moderate tumor involvement of the liver.","Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2824523/),[h] / [ml·ug],1.43,57141,DB01435,Antipyrine
,2824523,AUCadriamycinol/AUCadriamycin ratio,"Unlike adriamycin and antipyrine, adriamycinol was found to have a significantly longer t1/2term (60.5 vs 28.3 h, P less than 0.001), an increased AUC (3.00 vs 1.43 h/ug per ml, P less than 0.02), and a higher AUCadriamycinol/AUCadriamycin ratio (0.94 vs 0.52, P less than 0.02) in patients with moderate tumor involvement of the liver.","Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2824523/),,0.94,57142,DB01435,Antipyrine
,2824523,AUCadriamycinol/AUCadriamycin ratio,"Unlike adriamycin and antipyrine, adriamycinol was found to have a significantly longer t1/2term (60.5 vs 28.3 h, P less than 0.001), an increased AUC (3.00 vs 1.43 h/ug per ml, P less than 0.02), and a higher AUCadriamycinol/AUCadriamycin ratio (0.94 vs 0.52, P less than 0.02) in patients with moderate tumor involvement of the liver.","Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2824523/),,0.52,57143,DB01435,Antipyrine
,10985077,t1/2,"In comparison to the rats without CCl4 intoxication (t1/2: 2.2 +/- 0.9 h; Cl/F: 0.30 +/- 0.01 L/h/Kg; P450: 0.611 +/- 0.190 nmol/mg protein), CCl4 administration significantly decreased elimination (t1/2: 12.0 +/- 3.9 h) and oral clearance (Cl/F: 0.049 +/- 0.018 L/h/kg) of antipyrine, and markedly reduced the content of P450 (0.075 +/- 0.011 nmol/mg protein).",Improvement of phase I drug metabolism with Schisandra chinensis against CCl4 hepatotoxicity in a rat model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10985077/),h,2.2,58147,DB01435,Antipyrine
,10985077,Cl/F,"In comparison to the rats without CCl4 intoxication (t1/2: 2.2 +/- 0.9 h; Cl/F: 0.30 +/- 0.01 L/h/Kg; P450: 0.611 +/- 0.190 nmol/mg protein), CCl4 administration significantly decreased elimination (t1/2: 12.0 +/- 3.9 h) and oral clearance (Cl/F: 0.049 +/- 0.018 L/h/kg) of antipyrine, and markedly reduced the content of P450 (0.075 +/- 0.011 nmol/mg protein).",Improvement of phase I drug metabolism with Schisandra chinensis against CCl4 hepatotoxicity in a rat model. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10985077/),[l] / [h·kg],0.30,58148,DB01435,Antipyrine
,10985077,P450,"In comparison to the rats without CCl4 intoxication (t1/2: 2.2 +/- 0.9 h; Cl/F: 0.30 +/- 0.01 L/h/Kg; P450: 0.611 +/- 0.190 nmol/mg protein), CCl4 administration significantly decreased elimination (t1/2: 12.0 +/- 3.9 h) and oral clearance (Cl/F: 0.049 +/- 0.018 L/h/kg) of antipyrine, and markedly reduced the content of P450 (0.075 +/- 0.011 nmol/mg protein).",Improvement of phase I drug metabolism with Schisandra chinensis against CCl4 hepatotoxicity in a rat model. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10985077/),[nM] / [mg],0.611,58149,DB01435,Antipyrine
,10985077,elimination (t1/2,"In comparison to the rats without CCl4 intoxication (t1/2: 2.2 +/- 0.9 h; Cl/F: 0.30 +/- 0.01 L/h/Kg; P450: 0.611 +/- 0.190 nmol/mg protein), CCl4 administration significantly decreased elimination (t1/2: 12.0 +/- 3.9 h) and oral clearance (Cl/F: 0.049 +/- 0.018 L/h/kg) of antipyrine, and markedly reduced the content of P450 (0.075 +/- 0.011 nmol/mg protein).",Improvement of phase I drug metabolism with Schisandra chinensis against CCl4 hepatotoxicity in a rat model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10985077/),h,12.0,58150,DB01435,Antipyrine
,10985077,oral clearance (Cl/F,"In comparison to the rats without CCl4 intoxication (t1/2: 2.2 +/- 0.9 h; Cl/F: 0.30 +/- 0.01 L/h/Kg; P450: 0.611 +/- 0.190 nmol/mg protein), CCl4 administration significantly decreased elimination (t1/2: 12.0 +/- 3.9 h) and oral clearance (Cl/F: 0.049 +/- 0.018 L/h/kg) of antipyrine, and markedly reduced the content of P450 (0.075 +/- 0.011 nmol/mg protein).",Improvement of phase I drug metabolism with Schisandra chinensis against CCl4 hepatotoxicity in a rat model. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10985077/),[l] / [h·kg],0.049,58151,DB01435,Antipyrine
,10985077,t1/2,"Data obtained from intoxicated animals treated by Schisandra extract, compared to those without treatment, showed significant (p < 0.05) improvement in the t1/2 (4.45 +/- 1.7 h) and Cl/F (0.096 +/- 0.018 ml/h) estimates of antipyrine and a 2-3 fold increase in P450 level (0.190 +/- 0.072 nmol/mg protein).",Improvement of phase I drug metabolism with Schisandra chinensis against CCl4 hepatotoxicity in a rat model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10985077/),h,4.45,58152,DB01435,Antipyrine
,10985077,Cl/F,"Data obtained from intoxicated animals treated by Schisandra extract, compared to those without treatment, showed significant (p < 0.05) improvement in the t1/2 (4.45 +/- 1.7 h) and Cl/F (0.096 +/- 0.018 ml/h) estimates of antipyrine and a 2-3 fold increase in P450 level (0.190 +/- 0.072 nmol/mg protein).",Improvement of phase I drug metabolism with Schisandra chinensis against CCl4 hepatotoxicity in a rat model. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10985077/),[ml] / [h],0.096,58153,DB01435,Antipyrine
,10985077,P450 level,"Data obtained from intoxicated animals treated by Schisandra extract, compared to those without treatment, showed significant (p < 0.05) improvement in the t1/2 (4.45 +/- 1.7 h) and Cl/F (0.096 +/- 0.018 ml/h) estimates of antipyrine and a 2-3 fold increase in P450 level (0.190 +/- 0.072 nmol/mg protein).",Improvement of phase I drug metabolism with Schisandra chinensis against CCl4 hepatotoxicity in a rat model. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10985077/),[nM] / [mg],0.190,58154,DB01435,Antipyrine
,7460483,clearance,"No differences were observed in cimetidine clearance between the group with peptic ulcer (556 +/- 44 ml/min, mean +/- SEM) and the group with cirrhosis (606 +/- 64 ml/min).",Cimetidine clearance and bioavailability in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460483/),[ml] / [min],556,58399,DB01435,Antipyrine
,7460483,clearance,"No differences were observed in cimetidine clearance between the group with peptic ulcer (556 +/- 44 ml/min, mean +/- SEM) and the group with cirrhosis (606 +/- 64 ml/min).",Cimetidine clearance and bioavailability in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460483/),[ml] / [min],606,58400,DB01435,Antipyrine
,7460483,bioavailability,The bioavailability of cimetidine was unchanged (84 +/- 4% and 97 +/- 7%).,Cimetidine clearance and bioavailability in hepatic cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460483/),%,84,58401,DB01435,Antipyrine
,7460483,bioavailability,The bioavailability of cimetidine was unchanged (84 +/- 4% and 97 +/- 7%).,Cimetidine clearance and bioavailability in hepatic cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460483/),%,97,58402,DB01435,Antipyrine
,1823403,desaggregation time,"This tablets had a spongy aspect, with a desaggregation time of 1-2 min.; the latter (classic tablets) were regularly and the desaggregation time in about 9 min.",[Formulations and bioavailability of propyphenazone in lyophilized tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823403/),min,1-2,60503,DB01435,Antipyrine
,1823403,desaggregation time,"This tablets had a spongy aspect, with a desaggregation time of 1-2 min.; the latter (classic tablets) were regularly and the desaggregation time in about 9 min.",[Formulations and bioavailability of propyphenazone in lyophilized tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823403/),min,9,60504,DB01435,Antipyrine
,3602088,clearance,"Results showed that mean (+/- SD, n = 3) acetaminophen clearance was similar in both horses (4.84 +/- 0.637 ml/min/kg) and humans (4.68 +/- 0.691 ml/min/kg).",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],4.84,61109,DB01435,Antipyrine
,3602088,clearance,"Results showed that mean (+/- SD, n = 3) acetaminophen clearance was similar in both horses (4.84 +/- 0.637 ml/min/kg) and humans (4.68 +/- 0.691 ml/min/kg).",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],4.68,61110,DB01435,Antipyrine
,3602088,clearance,"However, antipyrine clearance was 10 times greater in horses (5.83 +/- 2.21 ml/min/kg) than in humans (0.536 +/- 0.110 ml/min/kg), which may reflect enhanced hepatic microsomal activity in horses.",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],5.83,61111,DB01435,Antipyrine
,3602088,clearance,"However, antipyrine clearance was 10 times greater in horses (5.83 +/- 2.21 ml/min/kg) than in humans (0.536 +/- 0.110 ml/min/kg), which may reflect enhanced hepatic microsomal activity in horses.",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],0.536,61112,DB01435,Antipyrine
,3602088,clearance,"Although lidocaine clearance in humans was similar to estimated hepatic blood flow (20.6 +/- 5.81 ml/min/kg), clearance in horses was more than 2 times greater (52.0 +/- 11.7 ml/min/kg).",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],20.6,61113,DB01435,Antipyrine
,3602088,clearance,"Although lidocaine clearance in humans was similar to estimated hepatic blood flow (20.6 +/- 5.81 ml/min/kg), clearance in horses was more than 2 times greater (52.0 +/- 11.7 ml/min/kg).",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],52.0,61114,DB01435,Antipyrine
,3508566,clearance,"The oral administration of hydralazine hydrochloride, 7.5 mg/kg, 15 min prior to antipyrine administration reduced antipyrine clearance from 9.66 +/- 1.18 to 8.19 +/- 0.76 ml/min/kg (P less than 0.05).",Effect of hydralazine on the elimination of antipyrine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508566/),[ml] / [kg·min],9.66,61364,DB01435,Antipyrine
,3508566,clearance,"The oral administration of hydralazine hydrochloride, 7.5 mg/kg, 15 min prior to antipyrine administration reduced antipyrine clearance from 9.66 +/- 1.18 to 8.19 +/- 0.76 ml/min/kg (P less than 0.05).",Effect of hydralazine on the elimination of antipyrine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508566/),[ml] / [kg·min],8.19,61365,DB01435,Antipyrine
,3956050,half-life,"In the 6 women studied prospectively the mean salivary antipyrine half-life was 14.91 +/- 1.5 hours (SEM) before administering the injection, and 13.56 +/- 0.73 at 2 weeks, 15.13 +/- 1.86 at 8 weeks and 15.21 +/- 2.46 hours at 12 weeks after the injection.",Salivary antipyrine half-life during injectable progestagen contraception. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956050/),h,14.91,61629,DB01435,Antipyrine
,3956050,half-life,"In the 6 women studied prospectively the mean salivary antipyrine half-life was 14.91 +/- 1.5 hours (SEM) before administering the injection, and 13.56 +/- 0.73 at 2 weeks, 15.13 +/- 1.86 at 8 weeks and 15.21 +/- 2.46 hours at 12 weeks after the injection.",Salivary antipyrine half-life during injectable progestagen contraception. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956050/),,13.56,61630,DB01435,Antipyrine
,3956050,half-life,"In the 6 women studied prospectively the mean salivary antipyrine half-life was 14.91 +/- 1.5 hours (SEM) before administering the injection, and 13.56 +/- 0.73 at 2 weeks, 15.13 +/- 1.86 at 8 weeks and 15.21 +/- 2.46 hours at 12 weeks after the injection.",Salivary antipyrine half-life during injectable progestagen contraception. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956050/),h,15.13,61631,DB01435,Antipyrine
,3956050,half-life,"In the 6 women studied prospectively the mean salivary antipyrine half-life was 14.91 +/- 1.5 hours (SEM) before administering the injection, and 13.56 +/- 0.73 at 2 weeks, 15.13 +/- 1.86 at 8 weeks and 15.21 +/- 2.46 hours at 12 weeks after the injection.",Salivary antipyrine half-life during injectable progestagen contraception. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956050/),h,15.21,61632,DB01435,Antipyrine
,3956050,half-life,The mean antipyrine half-life in the 5 long term users of injectable progestagen was 14.21 +/- 2.53 hours compared with 13.66 +/- 0.98 hours in non-users.,Salivary antipyrine half-life during injectable progestagen contraception. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956050/),h,14.21,61633,DB01435,Antipyrine
,3956050,half-life,The mean antipyrine half-life in the 5 long term users of injectable progestagen was 14.21 +/- 2.53 hours compared with 13.66 +/- 0.98 hours in non-users.,Salivary antipyrine half-life during injectable progestagen contraception. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956050/),h,13.66,61634,DB01435,Antipyrine
,7826682,clearance,2. The mean +/- SD of the antipyrine clearance was 2.4 +/- 1.1 h-1 (range 1.0-5.5 l h-1) and the corresponding value per kg body weight was 0.6 +/- 0.2 ml min-1 kg-1.,Elimination studies of antipyrine and its metabolites in healthy Saudi Arabians. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826682/),1/[h],2.4,62478,DB01435,Antipyrine
,7826682,clearance,2. The mean +/- SD of the antipyrine clearance was 2.4 +/- 1.1 h-1 (range 1.0-5.5 l h-1) and the corresponding value per kg body weight was 0.6 +/- 0.2 ml min-1 kg-1.,Elimination studies of antipyrine and its metabolites in healthy Saudi Arabians. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826682/),[ml] / [kg·min],0.6,62479,DB01435,Antipyrine
,7826682,Urinary excretion,"Urinary excretion of antipyrine (AP), 4-OH AP, NOR AP and 3-OHM AP expressed as a percentage of the oral dose of antipyrine given was 2.8 +/- 2.2, 14.5 +/- 6.9, 12.3 +/- 5.6 and 7.6 +/- 3.2 respectively.",Elimination studies of antipyrine and its metabolites in healthy Saudi Arabians. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826682/),,2.8,62480,DB01435,Antipyrine
,7826682,Urinary excretion,"Urinary excretion of antipyrine (AP), 4-OH AP, NOR AP and 3-OHM AP expressed as a percentage of the oral dose of antipyrine given was 2.8 +/- 2.2, 14.5 +/- 6.9, 12.3 +/- 5.6 and 7.6 +/- 3.2 respectively.",Elimination studies of antipyrine and its metabolites in healthy Saudi Arabians. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826682/),,14.5,62481,DB01435,Antipyrine
,7826682,Urinary excretion,"Urinary excretion of antipyrine (AP), 4-OH AP, NOR AP and 3-OHM AP expressed as a percentage of the oral dose of antipyrine given was 2.8 +/- 2.2, 14.5 +/- 6.9, 12.3 +/- 5.6 and 7.6 +/- 3.2 respectively.",Elimination studies of antipyrine and its metabolites in healthy Saudi Arabians. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826682/),,12.3,62482,DB01435,Antipyrine
,7826682,Urinary excretion,"Urinary excretion of antipyrine (AP), 4-OH AP, NOR AP and 3-OHM AP expressed as a percentage of the oral dose of antipyrine given was 2.8 +/- 2.2, 14.5 +/- 6.9, 12.3 +/- 5.6 and 7.6 +/- 3.2 respectively.",Elimination studies of antipyrine and its metabolites in healthy Saudi Arabians. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826682/),,7.6,62483,DB01435,Antipyrine
,30481645,IC50,"According to AChE enzyme inhibition assay, compounds 3e and 3g were found as the most potent derivatives with IC50 values of 0.285 µM and 0.057 µM, respectively.",Synthesis and biological evaluation of new pyrazolone Schiff bases as monoamine oxidase and cholinesterase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30481645/),μM,0.285,63266,DB01435,Antipyrine
,30481645,IC50,"According to AChE enzyme inhibition assay, compounds 3e and 3g were found as the most potent derivatives with IC50 values of 0.285 µM and 0.057 µM, respectively.",Synthesis and biological evaluation of new pyrazolone Schiff bases as monoamine oxidase and cholinesterase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30481645/),μM,0.057,63267,DB01435,Antipyrine
,30481645,IC50,"Also, compounds 3a (IC50 = 0.114 µM), 3h (IC50 = 0.049 µM), and 3i (IC50 = 0.054 µM) were the most active derivatives against MAO-B enzyme activity.",Synthesis and biological evaluation of new pyrazolone Schiff bases as monoamine oxidase and cholinesterase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30481645/),μM,0.114,63268,DB01435,Antipyrine
,30481645,IC50,"Also, compounds 3a (IC50 = 0.114 µM), 3h (IC50 = 0.049 µM), and 3i (IC50 = 0.054 µM) were the most active derivatives against MAO-B enzyme activity.",Synthesis and biological evaluation of new pyrazolone Schiff bases as monoamine oxidase and cholinesterase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30481645/),μM,0.049,63269,DB01435,Antipyrine
,30481645,IC50,"Also, compounds 3a (IC50 = 0.114 µM), 3h (IC50 = 0.049 µM), and 3i (IC50 = 0.054 µM) were the most active derivatives against MAO-B enzyme activity.",Synthesis and biological evaluation of new pyrazolone Schiff bases as monoamine oxidase and cholinesterase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30481645/),μM,0.054,63270,DB01435,Antipyrine
,8690814,absolute bioavailability,"After a single, oral dose of ondansetron, mean absolute bioavailability increased markedly with increased hepatic insufficiency (approaching 100% in the group with severe hepatic impairment versus 66% for control subjects).",Pharmacokinetics of ondansetron in patients with hepatic insufficiency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690814/),%,100,64283,DB01435,Antipyrine
,8690814,absolute bioavailability,"After a single, oral dose of ondansetron, mean absolute bioavailability increased markedly with increased hepatic insufficiency (approaching 100% in the group with severe hepatic impairment versus 66% for control subjects).",Pharmacokinetics of ondansetron in patients with hepatic insufficiency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690814/),%,66,64284,DB01435,Antipyrine
,849678,elimination half-life,The average elimination half-life of hexobarbital had decreased from 407 to 171 min and its metabolic clearance had increased almost threefold.,Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/849678/),min,407 to 171,65632,DB01435,Antipyrine
,849678,elimination half-life,"In contrast, the average elimination half-life of antipyrine was virtually the same on both occasions (6.9 and 7.2 hr) and there was no change in metabolic clearance.",Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/849678/),h,6.9,65633,DB01435,Antipyrine
,849678,elimination half-life,"In contrast, the average elimination half-life of antipyrine was virtually the same on both occasions (6.9 and 7.2 hr) and there was no change in metabolic clearance.",Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/849678/),h,7.2,65634,DB01435,Antipyrine
,2565205,absolute bioavailability,"Despite complete AP absorption, absolute bioavailability of AP was 78 +/- 12% under basal conditions, suggesting that AP does undergo some degree of presystemic elimination, approximately 22%.",On the antipyrine test in laboratory animals. Studies in the dog and monkey. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565205/),%,78,65736,DB01435,Antipyrine
,2565205,bioavailability,"After PB administration of 20 mg/kg/day for 9 days, po, AP bioavailability decreased to 60 +/- 14%.",On the antipyrine test in laboratory animals. Studies in the dog and monkey. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565205/),%,60,65737,DB01435,Antipyrine
,2565205,systemic clearance,The systemic clearance of AP increased from 9.4 +/- 2.3 ml/min/kg under basal conditions to 27.5 +/- 4.6 ml/min/kg following PB.,On the antipyrine test in laboratory animals. Studies in the dog and monkey. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565205/),[ml] / [kg·min],9.4,65738,DB01435,Antipyrine
,2565205,systemic clearance,The systemic clearance of AP increased from 9.4 +/- 2.3 ml/min/kg under basal conditions to 27.5 +/- 4.6 ml/min/kg following PB.,On the antipyrine test in laboratory animals. Studies in the dog and monkey. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565205/),[ml] / [kg·min],27.5,65739,DB01435,Antipyrine
,2565205,half-life,"PB decreased mean plasma AP half-life from 71.5 min under basal conditions to 27.7 min, and mean hepatic blood flow increased from 0.49 liters/min to 0.63 liters/min.",On the antipyrine test in laboratory animals. Studies in the dog and monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565205/),min,71.5,65740,DB01435,Antipyrine
,2565205,half-life,"PB decreased mean plasma AP half-life from 71.5 min under basal conditions to 27.7 min, and mean hepatic blood flow increased from 0.49 liters/min to 0.63 liters/min.",On the antipyrine test in laboratory animals. Studies in the dog and monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565205/),min,27.7,65741,DB01435,Antipyrine
,2565205,hepatic blood flow,"PB decreased mean plasma AP half-life from 71.5 min under basal conditions to 27.7 min, and mean hepatic blood flow increased from 0.49 liters/min to 0.63 liters/min.",On the antipyrine test in laboratory animals. Studies in the dog and monkey. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565205/),[l] / [min],0.49,65742,DB01435,Antipyrine
,2565205,hepatic blood flow,"PB decreased mean plasma AP half-life from 71.5 min under basal conditions to 27.7 min, and mean hepatic blood flow increased from 0.49 liters/min to 0.63 liters/min.",On the antipyrine test in laboratory animals. Studies in the dog and monkey. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565205/),[l] / [min],0.63,65743,DB01435,Antipyrine
,2565205,hepatic extraction ratio,Induction doubled the hepatic extraction ratio for AP to 0.4 from 0.2 under basal conditions.,On the antipyrine test in laboratory animals. Studies in the dog and monkey. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565205/),,0.4,65744,DB01435,Antipyrine
,2565205,hepatic extraction ratio,Induction doubled the hepatic extraction ratio for AP to 0.4 from 0.2 under basal conditions.,On the antipyrine test in laboratory animals. Studies in the dog and monkey. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565205/),,0.2,65745,DB01435,Antipyrine
,2720132,Vm,"A computer method based on the integrated form of Michaelis-Menten equation which reproduces the entire time course of drug absorption from the data found in three intestinal perfusion series at different initial concentrations, yielded Vm and Km values of 12.0 mg h-1 and 8.0 mg, respectively, in the mean segment of the small intestine, a rather selective absorption site for baclofen.",Evidence of a specialized transport mechanism for the intestinal absorption of baclofen. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720132/),[mg] / [h],12.0,65911,DB01435,Antipyrine
,2720132,Km,"A computer method based on the integrated form of Michaelis-Menten equation which reproduces the entire time course of drug absorption from the data found in three intestinal perfusion series at different initial concentrations, yielded Vm and Km values of 12.0 mg h-1 and 8.0 mg, respectively, in the mean segment of the small intestine, a rather selective absorption site for baclofen.",Evidence of a specialized transport mechanism for the intestinal absorption of baclofen. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720132/),mg,8.0,65912,DB01435,Antipyrine
,21083168,lower limit of detection,The lower limit of detection was 0.04 µg/ml (160 pg on column).,"Quantification of 4-methylaminoantipyrine, the active metabolite of dipyrone, in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21083168/),[μg] / [ml],0.04,66184,DB01435,Antipyrine
,21083168,recovery,The recovery was 80%.,"Quantification of 4-methylaminoantipyrine, the active metabolite of dipyrone, in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21083168/),%,80,66185,DB01435,Antipyrine
,6128298,clearance,"In control experiments (no other drug present), antipyrine clearance was 32.5 +/- 0.9 ml per hr.",H2-receptor antagonists and hepatic drug disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128298/),[ml] / [h],32.5,67082,DB01435,Antipyrine
,6128298,clearance,"This was greatly reduced in the presence of cimetidine (clearance = 10.1 +/- 0.8 and 5.8 +/- 1.5 ml per hr after 1 and 5 mg doses, p less than 0.01) and burimamide (4.5 +/- 0.6 and 3.0 +/- 1.7 ml per hr, p less than 0.001).",H2-receptor antagonists and hepatic drug disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128298/),[ml] / [h],10.1,67083,DB01435,Antipyrine
,6128298,clearance,"This was greatly reduced in the presence of cimetidine (clearance = 10.1 +/- 0.8 and 5.8 +/- 1.5 ml per hr after 1 and 5 mg doses, p less than 0.01) and burimamide (4.5 +/- 0.6 and 3.0 +/- 1.7 ml per hr, p less than 0.001).",H2-receptor antagonists and hepatic drug disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128298/),[ml] / [h],5.8,67084,DB01435,Antipyrine
,6128298,clearance,"This was greatly reduced in the presence of cimetidine (clearance = 10.1 +/- 0.8 and 5.8 +/- 1.5 ml per hr after 1 and 5 mg doses, p less than 0.01) and burimamide (4.5 +/- 0.6 and 3.0 +/- 1.7 ml per hr, p less than 0.001).",H2-receptor antagonists and hepatic drug disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128298/),[ml] / [h],4.5,67085,DB01435,Antipyrine
,6128298,clearance,"This was greatly reduced in the presence of cimetidine (clearance = 10.1 +/- 0.8 and 5.8 +/- 1.5 ml per hr after 1 and 5 mg doses, p less than 0.01) and burimamide (4.5 +/- 0.6 and 3.0 +/- 1.7 ml per hr, p less than 0.001).",H2-receptor antagonists and hepatic drug disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128298/),[ml] / [h],3.0,67086,DB01435,Antipyrine
,3595702,half-life,"The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h).",Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),h,34.4,67748,DB01435,Antipyrine
,3595702,half-life,"The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h).",Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),h,50.2,67749,DB01435,Antipyrine
,3595702,half-life,"The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h).",Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),h,5.1,67750,DB01435,Antipyrine
,3595702,half-life,"The half-life of chlorpropamide was significantly shorter in the patients (34.4 h) than in the healthy volunteers (50.2 h), but the difference between the groups in the half-life of antipyrine was even more pronounced (5.1 vs 11.4 h).",Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),h,11.4,67751,DB01435,Antipyrine
,3595702,clearance,The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),[ml] / [h·kg],2.99,67752,DB01435,Antipyrine
,3595702,clearance,The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),[ml] / [h·kg],1.60,67753,DB01435,Antipyrine
,3595702,volume of distribution,The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),[ml] / [kg],126,67754,DB01435,Antipyrine
,3595702,volume of distribution,The clearance and volume of distribution of total chlorpropamide were significantly higher in the patients (2.99 ml X h-1 X kg-1 and 126 ml X kg-1) than in the healthy volunteers (1.60 ml X h-1 X kg-1 and 106 ml X kg-1).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),[ml] / [kg],106,67755,DB01435,Antipyrine
,3595702,unbound fraction,The unbound fraction of chlorpropamide in serum was also higher in the patients (5.7%) than in the healthy subjects (4.4%).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),%,5.7,67756,DB01435,Antipyrine
,3595702,unbound fraction,The unbound fraction of chlorpropamide in serum was also higher in the patients (5.7%) than in the healthy subjects (4.4%).,Pharmacokinetics of chlorpropamide in epileptic patients: effects of enzyme induction and urine pH on chlorpropamide elimination. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595702/),%,4.4,67757,DB01435,Antipyrine
,428733,elimination half-time,"The results showed only a slight increase in the absorption half-time in old subjects, and a marked increase in elimination half-time (3.71 and 2.38 h in old and young subjects, respectively; t = 2.33: p less than 0.05) and in the volume of distribution (5.51 and 3.83 liters respectively; t = 3.20: p less than 0.1).",Pharmacokinetics of salicylates in elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/428733/),h,3.71,68406,DB01435,Antipyrine
,428733,elimination half-time,"The results showed only a slight increase in the absorption half-time in old subjects, and a marked increase in elimination half-time (3.71 and 2.38 h in old and young subjects, respectively; t = 2.33: p less than 0.05) and in the volume of distribution (5.51 and 3.83 liters respectively; t = 3.20: p less than 0.1).",Pharmacokinetics of salicylates in elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/428733/),h,2.38,68407,DB01435,Antipyrine
,428733,volume of distribution,"The results showed only a slight increase in the absorption half-time in old subjects, and a marked increase in elimination half-time (3.71 and 2.38 h in old and young subjects, respectively; t = 2.33: p less than 0.05) and in the volume of distribution (5.51 and 3.83 liters respectively; t = 3.20: p less than 0.1).",Pharmacokinetics of salicylates in elderly. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/428733/),l,5.51,68408,DB01435,Antipyrine
,428733,volume of distribution,"The results showed only a slight increase in the absorption half-time in old subjects, and a marked increase in elimination half-time (3.71 and 2.38 h in old and young subjects, respectively; t = 2.33: p less than 0.05) and in the volume of distribution (5.51 and 3.83 liters respectively; t = 3.20: p less than 0.1).",Pharmacokinetics of salicylates in elderly. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/428733/),l,3.83,68409,DB01435,Antipyrine
,1982762,elimination half-life,"However, the elimination half-life was 6.0 h in controls and 9.5 h in cirrhotics.",Pharmacokinetics after a single oral dose of bopindolol in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982762/),h,6.0,69236,DB01435,Antipyrine
,1982762,elimination half-life,"However, the elimination half-life was 6.0 h in controls and 9.5 h in cirrhotics.",Pharmacokinetics after a single oral dose of bopindolol in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982762/),h,9.5,69237,DB01435,Antipyrine
,43552,elimination half-life,Values of elimination half-life ranged from 8.3--31.2 h (mean 17.0 h) and did not vary significantly with dose.,"Single- and multiple-dose kinetics of estazolam, a triazolo benzodiazepine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/43552/),h,17.0,69442,DB01435,Antipyrine
,43552,observed accumulation ratio,"The mean observed accumulation ratio was 1.84, which was slightly larger than the predicted ratio of 1.53.","Single- and multiple-dose kinetics of estazolam, a triazolo benzodiazepine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/43552/),,1.84,69443,DB01435,Antipyrine
,1283384,clearance,The antipyrine clearance showed a significant decrease from 57.9 ml min-1 to 45.0 ml min-1.,Endogenous interferon plasma levels and antipyrine pharmacokinetics in patients with viral infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1283384/),[ml] / [min],57.9,69663,DB01435,Antipyrine
,1283384,clearance,The antipyrine clearance showed a significant decrease from 57.9 ml min-1 to 45.0 ml min-1.,Endogenous interferon plasma levels and antipyrine pharmacokinetics in patients with viral infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1283384/),[ml] / [min],45.0,69664,DB01435,Antipyrine
,8101676,plasma clearance,In the infected rafoxanide-treated group plasma clearance of antipyrine remained unchanged until 10 weeks after rafoxanide administration when it decreased from the preinfection value of 5.09 to 3.90 ml.kg/min.,Effect of early treatment with rafoxanide on antipyrine clearance in sheep infected with Fasciola hepatica. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8101676/),[kg·ml] / [min],5.09,70856,DB01435,Antipyrine
,7802401,flow rate,"For each compound, the placenta in 5 rabbits was perfused for 200 minutes with Earle's enriched bicarbonate buffer at flow rate of 1.5 ml/min.",Placental transfer of enrofloxacin and ciprofloxacin in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7802401/),[ml] / [min],1.5,70987,DB01435,Antipyrine
,7802401,Placental clearance,Placental clearance of the drugs was significantly (P < 0.01) different (0.88 +/- 0.13 ml/min for enrofloxacin and 0.06 +/- 0.02 ml/min for ciprofloxacin).,Placental transfer of enrofloxacin and ciprofloxacin in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7802401/),[ml] / [min],0.88,70988,DB01435,Antipyrine
,7802401,Placental clearance,Placental clearance of the drugs was significantly (P < 0.01) different (0.88 +/- 0.13 ml/min for enrofloxacin and 0.06 +/- 0.02 ml/min for ciprofloxacin).,Placental transfer of enrofloxacin and ciprofloxacin in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7802401/),[ml] / [min],0.06,70989,DB01435,Antipyrine
,3691602,clearance,During prednisolone administration antipyrine clearance decreased from 54.9 +/- 14.8 to 51.7 +/- 14.6 ml/min (mean +/- SD; p less than 0.05).,Influence of prednisolone on antipyrine elimination in patients with obstructive lung disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691602/),[ml] / [min],54.9,72209,DB01435,Antipyrine
,3691602,clearance,During prednisolone administration antipyrine clearance decreased from 54.9 +/- 14.8 to 51.7 +/- 14.6 ml/min (mean +/- SD; p less than 0.05).,Influence of prednisolone on antipyrine elimination in patients with obstructive lung disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691602/),[ml] / [min],51.7,72210,DB01435,Antipyrine
,6476571,apparent bioavailability,"Chloramphenicol also was administered to older calves by IM and subcutaneous routes, with an apparent bioavailability of 50% to 60%.",Chloramphenicol and the neonatal calf. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6476571/),%,50,73466,DB01435,Antipyrine
,6476571,apparent bioavailability,"Chloramphenicol also was administered to older calves by IM and subcutaneous routes, with an apparent bioavailability of 50% to 60%.",Chloramphenicol and the neonatal calf. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6476571/),%,60,73467,DB01435,Antipyrine
,6832206,clearance,The intravenous aminophylline study showed that habitual smoking had a significant (p less than 0.05) effect on plasma theophylline clearance (0.051 +/- 0.006 vs 0.035 +/- 0.004 l/kg/h).,Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832206/),[l] / [h·kg],0.051,74447,DB01435,Antipyrine
,6832206,clearance,The intravenous aminophylline study showed that habitual smoking had a significant (p less than 0.05) effect on plasma theophylline clearance (0.051 +/- 0.006 vs 0.035 +/- 0.004 l/kg/h).,Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832206/),[l] / [h·kg],0.035,74448,DB01435,Antipyrine
,17435173,IC50,"In vitro, metabolites elicited no substantial COX-1/COX-2 selectivity with MAA (IC50=2.55 micromol/L for COX-1; IC50=4.65 micromol/L for COX-2), being approximately 8.2- or 9-fold more potent than AA.",Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),[μM] / [l],2.55,76643,DB01435,Antipyrine
,17435173,IC50,"In vitro, metabolites elicited no substantial COX-1/COX-2 selectivity with MAA (IC50=2.55 micromol/L for COX-1; IC50=4.65 micromol/L for COX-2), being approximately 8.2- or 9-fold more potent than AA.",Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),[μM] / [l],4.65,76644,DB01435,Antipyrine
,17435173,IC50,COX inhibition correlated with MAA plasma levels (ex vivo IC50 values of 1.03 micromol/L [COX-1] and 0.87 micromol/L [COX-2]).,Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),[μM] / [l],1.03,76645,DB01435,Antipyrine
,17435173,IC50,COX inhibition correlated with MAA plasma levels (ex vivo IC50 values of 1.03 micromol/L [COX-1] and 0.87 micromol/L [COX-2]).,Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),[μM] / [l],0.87,76646,DB01435,Antipyrine
,17435173,Maximal inhibitions,"Maximal inhibitions of COX-1 and COX-2 were 94% and 87% (500 mg), 97% and 94% (1000 mg).",Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),%,94,76647,DB01435,Antipyrine
,17435173,Maximal inhibitions,"Maximal inhibitions of COX-1 and COX-2 were 94% and 87% (500 mg), 97% and 94% (1000 mg).",Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),%,87,76648,DB01435,Antipyrine
,17435173,Maximal inhibitions,"Maximal inhibitions of COX-1 and COX-2 were 94% and 87% (500 mg), 97% and 94% (1000 mg).",Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),%,97,76649,DB01435,Antipyrine
,7629928,elimination half-life,The elimination half-life of antipyrine in watered adult camels was 136.5 +/- 16.7 min.,Antipyrine disposition in the dehydrated camel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7629928/),min,136.5,78845,DB01435,Antipyrine
,6515128,t 1/2,"After transfusion with Fluosol DA 20%, the t 1/2 of sulfamethazine was increased from 3.15 +/- 0.56 to 7.65 +/- 2.41 hr (p less than 0.05) and the Vd was increased from 60.7 +/- 17.5 to 152 +/- 16 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),h,3.15,80475,DB01435,Antipyrine
,6515128,t 1/2,"After transfusion with Fluosol DA 20%, the t 1/2 of sulfamethazine was increased from 3.15 +/- 0.56 to 7.65 +/- 2.41 hr (p less than 0.05) and the Vd was increased from 60.7 +/- 17.5 to 152 +/- 16 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),h,7.65,80476,DB01435,Antipyrine
,6515128,Vd,"After transfusion with Fluosol DA 20%, the t 1/2 of sulfamethazine was increased from 3.15 +/- 0.56 to 7.65 +/- 2.41 hr (p less than 0.05) and the Vd was increased from 60.7 +/- 17.5 to 152 +/- 16 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),ml,60.7,80477,DB01435,Antipyrine
,6515128,Vd,"After transfusion with Fluosol DA 20%, the t 1/2 of sulfamethazine was increased from 3.15 +/- 0.56 to 7.65 +/- 2.41 hr (p less than 0.05) and the Vd was increased from 60.7 +/- 17.5 to 152 +/- 16 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),ml,152,80478,DB01435,Antipyrine
,6515128,AUC,"In contrast, after transfusion with stroma-free hemoglobin, the AUC of sulfamethazine was decreased from 129 +/- 28 to 80.5 +/- 27.7 micrograms X h X ml-1 (p less than 0.05) and there was an increase in Cl from 12.2 +/- 3.4 to 20.2 +/- 6.0 ml X h-1 (p less than 0.05) and Vd from 60.1 +/- 11.8 to 132 +/- 49 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),[h·μg] / [ml],129,80479,DB01435,Antipyrine
,6515128,AUC,"In contrast, after transfusion with stroma-free hemoglobin, the AUC of sulfamethazine was decreased from 129 +/- 28 to 80.5 +/- 27.7 micrograms X h X ml-1 (p less than 0.05) and there was an increase in Cl from 12.2 +/- 3.4 to 20.2 +/- 6.0 ml X h-1 (p less than 0.05) and Vd from 60.1 +/- 11.8 to 132 +/- 49 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),[h·μg] / [ml],80.5,80480,DB01435,Antipyrine
,6515128,Cl,"In contrast, after transfusion with stroma-free hemoglobin, the AUC of sulfamethazine was decreased from 129 +/- 28 to 80.5 +/- 27.7 micrograms X h X ml-1 (p less than 0.05) and there was an increase in Cl from 12.2 +/- 3.4 to 20.2 +/- 6.0 ml X h-1 (p less than 0.05) and Vd from 60.1 +/- 11.8 to 132 +/- 49 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),[ml] / [h],12.2,80481,DB01435,Antipyrine
,6515128,Cl,"In contrast, after transfusion with stroma-free hemoglobin, the AUC of sulfamethazine was decreased from 129 +/- 28 to 80.5 +/- 27.7 micrograms X h X ml-1 (p less than 0.05) and there was an increase in Cl from 12.2 +/- 3.4 to 20.2 +/- 6.0 ml X h-1 (p less than 0.05) and Vd from 60.1 +/- 11.8 to 132 +/- 49 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),[ml] / [h],20.2,80482,DB01435,Antipyrine
,6515128,Vd,"In contrast, after transfusion with stroma-free hemoglobin, the AUC of sulfamethazine was decreased from 129 +/- 28 to 80.5 +/- 27.7 micrograms X h X ml-1 (p less than 0.05) and there was an increase in Cl from 12.2 +/- 3.4 to 20.2 +/- 6.0 ml X h-1 (p less than 0.05) and Vd from 60.1 +/- 11.8 to 132 +/- 49 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),ml,60.1,80483,DB01435,Antipyrine
,6515128,Vd,"In contrast, after transfusion with stroma-free hemoglobin, the AUC of sulfamethazine was decreased from 129 +/- 28 to 80.5 +/- 27.7 micrograms X h X ml-1 (p less than 0.05) and there was an increase in Cl from 12.2 +/- 3.4 to 20.2 +/- 6.0 ml X h-1 (p less than 0.05) and Vd from 60.1 +/- 11.8 to 132 +/- 49 ml (p less than 0.05).","Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin, and sulfamethazine in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515128/),ml,132,80484,DB01435,Antipyrine
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,11.3 to 8.4,81404,DB01435,Antipyrine
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,10.7 to 7.6,81405,DB01435,Antipyrine
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,12.2 to 8.6,81406,DB01435,Antipyrine
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,10.6 to 8.6,81407,DB01435,Antipyrine
,29630939,absolute bioavailability,"Pharmacokinetic experiments performed with rats and beagles showed that the absolute bioavailability of EDR solution and enteric-coated pellets following oral administration were 33.85% ± 2.45% and 7.64% ± 1.03%, indicating that stomach absorption is better than intestinal adsorption for EDR.","Gastric retention pellets of edaravone with enhanced oral bioavailability: Absorption mechanism, development, and in vitro/in vivo evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29630939/),%,33.85,82058,DB01435,Antipyrine
,29630939,absolute bioavailability,"Pharmacokinetic experiments performed with rats and beagles showed that the absolute bioavailability of EDR solution and enteric-coated pellets following oral administration were 33.85% ± 2.45% and 7.64% ± 1.03%, indicating that stomach absorption is better than intestinal adsorption for EDR.","Gastric retention pellets of edaravone with enhanced oral bioavailability: Absorption mechanism, development, and in vitro/in vivo evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29630939/),%,7.64,82059,DB01435,Antipyrine
,29630939,absolute bioavailability,"However, the gastric retention pellets resulted in 68.96% absolute bioavailability and about 200% relative bioavailability in comparison to EDR solution, which was 9 times that of enteric-coated pellets.","Gastric retention pellets of edaravone with enhanced oral bioavailability: Absorption mechanism, development, and in vitro/in vivo evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29630939/),%,68.96,82060,DB01435,Antipyrine
,29630939,relative bioavailability,"However, the gastric retention pellets resulted in 68.96% absolute bioavailability and about 200% relative bioavailability in comparison to EDR solution, which was 9 times that of enteric-coated pellets.","Gastric retention pellets of edaravone with enhanced oral bioavailability: Absorption mechanism, development, and in vitro/in vivo evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29630939/),%,200,82061,DB01435,Antipyrine
,2260347,peak serum concentrations,Mean peak serum concentrations achieved in human volunteers after 50 and 100 mg (oral) are 3.1 and 7.0 mumols/L respectively.,Fluconazole: a new triazole antifungal agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),[mumols] / [l],3.1,82553,DB01435,Antipyrine
,2260347,peak serum concentrations,Mean peak serum concentrations achieved in human volunteers after 50 and 100 mg (oral) are 3.1 and 7.0 mumols/L respectively.,Fluconazole: a new triazole antifungal agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),[mumols] / [l],7.0,82554,DB01435,Antipyrine
,2260347,Protein binding,Protein binding is low (11 percent) and cerebrospinal fluid to serum ratio is 0.58 to 0.89.,Fluconazole: a new triazole antifungal agent. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),%,11,82555,DB01435,Antipyrine
,2260347,cerebrospinal fluid to serum ratio,Protein binding is low (11 percent) and cerebrospinal fluid to serum ratio is 0.58 to 0.89.,Fluconazole: a new triazole antifungal agent. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),,0.58 to 0.89,82556,DB01435,Antipyrine
,2260347,Serum half-life,Serum half-life is long (22-32 hours) and elimination is via renal clearance of unchanged drug.,Fluconazole: a new triazole antifungal agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),h,22-32,82557,DB01435,Antipyrine
,7985514,half-life,The half-life of antipyrine was found to be 18.8 +/- 4.89 h in 16 Han and 15.0 +/- 3.02 h in 17 Tibetan (P < 0.05) and the clearance was 1.35 +/- 0.37 L.h-1 in Han and 1.71 +/- 0.44 L.h-1 in Tibetan (P < 0.05).,Ethnic differences in disposition of antipyrine and acetaminophen between Tibetan and Han healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985514/),h,18.8,83279,DB01435,Antipyrine
,7985514,half-life,The half-life of antipyrine was found to be 18.8 +/- 4.89 h in 16 Han and 15.0 +/- 3.02 h in 17 Tibetan (P < 0.05) and the clearance was 1.35 +/- 0.37 L.h-1 in Han and 1.71 +/- 0.44 L.h-1 in Tibetan (P < 0.05).,Ethnic differences in disposition of antipyrine and acetaminophen between Tibetan and Han healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985514/),h,15.0,83280,DB01435,Antipyrine
,7985514,clearance,The half-life of antipyrine was found to be 18.8 +/- 4.89 h in 16 Han and 15.0 +/- 3.02 h in 17 Tibetan (P < 0.05) and the clearance was 1.35 +/- 0.37 L.h-1 in Han and 1.71 +/- 0.44 L.h-1 in Tibetan (P < 0.05).,Ethnic differences in disposition of antipyrine and acetaminophen between Tibetan and Han healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985514/),[l] / [h],1.35,83281,DB01435,Antipyrine
,7985514,clearance,The half-life of antipyrine was found to be 18.8 +/- 4.89 h in 16 Han and 15.0 +/- 3.02 h in 17 Tibetan (P < 0.05) and the clearance was 1.35 +/- 0.37 L.h-1 in Han and 1.71 +/- 0.44 L.h-1 in Tibetan (P < 0.05).,Ethnic differences in disposition of antipyrine and acetaminophen between Tibetan and Han healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985514/),[l] / [h],1.71,83282,DB01435,Antipyrine
,7985514,half-life,The half-life of acetaminophen was 3.1 +/- 0.86 h in Han and 3.2 +/- 1.12 h in Tibetan (P > 0.05).,Ethnic differences in disposition of antipyrine and acetaminophen between Tibetan and Han healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985514/),h,3.1,83283,DB01435,Antipyrine
,7985514,half-life,The half-life of acetaminophen was 3.1 +/- 0.86 h in Han and 3.2 +/- 1.12 h in Tibetan (P > 0.05).,Ethnic differences in disposition of antipyrine and acetaminophen between Tibetan and Han healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985514/),h,3.2,83284,DB01435,Antipyrine
,3619423,concentrations,"Mean concentrations in serum 5 min postinfusion were 3.08 and 2.14 micrograms/ml, and mean peak concentrations after oral dosing were 3.24 and 3.34 micrograms/ml in subjects with and without CF, respectively.",Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),[μg] / [ml],3.08,84111,DB01435,Antipyrine
,3619423,concentrations,"Mean concentrations in serum 5 min postinfusion were 3.08 and 2.14 micrograms/ml, and mean peak concentrations after oral dosing were 3.24 and 3.34 micrograms/ml in subjects with and without CF, respectively.",Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),[μg] / [ml],2.14,84112,DB01435,Antipyrine
,3619423,peak concentrations,"Mean concentrations in serum 5 min postinfusion were 3.08 and 2.14 micrograms/ml, and mean peak concentrations after oral dosing were 3.24 and 3.34 micrograms/ml in subjects with and without CF, respectively.",Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),[μg] / [ml],3.24,84113,DB01435,Antipyrine
,3619423,peak concentrations,"Mean concentrations in serum 5 min postinfusion were 3.08 and 2.14 micrograms/ml, and mean peak concentrations after oral dosing were 3.24 and 3.34 micrograms/ml in subjects with and without CF, respectively.",Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),[μg] / [ml],3.34,84114,DB01435,Antipyrine
,3619423,elimination half-life,"Mean values for elimination half-life in all subjects were 4.8 and 5.0 h after intravenous and oral administration, respectively.",Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),h,4.8,84115,DB01435,Antipyrine
,3619423,elimination half-life,"Mean values for elimination half-life in all subjects were 4.8 and 5.0 h after intravenous and oral administration, respectively.",Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),h,5.0,84116,DB01435,Antipyrine
,3619423,renal clearances,"The mean renal clearances in all subjects after intravenous and oral administration were 19.4 and 14.5 liters/h and accounted for 64 and 47% of the total clearance, respectively.",Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),[l] / [h],19.4,84117,DB01435,Antipyrine
,3619423,renal clearances,"The mean renal clearances in all subjects after intravenous and oral administration were 19.4 and 14.5 liters/h and accounted for 64 and 47% of the total clearance, respectively.",Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),[l] / [h],14.5,84118,DB01435,Antipyrine
,3619423,bioavailability,The mean bioavailability was 71.2% and did not differ between the groups.,Pharmacokinetics of ciprofloxacin in cystic fibrosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3619423/),%,71.2,84119,DB01435,Antipyrine
,2510135,oral clearance,Diltiazem 90 mg every 8 hours for 5 days decreased the oral clearance of antipyrine from 2.34 to 1.86 L/hour (p less than 0.05) and increased half-life from 12.7 to 15.9 hours (p less than 0.05).,The effects of encainide versus diltiazem on the oxidative metabolic pathways of antipyrine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510135/),[l] / [h],2,84358,DB01435,Antipyrine
,2510135,half-life,Diltiazem 90 mg every 8 hours for 5 days decreased the oral clearance of antipyrine from 2.34 to 1.86 L/hour (p less than 0.05) and increased half-life from 12.7 to 15.9 hours (p less than 0.05).,The effects of encainide versus diltiazem on the oxidative metabolic pathways of antipyrine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510135/),h,12,84359,DB01435,Antipyrine
,2345775,clearance,"The clearance of antipyrine was significantly increased (0.93 vs. 0.60 ml/min/kg, p less than 0.0001) and elimination half-life was correspondingly reduced (8.9 vs. 13.0 h, p less than 0.0001) in smokers compared to nonsmoking controls.",Differential effect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2345775/),[ml] / [kg·min],0.93,85439,DB01435,Antipyrine
,2345775,clearance,"The clearance of antipyrine was significantly increased (0.93 vs. 0.60 ml/min/kg, p less than 0.0001) and elimination half-life was correspondingly reduced (8.9 vs. 13.0 h, p less than 0.0001) in smokers compared to nonsmoking controls.",Differential effect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2345775/),[ml] / [kg·min],0.60,85440,DB01435,Antipyrine
,2345775,elimination half-life,"The clearance of antipyrine was significantly increased (0.93 vs. 0.60 ml/min/kg, p less than 0.0001) and elimination half-life was correspondingly reduced (8.9 vs. 13.0 h, p less than 0.0001) in smokers compared to nonsmoking controls.",Differential effect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2345775/),h,8.9,85441,DB01435,Antipyrine
,2345775,elimination half-life,"The clearance of antipyrine was significantly increased (0.93 vs. 0.60 ml/min/kg, p less than 0.0001) and elimination half-life was correspondingly reduced (8.9 vs. 13.0 h, p less than 0.0001) in smokers compared to nonsmoking controls.",Differential effect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2345775/),h,13.0,85442,DB01435,Antipyrine
,8941022,hepatic extraction,The mean hepatic extraction of fluvastatin was 67% after the jejunal perfusion and 73% after the intravenous infusion.,Jejunal permeability and hepatic extraction of fluvastatin in humans. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941022/),%,67,88754,DB01435,Antipyrine
,8941022,hepatic extraction,The mean hepatic extraction of fluvastatin was 67% after the jejunal perfusion and 73% after the intravenous infusion.,Jejunal permeability and hepatic extraction of fluvastatin in humans. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941022/),%,73,88755,DB01435,Antipyrine
,8941022,half-life,The half-life of fluvastatin was approximately 60 minutes after both administration routes.,Jejunal permeability and hepatic extraction of fluvastatin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941022/),min,60,88756,DB01435,Antipyrine
,29943417,maximum concentration,"In the goat, the MET rapidly converted into MAA and the mean maximum concentration was 183.97 μg/ml (at 0.08 hr) and 51.94 μg/ml (at 0.70 hr) after IV and IM administration, respectively.",Pharmacokinetic profiles of metamizole (dipyrone) active metabolites in goats and its residues in milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29943417/),[μg] / [ml],183.97,89089,DB01435,Antipyrine
,29943417,maximum concentration,"In the goat, the MET rapidly converted into MAA and the mean maximum concentration was 183.97 μg/ml (at 0.08 hr) and 51.94 μg/ml (at 0.70 hr) after IV and IM administration, respectively.",Pharmacokinetic profiles of metamizole (dipyrone) active metabolites in goats and its residues in milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29943417/),[μg] / [ml],51.94,89090,DB01435,Antipyrine
,8259696,relative bioavailabilities,"5. In comparison with a gavage study in the same rat (strain and age), bioavailability was lower in the diet study with relative bioavailabilities of 27, 22 and 61% for paracetamol, antipyrine and phenylbutazone, respectively.",Assessment of drug exposure in rat dietary studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8259696/),%,27,89177,DB01435,Antipyrine
,8259696,relative bioavailabilities,"5. In comparison with a gavage study in the same rat (strain and age), bioavailability was lower in the diet study with relative bioavailabilities of 27, 22 and 61% for paracetamol, antipyrine and phenylbutazone, respectively.",Assessment of drug exposure in rat dietary studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8259696/),%,22,89178,DB01435,Antipyrine
,8259696,relative bioavailabilities,"5. In comparison with a gavage study in the same rat (strain and age), bioavailability was lower in the diet study with relative bioavailabilities of 27, 22 and 61% for paracetamol, antipyrine and phenylbutazone, respectively.",Assessment of drug exposure in rat dietary studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8259696/),%,61,89179,DB01435,Antipyrine
,8259696,elimination half-lives,"6. In conclusion, drug exposure as expressed by AUC24 and Cmax can be accurately determined in rat studies using compound administration in the diet by measuring concentrations at three selected time points for compounds with elimination half-lives ranging from about 1 to 5 h.",Assessment of drug exposure in rat dietary studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8259696/),h,1 to 5,89180,DB01435,Antipyrine
,6538427,half-life,Cimetidine prolonged phenazone half-life from 12.7 +/- 1.0 h to 15.5 +/- 1.0 h (p less than 0.05) and decreased total plasma clearance of phenazone from 40.9 +/- 3.9 ml/min to 33.9 +/- 2.9 ml/min (p less than 0.05).,[Effect of metronidazole on phenazone metabolism]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538427/),h,12.7,90690,DB01435,Antipyrine
,6538427,half-life,Cimetidine prolonged phenazone half-life from 12.7 +/- 1.0 h to 15.5 +/- 1.0 h (p less than 0.05) and decreased total plasma clearance of phenazone from 40.9 +/- 3.9 ml/min to 33.9 +/- 2.9 ml/min (p less than 0.05).,[Effect of metronidazole on phenazone metabolism]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538427/),h,15.5,90691,DB01435,Antipyrine
,6538427,total plasma clearance,Cimetidine prolonged phenazone half-life from 12.7 +/- 1.0 h to 15.5 +/- 1.0 h (p less than 0.05) and decreased total plasma clearance of phenazone from 40.9 +/- 3.9 ml/min to 33.9 +/- 2.9 ml/min (p less than 0.05).,[Effect of metronidazole on phenazone metabolism]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538427/),[ml] / [min],40.9,90692,DB01435,Antipyrine
,6538427,total plasma clearance,Cimetidine prolonged phenazone half-life from 12.7 +/- 1.0 h to 15.5 +/- 1.0 h (p less than 0.05) and decreased total plasma clearance of phenazone from 40.9 +/- 3.9 ml/min to 33.9 +/- 2.9 ml/min (p less than 0.05).,[Effect of metronidazole on phenazone metabolism]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538427/),[ml] / [min],33.9,90693,DB01435,Antipyrine
,11510628,time to reach maximum observed plasma concentration,"In pharmacokinetic studies in humans, quetiapine was rapidly absorbed after oral administration, with median time to reach maximum observed plasma concentration ranging from 1 to 2 hours.",Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,1 to 2,91263,DB01435,Antipyrine
,11510628,terminal half-life,The drug is eliminated with a mean terminal half-life of approximately 7 hours.,Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,7,91264,DB01435,Antipyrine
,2905248,tmax,"A powder capsule formulation of the drug showed rapid absorption (tmax = 1 hour) and linear pharmacokinetics across the dose range 25 to 100mg, but produced some gastrointestinal intolerance.",Pharmacokinetics of roxatidine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905248/),h,1,91442,DB01435,Antipyrine
,2905248,tmax,"However, a granulated capsule formulation showed a much slower release (tmax = 3 hours) and was well tolerated.",Pharmacokinetics of roxatidine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905248/),h,3,91443,DB01435,Antipyrine
,2905248,plasma terminal half-life,The plasma terminal half-life of the granulated capsule averaged 6 hours and between 55 and 60% of the dose was recovered in the urine as roxatidine.,Pharmacokinetics of roxatidine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905248/),h,6,91444,DB01435,Antipyrine
,3130892,steady-state concentration,"2 VPA alone had no effect on antipyrine clearance, urinary 6 beta-hydroxycortisol excretion and a battery of psychomotor function tests after 3 days' treatment despite achieving a mean steady-state concentration (90 +/- 6 mg 1(-1)) well within the target range (50-100 mg 1(-1)) for the drug.",Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3130892/),mg,90,92013,DB01435,Antipyrine
,3130892,steady-state concentration,"2 VPA alone had no effect on antipyrine clearance, urinary 6 beta-hydroxycortisol excretion and a battery of psychomotor function tests after 3 days' treatment despite achieving a mean steady-state concentration (90 +/- 6 mg 1(-1)) well within the target range (50-100 mg 1(-1)) for the drug.",Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3130892/),mg,50-100,92014,DB01435,Antipyrine
,3141098,t1/2,The mean plasma antipyrine t1/2 for patients (42.2 hours) was longer (p less than 0.01) than that for subjects (11.7 hours).,Pharmacokinetics of flecainide in patients with cirrhosis of the liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141098/),h,42.2,93183,DB01435,Antipyrine
,3141098,t1/2,The mean plasma antipyrine t1/2 for patients (42.2 hours) was longer (p less than 0.01) than that for subjects (11.7 hours).,Pharmacokinetics of flecainide in patients with cirrhosis of the liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141098/),h,11.7,93184,DB01435,Antipyrine
,3141098,plasma t1/2,"For control subjects, the plasma t1/2 of flecainide (9.5 hours) was shorter (p less than 0.01), plasma clearance (9.1 ml/min/kg) was faster (p less than 0.01), and volume of distribution (7.5 L/kg) was smaller (p less than 0.05) compared with corresponding values in patients.",Pharmacokinetics of flecainide in patients with cirrhosis of the liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141098/),h,9.5,93185,DB01435,Antipyrine
,3141098,plasma clearance,"For control subjects, the plasma t1/2 of flecainide (9.5 hours) was shorter (p less than 0.01), plasma clearance (9.1 ml/min/kg) was faster (p less than 0.01), and volume of distribution (7.5 L/kg) was smaller (p less than 0.05) compared with corresponding values in patients.",Pharmacokinetics of flecainide in patients with cirrhosis of the liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141098/),[ml] / [kg·min],9.1,93186,DB01435,Antipyrine
,3141098,volume of distribution,"For control subjects, the plasma t1/2 of flecainide (9.5 hours) was shorter (p less than 0.01), plasma clearance (9.1 ml/min/kg) was faster (p less than 0.01), and volume of distribution (7.5 L/kg) was smaller (p less than 0.05) compared with corresponding values in patients.",Pharmacokinetics of flecainide in patients with cirrhosis of the liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141098/),[l] / [kg],7.5,93187,DB01435,Antipyrine
,3946177,clearance,"Following administration of digitoxin, 1 mg intravenously, the pharmacokinetics of this glycoside were studied in eight healthy volunteers and in eight patients with hepatorenal insufficiency (mean creatinine clearance 19.6 +/- 2.9 ml/min; antipyrine clearance 25.6 +/- 3.2 ml/min; means +/- SEM).",Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946177/),[ml] / [min],25.6,93446,DB01435,Antipyrine
,3946177,Plasma protein binding,Plasma protein binding of digitoxin (means +/- SEM) was 95.1 +/- 0.7% in the patients and 95.6 +/- 1.2% in the volunteers (NS).,Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946177/),%,95.1,93447,DB01435,Antipyrine
,3946177,Plasma protein binding,Plasma protein binding of digitoxin (means +/- SEM) was 95.1 +/- 0.7% in the patients and 95.6 +/- 1.2% in the volunteers (NS).,Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946177/),%,95.6,93448,DB01435,Antipyrine
,3946177,Total body clearance,Total body clearance of digitoxin was 0.0530 +/- 0.0040 ml/min/kg of body weight in the patients and 0.0547 +/- 0.0043 ml/min/kg of body weight in the healthy subjects (NS).,Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946177/),[ml] / [kg·min],0.0530,93449,DB01435,Antipyrine
,3946177,Total body clearance,Total body clearance of digitoxin was 0.0530 +/- 0.0040 ml/min/kg of body weight in the patients and 0.0547 +/- 0.0043 ml/min/kg of body weight in the healthy subjects (NS).,Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946177/),[ml] / [kg·min],0.0547,93450,DB01435,Antipyrine
,3946177,elimination half-lives,"When elimination half-lives of the patients and the volunteers were compared, there was also no significant difference (7.0 +/- 0.77 days in the patient group and 7.8 +/- 0.8 days in the volunteers).",Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946177/),d,7.0,93451,DB01435,Antipyrine
,3946177,elimination half-lives,"When elimination half-lives of the patients and the volunteers were compared, there was also no significant difference (7.0 +/- 0.77 days in the patient group and 7.8 +/- 0.8 days in the volunteers).",Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946177/),d,7.8,93452,DB01435,Antipyrine
,27426925,fetal transfer rates,"Following 3 h of perfusion, the fetal transfer rates of OP and its metabolite OC were 12.39%±3.26%, 10.17%±2.03%, respectively.",Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27426925/),%,12.39,93979,DB01435,Antipyrine
,27426925,fetal transfer rates,"Following 3 h of perfusion, the fetal transfer rates of OP and its metabolite OC were 12.39%±3.26%, 10.17%±2.03%, respectively.",Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27426925/),%,10.17,93980,DB01435,Antipyrine
,27426925,clearance index,"The clearance indexes of OP and OC were 0.36 ± 0.11 and 0.29 ± 0.06, respectively.",Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27426925/),,0.36,93981,DB01435,Antipyrine
,27426925,clearance index,"The clearance indexes of OP and OC were 0.36 ± 0.11 and 0.29 ± 0.06, respectively.",Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27426925/),,0.29,93982,DB01435,Antipyrine
,6319067,elimination t1/2,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.6,94730,DB01435,Antipyrine
,6319067,elimination t1/2,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.5,94731,DB01435,Antipyrine
,6319067,volume of distribution (Vd),"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.77,94732,DB01435,Antipyrine
,6319067,volume of distribution (Vd),"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.75,94733,DB01435,Antipyrine
,6319067,total clearance,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.77,94734,DB01435,Antipyrine
,6319067,total clearance,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.75,94735,DB01435,Antipyrine
,6319067,t1/2,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,32.3,94736,DB01435,Antipyrine
,6319067,t1/2,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,28.9,94737,DB01435,Antipyrine
,6319067,Vd,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.42,94738,DB01435,Antipyrine
,6319067,Vd,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.39,94739,DB01435,Antipyrine
,6319067,total clearance,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.42,94740,DB01435,Antipyrine
,6319067,total clearance,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.39,94741,DB01435,Antipyrine
,6319067,t1/2,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.7,94742,DB01435,Antipyrine
,6319067,t1/2,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.3,94743,DB01435,Antipyrine
,6319067,Vd,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],1.52,94744,DB01435,Antipyrine
,6319067,total clearance,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],1.52,94745,DB01435,Antipyrine
,6319067,total clearance,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],1.65,94746,DB01435,Antipyrine
,3440100,half-life,"The half-life of antipyrine was 12.2 +/- 1.3 h (mean + s.d.), while the apparent volume of distribution (V) was 0.67 +/- 0.11 l kg-1 (mean +/- s.d.) and the total body clearance was 40.7 +/- 3.2 ml kg-1 h-1 (mean +/- s.d.) in the healthy volunteers.",Disposition of antipyrine in African patients with Hodgkin's lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440100/),h,12.2,95682,DB01435,Antipyrine
,3440100,apparent volume of distribution (V),"The half-life of antipyrine was 12.2 +/- 1.3 h (mean + s.d.), while the apparent volume of distribution (V) was 0.67 +/- 0.11 l kg-1 (mean +/- s.d.) and the total body clearance was 40.7 +/- 3.2 ml kg-1 h-1 (mean +/- s.d.) in the healthy volunteers.",Disposition of antipyrine in African patients with Hodgkin's lymphoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440100/),[l] / [kg],0.67,95683,DB01435,Antipyrine
,3440100,total body clearance,"The half-life of antipyrine was 12.2 +/- 1.3 h (mean + s.d.), while the apparent volume of distribution (V) was 0.67 +/- 0.11 l kg-1 (mean +/- s.d.) and the total body clearance was 40.7 +/- 3.2 ml kg-1 h-1 (mean +/- s.d.) in the healthy volunteers.",Disposition of antipyrine in African patients with Hodgkin's lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440100/),[ml] / [h·kg],40.7,95684,DB01435,Antipyrine
,3440100,half-life,The antipyrine half-life in the patients with advanced Hodgkin's lymphoma was 17.1 +/- 2.7 h (mean +/- s.d.).,Disposition of antipyrine in African patients with Hodgkin's lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440100/),h,17.1,95685,DB01435,Antipyrine
,3440100,apparent volume of distribution,The apparent volume of distribution was 0.72 +/- 0.14 l kg-1 (mean +/- s.d.) which was larger than in healthy volunteers (P less than 0.05).,Disposition of antipyrine in African patients with Hodgkin's lymphoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440100/),[l] / [kg],0.72,95686,DB01435,Antipyrine
,3440100,total body clearance,The total body clearance was 30.3 +/- 9.4 ml kg-1 h-1 (mean + s.d.) and this was reduced compared with that in healthy volunteers (P less than 0.02).,Disposition of antipyrine in African patients with Hodgkin's lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440100/),[ml] / [h·kg],30.3,95687,DB01435,Antipyrine
,3440100,half-life,"After cytotoxic therapy the half-life in the patients with advanced Hodgkin's lymphoma was significantly decreased to 8.3 +/- 1.3 h (mean +/- s.d.) (P less than 0.07), and the apparent volume of distribution was reduced to 0.65 +/- 0.07 l kg-1 (mean +/- s.d.) (P less than 0.05) while the total body clearance increased to 52.8 +/- 5.5 ml kg-1 h-1 (mean +/- s.d.) (P less than 0.01).",Disposition of antipyrine in African patients with Hodgkin's lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440100/),h,8.3,95688,DB01435,Antipyrine
,3440100,apparent volume of distribution,"After cytotoxic therapy the half-life in the patients with advanced Hodgkin's lymphoma was significantly decreased to 8.3 +/- 1.3 h (mean +/- s.d.) (P less than 0.07), and the apparent volume of distribution was reduced to 0.65 +/- 0.07 l kg-1 (mean +/- s.d.) (P less than 0.05) while the total body clearance increased to 52.8 +/- 5.5 ml kg-1 h-1 (mean +/- s.d.) (P less than 0.01).",Disposition of antipyrine in African patients with Hodgkin's lymphoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440100/),[l] / [kg],0.65,95689,DB01435,Antipyrine
,3440100,total body clearance,"After cytotoxic therapy the half-life in the patients with advanced Hodgkin's lymphoma was significantly decreased to 8.3 +/- 1.3 h (mean +/- s.d.) (P less than 0.07), and the apparent volume of distribution was reduced to 0.65 +/- 0.07 l kg-1 (mean +/- s.d.) (P less than 0.05) while the total body clearance increased to 52.8 +/- 5.5 ml kg-1 h-1 (mean +/- s.d.) (P less than 0.01).",Disposition of antipyrine in African patients with Hodgkin's lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440100/),[ml] / [h·kg],52.8,95690,DB01435,Antipyrine
,15090289,half-life,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),h,12.4,96676,DB01435,Antipyrine
,15090289,half-life,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),h,16.8,96677,DB01435,Antipyrine
,15090289,area under the plasma concentration-time curve,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[mg·min] / [ml],27.9,96678,DB01435,Antipyrine
,15090289,area under the plasma concentration-time curve,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[mg·min] / [ml],38.1,96679,DB01435,Antipyrine
,15090289,total body clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[ml] / [min],61.2,96680,DB01435,Antipyrine
,15090289,total body clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[ml] / [min],43.7,96681,DB01435,Antipyrine
,15090289,renal clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[ml] / [min],7.45,96682,DB01435,Antipyrine
,15090289,renal clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[ml] / [min],5.31,96683,DB01435,Antipyrine
,15090289,renal clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[ml] / [min],15.4,96684,DB01435,Antipyrine
,15090289,renal clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[ml] / [min],10.3,96685,DB01435,Antipyrine
,15090289,renal clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[ml] / [min],4.31,96686,DB01435,Antipyrine
,15090289,renal clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[ml] / [min],3.65,96687,DB01435,Antipyrine
,15090289,renal clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[μg] / [24h],298,96688,DB01435,Antipyrine
,15090289,excretion,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[μg] / [24h],453,96689,DB01435,Antipyrine
,15090289,excretion,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[μg] / [24h],298,96690,DB01435,Antipyrine
,975719,serum half life,The mean antipyrine serum half life (+/-SE) for the group as a whole was 8.5 +/- 0.6 hr.,Antipyrin clearance in homozygous beta-thalassemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/975719/),h,8.5,96691,DB01435,Antipyrine
,975719,apparent volume of distribution,The mean apparent volume of distribution for antipyrine (+/-SE) in the subjects with thalassemia was 0.69 +/- 0.01 L/kg.,Antipyrin clearance in homozygous beta-thalassemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/975719/),[l] / [kg],0.69,96692,DB01435,Antipyrine
,975719,metabolic clearance rate,The mean metabolic clearance rate for antipyrine (+/-SE) in the group as a whole (1.07 +/- 0.08 ml/min/kg) is substantially higher than the metabolic clearance rates for antipyrine reported in normal adults.,Antipyrin clearance in homozygous beta-thalassemia. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/975719/),[ml] / [kg·min],1.07,96693,DB01435,Antipyrine
,4033137,clearances,"As expected, placental clearances (ml/h-1/kg-1) of antipyrine from mother to fetus (392 +/- 86) and from fetus to mother (448 +/- 107) did not significantly differ.",A rat model for the study of transplacental pharmacokinetics and its assessment with antipyrine and aminoisobutyric acid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4033137/),[ml] / [h],392,97032,DB01435,Antipyrine
,4033137,clearances,"As expected, placental clearances (ml/h-1/kg-1) of antipyrine from mother to fetus (392 +/- 86) and from fetus to mother (448 +/- 107) did not significantly differ.",A rat model for the study of transplacental pharmacokinetics and its assessment with antipyrine and aminoisobutyric acid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4033137/),[ml] / [h],448,97033,DB01435,Antipyrine
,4033137,clearance,"As an alternate approach, (3H)aminoisobutyric acid was either injected into the mother or into the fetuses, and maternal and fetal blood samples were sequentially collected in each case; the clearance of this agent from fetus to mother was 53 ml/h-1/kg-1, and, as expected, was much lower than that from mother to fetus (168 ml/h-1/kg-1).",A rat model for the study of transplacental pharmacokinetics and its assessment with antipyrine and aminoisobutyric acid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4033137/),[ml] / [h],53,97034,DB01435,Antipyrine
,4033137,clearance,"As an alternate approach, (3H)aminoisobutyric acid was either injected into the mother or into the fetuses, and maternal and fetal blood samples were sequentially collected in each case; the clearance of this agent from fetus to mother was 53 ml/h-1/kg-1, and, as expected, was much lower than that from mother to fetus (168 ml/h-1/kg-1).",A rat model for the study of transplacental pharmacokinetics and its assessment with antipyrine and aminoisobutyric acid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4033137/),[ml] / [h],168,97035,DB01435,Antipyrine
,7709592,half-life elimination,"Administration of H flexuosum significantly increased antipyrine half-life elimination from 99.5 +/- 15 min to 215.5 +/- 28 min, typical of an inhibitory-type effect on MFO.",The effects of Artemisia filifolia and Helenium flexuosum on disposition of antipyrine in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7709592/),min,99.5,98065,DB01435,Antipyrine
,7709592,half-life elimination,"Administration of H flexuosum significantly increased antipyrine half-life elimination from 99.5 +/- 15 min to 215.5 +/- 28 min, typical of an inhibitory-type effect on MFO.",The effects of Artemisia filifolia and Helenium flexuosum on disposition of antipyrine in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7709592/),min,215.5,98066,DB01435,Antipyrine
,28872908,Ctau,"However, based on simulation of PPK model for a virtual ALS population, the small difference of V2 was associated with a difference of Ctau around 1 ng/mL after infusion, which was minimal compared to Cmax of approximately 1000 ng/ml.",Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28872908/),[ng] / [ml],1,98633,DB01435,Antipyrine
,28872908,Cmax,"However, based on simulation of PPK model for a virtual ALS population, the small difference of V2 was associated with a difference of Ctau around 1 ng/mL after infusion, which was minimal compared to Cmax of approximately 1000 ng/ml.",Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28872908/),[ng] / [ml],1000,98634,DB01435,Antipyrine
,2038745,systemic clearance (Cls),"The mean systemic clearance (Cls) for AC in the adults and pups was 16.1 and 13.7 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],16.1,99215,DB01435,Antipyrine
,2038745,systemic clearance (Cls),"The mean systemic clearance (Cls) for AC in the adults and pups was 16.1 and 13.7 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],13.7,99216,DB01435,Antipyrine
,2038745,half-lives,"The mean half-lives of AC (t1/2) were 25.5 and 33.3 min in the adult and pup groups, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,25.5,99217,DB01435,Antipyrine
,2038745,half-lives,"The mean half-lives of AC (t1/2) were 25.5 and 33.3 min in the adult and pup groups, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,33.3,99218,DB01435,Antipyrine
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,97.5,99219,DB01435,Antipyrine
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,95.1,99220,DB01435,Antipyrine
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,347.6,99221,DB01435,Antipyrine
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],5.34,99222,DB01435,Antipyrine
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],6.30,99223,DB01435,Antipyrine
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],1.91,99224,DB01435,Antipyrine
,2038745,t1/2,The time course of SA was prolonged in the suckling pups (t1/2 of 633 min in the pups vs 78.7 min in the adult).,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,633,99225,DB01435,Antipyrine
,2038745,t1/2,The time course of SA was prolonged in the suckling pups (t1/2 of 633 min in the pups vs 78.7 min in the adult).,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,78.7,99226,DB01435,Antipyrine
,2038745,Cls,"The mean Cls values in the adults and the pups were 1.05 and 0.27 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],1.05,99227,DB01435,Antipyrine
,2038745,Cls,"The mean Cls values in the adults and the pups were 1.05 and 0.27 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],0.27,99228,DB01435,Antipyrine
,2038745,systemic clearance of unbound drug (Clu),The mean systemic clearance of unbound drug (Clu) for SA was 11.2 ml/min/kg in the adults and 0.92 ml/min/kg in the pups.,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],11.2,99229,DB01435,Antipyrine
,2038745,systemic clearance of unbound drug (Clu),The mean systemic clearance of unbound drug (Clu) for SA was 11.2 ml/min/kg in the adults and 0.92 ml/min/kg in the pups.,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],0.92,99230,DB01435,Antipyrine
,2038745,free fraction,"The serum protein binding of AC and AN was limited, whereas the mean free fraction for SA was 9.7% in adult serum and 32.5% in pup serum.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),%,9.7,99231,DB01435,Antipyrine
,2038745,free fraction,"The serum protein binding of AC and AN was limited, whereas the mean free fraction for SA was 9.7% in adult serum and 32.5% in pup serum.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),%,32.5,99232,DB01435,Antipyrine
,6662976,volume of distribution,"Between drug-free control and ibuprofen coadministration trials, there was no significant difference in antipyrine volume of distribution (0.69 vs. 0.69 liter/kg), elimination half-life (12.2 vs. 12.5 hours), or total metabolic clearance (0.69 vs. 0.70 ml/min/kg).",Ibuprofen does not impair antipyrine clearance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662976/),[l] / [kg],0.69,101570,DB01435,Antipyrine
,6662976,elimination half-life,"Between drug-free control and ibuprofen coadministration trials, there was no significant difference in antipyrine volume of distribution (0.69 vs. 0.69 liter/kg), elimination half-life (12.2 vs. 12.5 hours), or total metabolic clearance (0.69 vs. 0.70 ml/min/kg).",Ibuprofen does not impair antipyrine clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662976/),h,12.2,101571,DB01435,Antipyrine
,6662976,elimination half-life,"Between drug-free control and ibuprofen coadministration trials, there was no significant difference in antipyrine volume of distribution (0.69 vs. 0.69 liter/kg), elimination half-life (12.2 vs. 12.5 hours), or total metabolic clearance (0.69 vs. 0.70 ml/min/kg).",Ibuprofen does not impair antipyrine clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662976/),h,12.5,101572,DB01435,Antipyrine
,6662976,total metabolic clearance,"Between drug-free control and ibuprofen coadministration trials, there was no significant difference in antipyrine volume of distribution (0.69 vs. 0.69 liter/kg), elimination half-life (12.2 vs. 12.5 hours), or total metabolic clearance (0.69 vs. 0.70 ml/min/kg).",Ibuprofen does not impair antipyrine clearance. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662976/),[ml] / [kg·min],0.69,101573,DB01435,Antipyrine
,6662976,total metabolic clearance,"Between drug-free control and ibuprofen coadministration trials, there was no significant difference in antipyrine volume of distribution (0.69 vs. 0.69 liter/kg), elimination half-life (12.2 vs. 12.5 hours), or total metabolic clearance (0.69 vs. 0.70 ml/min/kg).",Ibuprofen does not impair antipyrine clearance. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662976/),[ml] / [kg·min],0.70,101574,DB01435,Antipyrine
,1355554,half-life,The measured half-life of antipyrine was 104 min and the volume of distribution was 830 mL kg-1.,The effect of intravenous pretreatment with small liposomes on the pharmacokinetics and metabolism of antipyrine in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1355554/),min,104,103461,DB01435,Antipyrine
,1355554,volume of distribution,The measured half-life of antipyrine was 104 min and the volume of distribution was 830 mL kg-1.,The effect of intravenous pretreatment with small liposomes on the pharmacokinetics and metabolism of antipyrine in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1355554/),[ml] / [kg],830,103462,DB01435,Antipyrine
,1355554,half-life,"The half-life after liposome treatment was 110 min and the volume of distribution was 790 mL kg-1, the metabolic pattern in the urine was also unaltered.",The effect of intravenous pretreatment with small liposomes on the pharmacokinetics and metabolism of antipyrine in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1355554/),min,110,103463,DB01435,Antipyrine
,1355554,volume of distribution,"The half-life after liposome treatment was 110 min and the volume of distribution was 790 mL kg-1, the metabolic pattern in the urine was also unaltered.",The effect of intravenous pretreatment with small liposomes on the pharmacokinetics and metabolism of antipyrine in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1355554/),[ml] / [kg],790,103464,DB01435,Antipyrine
,7450926,clearance,"The antipyrine clearance in controls was 30.1 +/- 2.5 ml/kg/h (S.E.M.), in patients with viral hepatitis 30.3 +/- 3.9 ml/kg/h and in liver cirrhosis 20.4 +/- 2.7 ml/kg/h.",Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7450926/),[ml] / [h·kg],30.1,106462,DB01435,Antipyrine
,7450926,clearance,"The antipyrine clearance in controls was 30.1 +/- 2.5 ml/kg/h (S.E.M.), in patients with viral hepatitis 30.3 +/- 3.9 ml/kg/h and in liver cirrhosis 20.4 +/- 2.7 ml/kg/h.",Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7450926/),[ml] / [h·kg],30.3,106463,DB01435,Antipyrine
,7450926,clearance,"The antipyrine clearance in controls was 30.1 +/- 2.5 ml/kg/h (S.E.M.), in patients with viral hepatitis 30.3 +/- 3.9 ml/kg/h and in liver cirrhosis 20.4 +/- 2.7 ml/kg/h.",Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7450926/),[ml] / [h·kg],20.4,106464,DB01435,Antipyrine
,1744936,half-life,Antipyrine half-life in goats (2.58 h) was shorter than that in sheep (4.04 h) and camels (18.78 h).,"Pharmacokinetics of antipyrine and sulphadimidine (sulfamethazine) in camels, sheep and goats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744936/),h,2.58,108055,DB01435,Antipyrine
,1744936,half-life,Antipyrine half-life in goats (2.58 h) was shorter than that in sheep (4.04 h) and camels (18.78 h).,"Pharmacokinetics of antipyrine and sulphadimidine (sulfamethazine) in camels, sheep and goats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744936/),h,4.04,108056,DB01435,Antipyrine
,1744936,half-life,Antipyrine half-life in goats (2.58 h) was shorter than that in sheep (4.04 h) and camels (18.78 h).,"Pharmacokinetics of antipyrine and sulphadimidine (sulfamethazine) in camels, sheep and goats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744936/),h,18.78,108057,DB01435,Antipyrine
,1744936,half-life,"Sulphadimidine half-life was 2.77 h in goats, 4.72 h in sheep and 7.36 h in camels.","Pharmacokinetics of antipyrine and sulphadimidine (sulfamethazine) in camels, sheep and goats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744936/),h,2.77,108058,DB01435,Antipyrine
,1744936,half-life,"Sulphadimidine half-life was 2.77 h in goats, 4.72 h in sheep and 7.36 h in camels.","Pharmacokinetics of antipyrine and sulphadimidine (sulfamethazine) in camels, sheep and goats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744936/),h,4.72,108059,DB01435,Antipyrine
,1744936,half-life,"Sulphadimidine half-life was 2.77 h in goats, 4.72 h in sheep and 7.36 h in camels.","Pharmacokinetics of antipyrine and sulphadimidine (sulfamethazine) in camels, sheep and goats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744936/),h,7.36,108060,DB01435,Antipyrine
,2625371,elimination half-life,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),h,29.5,108152,DB01435,Antipyrine
,2625371,clearance,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),[ml] / [h·kg],24,108153,DB01435,Antipyrine
,2625371,metabolic ratio,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),,18.8,108154,DB01435,Antipyrine
,2625371,half-life,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),h,8.8,108155,DB01435,Antipyrine
,2625371,half-life,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),h,9.8,108156,DB01435,Antipyrine
,2625371,metabolic ratio,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),,3.6,108157,DB01435,Antipyrine
,2625371,metabolic ratio,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),,3.8,108158,DB01435,Antipyrine
,2625371,apparent elimination half-life,In patients with cirrhosis the apparent elimination half-life of quinidine was longer (12.8 +/- 1.8 h) whereas after oral administration clearance of quinidine (15.6 +/- 3.5 l.h-1) and quinidine/3-hydroxyquinidine ratio (9.9 +/- 2.1) were not different from controls (quinidine clearance: 13.45 +/- 1.9 l.h-1; quinidine/3-hydroxyquinidine: 10.3 +/- 2.7).,Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),h,12.8,108159,DB01435,Antipyrine
,2625371,clearance,In patients with cirrhosis the apparent elimination half-life of quinidine was longer (12.8 +/- 1.8 h) whereas after oral administration clearance of quinidine (15.6 +/- 3.5 l.h-1) and quinidine/3-hydroxyquinidine ratio (9.9 +/- 2.1) were not different from controls (quinidine clearance: 13.45 +/- 1.9 l.h-1; quinidine/3-hydroxyquinidine: 10.3 +/- 2.7).,Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),[l] / [h],15.6,108160,DB01435,Antipyrine
,2625371,clearance,In patients with cirrhosis the apparent elimination half-life of quinidine was longer (12.8 +/- 1.8 h) whereas after oral administration clearance of quinidine (15.6 +/- 3.5 l.h-1) and quinidine/3-hydroxyquinidine ratio (9.9 +/- 2.1) were not different from controls (quinidine clearance: 13.45 +/- 1.9 l.h-1; quinidine/3-hydroxyquinidine: 10.3 +/- 2.7).,Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),,9.9,108161,DB01435,Antipyrine
,2625371,clearance,In patients with cirrhosis the apparent elimination half-life of quinidine was longer (12.8 +/- 1.8 h) whereas after oral administration clearance of quinidine (15.6 +/- 3.5 l.h-1) and quinidine/3-hydroxyquinidine ratio (9.9 +/- 2.1) were not different from controls (quinidine clearance: 13.45 +/- 1.9 l.h-1; quinidine/3-hydroxyquinidine: 10.3 +/- 2.7).,Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),[l] / [h],13.45,108162,DB01435,Antipyrine
,2625371,clearance,In patients with cirrhosis the apparent elimination half-life of quinidine was longer (12.8 +/- 1.8 h) whereas after oral administration clearance of quinidine (15.6 +/- 3.5 l.h-1) and quinidine/3-hydroxyquinidine ratio (9.9 +/- 2.1) were not different from controls (quinidine clearance: 13.45 +/- 1.9 l.h-1; quinidine/3-hydroxyquinidine: 10.3 +/- 2.7).,Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),,10.3,108163,DB01435,Antipyrine
,1606991,cumulative urinary excretion,The cumulative urinary excretion of antipyrine and its three major metabolites was significantly lower in patients [44 (18) %] than in controls [71 (8) %].,Disposition of antipyrine in patients with extensive metastatic liver disease. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606991/),%,44,109150,DB01435,Antipyrine
,1606991,cumulative urinary excretion,The cumulative urinary excretion of antipyrine and its three major metabolites was significantly lower in patients [44 (18) %] than in controls [71 (8) %].,Disposition of antipyrine in patients with extensive metastatic liver disease. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606991/),%,71,109151,DB01435,Antipyrine
,10616961,elimination half-life (t(1/2)),Results indicated that CCl4 significantly increased the elimination half-life (t(1/2)) of antipyrine from 2.59 +/- 1.04 to 11.25 +/- 3.91 h (P < 0.001) and decreased its clearance (CL) from 65.94 to 10.84 ml/h as compared to control.,Evaluation of the protective effects of Schisandra chinensis on Phase I drug metabolism using a CCl4 intoxication model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10616961/),h,2.59,109275,DB01435,Antipyrine
,10616961,elimination half-life (t(1/2)),Results indicated that CCl4 significantly increased the elimination half-life (t(1/2)) of antipyrine from 2.59 +/- 1.04 to 11.25 +/- 3.91 h (P < 0.001) and decreased its clearance (CL) from 65.94 to 10.84 ml/h as compared to control.,Evaluation of the protective effects of Schisandra chinensis on Phase I drug metabolism using a CCl4 intoxication model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10616961/),h,11.25,109276,DB01435,Antipyrine
,10616961,clearance (CL),Results indicated that CCl4 significantly increased the elimination half-life (t(1/2)) of antipyrine from 2.59 +/- 1.04 to 11.25 +/- 3.91 h (P < 0.001) and decreased its clearance (CL) from 65.94 to 10.84 ml/h as compared to control.,Evaluation of the protective effects of Schisandra chinensis on Phase I drug metabolism using a CCl4 intoxication model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10616961/),[ml] / [h],65.94,109277,DB01435,Antipyrine
,10616961,clearance (CL),Results indicated that CCl4 significantly increased the elimination half-life (t(1/2)) of antipyrine from 2.59 +/- 1.04 to 11.25 +/- 3.91 h (P < 0.001) and decreased its clearance (CL) from 65.94 to 10.84 ml/h as compared to control.,Evaluation of the protective effects of Schisandra chinensis on Phase I drug metabolism using a CCl4 intoxication model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10616961/),[ml] / [h],10.84,109278,DB01435,Antipyrine
,10616961,t(1/2),"Pretreatment with the Schisandra lignan fraction 30 min or 6 h before intoxication significantly (P < 0.001) improved antipyrine elimination by reducing its t(1/2) to 3.30 +/- 0.52 and 3.58 +/- 1.05 h, respectively.",Evaluation of the protective effects of Schisandra chinensis on Phase I drug metabolism using a CCl4 intoxication model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10616961/),h,3.30,109279,DB01435,Antipyrine
,10616961,t(1/2),"Pretreatment with the Schisandra lignan fraction 30 min or 6 h before intoxication significantly (P < 0.001) improved antipyrine elimination by reducing its t(1/2) to 3.30 +/- 0.52 and 3.58 +/- 1.05 h, respectively.",Evaluation of the protective effects of Schisandra chinensis on Phase I drug metabolism using a CCl4 intoxication model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10616961/),h,3.58,109280,DB01435,Antipyrine
,10616961,CL,"The corresponding improvements observed for CL, i.e. 49.06 +/- 21.75 ml/h (P < 0.01); 21.10 +/- 10.42 ml/h (P < 0.05), were also substantial.",Evaluation of the protective effects of Schisandra chinensis on Phase I drug metabolism using a CCl4 intoxication model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10616961/),[ml] / [h],49.06,109281,DB01435,Antipyrine
,10616961,CL,"The corresponding improvements observed for CL, i.e. 49.06 +/- 21.75 ml/h (P < 0.01); 21.10 +/- 10.42 ml/h (P < 0.05), were also substantial.",Evaluation of the protective effects of Schisandra chinensis on Phase I drug metabolism using a CCl4 intoxication model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10616961/),[ml] / [h],21.10,109282,DB01435,Antipyrine
,6813365,half-life,"In the control state, antipyrine half-life was longer in elderly than in young subjects (16.4 vs 11.0 hours), and metabolic clearance lower (0.48 vs 0.72 ml/min/kg).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),h,16.4,109996,DB01435,Antipyrine
,6813365,half-life,"In the control state, antipyrine half-life was longer in elderly than in young subjects (16.4 vs 11.0 hours), and metabolic clearance lower (0.48 vs 0.72 ml/min/kg).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),h,11.0,109997,DB01435,Antipyrine
,6813365,metabolic clearance,"In the control state, antipyrine half-life was longer in elderly than in young subjects (16.4 vs 11.0 hours), and metabolic clearance lower (0.48 vs 0.72 ml/min/kg).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),[ml] / [kg·min],0.48,109998,DB01435,Antipyrine
,6813365,metabolic clearance,"In the control state, antipyrine half-life was longer in elderly than in young subjects (16.4 vs 11.0 hours), and metabolic clearance lower (0.48 vs 0.72 ml/min/kg).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),[ml] / [kg·min],0.72,109999,DB01435,Antipyrine
,6813365,half-life,"However, coadministration of cimetidine prolonged antipyrine half-life to a similar extent in elderly and in young groups (150 and 153 per cent of control) and reduced metabolic clearance to a similar extent in both (79 vs 69 per cent of control) groups.",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,150,110000,DB01435,Antipyrine
,6813365,half-life,"However, coadministration of cimetidine prolonged antipyrine half-life to a similar extent in elderly and in young groups (150 and 153 per cent of control) and reduced metabolic clearance to a similar extent in both (79 vs 69 per cent of control) groups.",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,153,110001,DB01435,Antipyrine
,6813365,metabolic clearance,"However, coadministration of cimetidine prolonged antipyrine half-life to a similar extent in elderly and in young groups (150 and 153 per cent of control) and reduced metabolic clearance to a similar extent in both (79 vs 69 per cent of control) groups.",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,79,110002,DB01435,Antipyrine
,6813365,metabolic clearance,"However, coadministration of cimetidine prolonged antipyrine half-life to a similar extent in elderly and in young groups (150 and 153 per cent of control) and reduced metabolic clearance to a similar extent in both (79 vs 69 per cent of control) groups.",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,69,110003,DB01435,Antipyrine
,6813365,half-life,"As in the case of antipyrine, cimetidine prolonged desmethyldiazepam half-life similarly in young and elderly groups (175 vs 164 per cent of control) and similarly reduced metabolic clearance (51 vs 65 per cent of control).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,175,110004,DB01435,Antipyrine
,6813365,half-life,"As in the case of antipyrine, cimetidine prolonged desmethyldiazepam half-life similarly in young and elderly groups (175 vs 164 per cent of control) and similarly reduced metabolic clearance (51 vs 65 per cent of control).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,164,110005,DB01435,Antipyrine
,6813365,metabolic clearance,"As in the case of antipyrine, cimetidine prolonged desmethyldiazepam half-life similarly in young and elderly groups (175 vs 164 per cent of control) and similarly reduced metabolic clearance (51 vs 65 per cent of control).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,51,110006,DB01435,Antipyrine
,6813365,metabolic clearance,"As in the case of antipyrine, cimetidine prolonged desmethyldiazepam half-life similarly in young and elderly groups (175 vs 164 per cent of control) and similarly reduced metabolic clearance (51 vs 65 per cent of control).",Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6813365/),%,65,110007,DB01435,Antipyrine
,15359582,systemic clearance,"Testosterone BA was less than 10% by ID, IC, and IPV routes, due to high hepatic extraction, consistent with its high systemic clearance (63 ml x min(-1) x kg(-1)) and short terminal plasma half-life (23 min).",Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),[ml] / [kg·min],63,112742,DB01435,Antipyrine
,15359582,terminal plasma half-life,"Testosterone BA was less than 10% by ID, IC, and IPV routes, due to high hepatic extraction, consistent with its high systemic clearance (63 ml x min(-1) x kg(-1)) and short terminal plasma half-life (23 min).",Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),min,23,112743,DB01435,Antipyrine
,15359582,BA,"The IPV BA of amoxicillin was 95%+/-6% indicating the absence of hepatic extraction in the rat, but with an ID BA of approximately 39% suggesting incomplete GI absorption to be the main barrier to bioavailability.",Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),%,95,112744,DB01435,Antipyrine
,15359582,BA,"The IPV BA of amoxicillin was 95%+/-6% indicating the absence of hepatic extraction in the rat, but with an ID BA of approximately 39% suggesting incomplete GI absorption to be the main barrier to bioavailability.",Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),%,39,112745,DB01435,Antipyrine
,15359582,BA,Low oral BA of propranolol was due in part to first-pass hepatic extraction (IPV BA of 36%).,Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),%,36,112746,DB01435,Antipyrine
,1296183,%Qa,The mean %Qa for patients with Child A cirrhosis was significantly higher than that for 8 healthy subjects (34.8 +/- 7.9% vs 18.1 +/- 4.0; P < 0.01).,Clinical utility of quantitative assessment of liver haemodynamics in cirrhosis provided by dynamic hepatoscintigraphy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1296183/),%,34.8,113628,DB01435,Antipyrine
,1296183,%Qa,The mean %Qa for patients with Child A cirrhosis was significantly higher than that for 8 healthy subjects (34.8 +/- 7.9% vs 18.1 +/- 4.0; P < 0.01).,Clinical utility of quantitative assessment of liver haemodynamics in cirrhosis provided by dynamic hepatoscintigraphy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1296183/),,18.1,113629,DB01435,Antipyrine
,1761736,total body clearance,"Diltiazem decreased the total body clearance from 34.0 +/- 8.0 to 28.6 +/- 6.1 mL/min (P less than .01), and prolonged the elimination half-life from 12.6 +/- 3.0 to 14.3 +/- 2.5 hours (P less than .01) of antipyrine without any changes in volume of distribution.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),[ml] / [min],34.0,113680,DB01435,Antipyrine
,1761736,total body clearance,"Diltiazem decreased the total body clearance from 34.0 +/- 8.0 to 28.6 +/- 6.1 mL/min (P less than .01), and prolonged the elimination half-life from 12.6 +/- 3.0 to 14.3 +/- 2.5 hours (P less than .01) of antipyrine without any changes in volume of distribution.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),[ml] / [min],28.6,113681,DB01435,Antipyrine
,1761736,elimination half-life,"Diltiazem decreased the total body clearance from 34.0 +/- 8.0 to 28.6 +/- 6.1 mL/min (P less than .01), and prolonged the elimination half-life from 12.6 +/- 3.0 to 14.3 +/- 2.5 hours (P less than .01) of antipyrine without any changes in volume of distribution.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),h,12.6,113682,DB01435,Antipyrine
,1761736,elimination half-life,"Diltiazem decreased the total body clearance from 34.0 +/- 8.0 to 28.6 +/- 6.1 mL/min (P less than .01), and prolonged the elimination half-life from 12.6 +/- 3.0 to 14.3 +/- 2.5 hours (P less than .01) of antipyrine without any changes in volume of distribution.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),h,14.3,113683,DB01435,Antipyrine
,1761736,cumulative renal excretion,The cumulative renal excretion (% dose) of antipyrine was significantly increased from 2.23 +/- 0.73 to 2.78 +/- 0.83% (P less than .05).,The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),%,2.23,113684,DB01435,Antipyrine
,1761736,cumulative renal excretion,The cumulative renal excretion (% dose) of antipyrine was significantly increased from 2.23 +/- 0.73 to 2.78 +/- 0.83% (P less than .05).,The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),%,2.78,113685,DB01435,Antipyrine
,1761736,Clearances of production,"Clearances of production for three major antipyrine metabolites, norantipyrine (4.31 +/- 1.64 to 3.50 +/- 1.28 mL/min, P less than .01), 3-hydroxymethylantipyrine (4.67 +/- 1.63 to 3.82 +/- 1.34 mL/min, P less than .01) and 4-hydroxyantipyrine (10.47 +/- 3.41 to 8.16 +/- 2.82 mL/min, P less than .01) were reduced significantly by diltiazem.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),[ml] / [min],4.31,113686,DB01435,Antipyrine
,1761736,Clearances of production,"Clearances of production for three major antipyrine metabolites, norantipyrine (4.31 +/- 1.64 to 3.50 +/- 1.28 mL/min, P less than .01), 3-hydroxymethylantipyrine (4.67 +/- 1.63 to 3.82 +/- 1.34 mL/min, P less than .01) and 4-hydroxyantipyrine (10.47 +/- 3.41 to 8.16 +/- 2.82 mL/min, P less than .01) were reduced significantly by diltiazem.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),[ml] / [min],3.50,113687,DB01435,Antipyrine
,1761736,Clearances of production,"Clearances of production for three major antipyrine metabolites, norantipyrine (4.31 +/- 1.64 to 3.50 +/- 1.28 mL/min, P less than .01), 3-hydroxymethylantipyrine (4.67 +/- 1.63 to 3.82 +/- 1.34 mL/min, P less than .01) and 4-hydroxyantipyrine (10.47 +/- 3.41 to 8.16 +/- 2.82 mL/min, P less than .01) were reduced significantly by diltiazem.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),[ml] / [min],4.67,113688,DB01435,Antipyrine
,1761736,Clearances of production,"Clearances of production for three major antipyrine metabolites, norantipyrine (4.31 +/- 1.64 to 3.50 +/- 1.28 mL/min, P less than .01), 3-hydroxymethylantipyrine (4.67 +/- 1.63 to 3.82 +/- 1.34 mL/min, P less than .01) and 4-hydroxyantipyrine (10.47 +/- 3.41 to 8.16 +/- 2.82 mL/min, P less than .01) were reduced significantly by diltiazem.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),[ml] / [min],3.82,113689,DB01435,Antipyrine
,1761736,Clearances of production,"Clearances of production for three major antipyrine metabolites, norantipyrine (4.31 +/- 1.64 to 3.50 +/- 1.28 mL/min, P less than .01), 3-hydroxymethylantipyrine (4.67 +/- 1.63 to 3.82 +/- 1.34 mL/min, P less than .01) and 4-hydroxyantipyrine (10.47 +/- 3.41 to 8.16 +/- 2.82 mL/min, P less than .01) were reduced significantly by diltiazem.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),[ml] / [min],10.47,113690,DB01435,Antipyrine
,1761736,Clearances of production,"Clearances of production for three major antipyrine metabolites, norantipyrine (4.31 +/- 1.64 to 3.50 +/- 1.28 mL/min, P less than .01), 3-hydroxymethylantipyrine (4.67 +/- 1.63 to 3.82 +/- 1.34 mL/min, P less than .01) and 4-hydroxyantipyrine (10.47 +/- 3.41 to 8.16 +/- 2.82 mL/min, P less than .01) were reduced significantly by diltiazem.",The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761736/),[ml] / [min],8.16,113691,DB01435,Antipyrine
,3842695,t1/2 el,"In the mean, t1/2 el and Cl tot of antipyrine were found to be 16.1 h and 32.9 ml/min, t1/2 beta and Cl tot of adriamycin were 23.1 h and 877 ml/min.",Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3842695/),h,16.1,114078,DB01435,Antipyrine
,3842695,Cl tot,"In the mean, t1/2 el and Cl tot of antipyrine were found to be 16.1 h and 32.9 ml/min, t1/2 beta and Cl tot of adriamycin were 23.1 h and 877 ml/min.",Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3842695/),[ml] / [min],32.9,114079,DB01435,Antipyrine
,3842695,t1/2 beta,"In the mean, t1/2 el and Cl tot of antipyrine were found to be 16.1 h and 32.9 ml/min, t1/2 beta and Cl tot of adriamycin were 23.1 h and 877 ml/min.",Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3842695/),h,23.1,114080,DB01435,Antipyrine
,3842695,Cl tot,"In the mean, t1/2 el and Cl tot of antipyrine were found to be 16.1 h and 32.9 ml/min, t1/2 beta and Cl tot of adriamycin were 23.1 h and 877 ml/min.",Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3842695/),[ml] / [min],877,114081,DB01435,Antipyrine
,3842695,AUC adriamycinol/AUC adriamycin ratio,A relationship between the AUC adriamycinol/AUC adriamycin ratio (which was 0.52 in the mean) and the antipyrine elimination rate did not exist.,Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3842695/),,0.52,114082,DB01435,Antipyrine
less,3842695,elimination half-life,"As compared to the patients with elimination half-life values of less than 20 h, five patients with antipyrine elimination half-life values of more than 20 h had a significantly longer adriamycin elimination beta-phase and a stronger depressive effect on the white blood cells.",Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3842695/),h,20,114083,DB01435,Antipyrine
more,3842695,elimination half-life,"As compared to the patients with elimination half-life values of less than 20 h, five patients with antipyrine elimination half-life values of more than 20 h had a significantly longer adriamycin elimination beta-phase and a stronger depressive effect on the white blood cells.",Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3842695/),h,20,114084,DB01435,Antipyrine
,28633547,polydispersity index,"The liquid LNS (L-LNS) with Capryol™ PGMC (Oil), Cremophor® RH 40:Labrasol®:TPGS 1000 (1:0.8:0.2) (Surfactant) and Transcutol P® (Co-surfactant) were optimized to form microemulsion having droplet size (16.25 nm), polydispersity index (0.039), % Transmittance (99.85%), and self-emulsification time (32 s).","Lipid-based nanosystem of edaravone: development, optimization, characterization and in vitro/in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28633547/),,0.039,116811,DB01435,Antipyrine
,28633547,% Transmittance,"The liquid LNS (L-LNS) with Capryol™ PGMC (Oil), Cremophor® RH 40:Labrasol®:TPGS 1000 (1:0.8:0.2) (Surfactant) and Transcutol P® (Co-surfactant) were optimized to form microemulsion having droplet size (16.25 nm), polydispersity index (0.039), % Transmittance (99.85%), and self-emulsification time (32 s).","Lipid-based nanosystem of edaravone: development, optimization, characterization and in vitro/in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28633547/),%,99.85,116812,DB01435,Antipyrine
,1934861,clearance,"Antipyrine clearance was increased significantly from baseline (0.50 +/- 0.31 ml/min/kg) on study days 4, 7, and 14 (p less than 0.0001).",Effect of neurotrauma on hepatic drug clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1934861/),[ml] / [kg·min],0.50,117567,DB01435,Antipyrine
,1934861,clearance,A significant increase was also observed in lorazepam clearance on study day 14 relative to baseline (1.39 +/- 0.56 ml/min/kg) (p less than 0.005).,Effect of neurotrauma on hepatic drug clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1934861/),[ml] / [kg·min],1.39,117568,DB01435,Antipyrine
,29112064,fetal transfer rate (FTR),"For elvitegravir, in open-circuit experiments the mean (±SD) fetal transfer rate (FTR) (fetal/maternal concentration at steady state from 30 to 90 min) was 19 ± 13% and the mean clearance index was 0.46 ± 0.21; in the closed-circuit model, after 3 h of perfusion the FTR was 20 ± 10% and the mean accumulation index was 12.28 ± 5.57.",Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29112064/),%,19,117957,DB01435,Antipyrine
,29112064,clearance index,"For elvitegravir, in open-circuit experiments the mean (±SD) fetal transfer rate (FTR) (fetal/maternal concentration at steady state from 30 to 90 min) was 19 ± 13% and the mean clearance index was 0.46 ± 0.21; in the closed-circuit model, after 3 h of perfusion the FTR was 20 ± 10% and the mean accumulation index was 12.28 ± 5.57.",Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29112064/),,0.46,117958,DB01435,Antipyrine
,29112064,FTR,"For elvitegravir, in open-circuit experiments the mean (±SD) fetal transfer rate (FTR) (fetal/maternal concentration at steady state from 30 to 90 min) was 19 ± 13% and the mean clearance index was 0.46 ± 0.21; in the closed-circuit model, after 3 h of perfusion the FTR was 20 ± 10% and the mean accumulation index was 12.28 ± 5.57.",Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29112064/),%,20,117959,DB01435,Antipyrine
,29112064,accumulation index,"For elvitegravir, in open-circuit experiments the mean (±SD) fetal transfer rate (FTR) (fetal/maternal concentration at steady state from 30 to 90 min) was 19 ± 13% and the mean clearance index was 0.46 ± 0.21; in the closed-circuit model, after 3 h of perfusion the FTR was 20 ± 10% and the mean accumulation index was 12.28 ± 5.57.",Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29112064/),,12.28,117960,DB01435,Antipyrine
,29112064,clearance index,"For cobicistat, in the open perfusions the FTR was 23 ± 13% and the mean clearance index was 0.63 ± 0.34; in the closed perfusions after 3 h the fetal-to-maternal ratio of cobicistat was 21 ± 11%.",Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29112064/),,0.63,117961,DB01435,Antipyrine
,29112064,accumulation index,The mean accumulation index was 3.46 ± 2.19 CONCLUSION::,Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29112064/),,3.46,117962,DB01435,Antipyrine
,2073104,total plasma clearance,"The total plasma clearance of antipyrine was decreased from 0.130 +/- 0.007 to 0.090 +/- 0.005 liter/h (mean +/- standard error of the mean) (P less than 0.01) by ciprofloxacin, while the half-life at beta (elimination) phase and the area under the concentration-time curve for antipyrine were increased from 1.90 +/- 0.22 to 2.83 +/- 0.29 h (P less than 0.05) and from 43.25 +/- 3.35 to 52.41 +/- 2.31 mg.h/liter (P less than 0.05), respectively.",Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073104/),[l] / [h],0.130,118131,DB01435,Antipyrine
,2073104,total plasma clearance,"The total plasma clearance of antipyrine was decreased from 0.130 +/- 0.007 to 0.090 +/- 0.005 liter/h (mean +/- standard error of the mean) (P less than 0.01) by ciprofloxacin, while the half-life at beta (elimination) phase and the area under the concentration-time curve for antipyrine were increased from 1.90 +/- 0.22 to 2.83 +/- 0.29 h (P less than 0.05) and from 43.25 +/- 3.35 to 52.41 +/- 2.31 mg.h/liter (P less than 0.05), respectively.",Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073104/),[l] / [h],0.090,118132,DB01435,Antipyrine
,2073104,half-life at beta (elimination) phase,"The total plasma clearance of antipyrine was decreased from 0.130 +/- 0.007 to 0.090 +/- 0.005 liter/h (mean +/- standard error of the mean) (P less than 0.01) by ciprofloxacin, while the half-life at beta (elimination) phase and the area under the concentration-time curve for antipyrine were increased from 1.90 +/- 0.22 to 2.83 +/- 0.29 h (P less than 0.05) and from 43.25 +/- 3.35 to 52.41 +/- 2.31 mg.h/liter (P less than 0.05), respectively.",Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073104/),h,1.90,118133,DB01435,Antipyrine
,2073104,area under the concentration-time curve,"The total plasma clearance of antipyrine was decreased from 0.130 +/- 0.007 to 0.090 +/- 0.005 liter/h (mean +/- standard error of the mean) (P less than 0.01) by ciprofloxacin, while the half-life at beta (elimination) phase and the area under the concentration-time curve for antipyrine were increased from 1.90 +/- 0.22 to 2.83 +/- 0.29 h (P less than 0.05) and from 43.25 +/- 3.35 to 52.41 +/- 2.31 mg.h/liter (P less than 0.05), respectively.",Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073104/),h,2.83,118134,DB01435,Antipyrine
,2073104,area under the concentration-time curve,"The total plasma clearance of antipyrine was decreased from 0.130 +/- 0.007 to 0.090 +/- 0.005 liter/h (mean +/- standard error of the mean) (P less than 0.01) by ciprofloxacin, while the half-life at beta (elimination) phase and the area under the concentration-time curve for antipyrine were increased from 1.90 +/- 0.22 to 2.83 +/- 0.29 h (P less than 0.05) and from 43.25 +/- 3.35 to 52.41 +/- 2.31 mg.h/liter (P less than 0.05), respectively.",Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073104/),[h·mg] / [l],43.25,118135,DB01435,Antipyrine
,2073104,area under the concentration-time curve,"The total plasma clearance of antipyrine was decreased from 0.130 +/- 0.007 to 0.090 +/- 0.005 liter/h (mean +/- standard error of the mean) (P less than 0.01) by ciprofloxacin, while the half-life at beta (elimination) phase and the area under the concentration-time curve for antipyrine were increased from 1.90 +/- 0.22 to 2.83 +/- 0.29 h (P less than 0.05) and from 43.25 +/- 3.35 to 52.41 +/- 2.31 mg.h/liter (P less than 0.05), respectively.",Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2073104/),[h·mg] / [l],52.41,118136,DB01435,Antipyrine
,8055680,terminal elimination half-life,The terminal elimination half-life is between 20 and 50 hours.,Clinical pharmacokinetics of ticlopidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8055680/),h,20 and 50,118182,DB01435,Antipyrine
,24133013,flow rate,"Chromatographic separations were achieved on an Agilent Zorbax SB-Aq (100 × 2.1 mm, 3.5 μm) column, with a gradient of water (containing 0.03% formic acid) and methanol as the mobile phase at a flow rate of 0.3 mL/min.",Development and application of a LC-MS/MS assay for the simultaneous quantification of edaravone and taurine in beagle plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24133013/),[ml] / [min],0.3,118523,DB01435,Antipyrine
,24133013,m/z,"The analyte detection was carried out in multiple reaction monitoring mode and the optimized precursor-to-product transitions of m/z [M+H](+) 175.1 → 133.0 (edaravone), m/z [M+H](+) 189.1 → 147.0 (3-methyl-1-p-tolyl-5-pyrazolone, internal standard, IS), m/z [M-H](-) 124.1→80.0 (taurine), and m/z [M-H](-) 172.0 → 80.0 (sulfanilic acid, IS) were employed to quantify edaravone, taurine, and their corresponding ISs, respectively.",Development and application of a LC-MS/MS assay for the simultaneous quantification of edaravone and taurine in beagle plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24133013/),,189.1,118524,DB01435,Antipyrine
,24133013,m/z,"The analyte detection was carried out in multiple reaction monitoring mode and the optimized precursor-to-product transitions of m/z [M+H](+) 175.1 → 133.0 (edaravone), m/z [M+H](+) 189.1 → 147.0 (3-methyl-1-p-tolyl-5-pyrazolone, internal standard, IS), m/z [M-H](-) 124.1→80.0 (taurine), and m/z [M-H](-) 172.0 → 80.0 (sulfanilic acid, IS) were employed to quantify edaravone, taurine, and their corresponding ISs, respectively.",Development and application of a LC-MS/MS assay for the simultaneous quantification of edaravone and taurine in beagle plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24133013/),,147.0,118525,DB01435,Antipyrine
,24133013,m/z,"The analyte detection was carried out in multiple reaction monitoring mode and the optimized precursor-to-product transitions of m/z [M+H](+) 175.1 → 133.0 (edaravone), m/z [M+H](+) 189.1 → 147.0 (3-methyl-1-p-tolyl-5-pyrazolone, internal standard, IS), m/z [M-H](-) 124.1→80.0 (taurine), and m/z [M-H](-) 172.0 → 80.0 (sulfanilic acid, IS) were employed to quantify edaravone, taurine, and their corresponding ISs, respectively.",Development and application of a LC-MS/MS assay for the simultaneous quantification of edaravone and taurine in beagle plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24133013/),,124,118526,DB01435,Antipyrine
,24133013,m/z,"The analyte detection was carried out in multiple reaction monitoring mode and the optimized precursor-to-product transitions of m/z [M+H](+) 175.1 → 133.0 (edaravone), m/z [M+H](+) 189.1 → 147.0 (3-methyl-1-p-tolyl-5-pyrazolone, internal standard, IS), m/z [M-H](-) 124.1→80.0 (taurine), and m/z [M-H](-) 172.0 → 80.0 (sulfanilic acid, IS) were employed to quantify edaravone, taurine, and their corresponding ISs, respectively.",Development and application of a LC-MS/MS assay for the simultaneous quantification of edaravone and taurine in beagle plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24133013/),,172,118527,DB01435,Antipyrine
,24133013,LOD,"The LOD and the lower LOQ were 0.01 and 0.05 μg/mL for edaravone and 0.66 and 2 μg/mL for taurine, respectively.",Development and application of a LC-MS/MS assay for the simultaneous quantification of edaravone and taurine in beagle plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24133013/),[μg] / [ml],0.01,118528,DB01435,Antipyrine
,24133013,LOD,"The LOD and the lower LOQ were 0.01 and 0.05 μg/mL for edaravone and 0.66 and 2 μg/mL for taurine, respectively.",Development and application of a LC-MS/MS assay for the simultaneous quantification of edaravone and taurine in beagle plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24133013/),[μg] / [ml],0.05,118529,DB01435,Antipyrine
,24133013,LOD,"The LOD and the lower LOQ were 0.01 and 0.05 μg/mL for edaravone and 0.66 and 2 μg/mL for taurine, respectively.",Development and application of a LC-MS/MS assay for the simultaneous quantification of edaravone and taurine in beagle plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24133013/),[μg] / [ml],0.66,118530,DB01435,Antipyrine
,24133013,LOD,"The LOD and the lower LOQ were 0.01 and 0.05 μg/mL for edaravone and 0.66 and 2 μg/mL for taurine, respectively.",Development and application of a LC-MS/MS assay for the simultaneous quantification of edaravone and taurine in beagle plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24133013/),[μg] / [ml],2,118531,DB01435,Antipyrine
,12130720,total volume of distribution,"The total volume of distribution of the highly lipophilic drug thiopental was more than 60% larger than that of antipyrine, 53 versus 33 liters, respectively.",The concordance of early antipyrine and thiopental distribution kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130720/),l,53,119036,DB01435,Antipyrine
,12130720,total volume of distribution,"The total volume of distribution of the highly lipophilic drug thiopental was more than 60% larger than that of antipyrine, 53 versus 33 liters, respectively.",The concordance of early antipyrine and thiopental distribution kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130720/),l,33,119037,DB01435,Antipyrine
,1413873,peak plasma concentrations,"2. After the first dose, peak plasma concentrations (median 0.31, range 0.08-0.80 mg/l) were generally found at 2 h.",Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413873/),[mg] / [l],0.31,119062,DB01435,Antipyrine
,1413873,AUC,The median AUC value for this first dosage interval (AUC tau) was 0.97 (range 0.41-3.49) mg h l-1.,Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413873/),[h·mg] / [l],0.97,119063,DB01435,Antipyrine
,1413873,AUC tau),The median AUC value for this first dosage interval (AUC tau) was 0.97 (range 0.41-3.49) mg h l-1.,Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413873/),[h·mg] / [l],0.97,119064,DB01435,Antipyrine
,1413873,half-life,"From 30 h after the final dose, drug levels declined exponentially with a median half-life of 28.8 (range less than or equal to 20-50) h. 4.",Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413873/),h,28.8,119065,DB01435,Antipyrine
,1413873,peak concentration,"Following the final dose, the median peak concentration and AUC tau were 0.99 (range 0.22-2.12) mg/l and 4.06 (range 0.90-15.2) mg h l-1 respectively.",Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413873/),[mg] / [l],0.99,119066,DB01435,Antipyrine
,1413873,AUC tau,"Following the final dose, the median peak concentration and AUC tau were 0.99 (range 0.22-2.12) mg/l and 4.06 (range 0.90-15.2) mg h l-1 respectively.",Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413873/),[h·mg] / [l],4.06,119067,DB01435,Antipyrine
,1413873,accumulation factor,"Based on AUC values, the mean accumulation factor +/- SD was 3.73 +/- 1.14.",Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413873/),,3.73,119068,DB01435,Antipyrine
,6613161,urinary recoveries,"After ingestion of [N-14CH3]antipyrine by two healthy male subjects, the urinary recoveries of radioactivity plus norantipyrine (non-radioactive) were 63 and 73%.",Human metabolism of antipyrine labelled with 14C in the pyrazolone ring or in the N-methyl group. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6613161/),%,63,119672,DB01435,Antipyrine
,6613161,urinary recoveries,"After ingestion of [N-14CH3]antipyrine by two healthy male subjects, the urinary recoveries of radioactivity plus norantipyrine (non-radioactive) were 63 and 73%.",Human metabolism of antipyrine labelled with 14C in the pyrazolone ring or in the N-methyl group. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6613161/),%,73,119673,DB01435,Antipyrine
,6613161,urinary recoveries,"After ingestion of [3-14C]antipyrine in the same two subjects, the urinary recoveries of radioactivity were 84 and 99%.",Human metabolism of antipyrine labelled with 14C in the pyrazolone ring or in the N-methyl group. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6613161/),%,84,119674,DB01435,Antipyrine
,6613161,urinary recoveries,"After ingestion of [3-14C]antipyrine in the same two subjects, the urinary recoveries of radioactivity were 84 and 99%.",Human metabolism of antipyrine labelled with 14C in the pyrazolone ring or in the N-methyl group. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6613161/),%,99,119675,DB01435,Antipyrine
,3741715,oral clearance,The oral clearance of antipyrine was decreased from 2.18 to 1.95 l h-1 (P less than 0.01) by verapamil (80 mg three times daily for 2 days prior to antipyrine administration and 2 days following) while half-life was increased from 13.2 to 15.6 h (P less than 0.01).,The effect of verapamil on antipyrine pharmacokinetics and metabolism in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741715/),[l] / [h],2,120073,DB01435,Antipyrine
,3741715,oral clearance,The oral clearance of antipyrine was decreased from 2.18 to 1.95 l h-1 (P less than 0.01) by verapamil (80 mg three times daily for 2 days prior to antipyrine administration and 2 days following) while half-life was increased from 13.2 to 15.6 h (P less than 0.01).,The effect of verapamil on antipyrine pharmacokinetics and metabolism in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741715/),[l] / [h],1,120074,DB01435,Antipyrine
,3741715,half-life,The oral clearance of antipyrine was decreased from 2.18 to 1.95 l h-1 (P less than 0.01) by verapamil (80 mg three times daily for 2 days prior to antipyrine administration and 2 days following) while half-life was increased from 13.2 to 15.6 h (P less than 0.01).,The effect of verapamil on antipyrine pharmacokinetics and metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741715/),h,13,120075,DB01435,Antipyrine
,6487466,time to peak plasma concentration,The time to peak plasma concentration was delayed by an average of 46 min (P less than 0.01) and the peak plasma concentration was significantly lower (P less than 0.05) if delayed capsule transit occurred.,Antipyrine absorption after delayed oesophageal capsule transit. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487466/),min,46,120549,DB01435,Antipyrine
,3828961,half-life time (t0.5),"The mean phenazone half-life time (t0.5) was significantly shorter in patients with breast cancer (8.880 +/- 2.5585 h) than in healthy persons (12.024 +/- 3.8486 h, P less than 0.001).",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),h,8.880,120567,DB01435,Antipyrine
,3828961,half-life time (t0.5),"The mean phenazone half-life time (t0.5) was significantly shorter in patients with breast cancer (8.880 +/- 2.5585 h) than in healthy persons (12.024 +/- 3.8486 h, P less than 0.001).",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),h,12.024,120568,DB01435,Antipyrine
,3828961,elimination rate constant (K,"Mean elimination rate constant (K, 0.063 +/- 0.0197 h-1) and mean metabolic clearance rate (MCR, 54.968 +/- 20.3476 ml/min) differed statistically (P less than 0.01) from the same parameters in control group, where K was 0.063 +/- 0.0197 h-1, MCR was 41.832 +/- 14.7153 ml/min.",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),1/[h],0.063,120569,DB01435,Antipyrine
,3828961,metabolic clearance rate (MCR,"Mean elimination rate constant (K, 0.063 +/- 0.0197 h-1) and mean metabolic clearance rate (MCR, 54.968 +/- 20.3476 ml/min) differed statistically (P less than 0.01) from the same parameters in control group, where K was 0.063 +/- 0.0197 h-1, MCR was 41.832 +/- 14.7153 ml/min.",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),[ml] / [min],54.968,120570,DB01435,Antipyrine
,3828961,K,"Mean elimination rate constant (K, 0.063 +/- 0.0197 h-1) and mean metabolic clearance rate (MCR, 54.968 +/- 20.3476 ml/min) differed statistically (P less than 0.01) from the same parameters in control group, where K was 0.063 +/- 0.0197 h-1, MCR was 41.832 +/- 14.7153 ml/min.",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),1/[h],0.063,120571,DB01435,Antipyrine
,3828961,MCR,"Mean elimination rate constant (K, 0.063 +/- 0.0197 h-1) and mean metabolic clearance rate (MCR, 54.968 +/- 20.3476 ml/min) differed statistically (P less than 0.01) from the same parameters in control group, where K was 0.063 +/- 0.0197 h-1, MCR was 41.832 +/- 14.7153 ml/min.",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),[ml] / [min],41.832,120572,DB01435,Antipyrine
,7959316,clearance index,The clearance index of d4T was 0.24 +/- 0.07 at 1.0 micrograms/ml and 0.235 +/- 0.045 at 10.0 micrograms/ml.,The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959316/),,0.24,122016,DB01435,Antipyrine
,7959316,clearance index,The clearance index of d4T was 0.24 +/- 0.07 at 1.0 micrograms/ml and 0.235 +/- 0.045 at 10.0 micrograms/ml.,The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959316/),,0.235,122017,DB01435,Antipyrine
,7757313,relative bioavailability,The relative bioavailability of the capsule formulation of antipyrine was 97%.,Antipyrine repeatability and comparison of the powder and capsule formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757313/),%,97,122642,DB01435,Antipyrine
,10362265,plasma elimination half-lives (t1/2),"The plasma elimination half-lives (t1/2) were 1.2 h for antipyrine, 11.9 h for warfarin and 5.2-12.9 h for paracetamol.","Pharmacokinetics of antipyrine, warfarin and paracetamol in the brushtail possum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10362265/),h,1.2,123048,DB01435,Antipyrine
,10362265,plasma elimination half-lives (t1/2),"The plasma elimination half-lives (t1/2) were 1.2 h for antipyrine, 11.9 h for warfarin and 5.2-12.9 h for paracetamol.","Pharmacokinetics of antipyrine, warfarin and paracetamol in the brushtail possum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10362265/),h,11.9,123049,DB01435,Antipyrine
,10362265,plasma elimination half-lives (t1/2),"The plasma elimination half-lives (t1/2) were 1.2 h for antipyrine, 11.9 h for warfarin and 5.2-12.9 h for paracetamol.","Pharmacokinetics of antipyrine, warfarin and paracetamol in the brushtail possum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10362265/),h,5.2-12.9,123050,DB01435,Antipyrine
,750270,half-life,The mean antipyrine half-life was significantly longer (21.5 +/- 1.5 hr) in 3 patients with disseminated gastric carcinoma compared to control subjects (9.3 +/- 1.5 hr) (P less than 0.001).,Microsomal enzymes in patients with gastric carcinoma as determined by plasma half-life of antipyrine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/750270/),h,21.5,123508,DB01435,Antipyrine
,750270,half-life,The mean antipyrine half-life was significantly longer (21.5 +/- 1.5 hr) in 3 patients with disseminated gastric carcinoma compared to control subjects (9.3 +/- 1.5 hr) (P less than 0.001).,Microsomal enzymes in patients with gastric carcinoma as determined by plasma half-life of antipyrine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/750270/),h,9.3,123509,DB01435,Antipyrine
,750270,metabolic clearance rate,"Similarily, the mean metabolic clearance rate of antipyrine was significantly lower (22.8 +/- 5.0 ml/hr/kg) in patients with disseminated gastric carcinoma compared to control subjects (52.6 +/- 13.4 ml/hr/kg) (P less than 0.02).",Microsomal enzymes in patients with gastric carcinoma as determined by plasma half-life of antipyrine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/750270/),[ml] / [h·kg],22.8,123510,DB01435,Antipyrine
,750270,metabolic clearance rate,"Similarily, the mean metabolic clearance rate of antipyrine was significantly lower (22.8 +/- 5.0 ml/hr/kg) in patients with disseminated gastric carcinoma compared to control subjects (52.6 +/- 13.4 ml/hr/kg) (P less than 0.02).",Microsomal enzymes in patients with gastric carcinoma as determined by plasma half-life of antipyrine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/750270/),[ml] / [h·kg],52.6,123511,DB01435,Antipyrine
,12705971,m/z,The respective mass transitions used for quantification of etoricoxib and phenazone were m/z 359.2-->280.2 and m/z 189.0-->104.1.,Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705971/),,359.2,125589,DB01435,Antipyrine
,12705971,m/z,The respective mass transitions used for quantification of etoricoxib and phenazone were m/z 359.2-->280.2 and m/z 189.0-->104.1.,Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705971/),,280.2,125590,DB01435,Antipyrine
,12705971,m/z,The respective mass transitions used for quantification of etoricoxib and phenazone were m/z 359.2-->280.2 and m/z 189.0-->104.1.,Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705971/),,189.0,125591,DB01435,Antipyrine
,12705971,m/z,The respective mass transitions used for quantification of etoricoxib and phenazone were m/z 359.2-->280.2 and m/z 189.0-->104.1.,Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12705971/),,104.1,125592,DB01435,Antipyrine
,8633656,transfer clearance,The maternal-fetal transfer clearance of zalcitabine (0.41 +/- 0.16 ml/min/kg) was not significantly different from the fetal-maternal transfer clearance of the drug (0.66 +/ 0.30 ml/min/kg).,"Mechanism and rate of placental transfer of zalcitabine (2',3'-dideoxycytidine) in Macaca nemestrina. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8633656/),[ml] / [kg·min],0.41,126263,DB01435,Antipyrine
,8633656,transfer clearance,The maternal-fetal transfer clearance of zalcitabine (0.41 +/- 0.16 ml/min/kg) was not significantly different from the fetal-maternal transfer clearance of the drug (0.66 +/ 0.30 ml/min/kg).,"Mechanism and rate of placental transfer of zalcitabine (2',3'-dideoxycytidine) in Macaca nemestrina. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8633656/),[ml] / [kg·min],0.66,126264,DB01435,Antipyrine
,8633656,placental transfer rate,The placental transfer rate of zalcitabine was 11% (+/-4%) that of antipyrine.,"Mechanism and rate of placental transfer of zalcitabine (2',3'-dideoxycytidine) in Macaca nemestrina. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8633656/),%,11,126265,DB01435,Antipyrine
,8738854,absolute bioavailability,Its absolute bioavailability is 77% and does not change upon multiple dosing.,Pharmacokinetics of pantoprazole in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),%,77,126641,DB01435,Antipyrine
,8738854,Cmax,"Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h.",Pharmacokinetics of pantoprazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),[mg] / [l],2.5,126642,DB01435,Antipyrine
,8738854,tmax,"Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h.",Pharmacokinetics of pantoprazole in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),h,2-3,126643,DB01435,Antipyrine
,8738854,AUC(O,"The AUC(O,inf.) is approximately 5 mgxh/l.",Pharmacokinetics of pantoprazole in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),[h·mg] / [l],5,126644,DB01435,Antipyrine
,8738854,total serum clearance,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination halflife of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),[l] / [h·kg],0.1,126645,DB01435,Antipyrine
,8738854,serum elimination halflife,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination halflife of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),h,1.1,126646,DB01435,Antipyrine
,8738854,apparent volume of distribution,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination halflife of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),[l] / [kg],0.15,126647,DB01435,Antipyrine
,8738854,half-life,"In patients with severe liver cirrhosis, the decreased rate of metabolism results in a half-life of 7-9 h.",Pharmacokinetics of pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),h,7-9,126648,DB01435,Antipyrine
,8738854,half-life,"The clearance of pantoprazole is only slightly affected by age, its half-life being approximately 1.25 h in the elderly.",Pharmacokinetics of pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),h,1.25,126649,DB01435,Antipyrine
,6704506,plasma half-life,The mean plasma half-life of antipyrine was 10.2 h and the mean plasma clearance was 2.561 h-1 1.73 m-2 before vitamin C restriction.,The influence of vitamin C on antipyrine pharmacokinetics in elderly men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6704506/),h,10.2,127087,DB01435,Antipyrine
,6704506,plasma clearance,The mean plasma half-life of antipyrine was 10.2 h and the mean plasma clearance was 2.561 h-1 1.73 m-2 before vitamin C restriction.,The influence of vitamin C on antipyrine pharmacokinetics in elderly men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6704506/),[1.73] / [(m)^2·h],2.561,127088,DB01435,Antipyrine
,7194086,relative bioavailabilities,The estimated relative bioavailabilities of the single substances in the suppository formulation vary between 120% for propyphenazone and 83% for phenobarbital in comparison to the tablets.,"[A comparative pharmacokinetic study for tablet and suppository formulations of a combination product of caffeine, ethaverine, propyphenazone, paracetamol and phenobarbital (author's transl)]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194086/),%,120,127131,DB01435,Antipyrine
,7194086,relative bioavailabilities,The estimated relative bioavailabilities of the single substances in the suppository formulation vary between 120% for propyphenazone and 83% for phenobarbital in comparison to the tablets.,"[A comparative pharmacokinetic study for tablet and suppository formulations of a combination product of caffeine, ethaverine, propyphenazone, paracetamol and phenobarbital (author's transl)]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194086/),%,83,127132,DB01435,Antipyrine
,9186253,half-life,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),h,15.5,128388,DB01435,Antipyrine
,9186253,half-life,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),h,14.1,128389,DB01435,Antipyrine
,9186253,excretion,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[nM] / [d],488,128390,DB01435,Antipyrine
,9186253,excretion,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[nM] / [d],470,128391,DB01435,Antipyrine
,9186253,concentration ratio,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),,6.8,128392,DB01435,Antipyrine
,9186253,concentration ratio,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),,6.1,128393,DB01435,Antipyrine
,9186253,half-life,"No difference in pharmacokinetic parameters between VGB and placebo sessions were found for ethinyl estradiol (half-life, 12.5 +/- 3.2 vs.","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),,12.5,128394,DB01435,Antipyrine
,9186253,AUC,"13.9 +/- 3.2 h; AUC, 874 +/- 301 vs. 939 +/- 272 ng/ L/h) and levonorgestrel (half-life, 17.7 +/- 5.2 vs.","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[ng] / [h·l],874,128395,DB01435,Antipyrine
,9186253,AUC,"13.9 +/- 3.2 h; AUC, 874 +/- 301 vs. 939 +/- 272 ng/ L/h) and levonorgestrel (half-life, 17.7 +/- 5.2 vs.","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[ng] / [h·l],939,128396,DB01435,Antipyrine
,9186253,half-life,"13.9 +/- 3.2 h; AUC, 874 +/- 301 vs. 939 +/- 272 ng/ L/h) and levonorgestrel (half-life, 17.7 +/- 5.2 vs.","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),,17.7,128397,DB01435,Antipyrine
,9186253,AUC,"23.1 +/- 9.8 h; AUC, 27.5 +/- 9.6 vs. 30.0 +/- 12.0 micrograms/L/h).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[μg] / [h·l],27.5,128398,DB01435,Antipyrine
,9186253,AUC,"23.1 +/- 9.8 h; AUC, 27.5 +/- 9.6 vs. 30.0 +/- 12.0 micrograms/L/h).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[μg] / [h·l],30.0,128399,DB01435,Antipyrine
,1937348,area under the plasma concentration-time curve (AUC,"Due to the small number of subjects, comparison of the NF pharmacokinetics at dose 1 and 26 failed to show a bimodality in the frequency distribution of its area under the plasma concentration-time curve (AUC 274.5 to 317.1 ng ml-1 h, NS).",Lack of effect by nifedipine on hepatic mixed function oxidase in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1937348/),[h·ng] / [ml],274.5 to 317.1,128876,DB01435,Antipyrine
,1937348,t1/2,"Hepatic microsomal autoinduction (t1/2 2.87 to 3.06 h, NS) was not found.",Lack of effect by nifedipine on hepatic mixed function oxidase in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1937348/),h,2.87 to 3.06,128877,DB01435,Antipyrine
,1937348,urinary excretion,"Unlike what has been suggested by in vitro studies, NF treatment did not modify significantly the urinary excretion of 6 beta-hydroxycortisol (318 to 265 micrograms/d, NS).",Lack of effect by nifedipine on hepatic mixed function oxidase in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1937348/),[μg] / [d],318 to 265,128878,DB01435,Antipyrine
,6129344,half-life,Antipyrine half-life was shortened in all patients from a mean value of 12.3 +/- 3.9 h to 7.8 +/- 2.0 h and antipyrine clearance was increased from 39.0 +/- 16.0 ml/min to 57.6 +/- 13.7 ml/min.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),h,12.3,129319,DB01435,Antipyrine
,6129344,half-life,Antipyrine half-life was shortened in all patients from a mean value of 12.3 +/- 3.9 h to 7.8 +/- 2.0 h and antipyrine clearance was increased from 39.0 +/- 16.0 ml/min to 57.6 +/- 13.7 ml/min.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),h,7.8,129320,DB01435,Antipyrine
,6129344,clearance,Antipyrine half-life was shortened in all patients from a mean value of 12.3 +/- 3.9 h to 7.8 +/- 2.0 h and antipyrine clearance was increased from 39.0 +/- 16.0 ml/min to 57.6 +/- 13.7 ml/min.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[ml] / [min],39.0,129321,DB01435,Antipyrine
,6129344,clearance,Antipyrine half-life was shortened in all patients from a mean value of 12.3 +/- 3.9 h to 7.8 +/- 2.0 h and antipyrine clearance was increased from 39.0 +/- 16.0 ml/min to 57.6 +/- 13.7 ml/min.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[ml] / [min],57.6,129322,DB01435,Antipyrine
,6129344,volume of distribution,"In contrast the volume of distribution of antipyrine was unaffected; the values being 38.0 +/- 8.6 liters and 37.4 +/- 5.7 liters, respectively.",Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),l,38.0,129323,DB01435,Antipyrine
,6129344,volume of distribution,"In contrast the volume of distribution of antipyrine was unaffected; the values being 38.0 +/- 8.6 liters and 37.4 +/- 5.7 liters, respectively.",Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),l,37.4,129324,DB01435,Antipyrine
,6129344,excretion,In all patients the excretion of 6-beta-OH-cortisol in the urine went up from 65.0 +/- 25.7 micrograms/24 h to 346.8 +/- 193.4 micrograms/24 h.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[μg] / [24·h],65.0,129325,DB01435,Antipyrine
,6129344,excretion,In all patients the excretion of 6-beta-OH-cortisol in the urine went up from 65.0 +/- 25.7 micrograms/24 h to 346.8 +/- 193.4 micrograms/24 h.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[μg] / [24·h],346.8,129326,DB01435,Antipyrine
,6129344,GGT,After 21 days of treatment the GGT increased from 17.4 +/- 4.9 units/liter to 32.6 +/- 12.5 units/liter,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[units] / [l],17.4,129327,DB01435,Antipyrine
,6129344,GGT,After 21 days of treatment the GGT increased from 17.4 +/- 4.9 units/liter to 32.6 +/- 12.5 units/liter,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[units] / [l],32.6,129328,DB01435,Antipyrine
,7751582,clearance,"Antipyrine clearance (mean +/- SD) was significantly lower in patients with chronic hepatitis C, 1.2 +/- 0.7 l.h-1 (n = 12), than in controls (n = 18), 2.2 +/- 1.0 l.h-1 (p = 0.006).",Antipyrine clearance and metabolite excretion in patients with chronic hepatitis C. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751582/),[l] / [h],1.2,129382,DB01435,Antipyrine
,7751582,clearance,"Antipyrine clearance (mean +/- SD) was significantly lower in patients with chronic hepatitis C, 1.2 +/- 0.7 l.h-1 (n = 12), than in controls (n = 18), 2.2 +/- 1.0 l.h-1 (p = 0.006).",Antipyrine clearance and metabolite excretion in patients with chronic hepatitis C. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751582/),[l] / [h],2.2,129383,DB01435,Antipyrine
,3225771,peak plasma concentrations,The peak plasma concentrations ranged from 7.2 micrograms/mL with the 15-mg/d dose to 82 micrograms/mL with the 400-mg/d dose.,Autoinduction of phenobarbital elimination in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3225771/),[μg] / [ml],7.2,130138,DB01435,Antipyrine
,3225771,peak plasma concentrations,The peak plasma concentrations ranged from 7.2 micrograms/mL with the 15-mg/d dose to 82 micrograms/mL with the 400-mg/d dose.,Autoinduction of phenobarbital elimination in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3225771/),[μg] / [ml],82,130139,DB01435,Antipyrine
,3225771,elimination rate constant,The major determinant of this increased clearance was an increase in the elimination rate constant of phenobarbital from 0.18 h-1 at the 15-mg/d dose to 0.36 h-1 at the 400-mg/d dose.,Autoinduction of phenobarbital elimination in the dog. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3225771/),1/[h],0.18,130140,DB01435,Antipyrine
,3225771,elimination rate constant,The major determinant of this increased clearance was an increase in the elimination rate constant of phenobarbital from 0.18 h-1 at the 15-mg/d dose to 0.36 h-1 at the 400-mg/d dose.,Autoinduction of phenobarbital elimination in the dog. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3225771/),1/[h],0.36,130141,DB01435,Antipyrine
,407043,half-life,Five workers occupationally exposed to Aroclor 1016 in a capacitor-manufacturing plant showed a significantly lower mean antipyrine half-life (10.8 hr) than the mean half-life of 15.6 hr in non-PCBs-exposed normal subjects.,Alterations in drug metabolism in workers exposed to polychlorinated biphenyls. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/407043/),h,10.8,132703,DB01435,Antipyrine
,407043,half-life,Five workers occupationally exposed to Aroclor 1016 in a capacitor-manufacturing plant showed a significantly lower mean antipyrine half-life (10.8 hr) than the mean half-life of 15.6 hr in non-PCBs-exposed normal subjects.,Alterations in drug metabolism in workers exposed to polychlorinated biphenyls. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/407043/),h,15.6,132704,DB01435,Antipyrine
,24070396,clearance index,"The normalized transfer of pravastatin (clearance index) to antipyrine in the fetal-to-maternal direction (0.48 ± 0.07) was higher than its transfer in the maternal-to-fetal direction (0.36 ± 0.07, P < .01).",Transplacental transfer and distribution of pravastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24070396/),,0.,132994,DB01435,Antipyrine
,1591403,clearance,Placental clearance was linear up to 2.0 mL/min for TH and 1.5 mL/min for AP.,In situ perfusion in the rabbit: effects of different umbilical flow rates on placental transfer of compounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1591403/),[ml] / [min],2.0,133367,DB01435,Antipyrine
,1591403,clearance,Placental clearance was linear up to 2.0 mL/min for TH and 1.5 mL/min for AP.,In situ perfusion in the rabbit: effects of different umbilical flow rates on placental transfer of compounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1591403/),[ml] / [min],1.5,133368,DB01435,Antipyrine
,1591403,um,The umbilical flow rate limit was 1.76 +/- 0.29 mL/min for TH and 1.72 +/- 0.49 mL/min for AP.,In situ perfusion in the rabbit: effects of different umbilical flow rates on placental transfer of compounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1591403/),[ml] / [min],1.76,133369,DB01435,Antipyrine
,1591403,um,The umbilical flow rate limit was 1.76 +/- 0.29 mL/min for TH and 1.72 +/- 0.49 mL/min for AP.,In situ perfusion in the rabbit: effects of different umbilical flow rates on placental transfer of compounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1591403/),[ml] / [min],1.72,133370,DB01435,Antipyrine
,1591403,clearance index,The clearance index was 0.71 +/- 0.04.,In situ perfusion in the rabbit: effects of different umbilical flow rates on placental transfer of compounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1591403/),,0.71,133371,DB01435,Antipyrine
,1591403,resistances,Placental resistances did not change significantly at all flow rates with mean values between 6 and 9 mmHg/mL/min.,In situ perfusion in the rabbit: effects of different umbilical flow rates on placental transfer of compounds. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1591403/),[mmhg] / [min·ml],6 and 9,133372,DB01435,Antipyrine
,2246703,plasma clearance,Patients with CF had a significantly greater plasma clearance of lorazepam (56.5 +/- 5.2 vs 25.9 +/- 1.9 ml/min/m2) and ICG (892.5 +/- 176.4 vs 256.5 +/- 41.7 ml/min/m2) but not of antipyrine (27.2 +/- 3.8 vs 20.7 +/- 2.0 ml/min/m2) in comparison with control subjects.,Enhanced hepatic drug clearance in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2246703/),[ml] / [m2·min],56.5,135031,DB01435,Antipyrine
,2246703,plasma clearance,Patients with CF had a significantly greater plasma clearance of lorazepam (56.5 +/- 5.2 vs 25.9 +/- 1.9 ml/min/m2) and ICG (892.5 +/- 176.4 vs 256.5 +/- 41.7 ml/min/m2) but not of antipyrine (27.2 +/- 3.8 vs 20.7 +/- 2.0 ml/min/m2) in comparison with control subjects.,Enhanced hepatic drug clearance in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2246703/),[ml] / [m2·min],25.9,135032,DB01435,Antipyrine
,2246703,plasma clearance,Patients with CF had a significantly greater plasma clearance of lorazepam (56.5 +/- 5.2 vs 25.9 +/- 1.9 ml/min/m2) and ICG (892.5 +/- 176.4 vs 256.5 +/- 41.7 ml/min/m2) but not of antipyrine (27.2 +/- 3.8 vs 20.7 +/- 2.0 ml/min/m2) in comparison with control subjects.,Enhanced hepatic drug clearance in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2246703/),[ml] / [m2·min],892.5,135033,DB01435,Antipyrine
,2246703,plasma clearance,Patients with CF had a significantly greater plasma clearance of lorazepam (56.5 +/- 5.2 vs 25.9 +/- 1.9 ml/min/m2) and ICG (892.5 +/- 176.4 vs 256.5 +/- 41.7 ml/min/m2) but not of antipyrine (27.2 +/- 3.8 vs 20.7 +/- 2.0 ml/min/m2) in comparison with control subjects.,Enhanced hepatic drug clearance in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2246703/),[ml] / [m2·min],256.5,135034,DB01435,Antipyrine
,2246703,plasma clearance,Patients with CF had a significantly greater plasma clearance of lorazepam (56.5 +/- 5.2 vs 25.9 +/- 1.9 ml/min/m2) and ICG (892.5 +/- 176.4 vs 256.5 +/- 41.7 ml/min/m2) but not of antipyrine (27.2 +/- 3.8 vs 20.7 +/- 2.0 ml/min/m2) in comparison with control subjects.,Enhanced hepatic drug clearance in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2246703/),[ml] / [m2·min],27.2,135035,DB01435,Antipyrine
,2246703,plasma clearance,Patients with CF had a significantly greater plasma clearance of lorazepam (56.5 +/- 5.2 vs 25.9 +/- 1.9 ml/min/m2) and ICG (892.5 +/- 176.4 vs 256.5 +/- 41.7 ml/min/m2) but not of antipyrine (27.2 +/- 3.8 vs 20.7 +/- 2.0 ml/min/m2) in comparison with control subjects.,Enhanced hepatic drug clearance in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2246703/),[ml] / [m2·min],20.7,135036,DB01435,Antipyrine
,8156973,half-life,MHD is eliminated with a half-life of about 8-10 h.,Clinical pharmacology and pharmacokinetics of oxcarbazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8156973/),h,8-10,135672,DB01435,Antipyrine
,23284109,clearance,"6.9 ± 2.0 nmol mL(-1), p <0.05) and a significant decrease in liver monooxygenase function (antipyrine clearance: 18.3 ± 11.1 vs.",Oxidative stress and liver monooxygenase function after heart valve surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23284109/),,18.3,137093,DB01435,Antipyrine
,23284109,clearance,"On the 3rd-4th and 11th-12th postoperative days, the intensity of oxidative stress decreased and monooxygenase function returned to baseline (antipyrine clearance: 45.6 ± 17.9 vs. 39.0 ± 18.9 mL kg(-1)h(-1)).",Oxidative stress and liver monooxygenase function after heart valve surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23284109/),[ml] / [kg],45.6,137094,DB01435,Antipyrine
,23284109,clearance,"On the 3rd-4th and 11th-12th postoperative days, the intensity of oxidative stress decreased and monooxygenase function returned to baseline (antipyrine clearance: 45.6 ± 17.9 vs. 39.0 ± 18.9 mL kg(-1)h(-1)).",Oxidative stress and liver monooxygenase function after heart valve surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23284109/),[ml] / [kg],39.0,137095,DB01435,Antipyrine
,9524314,ktransfer,"PABA appeared in the fetal compartment faster than AP (ktransfer = 0.064 and 0.046 min-1, respectively).",Pharmacokinetic examination of p-aminobenzoic acid passage through the placenta and the small intestine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9524314/),1/[min],0.064,137277,DB01435,Antipyrine
,9524314,ktransfer,"PABA appeared in the fetal compartment faster than AP (ktransfer = 0.064 and 0.046 min-1, respectively).",Pharmacokinetic examination of p-aminobenzoic acid passage through the placenta and the small intestine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9524314/),1/[min],0.046,137278,DB01435,Antipyrine
,9524314,Clp,"The rate of equilibration between the maternal and fetal compartments and placental clearance were lower for PABA than for AP (kequilibration = 0.011 and 0.020 min-1; Clp = 0.22 and 0.33 ml/min, respectively); the feto-maternal concentration ratios at equilibrium (FMCReq) were, however, mutually comparable.",Pharmacokinetic examination of p-aminobenzoic acid passage through the placenta and the small intestine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9524314/),[ml] / [min],0.22,137279,DB01435,Antipyrine
,9524314,Clp,"The rate of equilibration between the maternal and fetal compartments and placental clearance were lower for PABA than for AP (kequilibration = 0.011 and 0.020 min-1; Clp = 0.22 and 0.33 ml/min, respectively); the feto-maternal concentration ratios at equilibrium (FMCReq) were, however, mutually comparable.",Pharmacokinetic examination of p-aminobenzoic acid passage through the placenta and the small intestine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9524314/),[ml] / [min],0.33,137280,DB01435,Antipyrine
,9524314,ka,"Similarly, PABA proved to be absorbed from the small intestine significantly faster than AP (ka = 0.824 min-1 and 0.479 min-1; tmax = 3.1 min and 8.9 min, respectively).",Pharmacokinetic examination of p-aminobenzoic acid passage through the placenta and the small intestine in rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9524314/),1/[min],0.824,137281,DB01435,Antipyrine
,9524314,ka,"Similarly, PABA proved to be absorbed from the small intestine significantly faster than AP (ka = 0.824 min-1 and 0.479 min-1; tmax = 3.1 min and 8.9 min, respectively).",Pharmacokinetic examination of p-aminobenzoic acid passage through the placenta and the small intestine in rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9524314/),1/[min],0.479,137282,DB01435,Antipyrine
,9524314,tmax,"Similarly, PABA proved to be absorbed from the small intestine significantly faster than AP (ka = 0.824 min-1 and 0.479 min-1; tmax = 3.1 min and 8.9 min, respectively).",Pharmacokinetic examination of p-aminobenzoic acid passage through the placenta and the small intestine in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9524314/),min,3.1,137283,DB01435,Antipyrine
,9524314,tmax,"Similarly, PABA proved to be absorbed from the small intestine significantly faster than AP (ka = 0.824 min-1 and 0.479 min-1; tmax = 3.1 min and 8.9 min, respectively).",Pharmacokinetic examination of p-aminobenzoic acid passage through the placenta and the small intestine in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9524314/),min,8.9,137284,DB01435,Antipyrine
,9524314,Vd,"The apparent volume of distribution (Vd) of AP in non-pregnant animals showed that the drug is distributed into the whole body water as expected (Vd = 0.66 l/kg); however, Vd of AP in pregnant animals was estimated to be 1.81 l/kg.",Pharmacokinetic examination of p-aminobenzoic acid passage through the placenta and the small intestine in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9524314/),[l] / [kg],0.66,137285,DB01435,Antipyrine
,9524314,Vd,"The apparent volume of distribution (Vd) of AP in non-pregnant animals showed that the drug is distributed into the whole body water as expected (Vd = 0.66 l/kg); however, Vd of AP in pregnant animals was estimated to be 1.81 l/kg.",Pharmacokinetic examination of p-aminobenzoic acid passage through the placenta and the small intestine in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9524314/),[l] / [kg],1.81,137286,DB01435,Antipyrine
,21261677,DA/PA ratio,"Mean DA/PA ratio after oral administration of diclofenac to the mother was estimated to be 39.0%, whereas both of the corresponding values after oral administration of antipyrine and salicylic acid were estimated to be 5.9%.",Prediction and evaluation of fetal toxicity induced by NSAIDs using transplacental kinetic parameters obtained from human placental perfusion studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21261677/),%,39.0,138449,DB01435,Antipyrine
,21261677,DA/PA ratio,"Mean DA/PA ratio after oral administration of diclofenac to the mother was estimated to be 39.0%, whereas both of the corresponding values after oral administration of antipyrine and salicylic acid were estimated to be 5.9%.",Prediction and evaluation of fetal toxicity induced by NSAIDs using transplacental kinetic parameters obtained from human placental perfusion studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21261677/),%,5.9,138450,DB01435,Antipyrine
,15217988,dissociation constants (KI),"In vitro, the dissociation constants (KI) for ABT as the P450 mechanism-based inactivator were determined to be 45.6 and 193 microM, and the maximal inactivation rate constants (kinact) were determined to be 0.089 and 0.075 min(-1) for the mouse and guinea pig liver microsomes, respectively.",Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217988/),μM,45.6,139333,DB01435,Antipyrine
,15217988,dissociation constants (KI),"In vitro, the dissociation constants (KI) for ABT as the P450 mechanism-based inactivator were determined to be 45.6 and 193 microM, and the maximal inactivation rate constants (kinact) were determined to be 0.089 and 0.075 min(-1) for the mouse and guinea pig liver microsomes, respectively.",Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217988/),μM,193,139334,DB01435,Antipyrine
,15217988,maximal inactivation rate constants (kinact),"In vitro, the dissociation constants (KI) for ABT as the P450 mechanism-based inactivator were determined to be 45.6 and 193 microM, and the maximal inactivation rate constants (kinact) were determined to be 0.089 and 0.075 min(-1) for the mouse and guinea pig liver microsomes, respectively.",Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217988/),1/[min],0.089,139335,DB01435,Antipyrine
,15217988,maximal inactivation rate constants (kinact),"In vitro, the dissociation constants (KI) for ABT as the P450 mechanism-based inactivator were determined to be 45.6 and 193 microM, and the maximal inactivation rate constants (kinact) were determined to be 0.089 and 0.075 min(-1) for the mouse and guinea pig liver microsomes, respectively.",Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217988/),1/[min],0.075,139336,DB01435,Antipyrine
,28635050,Transplacental transfer,"Transplacental transfer value at the steady state of ketoprofen was 4.82%, which was approximately half that of antipyrine (passive marker).",Prediction of sustained fetal toxicity induced by ketoprofen based on PK/PD analysis using human placental perfusion and rat toxicity data. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28635050/),%,4.82,140833,DB01435,Antipyrine
,9493498,AUC,"3. There was no significant difference in dose-corrected area under the outflow curve (AUC) for [14C]-sucrose, antipyrine or [14C]-taurocholate between the first and second doses whereas the mean propranolol AUC for the second dose was only 0.577+/-0.439 that for the first dose (P<0.05).",A priming dose of propranolol reduces the availability of a subsequent dose in the isolated perfused rat liver preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493498/),that,0.577,142044,DB01435,Antipyrine
,6370541,bioavailability,The bioavailability varies from 10% to over 80% in different subjects.,Clinical pharmacokinetics of labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),%,10,143406,DB01435,Antipyrine
over,6370541,bioavailability,The bioavailability varies from 10% to over 80% in different subjects.,Clinical pharmacokinetics of labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),%,80,143407,DB01435,Antipyrine
,6370541,bioavailability,"Average bioavailability has been reported to correlate with age, with values of approximately 30% in the 30- to 40-year age group and approximately 65% at 80 years.",Clinical pharmacokinetics of labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),%,30,143408,DB01435,Antipyrine
,6370541,bioavailability,"Average bioavailability has been reported to correlate with age, with values of approximately 30% in the 30- to 40-year age group and approximately 65% at 80 years.",Clinical pharmacokinetics of labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),%,65,143409,DB01435,Antipyrine
,6370541,apparent volume of distribution at equilibrium,"The apparent volume of distribution at equilibrium varies from approximately 200 to over 800L, suggesting that concentration of labetalol occurs in extravascular sites.",Clinical pharmacokinetics of labetalol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),l,200 to over 800,143410,DB01435,Antipyrine
,6370541,half-life,The half-life of labetalol in plasma is 3 to 3.5 hours.,Clinical pharmacokinetics of labetalol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),h,3 to 3.5,143411,DB01435,Antipyrine
,7965801,clearance,"In healthy and FIC cats, the clearance was 0.3 and 0.1 ml.min-1.kg-1, and the bioavailability of the intravesical dose was about 1 and 9%, respectively.",Effect of interstitial cystitis on drug absorption from urinary bladder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965801/),[ml] / [kg·min],0.3,143830,DB01435,Antipyrine
,7965801,clearance,"In healthy and FIC cats, the clearance was 0.3 and 0.1 ml.min-1.kg-1, and the bioavailability of the intravesical dose was about 1 and 9%, respectively.",Effect of interstitial cystitis on drug absorption from urinary bladder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965801/),[ml] / [kg·min],0.1,143831,DB01435,Antipyrine
,7965801,bioavailability,"In healthy and FIC cats, the clearance was 0.3 and 0.1 ml.min-1.kg-1, and the bioavailability of the intravesical dose was about 1 and 9%, respectively.",Effect of interstitial cystitis on drug absorption from urinary bladder. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965801/),%,1,143832,DB01435,Antipyrine
,7965801,bioavailability,"In healthy and FIC cats, the clearance was 0.3 and 0.1 ml.min-1.kg-1, and the bioavailability of the intravesical dose was about 1 and 9%, respectively.",Effect of interstitial cystitis on drug absorption from urinary bladder. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965801/),%,9,143833,DB01435,Antipyrine
,9368948,elimination half-life,Water deprivation was associated with a statistically significant (P < 0.01) increase in the plasma antipyrine elimination half-life from 10.85(1.14) hours to 14.00(1.05) hours.,Influence of short-term water deprivation on antipyrine disposition in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9368948/),h,10.85,144105,DB01435,Antipyrine
,9368948,elimination half-life,Water deprivation was associated with a statistically significant (P < 0.01) increase in the plasma antipyrine elimination half-life from 10.85(1.14) hours to 14.00(1.05) hours.,Influence of short-term water deprivation on antipyrine disposition in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9368948/),h,14.00,144106,DB01435,Antipyrine
,9368948,systemic clearance,In water deprived calves the systemic clearance of antipyrine was significantly (P < 0.05) decreased from 0.75(0.07) ml min-1 kg-1 to 0.56(0.05) ml min-1 kg-1.,Influence of short-term water deprivation on antipyrine disposition in calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9368948/),[ml] / [kg·min],0.75,144107,DB01435,Antipyrine
,9368948,systemic clearance,In water deprived calves the systemic clearance of antipyrine was significantly (P < 0.05) decreased from 0.75(0.07) ml min-1 kg-1 to 0.56(0.05) ml min-1 kg-1.,Influence of short-term water deprivation on antipyrine disposition in calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9368948/),[ml] / [kg·min],0.56,144108,DB01435,Antipyrine
,4074599,half-life,"Compared to controls, the mean half-life of this group was increased from 10.9 +/- 2.4 to 19.9 +/- 9.5 h (mean +/- s.d.; P less than or equal to 0.05) and clearance reduced from 3.81 +/- 0.74 to 2.18 +/- 0.80 l h-1 (P less than or equal to 0.01).",The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074599/),h,10.9,144514,DB01435,Antipyrine
,4074599,half-life,"Compared to controls, the mean half-life of this group was increased from 10.9 +/- 2.4 to 19.9 +/- 9.5 h (mean +/- s.d.; P less than or equal to 0.05) and clearance reduced from 3.81 +/- 0.74 to 2.18 +/- 0.80 l h-1 (P less than or equal to 0.01).",The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074599/),h,19.9,144515,DB01435,Antipyrine
,4074599,clearance,"Compared to controls, the mean half-life of this group was increased from 10.9 +/- 2.4 to 19.9 +/- 9.5 h (mean +/- s.d.; P less than or equal to 0.05) and clearance reduced from 3.81 +/- 0.74 to 2.18 +/- 0.80 l h-1 (P less than or equal to 0.01).",The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074599/),[l] / [h],3.81,144516,DB01435,Antipyrine
,4074599,clearance,"Compared to controls, the mean half-life of this group was increased from 10.9 +/- 2.4 to 19.9 +/- 9.5 h (mean +/- s.d.; P less than or equal to 0.05) and clearance reduced from 3.81 +/- 0.74 to 2.18 +/- 0.80 l h-1 (P less than or equal to 0.01).",The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074599/),[l] / [h],2.18,144517,DB01435,Antipyrine
,7075648,saliva/plasma concentration ratio,"The saliva/plasma concentration ratio was constant with time from about 3 h onwards, with a mean value of 0.87 after oral and 0.91 after i.v. administration.",Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075648/),,0.87,144998,DB01435,Antipyrine
,7075648,saliva/plasma concentration ratio,"The saliva/plasma concentration ratio was constant with time from about 3 h onwards, with a mean value of 0.87 after oral and 0.91 after i.v. administration.",Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075648/),,0.91,144999,DB01435,Antipyrine
≈,33704925,absolute bioavailability,"Mathematical modeling determined that equivalent exposures in plasma with the approved dose of the IV edaravone formulation, as reported previously, could be achieved when the oral edaravone formulation was administered at a dose of ≈100 mg, with an absolute bioavailability of ≈60%.","Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33704925/),%,60,147401,DB01435,Antipyrine
,9697419,body clearance (ClB),"The body clearance (ClB) of SDZ (1.70 +/- 0.14 ml/min/kg) was significantly higher than those of SDM (1.13 +/- 0.18 ml/min/kg), SMPZ (1.10 +/- 0.09 ml/min/kg) and SDMX (0.75 +/- 0.04 ml/min/kg).",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[ml] / [kg·min],1.70,147432,DB01435,Antipyrine
,9697419,body clearance (ClB),"The body clearance (ClB) of SDZ (1.70 +/- 0.14 ml/min/kg) was significantly higher than those of SDM (1.13 +/- 0.18 ml/min/kg), SMPZ (1.10 +/- 0.09 ml/min/kg) and SDMX (0.75 +/- 0.04 ml/min/kg).",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[ml] / [kg·min],1.13,147433,DB01435,Antipyrine
,9697419,body clearance (ClB),"The body clearance (ClB) of SDZ (1.70 +/- 0.14 ml/min/kg) was significantly higher than those of SDM (1.13 +/- 0.18 ml/min/kg), SMPZ (1.10 +/- 0.09 ml/min/kg) and SDMX (0.75 +/- 0.04 ml/min/kg).",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[ml] / [kg·min],1.10,147434,DB01435,Antipyrine
,9697419,body clearance (ClB),"The body clearance (ClB) of SDZ (1.70 +/- 0.14 ml/min/kg) was significantly higher than those of SDM (1.13 +/- 0.18 ml/min/kg), SMPZ (1.10 +/- 0.09 ml/min/kg) and SDMX (0.75 +/- 0.04 ml/min/kg).",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[ml] / [kg·min],0.75,147435,DB01435,Antipyrine
,9697419,volume of distribution at steady state (Vss),"In contrast, the volume of distribution at steady state (Vss) was similar for the four sulfonamides (0.68 +/- 0.08 L/kg, 0.63 +/- 0.07 L/kg, 0.47 +/- 0.06 L/kg, and 0.46 +/- 0.05 L/kg for SDM, SDZ, SMPZ and SDMX, respectively).",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[l] / [kg],0.68,147436,DB01435,Antipyrine
,9697419,volume of distribution at steady state (Vss),"In contrast, the volume of distribution at steady state (Vss) was similar for the four sulfonamides (0.68 +/- 0.08 L/kg, 0.63 +/- 0.07 L/kg, 0.47 +/- 0.06 L/kg, and 0.46 +/- 0.05 L/kg for SDM, SDZ, SMPZ and SDMX, respectively).",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[l] / [kg],0.63,147437,DB01435,Antipyrine
,9697419,volume of distribution at steady state (Vss),"In contrast, the volume of distribution at steady state (Vss) was similar for the four sulfonamides (0.68 +/- 0.08 L/kg, 0.63 +/- 0.07 L/kg, 0.47 +/- 0.06 L/kg, and 0.46 +/- 0.05 L/kg for SDM, SDZ, SMPZ and SDMX, respectively).",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[l] / [kg],0.47,147438,DB01435,Antipyrine
,9697419,volume of distribution at steady state (Vss),"In contrast, the volume of distribution at steady state (Vss) was similar for the four sulfonamides (0.68 +/- 0.08 L/kg, 0.63 +/- 0.07 L/kg, 0.47 +/- 0.06 L/kg, and 0.46 +/- 0.05 L/kg for SDM, SDZ, SMPZ and SDMX, respectively).",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[l] / [kg],0.46,147439,DB01435,Antipyrine
,9697419,ClB,Both ClB and Vss were significantly higher for TMP (4.36 +/- 0.60 ml/min/kg and 2.71 +/- 0.86 L/kg) than for sulfonamides.,Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[ml] / [kg·min],4.36,147440,DB01435,Antipyrine
,9697419,Vss,Both ClB and Vss were significantly higher for TMP (4.36 +/- 0.60 ml/min/kg and 2.71 +/- 0.86 L/kg) than for sulfonamides.,Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[l] / [kg],2.71,147441,DB01435,Antipyrine
,9697419,ClB,"Antipyrine ClB (3.49 +/- 0.35 ml/min/kg) and Vss (0.66 +/- 0.16 L/kg), determined in order to assess hepatic oxidative function and total body water volume, respectively, were either different from (ClB), or similar to (Vss), values calculated for sulfonamides.",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[ml] / [kg·min],3.49,147442,DB01435,Antipyrine
,9697419,Vss,"Antipyrine ClB (3.49 +/- 0.35 ml/min/kg) and Vss (0.66 +/- 0.16 L/kg), determined in order to assess hepatic oxidative function and total body water volume, respectively, were either different from (ClB), or similar to (Vss), values calculated for sulfonamides.",Pharmacokinetics of sulfonamides and trimethoprim in the donkey (Equus asinus). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9697419/),[l] / [kg],0.66,147443,DB01435,Antipyrine
,6129140,elimination half-life,"The absorption and distribution of mexiletine were not changed after rifampicin, but its elimination half-life fell from 8.5 +/- 0.8 h (mean +/- SE) to 5.0 +/- 0.4 h (p less than 0.01), and its nonrenal clearance increased from 435 +/- 68 ml/min to 711 +/- 101 ml/min (p less than 0.01).",Effect of rifampicin treatment on the kinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),h,8.5,148024,DB01435,Antipyrine
,6129140,elimination half-life,"The absorption and distribution of mexiletine were not changed after rifampicin, but its elimination half-life fell from 8.5 +/- 0.8 h (mean +/- SE) to 5.0 +/- 0.4 h (p less than 0.01), and its nonrenal clearance increased from 435 +/- 68 ml/min to 711 +/- 101 ml/min (p less than 0.01).",Effect of rifampicin treatment on the kinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),h,5.0,148025,DB01435,Antipyrine
,6129140,nonrenal clearance,"The absorption and distribution of mexiletine were not changed after rifampicin, but its elimination half-life fell from 8.5 +/- 0.8 h (mean +/- SE) to 5.0 +/- 0.4 h (p less than 0.01), and its nonrenal clearance increased from 435 +/- 68 ml/min to 711 +/- 101 ml/min (p less than 0.01).",Effect of rifampicin treatment on the kinetics of mexiletine. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),[ml] / [min],435,148026,DB01435,Antipyrine
,6129140,nonrenal clearance,"The absorption and distribution of mexiletine were not changed after rifampicin, but its elimination half-life fell from 8.5 +/- 0.8 h (mean +/- SE) to 5.0 +/- 0.4 h (p less than 0.01), and its nonrenal clearance increased from 435 +/- 68 ml/min to 711 +/- 101 ml/min (p less than 0.01).",Effect of rifampicin treatment on the kinetics of mexiletine. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),[ml] / [min],711,148027,DB01435,Antipyrine
,6129140,amount,The amount of unchanged mexiletine excreted in urine over two days decreased from 32 +/- 7 to 18 +/- 3 mg (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),mg,32,148028,DB01435,Antipyrine
,6129140,amount,The amount of unchanged mexiletine excreted in urine over two days decreased from 32 +/- 7 to 18 +/- 3 mg (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),mg,18,148029,DB01435,Antipyrine
,6129140,excreted,The amount of unchanged mexiletine excreted in urine over two days decreased from 32 +/- 7 to 18 +/- 3 mg (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),mg,32,148030,DB01435,Antipyrine
,6129140,excreted,The amount of unchanged mexiletine excreted in urine over two days decreased from 32 +/- 7 to 18 +/- 3 mg (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),mg,18,148031,DB01435,Antipyrine
,6129140,half-life,The half-life of antipyrine fell from 11.8 +/- 0.4 to 5.5 +/- 0.3 h and its clearance increased from 40 +/- 3 ml to 74 +/- 3 ml/min (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),h,11.8,148032,DB01435,Antipyrine
,6129140,half-life,The half-life of antipyrine fell from 11.8 +/- 0.4 to 5.5 +/- 0.3 h and its clearance increased from 40 +/- 3 ml to 74 +/- 3 ml/min (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),h,5.5,148033,DB01435,Antipyrine
,6129140,clearance,The half-life of antipyrine fell from 11.8 +/- 0.4 to 5.5 +/- 0.3 h and its clearance increased from 40 +/- 3 ml to 74 +/- 3 ml/min (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),ml,40,148034,DB01435,Antipyrine
,6129140,clearance,The half-life of antipyrine fell from 11.8 +/- 0.4 to 5.5 +/- 0.3 h and its clearance increased from 40 +/- 3 ml to 74 +/- 3 ml/min (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),[ml] / [min],74,148035,DB01435,Antipyrine
,3252045,clearance,"Both verapamil and diltiazem treatment decreased antipyrine clearance (verapamil, 42.5 to 30.1 ml/min, P less than .01; diltiazem, 41.7 to 29.9 ml/min, P less than .01), resulting in prolonged antipyrine half-life with no change in distribution volume.",Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252045/),[ml] / [min],42.5 to 30.1,149488,DB01435,Antipyrine
,3252045,clearance,"Both verapamil and diltiazem treatment decreased antipyrine clearance (verapamil, 42.5 to 30.1 ml/min, P less than .01; diltiazem, 41.7 to 29.9 ml/min, P less than .01), resulting in prolonged antipyrine half-life with no change in distribution volume.",Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252045/),[ml] / [min],41.7 to 29.9,149489,DB01435,Antipyrine
,3252045,clearance,"Effect on theophylline clearance differed between verapamil treatment (57.7 to 44.7 ml/min; P less than .01) and diltiazem treatment (50.2 to 49.4 ml/min; N.S.), with prolonged theophylline half-life during verapamil treatment, no change in half-life during diltiazem treatment and distribution volume unchanged by either treatment.",Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252045/),[ml] / [min],57.7 to 44.7,149490,DB01435,Antipyrine
,3252045,clearance,"Effect on theophylline clearance differed between verapamil treatment (57.7 to 44.7 ml/min; P less than .01) and diltiazem treatment (50.2 to 49.4 ml/min; N.S.), with prolonged theophylline half-life during verapamil treatment, no change in half-life during diltiazem treatment and distribution volume unchanged by either treatment.",Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252045/),[ml] / [min],50.2 to 49.4,149491,DB01435,Antipyrine
,8243505,clearance,Pharmacokinetic profile and urinary excretion of digitoxin and 4 metabolites were investigated in 9 patients with biopsy confirmed liver cirrhosis (median antipyrine clearance 20.0 +/- 5.4 ml/min; X +/- SEM) and were compared with that of 8 healthy volunteers (antipyrine clearance 36.9 +/- 4.9 ml/min) following intravenous and p.o. administration of 1 mg digitoxin.,Digitoxin and its metabolites in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [min],20.0,150963,DB01435,Antipyrine
,8243505,clearance,Pharmacokinetic profile and urinary excretion of digitoxin and 4 metabolites were investigated in 9 patients with biopsy confirmed liver cirrhosis (median antipyrine clearance 20.0 +/- 5.4 ml/min; X +/- SEM) and were compared with that of 8 healthy volunteers (antipyrine clearance 36.9 +/- 4.9 ml/min) following intravenous and p.o. administration of 1 mg digitoxin.,Digitoxin and its metabolites in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [min],36.9,150964,DB01435,Antipyrine
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.017,150965,DB01435,Antipyrine
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.011,150966,DB01435,Antipyrine
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.00340,150967,DB01435,Antipyrine
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.00223,150968,DB01435,Antipyrine
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.00006,150969,DB01435,Antipyrine
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.00016,150970,DB01435,Antipyrine
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.00041,150971,DB01435,Antipyrine
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.00088,150972,DB01435,Antipyrine
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.00135,150973,DB01435,Antipyrine
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),,0.00113,150974,DB01435,Antipyrine
,7758252,time to achieve maximal systemic concentrations (tmax,"The pharmacokinetics of dipyrone are characterised by rapid hydrolysis to the active moiety 4-methyl-amino-antipyrine (MAA), which has 85% bioavailability after oral administration in tablet form, and takes a short time to achieve maximal systemic concentrations (tmax of 1.2 to 2.0 hours).",Clinical pharmacokinetics of dipyrone and its metabolites. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),h,1.2 to 2.0,151448,DB01435,Antipyrine
,7758252,Absolute bioavailability,"Absolute bioavailability after intramuscular and rectal administration is 87 and 54%, respectively.",Clinical pharmacokinetics of dipyrone and its metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),%,87,151449,DB01435,Antipyrine
,7758252,Absolute bioavailability,"Absolute bioavailability after intramuscular and rectal administration is 87 and 54%, respectively.",Clinical pharmacokinetics of dipyrone and its metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),%,54,151450,DB01435,Antipyrine
,7758252,elimination half-life (t1/2),"MAA is further metabolised with a mean elimination half-life (t1/2) of 2.6 to 3.5 hours to 4-formyl-amino-antipyrine (FAA), which is an end-metabolite, and to 4-amino-antipyrine (AA), which is then acetylated to 4-acetyl-amino-antipyrine (AAA) by the polymorphic N-acetyl-transferase (t1/2 of AA is 3.8 hours in rapid acetylators and 5.5 hours in slow acetylators).",Clinical pharmacokinetics of dipyrone and its metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),h,2.6 to 3.5,151451,DB01435,Antipyrine
,7758252,t1/2,"MAA is further metabolised with a mean elimination half-life (t1/2) of 2.6 to 3.5 hours to 4-formyl-amino-antipyrine (FAA), which is an end-metabolite, and to 4-amino-antipyrine (AA), which is then acetylated to 4-acetyl-amino-antipyrine (AAA) by the polymorphic N-acetyl-transferase (t1/2 of AA is 3.8 hours in rapid acetylators and 5.5 hours in slow acetylators).",Clinical pharmacokinetics of dipyrone and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),h,3.8,151452,DB01435,Antipyrine
,7758252,t1/2,"MAA is further metabolised with a mean elimination half-life (t1/2) of 2.6 to 3.5 hours to 4-formyl-amino-antipyrine (FAA), which is an end-metabolite, and to 4-amino-antipyrine (AA), which is then acetylated to 4-acetyl-amino-antipyrine (AAA) by the polymorphic N-acetyl-transferase (t1/2 of AA is 3.8 hours in rapid acetylators and 5.5 hours in slow acetylators).",Clinical pharmacokinetics of dipyrone and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),h,5.5,151453,DB01435,Antipyrine
less,7758252,Protein binding,Protein binding of the 4 main metabolites is less than 60%.,Clinical pharmacokinetics of dipyrone and its metabolites. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),%,60,151454,DB01435,Antipyrine
,7758252,volume of distribution,The volume of distribution of MAA is about 1.15 L/kg of lean body mass.,Clinical pharmacokinetics of dipyrone and its metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),[l] / [kg],1.15,151455,DB01435,Antipyrine
,8105056,Clearance,"Clearance of antipyrine in the capsaicin-pretreated rats was significantly lower than that observed in the control rats (0.241 +/- 0.029 vs 0.344 +/- 0.034 L h-1 kg-1, P < 0.05).","Effects of capsaicin on the pharmacokinetics of antipyrine, theophylline and quinine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105056/),[l] / [h·kg],0.241,151535,DB01435,Antipyrine
,8105056,Clearance,"Clearance of antipyrine in the capsaicin-pretreated rats was significantly lower than that observed in the control rats (0.241 +/- 0.029 vs 0.344 +/- 0.034 L h-1 kg-1, P < 0.05).","Effects of capsaicin on the pharmacokinetics of antipyrine, theophylline and quinine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105056/),[l] / [h·kg],0.344,151536,DB01435,Antipyrine
,8105056,elimination half-life,"This is consistent with a prolongation in the elimination half-life of antipyrine in animals pretreated with capsaicin (2.06 +/- 0.30 vs 1.61 +/- 0.27 h), as the volume of distribution was not significantly changed.","Effects of capsaicin on the pharmacokinetics of antipyrine, theophylline and quinine in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105056/),h,2.06,151537,DB01435,Antipyrine
,8105056,elimination half-life,"This is consistent with a prolongation in the elimination half-life of antipyrine in animals pretreated with capsaicin (2.06 +/- 0.30 vs 1.61 +/- 0.27 h), as the volume of distribution was not significantly changed.","Effects of capsaicin on the pharmacokinetics of antipyrine, theophylline and quinine in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105056/),h,1.61,151538,DB01435,Antipyrine
,3387662,half-life,"At birth, the elimination rate of antipyrine was very low as reflected by a half-life of 24 hours.","Effects of age, sex and breed on antipyrine disposition in calves. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3387662/),h,24,152395,DB01435,Antipyrine
,8638398,total plasma clearance,A significant reduction in the total plasma clearance of antipyrine occurred from 60 to 100 days post-infection and a significant increase in mean residence time occurred by 80 days post-infection.,Experimental ovine fasciolosis: antipyrine clearance as indicator of liver damage. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638398/),d,60,152428,DB01435,Antipyrine
,8688997,Clearance,"Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h.","Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688997/),[ml] / [min],350,152437,DB01435,Antipyrine
,8688997,t1/2,"Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h.","Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688997/),h,4,152438,DB01435,Antipyrine
,8688997,Cmax,"Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h.","Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688997/),[μg] / [ml],0.7,152439,DB01435,Antipyrine
,8688997,Cmax,"Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h.","Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688997/),[μg] / [ml],1.7,152440,DB01435,Antipyrine
,8688997,Cmax,"Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h.","Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688997/),[μg] / [ml],4.4,152441,DB01435,Antipyrine
,4002755,half-life period of Antipyrine (t50),"In 14 male patients suffering from peptic ulcer the half-life period of Antipyrine (t50) was 8.6 +/- 0.6 h, whereas in the second test after 14 days it was 13 +/- 0.8 h.",[Effect of histamine H2 receptor blockers on hepatic elimination of drugs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4002755/),h,8.6,153031,DB01435,Antipyrine
,4002755,half-life period of Antipyrine (t50),"In 14 male patients suffering from peptic ulcer the half-life period of Antipyrine (t50) was 8.6 +/- 0.6 h, whereas in the second test after 14 days it was 13 +/- 0.8 h.",[Effect of histamine H2 receptor blockers on hepatic elimination of drugs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4002755/),h,13,153032,DB01435,Antipyrine
,4002755,systemic clearance (Cltot),The systemic clearance (Cltot) was estimated with 78 +/- 11.3 ml X min-1 before treatment and with 40.8 +/- 3.6 ml X min-1 after treatment.,[Effect of histamine H2 receptor blockers on hepatic elimination of drugs]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4002755/),[ml] / [min],78,153033,DB01435,Antipyrine
,4002755,systemic clearance (Cltot),The systemic clearance (Cltot) was estimated with 78 +/- 11.3 ml X min-1 before treatment and with 40.8 +/- 3.6 ml X min-1 after treatment.,[Effect of histamine H2 receptor blockers on hepatic elimination of drugs]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4002755/),[ml] / [min],40.8,153034,DB01435,Antipyrine
,20218012,peak plasma lorazepam concentrations,"Following single 4-mg oral doses, peak plasma lorazepam concentrations ranging from 40 to 70 ng/ml were reached within 3 hr of the dose.",Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),[ng] / [ml],40 to 70,156754,DB01435,Antipyrine
,20218012,absorption half-life,"Values of absorption half-life averaged 25 min (range 10.3-42.7 min), and elimination half-life (t1/2 beta) averaged 14.2 hr (range 8.4-23.9 hr).",Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),min,25,156755,DB01435,Antipyrine
,20218012,elimination half-life (t1/2 beta),"Values of absorption half-life averaged 25 min (range 10.3-42.7 min), and elimination half-life (t1/2 beta) averaged 14.2 hr (range 8.4-23.9 hr).",Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),h,14.2,156756,DB01435,Antipyrine
,20218012,accumulation half-life,"Values of accumulation half-life (mean 21.1 hr) were slightly longer than t1/2beta, and the two were not well correlated.",Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),h,21.1,156757,DB01435,Antipyrine
,20218012,accumulation ratios,"Observed accumulation ratios (mean 1.88) were very close to those predicted from the single-dose study (mean 1.77), but the correlation between the two (r = 0.51) was not significant in the small sample size.",Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),,1.88,156758,DB01435,Antipyrine
,20218012,accumulation ratios,"Observed accumulation ratios (mean 1.88) were very close to those predicted from the single-dose study (mean 1.77), but the correlation between the two (r = 0.51) was not significant in the small sample size.",Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),,1.77,156759,DB01435,Antipyrine
,20218012,"""Washout"" half-life","""Washout"" half-life values (mean 14.9 hr) were highly correlated with t1/2beta (r = 0.92).",Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),h,14.9,156760,DB01435,Antipyrine
,20218012,Clearance,Clearance of a single intravenous dose of antipyrine determined prior to the multiple-dose lorazepam study (mean 0.86 ml/min/kg) was essentially identical to that determined after the study (mean 0.87 ml/ min/kg).,Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),[ml] / [kg·min],0.86,156761,DB01435,Antipyrine
,20218012,Clearance,Clearance of a single intravenous dose of antipyrine determined prior to the multiple-dose lorazepam study (mean 0.86 ml/min/kg) was essentially identical to that determined after the study (mean 0.87 ml/ min/kg).,Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),[ml] / [kg·min],0.87,156762,DB01435,Antipyrine
,2015172,Elimination half-lives,4. Elimination half-lives (mean +/- s.e. mean) of 10-OH-CZ were unaltered by 2 weeks' therapy with OXC (before 11.3 +/- 1.1 h; after 13.9 +/- 3 h).,Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015172/),h,11.3,156873,DB01435,Antipyrine
,2015172,Elimination half-lives,4. Elimination half-lives (mean +/- s.e. mean) of 10-OH-CZ were unaltered by 2 weeks' therapy with OXC (before 11.3 +/- 1.1 h; after 13.9 +/- 3 h).,Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015172/),h,13.9,156874,DB01435,Antipyrine
,2015172,Trough plasma concentrations,Trough plasma concentrations of 10-OH-CZ at steady-state (31 +/- 2.2 mumol l-1) were higher than predicted (16.5 +/- 4 mumol l-1).,Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015172/),[μM] / [l],31,156875,DB01435,Antipyrine
,2015172,Trough plasma concentrations,Trough plasma concentrations of 10-OH-CZ at steady-state (31 +/- 2.2 mumol l-1) were higher than predicted (16.5 +/- 4 mumol l-1).,Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015172/),[μM] / [l],16.5,156876,DB01435,Antipyrine
,9760339,V(O2)max,"V(O2)max and velocity to obtain a blood lactate concentration of 4 mmol/l were significantly increased (from 129 to 149 ml x min-1 x kg-1 and from 5.6 to 6.1 m/s, respectively) as a result of training.",Exercise-training-induced alterations in hepatic function in mares. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9760339/),[ml] / [kg·min],129,157388,DB01435,Antipyrine
,9760339,V(O2)max,"V(O2)max and velocity to obtain a blood lactate concentration of 4 mmol/l were significantly increased (from 129 to 149 ml x min-1 x kg-1 and from 5.6 to 6.1 m/s, respectively) as a result of training.",Exercise-training-induced alterations in hepatic function in mares. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9760339/),[ml] / [kg·min],149,157389,DB01435,Antipyrine
,9760339,V(O2)max,"V(O2)max and velocity to obtain a blood lactate concentration of 4 mmol/l were significantly increased (from 129 to 149 ml x min-1 x kg-1 and from 5.6 to 6.1 m/s, respectively) as a result of training.",Exercise-training-induced alterations in hepatic function in mares. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9760339/),[m] / [s],5.6,157390,DB01435,Antipyrine
,9760339,velocity,"V(O2)max and velocity to obtain a blood lactate concentration of 4 mmol/l were significantly increased (from 129 to 149 ml x min-1 x kg-1 and from 5.6 to 6.1 m/s, respectively) as a result of training.",Exercise-training-induced alterations in hepatic function in mares. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9760339/),[ml] / [kg·min],129,157391,DB01435,Antipyrine
,9760339,velocity,"V(O2)max and velocity to obtain a blood lactate concentration of 4 mmol/l were significantly increased (from 129 to 149 ml x min-1 x kg-1 and from 5.6 to 6.1 m/s, respectively) as a result of training.",Exercise-training-induced alterations in hepatic function in mares. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9760339/),[ml] / [kg·min],149,157392,DB01435,Antipyrine
,9760339,velocity,"V(O2)max and velocity to obtain a blood lactate concentration of 4 mmol/l were significantly increased (from 129 to 149 ml x min-1 x kg-1 and from 5.6 to 6.1 m/s, respectively) as a result of training.",Exercise-training-induced alterations in hepatic function in mares. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9760339/),[m] / [s],5.6,157393,DB01435,Antipyrine
,9760339,velocity,"V(O2)max and velocity to obtain a blood lactate concentration of 4 mmol/l were significantly increased (from 129 to 149 ml x min-1 x kg-1 and from 5.6 to 6.1 m/s, respectively) as a result of training.",Exercise-training-induced alterations in hepatic function in mares. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9760339/),[m] / [s],6.1,157394,DB01435,Antipyrine
,9760339,plasma clearance,"The plasma clearance and volume of distribution of antipyrine increased significantly in the trained group (from 5.5 to 6.4 ml x min-1 x kg-1 and from 813 to 881 ml/kg, respectively) and decreased significantly in the untrained group.",Exercise-training-induced alterations in hepatic function in mares. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9760339/),[ml] / [kg·min],5.5 to 6.4,157395,DB01435,Antipyrine
,9760339,volume of distribution,"The plasma clearance and volume of distribution of antipyrine increased significantly in the trained group (from 5.5 to 6.4 ml x min-1 x kg-1 and from 813 to 881 ml/kg, respectively) and decreased significantly in the untrained group.",Exercise-training-induced alterations in hepatic function in mares. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9760339/),[ml] / [kg],813 to 881,157396,DB01435,Antipyrine
,7808782,placental clearance index,"Mother-to-foetus in vitro transfer of CPO is high, similar to that of amoxicillin, with a placental clearance index of 0.20.",[Placental penetration of cefpirome (HR 810): study of fetal concentrations after in vitro infusions of human placenta at term]. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7808782/),,0.20,158729,DB01435,Antipyrine
,6473507,Blood elimination half-lives,"Blood elimination half-lives of AP and HB were more than four times longer in PCS rats than in control rats, increasing from 63.7 +/- 3.9 to 291 +/- 66 min, and from 20.1 +/- 1.8 to 84.2 +/- 7.6 min, respectively.",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),min,63.7,159251,DB01435,Antipyrine
,6473507,Blood elimination half-lives,"Blood elimination half-lives of AP and HB were more than four times longer in PCS rats than in control rats, increasing from 63.7 +/- 3.9 to 291 +/- 66 min, and from 20.1 +/- 1.8 to 84.2 +/- 7.6 min, respectively.",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),min,291,159252,DB01435,Antipyrine
,6473507,Blood elimination half-lives,"Blood elimination half-lives of AP and HB were more than four times longer in PCS rats than in control rats, increasing from 63.7 +/- 3.9 to 291 +/- 66 min, and from 20.1 +/- 1.8 to 84.2 +/- 7.6 min, respectively.",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),min,20.1,159253,DB01435,Antipyrine
,6473507,Blood elimination half-lives,"Blood elimination half-lives of AP and HB were more than four times longer in PCS rats than in control rats, increasing from 63.7 +/- 3.9 to 291 +/- 66 min, and from 20.1 +/- 1.8 to 84.2 +/- 7.6 min, respectively.",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),min,84.2,159254,DB01435,Antipyrine
,6473507,Intrinsic clearance of,"Intrinsic clearance of HB (CLint, HB) was 167 +/- 19 ml/min/kg in controls and 27 +/- 4 ml/min/kg in PCS rats (CLpcs, HB).",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),[ml] / [kg·min],167,159255,DB01435,Antipyrine
,6473507,CLpcs,"Intrinsic clearance of HB (CLint, HB) was 167 +/- 19 ml/min/kg in controls and 27 +/- 4 ml/min/kg in PCS rats (CLpcs, HB).",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),[ml] / [kg·min],27,159256,DB01435,Antipyrine
,6473507,Intrinsic clearance,"Intrinsic clearance of AP (CLint, AP) in control rats was 15.1 +/- 0.7 ml/min/kg and 5.9 +/- 0.7 ml/min/kg in PCS rats (CLpcs, AP).",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),[ml] / [kg·min],15.1,159257,DB01435,Antipyrine
,6473507,Intrinsic clearance,"Intrinsic clearance of AP (CLint, AP) in control rats was 15.1 +/- 0.7 ml/min/kg and 5.9 +/- 0.7 ml/min/kg in PCS rats (CLpcs, AP).",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),[ml] / [kg·min],5.9,159258,DB01435,Antipyrine
,6473507,CLpcs,"Intrinsic clearance of AP (CLint, AP) in control rats was 15.1 +/- 0.7 ml/min/kg and 5.9 +/- 0.7 ml/min/kg in PCS rats (CLpcs, AP).",Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473507/),[ml] / [kg·min],5.9,159259,DB01435,Antipyrine
less,2103402,t1/2,"Eight patients had AP t1/2 less than 15 h, while 10 had AP t1/2 greater than 15 h.",Antipyrine elimination test as a guideline for selecting patients for transhepatic biliary drainage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2103402/),h,15,161197,DB01435,Antipyrine
greater,2103402,t1/2,"Eight patients had AP t1/2 less than 15 h, while 10 had AP t1/2 greater than 15 h.",Antipyrine elimination test as a guideline for selecting patients for transhepatic biliary drainage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2103402/),h,15,161198,DB01435,Antipyrine
less,2103402,t1/2,Patients with AP t1/2 less than 15 h had significantly faster recovery after PTBD than patients with AP t1/2 greater than 15 h.,Antipyrine elimination test as a guideline for selecting patients for transhepatic biliary drainage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2103402/),h,15,161199,DB01435,Antipyrine
greater,2103402,t1/2,Patients with AP t1/2 less than 15 h had significantly faster recovery after PTBD than patients with AP t1/2 greater than 15 h.,Antipyrine elimination test as a guideline for selecting patients for transhepatic biliary drainage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2103402/),h,15,161200,DB01435,Antipyrine
less,2103402,t1/2,"If PTBD can be restricted to those with AP t1/2 less than 15 h, the advantages of preliminary PTBD can be achieved with minimum complications.",Antipyrine elimination test as a guideline for selecting patients for transhepatic biliary drainage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2103402/),h,15,161201,DB01435,Antipyrine
,11476153,pulmonary retention,"The average pulmonary retention of styrene was 62 +/- 7% at both exposure concentrations, and the 24-h excretion of MA and PGA accounted for 58% of the dose at both concentrations.",Metabolic capacity and interindividual variation in toxicokinetics of styrene in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11476153/),%,62,162727,DB01435,Antipyrine
,11476153,apparent blood clearance,"Although other explanations cannot be excluded, this lack of correlation might be due to the high apparent blood clearance (1.4 l/min) of styrene, indicating that styrene metabolism is liver-blood-flow-dependent.",Metabolic capacity and interindividual variation in toxicokinetics of styrene in volunteers. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11476153/),[l] / [min],1.4,162728,DB01435,Antipyrine
,1065903,plasma half-life,The mean plasma half-life for antipyrine was 17.5 hr on the high carbohydrate-low protein diet and 9.2 hr on the low carbohydrate-high protein diet.,Interactions between nutritional factors and drug biotransformations in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1065903/),h,17.5,163495,DB01435,Antipyrine
,1065903,plasma half-life,The mean plasma half-life for antipyrine was 17.5 hr on the high carbohydrate-low protein diet and 9.2 hr on the low carbohydrate-high protein diet.,Interactions between nutritional factors and drug biotransformations in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1065903/),h,9.2,163496,DB01435,Antipyrine
,1065903,plasma half-life,The mean plasma half-life for theophylline was 8.9 hr on the high carbohydrate-low protein diet and 5.9 hr on the low carbohydrate-high protein diet.,Interactions between nutritional factors and drug biotransformations in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1065903/),h,8.9,163497,DB01435,Antipyrine
,1065903,plasma half-life,The mean plasma half-life for theophylline was 8.9 hr on the high carbohydrate-low protein diet and 5.9 hr on the low carbohydrate-high protein diet.,Interactions between nutritional factors and drug biotransformations in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1065903/),h,5.9,163498,DB01435,Antipyrine
,3208791,peak plasma concentrations,"In dogs, the chronic administration of 400 mg/d of phenobarbital produced peak plasma concentrations of 78 micrograms/ml which so markedly induced the metabolism of antipyrine that the conventional schemes by which antipyrine kinetics assess induction were rendered invalid.",The effect of induction with phenobarbital on the kinetics and bioavailability of antipyrine in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208791/),[μg] / [ml],78,163947,DB01435,Antipyrine
,3208791,bioavailability,The bioavailability of antipyrine was only 20% due to first-pass metabolism.,The effect of induction with phenobarbital on the kinetics and bioavailability of antipyrine in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208791/),%,20,163948,DB01435,Antipyrine
,3208791,clearance,"Induction raised the observed antipyrine clearance to 31 ml/min/kg, a value approaching hepatic blood flow.",The effect of induction with phenobarbital on the kinetics and bioavailability of antipyrine in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208791/),[ml] / [kg·min],31,163949,DB01435,Antipyrine
,3208791,induction factor,"Acknowledging that antipyrine is nonideal, one can calculate a correct induction factor of 13.6.",The effect of induction with phenobarbital on the kinetics and bioavailability of antipyrine in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208791/),,13.6,163950,DB01435,Antipyrine
,8163717,oral clearance,"Antipyrine oral clearance increased from a starting value of .74 mL/minute/kg to .98 (+32%, P < .01) after 7 days of moricizine administration (250 mg every 8 hours) and to 1.15 mL/minute/kg after 14 days (+47%, P < .05); t1/2 was correspondingly reduced.",Enzyme induction by moricizine: time course and extent in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8163717/),[ml] / [kg·min],.74,164053,DB01435,Antipyrine
,8163717,oral clearance,"Antipyrine oral clearance increased from a starting value of .74 mL/minute/kg to .98 (+32%, P < .01) after 7 days of moricizine administration (250 mg every 8 hours) and to 1.15 mL/minute/kg after 14 days (+47%, P < .05); t1/2 was correspondingly reduced.",Enzyme induction by moricizine: time course and extent in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8163717/),,.98,164054,DB01435,Antipyrine
,8163717,oral clearance,"Antipyrine oral clearance increased from a starting value of .74 mL/minute/kg to .98 (+32%, P < .01) after 7 days of moricizine administration (250 mg every 8 hours) and to 1.15 mL/minute/kg after 14 days (+47%, P < .05); t1/2 was correspondingly reduced.",Enzyme induction by moricizine: time course and extent in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8163717/),[ml] / [kg·min],1.15,164055,DB01435,Antipyrine
,8163717,oral clearance,"Moricizine oral clearance increased from a baseline of 3.01 L/hour/kg to 3.62 (+20%, P < .05) after 6 days of oral moricizine and 4.66 (+51%, not significant) after 13 days.",Enzyme induction by moricizine: time course and extent in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8163717/),[l] / [h·kg],3.01,164056,DB01435,Antipyrine
,8163717,oral clearance,"Moricizine oral clearance increased from a baseline of 3.01 L/hour/kg to 3.62 (+20%, P < .05) after 6 days of oral moricizine and 4.66 (+51%, not significant) after 13 days.",Enzyme induction by moricizine: time course and extent in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8163717/),,3.62,164057,DB01435,Antipyrine
,8163717,oral clearance,"Moricizine oral clearance increased from a baseline of 3.01 L/hour/kg to 3.62 (+20%, P < .05) after 6 days of oral moricizine and 4.66 (+51%, not significant) after 13 days.",Enzyme induction by moricizine: time course and extent in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8163717/),,4.,164058,DB01435,Antipyrine
,1427580,blood clearances,The mean blood clearances of antipyrine and aminopyrine in cirrhotic patients (0.220 +/- 0.085 ml/min/kg and 1.13 +/- 0.56 ml/min/kg; n = 64) was 50% and 38% of that of normal subjects (0.440 +/- 0.110 ml/min/kg and 2.95 +/- 0.59 ml/min/kg; n = 11).,A comparison between antipyrine and aminopyrine blood clearances. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1427580/),[ml] / [kg·min],0.220,164215,DB01435,Antipyrine
,1427580,blood clearances,The mean blood clearances of antipyrine and aminopyrine in cirrhotic patients (0.220 +/- 0.085 ml/min/kg and 1.13 +/- 0.56 ml/min/kg; n = 64) was 50% and 38% of that of normal subjects (0.440 +/- 0.110 ml/min/kg and 2.95 +/- 0.59 ml/min/kg; n = 11).,A comparison between antipyrine and aminopyrine blood clearances. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1427580/),[ml] / [kg·min],1.13,164216,DB01435,Antipyrine
,1427580,blood clearances,The mean blood clearances of antipyrine and aminopyrine in cirrhotic patients (0.220 +/- 0.085 ml/min/kg and 1.13 +/- 0.56 ml/min/kg; n = 64) was 50% and 38% of that of normal subjects (0.440 +/- 0.110 ml/min/kg and 2.95 +/- 0.59 ml/min/kg; n = 11).,A comparison between antipyrine and aminopyrine blood clearances. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1427580/),[ml] / [kg·min],0.440,164217,DB01435,Antipyrine
,1427580,blood clearances,The mean blood clearances of antipyrine and aminopyrine in cirrhotic patients (0.220 +/- 0.085 ml/min/kg and 1.13 +/- 0.56 ml/min/kg; n = 64) was 50% and 38% of that of normal subjects (0.440 +/- 0.110 ml/min/kg and 2.95 +/- 0.59 ml/min/kg; n = 11).,A comparison between antipyrine and aminopyrine blood clearances. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1427580/),[ml] / [kg·min],2.95,164218,DB01435,Antipyrine
,24807346,fetal-to-maternal,"There was slower transfer of dabigatran compared with antipyrine from the maternal-to-fetal circulation, because the median fetal-to-maternal concentration ratio was 0.33 (interquartile range 0.29-0.38) after 3 hours (n=3).",Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24807346/),,0.33,164557,DB01435,Antipyrine
,24807346,concentration ratio,"There was slower transfer of dabigatran compared with antipyrine from the maternal-to-fetal circulation, because the median fetal-to-maternal concentration ratio was 0.33 (interquartile range 0.29-0.38) after 3 hours (n=3).",Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24807346/),,0.33,164558,DB01435,Antipyrine
,24807346,f,"The prodrug, dabigatran etexilate mesylate, had limited placental transfer as characterized by a fetal-to-maternal ratio of 0.17 (interquartile range 0.15-0.17) after 3 hours (n=3).",Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24807346/),,0.17,164559,DB01435,Antipyrine
,12071338,clearance rates,Untreated type 1 patients eliminated antipyrine rapidly and insulin treatment normalised antipyrine elimination (clearance rates 89.5 +/- 20.3 versus 58.8 +/- 17.2 ml/min.; P<0.001).,"Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071338/),[ml] / [min],89.5,164975,DB01435,Antipyrine
,12071338,clearance rates,Untreated type 1 patients eliminated antipyrine rapidly and insulin treatment normalised antipyrine elimination (clearance rates 89.5 +/- 20.3 versus 58.8 +/- 17.2 ml/min.; P<0.001).,"Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071338/),[ml] / [min],58.8,164976,DB01435,Antipyrine
,3360112,oral clearance,"At the end of the course a decrease of oral clearance of VP as compared with its beginning (from 3.02 to 1.57 l/min, p less than 0.01) and an increase of the drug half-life (from 6.48 to 9.49 hrs, p less than 0.01) were found.",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),[l] / [min],3.02,166668,DB01435,Antipyrine
,3360112,oral clearance,"At the end of the course a decrease of oral clearance of VP as compared with its beginning (from 3.02 to 1.57 l/min, p less than 0.01) and an increase of the drug half-life (from 6.48 to 9.49 hrs, p less than 0.01) were found.",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),[l] / [min],1,166669,DB01435,Antipyrine
,3360112,half-life,"At the end of the course a decrease of oral clearance of VP as compared with its beginning (from 3.02 to 1.57 l/min, p less than 0.01) and an increase of the drug half-life (from 6.48 to 9.49 hrs, p less than 0.01) were found.",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),h,6,166670,DB01435,Antipyrine
,3360112,half-life,"At the end of the course a decrease of oral clearance of VP as compared with its beginning (from 3.02 to 1.57 l/min, p less than 0.01) and an increase of the drug half-life (from 6.48 to 9.49 hrs, p less than 0.01) were found.",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),h,9,166671,DB01435,Antipyrine
,3360112,Half-lives,"Half-lives of nor-VP and D-617 at the end of VP course (12.1 and 19.7 hrs, respectively) were also higher than at its beginning (8.7 and 14.2 hrs, respectively), half-life of D-620 underwent no significant changes (29.5 hrs at the beginning and 31.6 hrs at the end of VP course).",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),h,12.1,166672,DB01435,Antipyrine
,3360112,Half-lives,"Half-lives of nor-VP and D-617 at the end of VP course (12.1 and 19.7 hrs, respectively) were also higher than at its beginning (8.7 and 14.2 hrs, respectively), half-life of D-620 underwent no significant changes (29.5 hrs at the beginning and 31.6 hrs at the end of VP course).",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),h,19.7,166673,DB01435,Antipyrine
,3360112,Half-lives,"Half-lives of nor-VP and D-617 at the end of VP course (12.1 and 19.7 hrs, respectively) were also higher than at its beginning (8.7 and 14.2 hrs, respectively), half-life of D-620 underwent no significant changes (29.5 hrs at the beginning and 31.6 hrs at the end of VP course).",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),h,8.7,166674,DB01435,Antipyrine
,3360112,Half-lives,"Half-lives of nor-VP and D-617 at the end of VP course (12.1 and 19.7 hrs, respectively) were also higher than at its beginning (8.7 and 14.2 hrs, respectively), half-life of D-620 underwent no significant changes (29.5 hrs at the beginning and 31.6 hrs at the end of VP course).",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),h,14.2,166675,DB01435,Antipyrine
,3360112,half-life,"Half-lives of nor-VP and D-617 at the end of VP course (12.1 and 19.7 hrs, respectively) were also higher than at its beginning (8.7 and 14.2 hrs, respectively), half-life of D-620 underwent no significant changes (29.5 hrs at the beginning and 31.6 hrs at the end of VP course).",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),h,29.5,166676,DB01435,Antipyrine
,3360112,half-life,"Half-lives of nor-VP and D-617 at the end of VP course (12.1 and 19.7 hrs, respectively) were also higher than at its beginning (8.7 and 14.2 hrs, respectively), half-life of D-620 underwent no significant changes (29.5 hrs at the beginning and 31.6 hrs at the end of VP course).",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),h,31.6,166677,DB01435,Antipyrine
,3360112,clearance,"At the end of VP course the patients exhibited a decrease of antipyrine clearance (to 28.7 versus 43.2 ml/min at the beginning of VP course, p less than 0.01) that indicates a reduced activity of oxidative microsomal enzymes of the liver due to long-term VP therapy.",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),[ml] / [min],28.7,166678,DB01435,Antipyrine
,3360112,clearance,"At the end of VP course the patients exhibited a decrease of antipyrine clearance (to 28.7 versus 43.2 ml/min at the beginning of VP course, p less than 0.01) that indicates a reduced activity of oxidative microsomal enzymes of the liver due to long-term VP therapy.",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),[ml] / [min],43.2,166679,DB01435,Antipyrine
,7908631,clearance (AP Cl),"12 subjects had normal renal and hepatic function (mean creatinine clearance (GFR) 107 +/- 240 ml/min, antipyrine clearance (AP Cl) 47 +/- 10.2 ml/min; x +/- SD), 13 subjects had impaired renal function (mean GFR 38 +/- 11.5 ml/min, AP Cl 39 +/- 4.0 ml/min), and 12 patients had liver cirrhosis which was confirmed by liver biopsy (mean AP Cl 18 +/- 9.2 ml/min, GFR 92 +/- 8.1 ml/min).",Bunazosin in patients with impaired hepatic or renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908631/),[ml] / [min],47,166814,DB01435,Antipyrine
,7908631,Cl,"12 subjects had normal renal and hepatic function (mean creatinine clearance (GFR) 107 +/- 240 ml/min, antipyrine clearance (AP Cl) 47 +/- 10.2 ml/min; x +/- SD), 13 subjects had impaired renal function (mean GFR 38 +/- 11.5 ml/min, AP Cl 39 +/- 4.0 ml/min), and 12 patients had liver cirrhosis which was confirmed by liver biopsy (mean AP Cl 18 +/- 9.2 ml/min, GFR 92 +/- 8.1 ml/min).",Bunazosin in patients with impaired hepatic or renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908631/),[ml] / [min],39,166815,DB01435,Antipyrine
,7908631,AP Cl,"12 subjects had normal renal and hepatic function (mean creatinine clearance (GFR) 107 +/- 240 ml/min, antipyrine clearance (AP Cl) 47 +/- 10.2 ml/min; x +/- SD), 13 subjects had impaired renal function (mean GFR 38 +/- 11.5 ml/min, AP Cl 39 +/- 4.0 ml/min), and 12 patients had liver cirrhosis which was confirmed by liver biopsy (mean AP Cl 18 +/- 9.2 ml/min, GFR 92 +/- 8.1 ml/min).",Bunazosin in patients with impaired hepatic or renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908631/),[ml] / [min],18,166816,DB01435,Antipyrine
,7908631,area under the plasma level time curve (AUC0-infinity),The area under the plasma level time curve (AUC0-infinity) of bunazosin increased from 96.6 +/- 48.7 micrograms.,Bunazosin in patients with impaired hepatic or renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908631/),μg,96.6,166817,DB01435,Antipyrine
,7468228,systemic availability,"The systemic availability of oral antipyrine after cyclophosphamide pretreatment (0.88) was not changed, but the metabolic clearance of the drug was reduced.",The effect of antineoplastic drugs on the pharmacokinetics of antipyrine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7468228/),,0.88,167737,DB01435,Antipyrine
,9408858,apparent pulmonary tissue volume,The apparent pulmonary tissue volume of lidocaine (39 ml/kg) was nearly ninefold greater than that of antipyrine (4.5 ml/kg).,A recirculatory model of the pulmonary uptake and pharmacokinetics of lidocaine based on analysis of arterial and mixed venous data from dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408858/),[ml] / [kg],39,168422,DB01435,Antipyrine
,9408858,apparent pulmonary tissue volume,The apparent pulmonary tissue volume of lidocaine (39 ml/kg) was nearly ninefold greater than that of antipyrine (4.5 ml/kg).,A recirculatory model of the pulmonary uptake and pharmacokinetics of lidocaine based on analysis of arterial and mixed venous data from dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408858/),[ml] / [kg],4.5,168423,DB01435,Antipyrine
,6714293,total body clearance,"The total body clearance of phenprocoumon was higher in the cirrhotic patients (1.64 +/- 0.16 ml/h/kg mean +/- SEM) than in the healthy volunteers (0.90 +/- 0.07 ml/h/kg), however the free drug clearance was not significantly different in the patients (144 +/- 14 ml/h/kg) compared with normal (113 +/- 11 ml/h/kg).",The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714293/),[ml] / [h·kg],1.64,168572,DB01435,Antipyrine
,6714293,total body clearance,"The total body clearance of phenprocoumon was higher in the cirrhotic patients (1.64 +/- 0.16 ml/h/kg mean +/- SEM) than in the healthy volunteers (0.90 +/- 0.07 ml/h/kg), however the free drug clearance was not significantly different in the patients (144 +/- 14 ml/h/kg) compared with normal (113 +/- 11 ml/h/kg).",The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714293/),[ml] / [h·kg],0.90,168573,DB01435,Antipyrine
,6714293,free drug clearance,"The total body clearance of phenprocoumon was higher in the cirrhotic patients (1.64 +/- 0.16 ml/h/kg mean +/- SEM) than in the healthy volunteers (0.90 +/- 0.07 ml/h/kg), however the free drug clearance was not significantly different in the patients (144 +/- 14 ml/h/kg) compared with normal (113 +/- 11 ml/h/kg).",The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714293/),[ml] / [h·kg],144,168574,DB01435,Antipyrine
,6714293,free drug clearance,"The total body clearance of phenprocoumon was higher in the cirrhotic patients (1.64 +/- 0.16 ml/h/kg mean +/- SEM) than in the healthy volunteers (0.90 +/- 0.07 ml/h/kg), however the free drug clearance was not significantly different in the patients (144 +/- 14 ml/h/kg) compared with normal (113 +/- 11 ml/h/kg).",The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714293/),[ml] / [h·kg],113,168575,DB01435,Antipyrine
,6714293,clearance,In contrast the clearance of antipyrine was much reduced in the cirrhotic group (17.5 +/- 2.9 ml/h/kg) compared with normal (35.6 +/- 3.9 ml/h/kg).,The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714293/),[ml] / [h·kg],17.5,168576,DB01435,Antipyrine
,6714293,clearance,In contrast the clearance of antipyrine was much reduced in the cirrhotic group (17.5 +/- 2.9 ml/h/kg) compared with normal (35.6 +/- 3.9 ml/h/kg).,The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714293/),[ml] / [h·kg],35.6,168577,DB01435,Antipyrine
,15739818,peak,"Mean vancomycin maternal peak and trough concentrations ranged from 30.0 to 51.5 microg/ml and 7.7 to 16.4 microg/ml, respectively.",Transplacental passage of vancomycin in the ex vivo human perfusion model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739818/),[μg] / [ml],30.0 to 51.5,169141,DB01435,Antipyrine
,15739818,trough concentrations,"Mean vancomycin maternal peak and trough concentrations ranged from 30.0 to 51.5 microg/ml and 7.7 to 16.4 microg/ml, respectively.",Transplacental passage of vancomycin in the ex vivo human perfusion model. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739818/),[μg] / [ml],7.7 to 16.4,169142,DB01435,Antipyrine
,15739818,peak,Clearance indexes were minimal with a mean peak range of 0.000-0.080 and a mean trough range of 0.00-0.17.,Transplacental passage of vancomycin in the ex vivo human perfusion model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739818/),,0.000-0.080,169143,DB01435,Antipyrine
,15739818,trough,Clearance indexes were minimal with a mean peak range of 0.000-0.080 and a mean trough range of 0.00-0.17.,Transplacental passage of vancomycin in the ex vivo human perfusion model. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739818/),,0.00-0.17,169144,DB01435,Antipyrine
>,15739818,transport fraction,"For each placenta, transport fraction for antipyrine 14C was > 1.85 with a single pass of > 40%.",Transplacental passage of vancomycin in the ex vivo human perfusion model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739818/),,1.85,169145,DB01435,Antipyrine
,15739818,peak clearance index,The mean peak clearance index was zero after perfusing the placenta for up to 5 h with 35.8 microg/ml of vancomycin.,Transplacental passage of vancomycin in the ex vivo human perfusion model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739818/),,zero,169146,DB01435,Antipyrine
,15739818,peak clearance index,The mean peak clearance index was zero after perfusing the placenta for up to 5 h with 35.8 microg/ml of vancomycin.,Transplacental passage of vancomycin in the ex vivo human perfusion model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15739818/),[μg] / [ml],35.8,169147,DB01435,Antipyrine
,7988100,terminal elimination half-life,"Following administration of single doses, fluvoxamine shows a biphasic elimination with a mean terminal elimination half-life of about 15 to 20 hours.",Clinical pharmacokinetics of fluvoxamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988100/),h,15 to 20,171285,DB01435,Antipyrine
,2937866,CL/F,The mean (+/- SD) pre-vaccination CL/F was 3.65 (+/- 0.75) 1/hr.,Hepatitis B vaccine and antipyrine clearance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2937866/),[1] / [h],3.65,171427,DB01435,Antipyrine
,9669082,elimination half-lives,"The data obtained (mean +/- SEM and median in brackets) in camels and horses, respectively, were as follows: the elimination half-lives were 3.25 +/- 0.23 (3.19) and 3.09 +/- 0.25 (2.90) hr; the apparent volumes of distribution (area method) were 0.691 +/- 0.045 (0.648) and 0.642 +/- 0.034 (0.676) l/kg; the volumes of distribution at steady state were 0.659 +/- 0.040 (0.607) and 0.620 +/- 0.030 (0.653) l/kg; the volume of the central compartment of the two-compartment pharmacokinetic model were 0.386 +/- 0.0523 (0.349) and 0.298 +/- 0.05 (0.308) l/kg; total body clearances were 0.148 +/- 0.008 (0.158) and 0.145 +/- 0.007 (0.147) l/kg/hr; the areas under the curves to infinity were 171.0 +/- 9 (165) and 175 +/- 8.0 (170) micrograms.","The activity of mixed function oxidases, estimated by in vivo antipyrine clearance, is similar in horses and camels. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669082/),h,3.25,173451,DB01435,Antipyrine
,9669082,elimination half-lives,"The data obtained (mean +/- SEM and median in brackets) in camels and horses, respectively, were as follows: the elimination half-lives were 3.25 +/- 0.23 (3.19) and 3.09 +/- 0.25 (2.90) hr; the apparent volumes of distribution (area method) were 0.691 +/- 0.045 (0.648) and 0.642 +/- 0.034 (0.676) l/kg; the volumes of distribution at steady state were 0.659 +/- 0.040 (0.607) and 0.620 +/- 0.030 (0.653) l/kg; the volume of the central compartment of the two-compartment pharmacokinetic model were 0.386 +/- 0.0523 (0.349) and 0.298 +/- 0.05 (0.308) l/kg; total body clearances were 0.148 +/- 0.008 (0.158) and 0.145 +/- 0.007 (0.147) l/kg/hr; the areas under the curves to infinity were 171.0 +/- 9 (165) and 175 +/- 8.0 (170) micrograms.","The activity of mixed function oxidases, estimated by in vivo antipyrine clearance, is similar in horses and camels. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669082/),h,3.09,173452,DB01435,Antipyrine
,9669082,apparent volumes of distribution,"The data obtained (mean +/- SEM and median in brackets) in camels and horses, respectively, were as follows: the elimination half-lives were 3.25 +/- 0.23 (3.19) and 3.09 +/- 0.25 (2.90) hr; the apparent volumes of distribution (area method) were 0.691 +/- 0.045 (0.648) and 0.642 +/- 0.034 (0.676) l/kg; the volumes of distribution at steady state were 0.659 +/- 0.040 (0.607) and 0.620 +/- 0.030 (0.653) l/kg; the volume of the central compartment of the two-compartment pharmacokinetic model were 0.386 +/- 0.0523 (0.349) and 0.298 +/- 0.05 (0.308) l/kg; total body clearances were 0.148 +/- 0.008 (0.158) and 0.145 +/- 0.007 (0.147) l/kg/hr; the areas under the curves to infinity were 171.0 +/- 9 (165) and 175 +/- 8.0 (170) micrograms.","The activity of mixed function oxidases, estimated by in vivo antipyrine clearance, is similar in horses and camels. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669082/),[l] / [kg],0.691,173453,DB01435,Antipyrine
,9669082,apparent volumes of distribution,"The data obtained (mean +/- SEM and median in brackets) in camels and horses, respectively, were as follows: the elimination half-lives were 3.25 +/- 0.23 (3.19) and 3.09 +/- 0.25 (2.90) hr; the apparent volumes of distribution (area method) were 0.691 +/- 0.045 (0.648) and 0.642 +/- 0.034 (0.676) l/kg; the volumes of distribution at steady state were 0.659 +/- 0.040 (0.607) and 0.620 +/- 0.030 (0.653) l/kg; the volume of the central compartment of the two-compartment pharmacokinetic model were 0.386 +/- 0.0523 (0.349) and 0.298 +/- 0.05 (0.308) l/kg; total body clearances were 0.148 +/- 0.008 (0.158) and 0.145 +/- 0.007 (0.147) l/kg/hr; the areas under the curves to infinity were 171.0 +/- 9 (165) and 175 +/- 8.0 (170) micrograms.","The activity of mixed function oxidases, estimated by in vivo antipyrine clearance, is similar in horses and camels. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669082/),[l] / [kg],0.642,173454,DB01435,Antipyrine
,9669082,volumes of distribution at steady state,"The data obtained (mean +/- SEM and median in brackets) in camels and horses, respectively, were as follows: the elimination half-lives were 3.25 +/- 0.23 (3.19) and 3.09 +/- 0.25 (2.90) hr; the apparent volumes of distribution (area method) were 0.691 +/- 0.045 (0.648) and 0.642 +/- 0.034 (0.676) l/kg; the volumes of distribution at steady state were 0.659 +/- 0.040 (0.607) and 0.620 +/- 0.030 (0.653) l/kg; the volume of the central compartment of the two-compartment pharmacokinetic model were 0.386 +/- 0.0523 (0.349) and 0.298 +/- 0.05 (0.308) l/kg; total body clearances were 0.148 +/- 0.008 (0.158) and 0.145 +/- 0.007 (0.147) l/kg/hr; the areas under the curves to infinity were 171.0 +/- 9 (165) and 175 +/- 8.0 (170) micrograms.","The activity of mixed function oxidases, estimated by in vivo antipyrine clearance, is similar in horses and camels. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669082/),[l] / [kg],0.659,173455,DB01435,Antipyrine
,9669082,volumes of distribution at steady state,"The data obtained (mean +/- SEM and median in brackets) in camels and horses, respectively, were as follows: the elimination half-lives were 3.25 +/- 0.23 (3.19) and 3.09 +/- 0.25 (2.90) hr; the apparent volumes of distribution (area method) were 0.691 +/- 0.045 (0.648) and 0.642 +/- 0.034 (0.676) l/kg; the volumes of distribution at steady state were 0.659 +/- 0.040 (0.607) and 0.620 +/- 0.030 (0.653) l/kg; the volume of the central compartment of the two-compartment pharmacokinetic model were 0.386 +/- 0.0523 (0.349) and 0.298 +/- 0.05 (0.308) l/kg; total body clearances were 0.148 +/- 0.008 (0.158) and 0.145 +/- 0.007 (0.147) l/kg/hr; the areas under the curves to infinity were 171.0 +/- 9 (165) and 175 +/- 8.0 (170) micrograms.","The activity of mixed function oxidases, estimated by in vivo antipyrine clearance, is similar in horses and camels. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669082/),[l] / [kg],0.620,173456,DB01435,Antipyrine
,9669082,volume of the central compartment,"The data obtained (mean +/- SEM and median in brackets) in camels and horses, respectively, were as follows: the elimination half-lives were 3.25 +/- 0.23 (3.19) and 3.09 +/- 0.25 (2.90) hr; the apparent volumes of distribution (area method) were 0.691 +/- 0.045 (0.648) and 0.642 +/- 0.034 (0.676) l/kg; the volumes of distribution at steady state were 0.659 +/- 0.040 (0.607) and 0.620 +/- 0.030 (0.653) l/kg; the volume of the central compartment of the two-compartment pharmacokinetic model were 0.386 +/- 0.0523 (0.349) and 0.298 +/- 0.05 (0.308) l/kg; total body clearances were 0.148 +/- 0.008 (0.158) and 0.145 +/- 0.007 (0.147) l/kg/hr; the areas under the curves to infinity were 171.0 +/- 9 (165) and 175 +/- 8.0 (170) micrograms.","The activity of mixed function oxidases, estimated by in vivo antipyrine clearance, is similar in horses and camels. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669082/),[l] / [kg],0.386,173457,DB01435,Antipyrine
,9669082,volume of the central compartment,"The data obtained (mean +/- SEM and median in brackets) in camels and horses, respectively, were as follows: the elimination half-lives were 3.25 +/- 0.23 (3.19) and 3.09 +/- 0.25 (2.90) hr; the apparent volumes of distribution (area method) were 0.691 +/- 0.045 (0.648) and 0.642 +/- 0.034 (0.676) l/kg; the volumes of distribution at steady state were 0.659 +/- 0.040 (0.607) and 0.620 +/- 0.030 (0.653) l/kg; the volume of the central compartment of the two-compartment pharmacokinetic model were 0.386 +/- 0.0523 (0.349) and 0.298 +/- 0.05 (0.308) l/kg; total body clearances were 0.148 +/- 0.008 (0.158) and 0.145 +/- 0.007 (0.147) l/kg/hr; the areas under the curves to infinity were 171.0 +/- 9 (165) and 175 +/- 8.0 (170) micrograms.","The activity of mixed function oxidases, estimated by in vivo antipyrine clearance, is similar in horses and camels. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669082/),[l] / [kg],0.298,173458,DB01435,Antipyrine
,9669082,total body clearances,"The data obtained (mean +/- SEM and median in brackets) in camels and horses, respectively, were as follows: the elimination half-lives were 3.25 +/- 0.23 (3.19) and 3.09 +/- 0.25 (2.90) hr; the apparent volumes of distribution (area method) were 0.691 +/- 0.045 (0.648) and 0.642 +/- 0.034 (0.676) l/kg; the volumes of distribution at steady state were 0.659 +/- 0.040 (0.607) and 0.620 +/- 0.030 (0.653) l/kg; the volume of the central compartment of the two-compartment pharmacokinetic model were 0.386 +/- 0.0523 (0.349) and 0.298 +/- 0.05 (0.308) l/kg; total body clearances were 0.148 +/- 0.008 (0.158) and 0.145 +/- 0.007 (0.147) l/kg/hr; the areas under the curves to infinity were 171.0 +/- 9 (165) and 175 +/- 8.0 (170) micrograms.","The activity of mixed function oxidases, estimated by in vivo antipyrine clearance, is similar in horses and camels. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669082/),l,0.148,173459,DB01435,Antipyrine
,9669082,total body clearances,"The data obtained (mean +/- SEM and median in brackets) in camels and horses, respectively, were as follows: the elimination half-lives were 3.25 +/- 0.23 (3.19) and 3.09 +/- 0.25 (2.90) hr; the apparent volumes of distribution (area method) were 0.691 +/- 0.045 (0.648) and 0.642 +/- 0.034 (0.676) l/kg; the volumes of distribution at steady state were 0.659 +/- 0.040 (0.607) and 0.620 +/- 0.030 (0.653) l/kg; the volume of the central compartment of the two-compartment pharmacokinetic model were 0.386 +/- 0.0523 (0.349) and 0.298 +/- 0.05 (0.308) l/kg; total body clearances were 0.148 +/- 0.008 (0.158) and 0.145 +/- 0.007 (0.147) l/kg/hr; the areas under the curves to infinity were 171.0 +/- 9 (165) and 175 +/- 8.0 (170) micrograms.","The activity of mixed function oxidases, estimated by in vivo antipyrine clearance, is similar in horses and camels. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669082/),l,0.145,173460,DB01435,Antipyrine
,1971570,Apparent kis,"Apparent kis for disappearance of diltiazem were: MA, 88.3 microM; M1, 608 microM; M2 (desacetyl N-desmethyldiltiazem), 495 microM; M4 (desacetyl O-desmethyldiltiazem), 152 microM; and M6 (desacetyl N,O-desmethyldiltiazem), 448 microM.",Metabolite inhibition of parent drug biotransformation. Studies of diltiazem. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971570/),μM,88.3,173513,DB01435,Antipyrine
,1971570,Apparent kis,"Apparent kis for disappearance of diltiazem were: MA, 88.3 microM; M1, 608 microM; M2 (desacetyl N-desmethyldiltiazem), 495 microM; M4 (desacetyl O-desmethyldiltiazem), 152 microM; and M6 (desacetyl N,O-desmethyldiltiazem), 448 microM.",Metabolite inhibition of parent drug biotransformation. Studies of diltiazem. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971570/),μM,608,173514,DB01435,Antipyrine
,1971570,Apparent kis,"Apparent kis for disappearance of diltiazem were: MA, 88.3 microM; M1, 608 microM; M2 (desacetyl N-desmethyldiltiazem), 495 microM; M4 (desacetyl O-desmethyldiltiazem), 152 microM; and M6 (desacetyl N,O-desmethyldiltiazem), 448 microM.",Metabolite inhibition of parent drug biotransformation. Studies of diltiazem. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971570/),μM,495,173515,DB01435,Antipyrine
,1971570,Apparent kis,"Apparent kis for disappearance of diltiazem were: MA, 88.3 microM; M1, 608 microM; M2 (desacetyl N-desmethyldiltiazem), 495 microM; M4 (desacetyl O-desmethyldiltiazem), 152 microM; and M6 (desacetyl N,O-desmethyldiltiazem), 448 microM.",Metabolite inhibition of parent drug biotransformation. Studies of diltiazem. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971570/),μM,152,173516,DB01435,Antipyrine
,1971570,Apparent kis,"Apparent kis for disappearance of diltiazem were: MA, 88.3 microM; M1, 608 microM; M2 (desacetyl N-desmethyldiltiazem), 495 microM; M4 (desacetyl O-desmethyldiltiazem), 152 microM; and M6 (desacetyl N,O-desmethyldiltiazem), 448 microM.",Metabolite inhibition of parent drug biotransformation. Studies of diltiazem. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971570/),μM,448,173517,DB01435,Antipyrine
,3567053,clearance,"The clearance of antipyrine was significantly lower during an acute porphyric attack (median: 0.34 ml min-1 kg-1; range: 0.1-0.71, P less than 0.05) than in patients in remission (median: 0.53 ml min-1 kg-1; range: 0.28-0.87) or controls (median: 0.52 ml min-1 kg-1; range: 0.32-0.93).",Antipyrine metabolism in acute hepatic porphyria in relapse and remission. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567053/),[ml] / [kg·min],0.34,173789,DB01435,Antipyrine
,3567053,clearance,"The clearance of antipyrine was significantly lower during an acute porphyric attack (median: 0.34 ml min-1 kg-1; range: 0.1-0.71, P less than 0.05) than in patients in remission (median: 0.53 ml min-1 kg-1; range: 0.28-0.87) or controls (median: 0.52 ml min-1 kg-1; range: 0.32-0.93).",Antipyrine metabolism in acute hepatic porphyria in relapse and remission. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567053/),[ml] / [kg·min],0.53,173790,DB01435,Antipyrine
,3567053,clearance,"The clearance of antipyrine was significantly lower during an acute porphyric attack (median: 0.34 ml min-1 kg-1; range: 0.1-0.71, P less than 0.05) than in patients in remission (median: 0.53 ml min-1 kg-1; range: 0.28-0.87) or controls (median: 0.52 ml min-1 kg-1; range: 0.32-0.93).",Antipyrine metabolism in acute hepatic porphyria in relapse and remission. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3567053/),[ml] / [kg·min],0.52,173791,DB01435,Antipyrine
,2714916,CL,Its CL varied between 75 and 119 percent intra-individually.,Investigations on the dose-dependent pharmacokinetics of adriamycin and its metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714916/),%,75 and 119,174345,DB01435,Antipyrine
,17701670,differential transport rate,"The differential transport rate of carboplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.60, 1.35, 2.52, 3.72, and 4.49 minutes in 12 perfusions, representing 1.16 +/- 0.10, 1.06 +/- 0.06, 1.00 +/- 0.02, 0.98 +/- 0.01, and 0.99 +/- 0.01, respectively, times the antipyrine reference value.",Maternal-fetal transport kinetics of carboplatin in the perfused human placental lobule: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701670/),min,0.60,175264,DB01435,Antipyrine
,17701670,differential transport rate,"The differential transport rate of carboplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.60, 1.35, 2.52, 3.72, and 4.49 minutes in 12 perfusions, representing 1.16 +/- 0.10, 1.06 +/- 0.06, 1.00 +/- 0.02, 0.98 +/- 0.01, and 0.99 +/- 0.01, respectively, times the antipyrine reference value.",Maternal-fetal transport kinetics of carboplatin in the perfused human placental lobule: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701670/),min,1.35,175265,DB01435,Antipyrine
,17701670,differential transport rate,"The differential transport rate of carboplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.60, 1.35, 2.52, 3.72, and 4.49 minutes in 12 perfusions, representing 1.16 +/- 0.10, 1.06 +/- 0.06, 1.00 +/- 0.02, 0.98 +/- 0.01, and 0.99 +/- 0.01, respectively, times the antipyrine reference value.",Maternal-fetal transport kinetics of carboplatin in the perfused human placental lobule: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701670/),min,2.52,175266,DB01435,Antipyrine
,17701670,differential transport rate,"The differential transport rate of carboplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.60, 1.35, 2.52, 3.72, and 4.49 minutes in 12 perfusions, representing 1.16 +/- 0.10, 1.06 +/- 0.06, 1.00 +/- 0.02, 0.98 +/- 0.01, and 0.99 +/- 0.01, respectively, times the antipyrine reference value.",Maternal-fetal transport kinetics of carboplatin in the perfused human placental lobule: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701670/),min,3.72,175267,DB01435,Antipyrine
,17701670,differential transport rate,"The differential transport rate of carboplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.60, 1.35, 2.52, 3.72, and 4.49 minutes in 12 perfusions, representing 1.16 +/- 0.10, 1.06 +/- 0.06, 1.00 +/- 0.02, 0.98 +/- 0.01, and 0.99 +/- 0.01, respectively, times the antipyrine reference value.",Maternal-fetal transport kinetics of carboplatin in the perfused human placental lobule: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701670/),min,4.49,175268,DB01435,Antipyrine
,17701670,differential transport rate,"The differential transport rate of carboplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.60, 1.35, 2.52, 3.72, and 4.49 minutes in 12 perfusions, representing 1.16 +/- 0.10, 1.06 +/- 0.06, 1.00 +/- 0.02, 0.98 +/- 0.01, and 0.99 +/- 0.01, respectively, times the antipyrine reference value.",Maternal-fetal transport kinetics of carboplatin in the perfused human placental lobule: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701670/),,1.16,175269,DB01435,Antipyrine
,17701670,differential transport rate,"The differential transport rate of carboplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.60, 1.35, 2.52, 3.72, and 4.49 minutes in 12 perfusions, representing 1.16 +/- 0.10, 1.06 +/- 0.06, 1.00 +/- 0.02, 0.98 +/- 0.01, and 0.99 +/- 0.01, respectively, times the antipyrine reference value.",Maternal-fetal transport kinetics of carboplatin in the perfused human placental lobule: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701670/),,1.06,175270,DB01435,Antipyrine
,17701670,differential transport rate,"The differential transport rate of carboplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.60, 1.35, 2.52, 3.72, and 4.49 minutes in 12 perfusions, representing 1.16 +/- 0.10, 1.06 +/- 0.06, 1.00 +/- 0.02, 0.98 +/- 0.01, and 0.99 +/- 0.01, respectively, times the antipyrine reference value.",Maternal-fetal transport kinetics of carboplatin in the perfused human placental lobule: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701670/),,1.00,175271,DB01435,Antipyrine
,17701670,differential transport rate,"The differential transport rate of carboplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.60, 1.35, 2.52, 3.72, and 4.49 minutes in 12 perfusions, representing 1.16 +/- 0.10, 1.06 +/- 0.06, 1.00 +/- 0.02, 0.98 +/- 0.01, and 0.99 +/- 0.01, respectively, times the antipyrine reference value.",Maternal-fetal transport kinetics of carboplatin in the perfused human placental lobule: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701670/),,0.98,175272,DB01435,Antipyrine
,17701670,differential transport rate,"The differential transport rate of carboplatin for 10, 25, 50, 75, and 90% efflux fractions in fetal venous effluent averaged 0.60, 1.35, 2.52, 3.72, and 4.49 minutes in 12 perfusions, representing 1.16 +/- 0.10, 1.06 +/- 0.06, 1.00 +/- 0.02, 0.98 +/- 0.01, and 0.99 +/- 0.01, respectively, times the antipyrine reference value.",Maternal-fetal transport kinetics of carboplatin in the perfused human placental lobule: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701670/),,0.99,175273,DB01435,Antipyrine
,17701670,transport fraction (TF),"The transport fraction (TF) of carboplatin, expressed as the fraction of the drug appearing in the fetal vein during a study period of 5 minutes, averaged 9.00 +/- 0.52% of bolus dose, while antipyrine TF averaged 68.60 +/- 2.01% of injected bolus dose, representing 13.1% of reference marker value.",Maternal-fetal transport kinetics of carboplatin in the perfused human placental lobule: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701670/),%,9.00,175274,DB01435,Antipyrine
,17701670,TF,"The transport fraction (TF) of carboplatin, expressed as the fraction of the drug appearing in the fetal vein during a study period of 5 minutes, averaged 9.00 +/- 0.52% of bolus dose, while antipyrine TF averaged 68.60 +/- 2.01% of injected bolus dose, representing 13.1% of reference marker value.",Maternal-fetal transport kinetics of carboplatin in the perfused human placental lobule: in vitro study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17701670/),%,68.60,175275,DB01435,Antipyrine
,7627246,elimination half-life (T1/2),"Caffeine elimination half-life (T1/2) and clearance (CLo) were similar in obese and lean subjects (6.54 +/- 2.85 vs 6.08 +/- 2.23 h respectively and 100.7 +/- 49.5 vs 82.6 +/- 34.0 ml/min respectively, P > 0.05).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),h,6.54,175396,DB01435,Antipyrine
,7627246,clearance (CLo),"Caffeine elimination half-life (T1/2) and clearance (CLo) were similar in obese and lean subjects (6.54 +/- 2.85 vs 6.08 +/- 2.23 h respectively and 100.7 +/- 49.5 vs 82.6 +/- 34.0 ml/min respectively, P > 0.05).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),h,6.08,175397,DB01435,Antipyrine
,7627246,clearance (CLo),"Caffeine elimination half-life (T1/2) and clearance (CLo) were similar in obese and lean subjects (6.54 +/- 2.85 vs 6.08 +/- 2.23 h respectively and 100.7 +/- 49.5 vs 82.6 +/- 34.0 ml/min respectively, P > 0.05).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),[ml] / [min],100.7,175398,DB01435,Antipyrine
,7627246,clearance (CLo),"Caffeine elimination half-life (T1/2) and clearance (CLo) were similar in obese and lean subjects (6.54 +/- 2.85 vs 6.08 +/- 2.23 h respectively and 100.7 +/- 49.5 vs 82.6 +/- 34.0 ml/min respectively, P > 0.05).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),[ml] / [min],82.6,175399,DB01435,Antipyrine
,7627246,Varea,"Caffeine Varea was greater in group A than in Group B (48.3 +/- 11.4 vs 40.1 +/- 13.0 L respectively, P = 0.06) but when corrected for body weight significantly reduced values were obtained in the obese group (0.44 +/- 0.06 vs 0.59 +/- 0.10 L/kg respectively, P < 0.001).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),l,48.3,175400,DB01435,Antipyrine
,7627246,Varea,"Caffeine Varea was greater in group A than in Group B (48.3 +/- 11.4 vs 40.1 +/- 13.0 L respectively, P = 0.06) but when corrected for body weight significantly reduced values were obtained in the obese group (0.44 +/- 0.06 vs 0.59 +/- 0.10 L/kg respectively, P < 0.001).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),l,40.1,175401,DB01435,Antipyrine
,7627246,Varea,"Caffeine Varea was greater in group A than in Group B (48.3 +/- 11.4 vs 40.1 +/- 13.0 L respectively, P = 0.06) but when corrected for body weight significantly reduced values were obtained in the obese group (0.44 +/- 0.06 vs 0.59 +/- 0.10 L/kg respectively, P < 0.001).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),[l] / [kg],0.44,175402,DB01435,Antipyrine
,7627246,Varea,"Caffeine Varea was greater in group A than in Group B (48.3 +/- 11.4 vs 40.1 +/- 13.0 L respectively, P = 0.06) but when corrected for body weight significantly reduced values were obtained in the obese group (0.44 +/- 0.06 vs 0.59 +/- 0.10 L/kg respectively, P < 0.001).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),[l] / [kg],0.59,175403,DB01435,Antipyrine
,7627246,Varea,"In group A subjects caffeine and antipyrine Varea were similar (48.3 +/- 11.4 vs 49.9 +/- 9.3 L respectively, P > 0.3).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),l,48.3,175404,DB01435,Antipyrine
,7627246,Varea,"In group A subjects caffeine and antipyrine Varea were similar (48.3 +/- 11.4 vs 49.9 +/- 9.3 L respectively, P > 0.3).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),l,49.9,175405,DB01435,Antipyrine
,7627246,Varea,"Caffeine T1/2 and CLo were not significantly altered by the 30.2 +/- 12.3 kg weight loss obtained in Group C subjects, but caffeine Varea was significantly reduced (55.6 +/- 9.3 L before, 47.8 +/- 9.5 L after, P < 0.04) and Varea corrected for body weight was significantly increased (0.46 +/- 0.03 L/kg before, 0.52 +/- 0.05 L/kg after, P < 0.05).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),l,55.6,175406,DB01435,Antipyrine
,7627246,Varea,"Caffeine T1/2 and CLo were not significantly altered by the 30.2 +/- 12.3 kg weight loss obtained in Group C subjects, but caffeine Varea was significantly reduced (55.6 +/- 9.3 L before, 47.8 +/- 9.5 L after, P < 0.04) and Varea corrected for body weight was significantly increased (0.46 +/- 0.03 L/kg before, 0.52 +/- 0.05 L/kg after, P < 0.05).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),l,47.8,175407,DB01435,Antipyrine
,7627246,Varea,"Caffeine T1/2 and CLo were not significantly altered by the 30.2 +/- 12.3 kg weight loss obtained in Group C subjects, but caffeine Varea was significantly reduced (55.6 +/- 9.3 L before, 47.8 +/- 9.5 L after, P < 0.04) and Varea corrected for body weight was significantly increased (0.46 +/- 0.03 L/kg before, 0.52 +/- 0.05 L/kg after, P < 0.05).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),[l] / [kg],0.46,175408,DB01435,Antipyrine
,7627246,Varea,"Caffeine T1/2 and CLo were not significantly altered by the 30.2 +/- 12.3 kg weight loss obtained in Group C subjects, but caffeine Varea was significantly reduced (55.6 +/- 9.3 L before, 47.8 +/- 9.5 L after, P < 0.04) and Varea corrected for body weight was significantly increased (0.46 +/- 0.03 L/kg before, 0.52 +/- 0.05 L/kg after, P < 0.05).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),[l] / [kg],0.52,175409,DB01435,Antipyrine
,15797526,flow rate,"The mobile phase was a mixture of phosphate buffer (pH 7) and acetonitrile (80:20), which was run through a pump at a flow rate of 1.0 mL/min at ambient temperature.",High performance liquid chromatographic determination of N-butyryl glucosamine in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15797526/),[ml] / [min],1.0,175604,DB01435,Antipyrine
,11835082,clearance,"There was a lower antipyrine clearance in the group with hepatic disease as compared to normal volunteers (0.56 versus 0.80 ml min(minus sign1) kg(minus sign1), respectively, p = 0.022).",Disposition of Misoprostol and Its Active Metabolite in Impaired Hepatic Function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835082/),min·ml,0.56,175700,DB01435,Antipyrine
,11835082,clearance,"There was a lower antipyrine clearance in the group with hepatic disease as compared to normal volunteers (0.56 versus 0.80 ml min(minus sign1) kg(minus sign1), respectively, p = 0.022).",Disposition of Misoprostol and Its Active Metabolite in Impaired Hepatic Function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835082/),min·ml,0.80,175701,DB01435,Antipyrine
,8341815,clearance,Antipyrine clearance (5.5 +/- 2 l/h) is increased significatively in chronic alcoholics respect to the control group value (3.4 +/- 1 l/h) (p < 0.01).,[Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8341815/),[l] / [h],5.5,175858,DB01435,Antipyrine
,8341815,clearance,Antipyrine clearance (5.5 +/- 2 l/h) is increased significatively in chronic alcoholics respect to the control group value (3.4 +/- 1 l/h) (p < 0.01).,[Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8341815/),[l] / [h],3.4,175859,DB01435,Antipyrine
,8341815,Elimination half-life,Elimination half-life of antipyrine in chronic alcoholic groups (7.6 +/- 3 h) is decreased significatively respect to the control group value (11.2 +/- 2 h) (p < 0.01).,[Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8341815/),h,7.6,175860,DB01435,Antipyrine
,8341815,Elimination half-life,Elimination half-life of antipyrine in chronic alcoholic groups (7.6 +/- 3 h) is decreased significatively respect to the control group value (11.2 +/- 2 h) (p < 0.01).,[Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8341815/),h,11.2,175861,DB01435,Antipyrine
,3971637,plasma clearances,"The mean plasma clearances of carbamazepine were 19.8, 54.6 and 113.3 ml/h/kg in groups 1, 2 and 3, respectively.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),[ml] / [h·kg],19.8,176121,DB01435,Antipyrine
,3971637,plasma clearances,"The mean plasma clearances of carbamazepine were 19.8, 54.6 and 113.3 ml/h/kg in groups 1, 2 and 3, respectively.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),[ml] / [h·kg],54.6,176122,DB01435,Antipyrine
,3971637,plasma clearances,"The mean plasma clearances of carbamazepine were 19.8, 54.6 and 113.3 ml/h/kg in groups 1, 2 and 3, respectively.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),[ml] / [h·kg],113.3,176123,DB01435,Antipyrine
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,1.9,176124,DB01435,Antipyrine
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,3.3,176125,DB01435,Antipyrine
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,4.0,176126,DB01435,Antipyrine
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,23,176127,DB01435,Antipyrine
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,32,176128,DB01435,Antipyrine
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,24,176129,DB01435,Antipyrine
,6897933,elimination half-life,Oral contraceptive steroid subjects had a lower elimination half-life of acetaminophen (2.12 hours) than controls (2.71 hours) (P less than .005).,Increased metabolic clearance of acetaminophen with oral contraceptive use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6897933/),h,2.12,179262,DB01435,Antipyrine
,6897933,elimination half-life,Oral contraceptive steroid subjects had a lower elimination half-life of acetaminophen (2.12 hours) than controls (2.71 hours) (P less than .005).,Increased metabolic clearance of acetaminophen with oral contraceptive use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6897933/),h,2.71,179263,DB01435,Antipyrine
,6897933,Volume of distribution,"Volume of distribution was similar for both groups (oral contraceptive group, 1.04 liters/kg; controls, 0.96 liters/kg; NS).",Increased metabolic clearance of acetaminophen with oral contraceptive use. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6897933/),[l] / [kg],1.04,179264,DB01435,Antipyrine
,6897933,Volume of distribution,"Volume of distribution was similar for both groups (oral contraceptive group, 1.04 liters/kg; controls, 0.96 liters/kg; NS).",Increased metabolic clearance of acetaminophen with oral contraceptive use. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6897933/),[l] / [kg],0.96,179265,DB01435,Antipyrine
,6897933,Total metabolic clearance,"Total metabolic clearance was significantly higher in oral contraceptive subjects (5.81 ml/min/kg, versus 4.12 ml/min/kg for controls; P less than .02).",Increased metabolic clearance of acetaminophen with oral contraceptive use. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6897933/),[ml] / [kg·min],5.81,179266,DB01435,Antipyrine
,6897933,Total metabolic clearance,"Total metabolic clearance was significantly higher in oral contraceptive subjects (5.81 ml/min/kg, versus 4.12 ml/min/kg for controls; P less than .02).",Increased metabolic clearance of acetaminophen with oral contraceptive use. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6897933/),[ml] / [kg·min],4.12,179267,DB01435,Antipyrine
,991535,plasma half-life,"When the diets of 6 normal volunteers were changed from their usual home diets to low carbohydrate-high protein diets, the plasma half-life of antipyrine decreased from 16.2 hr to 9.5 hr, and the half-life of theophylline decreased from 8.1 hr to 5.2 hr.",Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991535/),h,16.2,179839,DB01435,Antipyrine
,991535,plasma half-life,"When the diets of 6 normal volunteers were changed from their usual home diets to low carbohydrate-high protein diets, the plasma half-life of antipyrine decreased from 16.2 hr to 9.5 hr, and the half-life of theophylline decreased from 8.1 hr to 5.2 hr.",Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991535/),h,9.5,179840,DB01435,Antipyrine
,991535,half-life,"When the diets of 6 normal volunteers were changed from their usual home diets to low carbohydrate-high protein diets, the plasma half-life of antipyrine decreased from 16.2 hr to 9.5 hr, and the half-life of theophylline decreased from 8.1 hr to 5.2 hr.",Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991535/),h,8.1,179841,DB01435,Antipyrine
,991535,half-life,"When the diets of 6 normal volunteers were changed from their usual home diets to low carbohydrate-high protein diets, the plasma half-life of antipyrine decreased from 16.2 hr to 9.5 hr, and the half-life of theophylline decreased from 8.1 hr to 5.2 hr.",Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991535/),h,5.2,179842,DB01435,Antipyrine
,991535,half-life,"When the subjects' diets were changed from low carbohydrate-high protein diets to a high carbohydrate-low protein diets, the mean antipyrine half-life increased from 9.5 hr to 15.6 hr and the mean theophylline half-life increased from 5.2 hr to 7.6 hr.",Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991535/),h,9.5,179843,DB01435,Antipyrine
,991535,half-life,"When the subjects' diets were changed from low carbohydrate-high protein diets to a high carbohydrate-low protein diets, the mean antipyrine half-life increased from 9.5 hr to 15.6 hr and the mean theophylline half-life increased from 5.2 hr to 7.6 hr.",Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991535/),h,15.6,179844,DB01435,Antipyrine
,991535,half-life,"When the subjects' diets were changed from low carbohydrate-high protein diets to a high carbohydrate-low protein diets, the mean antipyrine half-life increased from 9.5 hr to 15.6 hr and the mean theophylline half-life increased from 5.2 hr to 7.6 hr.",Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991535/),h,5.2,179845,DB01435,Antipyrine
,991535,half-life,"When the subjects' diets were changed from low carbohydrate-high protein diets to a high carbohydrate-low protein diets, the mean antipyrine half-life increased from 9.5 hr to 15.6 hr and the mean theophylline half-life increased from 5.2 hr to 7.6 hr.",Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991535/),h,7.6,179846,DB01435,Antipyrine
,15979264,small intestinal transit times,"The mean small intestinal transit times for the different treatments (control, PEG 400, propylene glycol, TPGS and Labarasol) were 183, 179, 195, 168 and 154 min, respectively.",Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979264/),min,183,183396,DB01435,Antipyrine
,15979264,small intestinal transit times,"The mean small intestinal transit times for the different treatments (control, PEG 400, propylene glycol, TPGS and Labarasol) were 183, 179, 195, 168 and 154 min, respectively.",Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979264/),min,179,183397,DB01435,Antipyrine
,15979264,small intestinal transit times,"The mean small intestinal transit times for the different treatments (control, PEG 400, propylene glycol, TPGS and Labarasol) were 183, 179, 195, 168 and 154 min, respectively.",Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979264/),min,195,183398,DB01435,Antipyrine
,15979264,small intestinal transit times,"The mean small intestinal transit times for the different treatments (control, PEG 400, propylene glycol, TPGS and Labarasol) were 183, 179, 195, 168 and 154 min, respectively.",Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979264/),min,168,183399,DB01435,Antipyrine
,15979264,small intestinal transit times,"The mean small intestinal transit times for the different treatments (control, PEG 400, propylene glycol, TPGS and Labarasol) were 183, 179, 195, 168 and 154 min, respectively.",Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979264/),min,154,183400,DB01435,Antipyrine
,15979264,absolute oral bioavailability,"The corresponding mean absolute oral bioavailability figures were 36, 32, 39, 42 and 32% for ampicillin and 76, 74, 85, 73 and 74% for antipyrine, respectively.",Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979264/),%,36,183401,DB01435,Antipyrine
,15979264,absolute oral bioavailability,"The corresponding mean absolute oral bioavailability figures were 36, 32, 39, 42 and 32% for ampicillin and 76, 74, 85, 73 and 74% for antipyrine, respectively.",Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979264/),%,32,183402,DB01435,Antipyrine
,15979264,absolute oral bioavailability,"The corresponding mean absolute oral bioavailability figures were 36, 32, 39, 42 and 32% for ampicillin and 76, 74, 85, 73 and 74% for antipyrine, respectively.",Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979264/),%,39,183403,DB01435,Antipyrine
,15979264,absolute oral bioavailability,"The corresponding mean absolute oral bioavailability figures were 36, 32, 39, 42 and 32% for ampicillin and 76, 74, 85, 73 and 74% for antipyrine, respectively.",Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979264/),%,42,183404,DB01435,Antipyrine
,15979264,absolute oral bioavailability,"The corresponding mean absolute oral bioavailability figures were 36, 32, 39, 42 and 32% for ampicillin and 76, 74, 85, 73 and 74% for antipyrine, respectively.",Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979264/),%,76,183405,DB01435,Antipyrine
,15979264,absolute oral bioavailability,"The corresponding mean absolute oral bioavailability figures were 36, 32, 39, 42 and 32% for ampicillin and 76, 74, 85, 73 and 74% for antipyrine, respectively.",Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979264/),%,74,183406,DB01435,Antipyrine
,15979264,absolute oral bioavailability,"The corresponding mean absolute oral bioavailability figures were 36, 32, 39, 42 and 32% for ampicillin and 76, 74, 85, 73 and 74% for antipyrine, respectively.",Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979264/),%,85,183407,DB01435,Antipyrine
,15979264,absolute oral bioavailability,"The corresponding mean absolute oral bioavailability figures were 36, 32, 39, 42 and 32% for ampicillin and 76, 74, 85, 73 and 74% for antipyrine, respectively.",Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979264/),%,73,183408,DB01435,Antipyrine
,7268788,peak plasma concentrations,"Mean peak plasma concentrations of antipyrine of 132, 137 and 155 microgram/ml in the rhesus monkey, the cynomolgus monkey and the baboon respectively were not observed until 5 min after intravenous injection.","Comparative pharmacokinetics of antipyrine (phenazone) in the baboon, cynomolgus monkey and rhesus monkey. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7268788/),[μg] / [ml],132,184339,DB01435,Antipyrine
,7268788,peak plasma concentrations,"Mean peak plasma concentrations of antipyrine of 132, 137 and 155 microgram/ml in the rhesus monkey, the cynomolgus monkey and the baboon respectively were not observed until 5 min after intravenous injection.","Comparative pharmacokinetics of antipyrine (phenazone) in the baboon, cynomolgus monkey and rhesus monkey. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7268788/),[μg] / [ml],137,184340,DB01435,Antipyrine
,7268788,peak plasma concentrations,"Mean peak plasma concentrations of antipyrine of 132, 137 and 155 microgram/ml in the rhesus monkey, the cynomolgus monkey and the baboon respectively were not observed until 5 min after intravenous injection.","Comparative pharmacokinetics of antipyrine (phenazone) in the baboon, cynomolgus monkey and rhesus monkey. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7268788/),[μg] / [ml],155,184341,DB01435,Antipyrine
,7268788,apparent half-life of elimination,"Thereafter, concentrations declined with an apparent half-life of elimination of 1.5-2 h.","Comparative pharmacokinetics of antipyrine (phenazone) in the baboon, cynomolgus monkey and rhesus monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7268788/),h,1.5-2,184342,DB01435,Antipyrine
,7268788,volume of distribution,"The mean volume of distribution was equivalent to 88, 73 and 66% of body weight in rhesus monkey, the cynomolgus monkey and the baboon, respectively.","Comparative pharmacokinetics of antipyrine (phenazone) in the baboon, cynomolgus monkey and rhesus monkey. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7268788/),%,88,184343,DB01435,Antipyrine
,7268788,volume of distribution,"The mean volume of distribution was equivalent to 88, 73 and 66% of body weight in rhesus monkey, the cynomolgus monkey and the baboon, respectively.","Comparative pharmacokinetics of antipyrine (phenazone) in the baboon, cynomolgus monkey and rhesus monkey. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7268788/),%,73,184344,DB01435,Antipyrine
,7268788,volume of distribution,"The mean volume of distribution was equivalent to 88, 73 and 66% of body weight in rhesus monkey, the cynomolgus monkey and the baboon, respectively.","Comparative pharmacokinetics of antipyrine (phenazone) in the baboon, cynomolgus monkey and rhesus monkey. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7268788/),%,66,184345,DB01435,Antipyrine
,7864254,EBF,"By use of this technique, baseline EBF and MBF were 37.8 +/- 3.53 (n = 21) and 47.2 +/- 4.56 (n = 5) ml.min-1.100 g-1, respectively, with an EBF/MBF ratio of 0.8.",H2 gas clearance technique for separating rat uterine blood flow into endometrial and myometrial components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7864254/),[ml] / [g·min],37.8,185358,DB01435,Antipyrine
,7864254,MBF,"By use of this technique, baseline EBF and MBF were 37.8 +/- 3.53 (n = 21) and 47.2 +/- 4.56 (n = 5) ml.min-1.100 g-1, respectively, with an EBF/MBF ratio of 0.8.",H2 gas clearance technique for separating rat uterine blood flow into endometrial and myometrial components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7864254/),[ml] / [g·min],47.2,185359,DB01435,Antipyrine
,7864254,EBF/MBF ratio,"By use of this technique, baseline EBF and MBF were 37.8 +/- 3.53 (n = 21) and 47.2 +/- 4.56 (n = 5) ml.min-1.100 g-1, respectively, with an EBF/MBF ratio of 0.8.",H2 gas clearance technique for separating rat uterine blood flow into endometrial and myometrial components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7864254/),,0.8,185360,DB01435,Antipyrine
,7864254,EBF/MBF ratio,"With the iodo[14C]antipyrine technique, the EBF/MBF ratio was 0.91 +/- 0.07 (n = 5), which is similar to that obtained with the H2 gas clearance technique.",H2 gas clearance technique for separating rat uterine blood flow into endometrial and myometrial components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7864254/),,0.91,185361,DB01435,Antipyrine
,412413,Plasma half-life,"Plasma half-life was increased and metabolic clearance rate was decreased in malnourished children (10.4 hr and 47.1 ml/hr per kg, respectively) in comparison to controls (6.3 hr and 70.1 ml/hr per kg, respectively).",Pharmacokinetic study of antipyrine in malnourished children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412413/),h,10.4,185558,DB01435,Antipyrine
,412413,Plasma half-life,"Plasma half-life was increased and metabolic clearance rate was decreased in malnourished children (10.4 hr and 47.1 ml/hr per kg, respectively) in comparison to controls (6.3 hr and 70.1 ml/hr per kg, respectively).",Pharmacokinetic study of antipyrine in malnourished children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412413/),h,6.3,185559,DB01435,Antipyrine
,412413,metabolic clearance rate,"Plasma half-life was increased and metabolic clearance rate was decreased in malnourished children (10.4 hr and 47.1 ml/hr per kg, respectively) in comparison to controls (6.3 hr and 70.1 ml/hr per kg, respectively).",Pharmacokinetic study of antipyrine in malnourished children. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412413/),[ml] / [h·kg],47.1,185560,DB01435,Antipyrine
,412413,metabolic clearance rate,"Plasma half-life was increased and metabolic clearance rate was decreased in malnourished children (10.4 hr and 47.1 ml/hr per kg, respectively) in comparison to controls (6.3 hr and 70.1 ml/hr per kg, respectively).",Pharmacokinetic study of antipyrine in malnourished children. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412413/),h,6.3,185561,DB01435,Antipyrine
,412413,metabolic clearance rate,"Plasma half-life was increased and metabolic clearance rate was decreased in malnourished children (10.4 hr and 47.1 ml/hr per kg, respectively) in comparison to controls (6.3 hr and 70.1 ml/hr per kg, respectively).",Pharmacokinetic study of antipyrine in malnourished children. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412413/),[ml] / [h·kg],70.1,185562,DB01435,Antipyrine
,412413,plasma half-life,Antipyrine plasma half-life decreased to 6.6 hr and metabolic clearance rate increased to 66.5 ml/hr per kg.,Pharmacokinetic study of antipyrine in malnourished children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412413/),h,6.6,185563,DB01435,Antipyrine
,412413,metabolic clearance rate,Antipyrine plasma half-life decreased to 6.6 hr and metabolic clearance rate increased to 66.5 ml/hr per kg.,Pharmacokinetic study of antipyrine in malnourished children. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412413/),[ml] / [h·kg],66.5,185564,DB01435,Antipyrine
,2702965,clearance,Mean antipyrine clearance (parameter of oxidative liver function) was 49.7 +/- 6.0 ml min-1 in the volunteers and 22.0 +/- 2.9 ml min-1 in the patients.,Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702965/),[ml] / [min],49.7,188697,DB01435,Antipyrine
,2702965,clearance,Mean antipyrine clearance (parameter of oxidative liver function) was 49.7 +/- 6.0 ml min-1 in the volunteers and 22.0 +/- 2.9 ml min-1 in the patients.,Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702965/),[ml] / [min],22.0,188698,DB01435,Antipyrine
,2702965,Plasma protein binding,Plasma protein binding of digitoxin (PPB) was 95.0 +/- 1.1% in the patients and 96.7 +/- 0.6% in the healthy subjects (n.s.).,Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702965/),%,95.0,188699,DB01435,Antipyrine
,2702965,Plasma protein binding,Plasma protein binding of digitoxin (PPB) was 95.0 +/- 1.1% in the patients and 96.7 +/- 0.6% in the healthy subjects (n.s.).,Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702965/),%,96.7,188700,DB01435,Antipyrine
,2702965,Total body clearance of digitoxin (Cltot),Total body clearance of digitoxin (Cltot) was 0.0728 +/- 0.0120 ml min-1 kg-1 in the patients and 0.0615 +/- 0.0027 ml min-1 kg-1 in normals (n.s.].,Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702965/),[ml] / [kg·min],0.0728,188701,DB01435,Antipyrine
,2702965,Total body clearance of digitoxin (Cltot),Total body clearance of digitoxin (Cltot) was 0.0728 +/- 0.0120 ml min-1 kg-1 in the patients and 0.0615 +/- 0.0027 ml min-1 kg-1 in normals (n.s.].,Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702965/),[ml] / [kg·min],0.0615,188702,DB01435,Antipyrine
,2702965,steady state plasma levels (Css),Mean steady state plasma levels (Css) of the patients were 18.3 +/- 4.7 ng ml-1 and 15.8 +/- 1.3 ng ml-1 in the normals (n.s.).,Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702965/),[ng] / [ml],18.3,188703,DB01435,Antipyrine
,2702965,steady state plasma levels (Css),Mean steady state plasma levels (Css) of the patients were 18.3 +/- 4.7 ng ml-1 and 15.8 +/- 1.3 ng ml-1 in the normals (n.s.).,Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702965/),[ng] / [ml],15.8,188704,DB01435,Antipyrine
,24135530,plasma concentration,"Geometric mean values of MCI-186 plasma concentration at the end of the infusion in cohorts 1 and 2 were 391 and 1,595 ng/ml, respectively.","Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24135530/),[ng] / [ml],391,188897,DB01435,Antipyrine
,24135530,plasma concentration,"Geometric mean values of MCI-186 plasma concentration at the end of the infusion in cohorts 1 and 2 were 391 and 1,595 ng/ml, respectively.","Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24135530/),[ng] / [ml],"1,595",188898,DB01435,Antipyrine
,11243492,TPTs,The TPTs of AMI and NOR were 81% and 62% of the freely diffusable antipyrine.,Transplacental transfer of amitriptyline and nortriptyline in isolated perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243492/),%,81,191715,DB01435,Antipyrine
,11243492,TPTs,The TPTs of AMI and NOR were 81% and 62% of the freely diffusable antipyrine.,Transplacental transfer of amitriptyline and nortriptyline in isolated perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243492/),%,62,191716,DB01435,Antipyrine
smaller,1122686,fever index,There was no significant change of these mean values in 19 normal volunteers who failed to develop significant fever (fever index smaller than 50).,Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122686/),,50,192698,DB01435,Antipyrine
greater,1122686,fever index,"Failure to obtain such a correlation may be attributable to the very small range of temperature elevation, extending from 37.9 degrees C to 39.2 degrees C, in the group of 14 subjects achieving significant etiocholanolone-induced fever (fever index greater than 50).",Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122686/),,50,192699,DB01435,Antipyrine
,9660037,clearance,"The plasma levels of IFNalpha and IFNgamma were significantly elevated from 4.7 U/ml to 12.6 U/ml and 0.3 U/ml to 3.4 U/ml, respectively, whereas the antipyrine clearance showed a decrease from 57.9 ml/min to 45 ml/min in the symptomatic interval of an acute viral infection.",Changes of antipyrine pharmacokinetics during influenza and after administration of interferon-alpha and -beta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660037/),[ml] / [min],57.9,193219,DB01435,Antipyrine
,9660037,clearance,"The plasma levels of IFNalpha and IFNgamma were significantly elevated from 4.7 U/ml to 12.6 U/ml and 0.3 U/ml to 3.4 U/ml, respectively, whereas the antipyrine clearance showed a decrease from 57.9 ml/min to 45 ml/min in the symptomatic interval of an acute viral infection.",Changes of antipyrine pharmacokinetics during influenza and after administration of interferon-alpha and -beta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660037/),[ml] / [min],45,193220,DB01435,Antipyrine
,9660037,clearance,In the first group we observed a decreased antipyrine clearance from 49.0 ml/min to 41.7 ml/min; in the second group the antipyrine clearance decreased from 49.0 ml/min to 41.7 ml/min.,Changes of antipyrine pharmacokinetics during influenza and after administration of interferon-alpha and -beta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660037/),[ml] / [min],49.0,193221,DB01435,Antipyrine
,9660037,clearance,In the first group we observed a decreased antipyrine clearance from 49.0 ml/min to 41.7 ml/min; in the second group the antipyrine clearance decreased from 49.0 ml/min to 41.7 ml/min.,Changes of antipyrine pharmacokinetics during influenza and after administration of interferon-alpha and -beta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660037/),[ml] / [min],41.7,193222,DB01435,Antipyrine
,908027,plasma clearance,The mean plasma clearance of antipyrine was 0.0475 +/- 0.009 liter/kg/hr in the tumor group and 0.0557 +/- 0.007 liter/kg/hr in the control group (p greater than 0.05).,Metabolic disposition of antipyrine in patients with lung cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/908027/),[l] / [h·kg],0.0475,193321,DB01435,Antipyrine
,908027,plasma clearance,The mean plasma clearance of antipyrine was 0.0475 +/- 0.009 liter/kg/hr in the tumor group and 0.0557 +/- 0.007 liter/kg/hr in the control group (p greater than 0.05).,Metabolic disposition of antipyrine in patients with lung cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/908027/),[l] / [h·kg],0.0557,193322,DB01435,Antipyrine
,908027,plasma elimination half-life,"The antipyrine plasma elimination half-life was longer in the group with tumors (9.5 +/- 1.3 hr) compared to the control group (7.7 +/- 1.3 hr), but the difference was not statistically significant (p greater than 0.05).",Metabolic disposition of antipyrine in patients with lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/908027/),h,9.5,193323,DB01435,Antipyrine
,908027,plasma elimination half-life,"The antipyrine plasma elimination half-life was longer in the group with tumors (9.5 +/- 1.3 hr) compared to the control group (7.7 +/- 1.3 hr), but the difference was not statistically significant (p greater than 0.05).",Metabolic disposition of antipyrine in patients with lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/908027/),h,7.7,193324,DB01435,Antipyrine
,239546,Total body clearance,Total body clearance of aminopyrine as obtained after an oral test dose increases more than twofold from 251 to 551 ml/min upon phenobarbital treatment.,Comparison of methods to study enzyme induction in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/239546/),[ml] / [min],251,195875,DB01435,Antipyrine
,239546,Total body clearance,Total body clearance of aminopyrine as obtained after an oral test dose increases more than twofold from 251 to 551 ml/min upon phenobarbital treatment.,Comparison of methods to study enzyme induction in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/239546/),[ml] / [min],551,195876,DB01435,Antipyrine
,6519152,plasma elimination half-life,"The peak level of alaproclate was reached after about 1.5 h, and after a distribution phase, its plasma elimination half-life was between 3.0 and 3.5 h.",Influence of alaproclate on antipyrine metabolite formation in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519152/),h,3.0 and 3.5,197415,DB01435,Antipyrine
,9447474,clearance,"Total caffeine clearance increased on average by 24% (from 1.65 to 2.05 ml/min, P = 0.1) 2 days after antipyrine dosing, and 25% (from 1.65 to 2.06 ml/min, P < 0.01) 5 days after the administration of antipyrine, whereas the half-life decreased by around 24% (from 5.3 to 4 h, P = 0.09) after 2 days and 26% (from 5.3 to 3.9 h, P = 0.05) after 5 days.",A pilot study of the effect of antipyrine on caffeine kinetics in six healthy volunteer subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9447474/),[ml] / [min],1.65 to 2.05,197432,DB01435,Antipyrine
,9447474,clearance,"Total caffeine clearance increased on average by 24% (from 1.65 to 2.05 ml/min, P = 0.1) 2 days after antipyrine dosing, and 25% (from 1.65 to 2.06 ml/min, P < 0.01) 5 days after the administration of antipyrine, whereas the half-life decreased by around 24% (from 5.3 to 4 h, P = 0.09) after 2 days and 26% (from 5.3 to 3.9 h, P = 0.05) after 5 days.",A pilot study of the effect of antipyrine on caffeine kinetics in six healthy volunteer subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9447474/),[ml] / [min],1.65 to 2.06,197433,DB01435,Antipyrine
,9447474,half-life,"Total caffeine clearance increased on average by 24% (from 1.65 to 2.05 ml/min, P = 0.1) 2 days after antipyrine dosing, and 25% (from 1.65 to 2.06 ml/min, P < 0.01) 5 days after the administration of antipyrine, whereas the half-life decreased by around 24% (from 5.3 to 4 h, P = 0.09) after 2 days and 26% (from 5.3 to 3.9 h, P = 0.05) after 5 days.",A pilot study of the effect of antipyrine on caffeine kinetics in six healthy volunteer subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9447474/),h,5.3 to 4,197434,DB01435,Antipyrine
,9447474,half-life,"Total caffeine clearance increased on average by 24% (from 1.65 to 2.05 ml/min, P = 0.1) 2 days after antipyrine dosing, and 25% (from 1.65 to 2.06 ml/min, P < 0.01) 5 days after the administration of antipyrine, whereas the half-life decreased by around 24% (from 5.3 to 4 h, P = 0.09) after 2 days and 26% (from 5.3 to 3.9 h, P = 0.05) after 5 days.",A pilot study of the effect of antipyrine on caffeine kinetics in six healthy volunteer subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9447474/),h,5.3 to 3.9,197435,DB01435,Antipyrine
,1488402,clearance,"Animals that received the i.v. dose of amoxycillin on the eighth day after jugular vein cannulation showed decreased clearance (4.0 +/- 0.3 ml/min) and steady-state volume of distribution (105 +/- 8 ml) compared to animals that received the i.v. dose on the fourth day (5.5 +/- 1.1 ml/min and 155 +/- 17 ml, respectively).",Influence of permanent cannulation of the jugular vein on pharmacokinetics of amoxycillin and antipyrine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488402/),[ml] / [min],4.0,199153,DB01435,Antipyrine
,1488402,steady-state volume of distribution,"Animals that received the i.v. dose of amoxycillin on the eighth day after jugular vein cannulation showed decreased clearance (4.0 +/- 0.3 ml/min) and steady-state volume of distribution (105 +/- 8 ml) compared to animals that received the i.v. dose on the fourth day (5.5 +/- 1.1 ml/min and 155 +/- 17 ml, respectively).",Influence of permanent cannulation of the jugular vein on pharmacokinetics of amoxycillin and antipyrine in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488402/),ml,105,199154,DB01435,Antipyrine
,1488402,steady-state volume of distribution,"Animals that received the i.v. dose of amoxycillin on the eighth day after jugular vein cannulation showed decreased clearance (4.0 +/- 0.3 ml/min) and steady-state volume of distribution (105 +/- 8 ml) compared to animals that received the i.v. dose on the fourth day (5.5 +/- 1.1 ml/min and 155 +/- 17 ml, respectively).",Influence of permanent cannulation of the jugular vein on pharmacokinetics of amoxycillin and antipyrine in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488402/),ml,155,199155,DB01435,Antipyrine
,1488402,oral bioavailability,"Rats first dosed by the i.v. route showed an oral bioavailability of 54 +/- 12%, whereas for those first dosed by the oral route the calculated bioavailability was 31 +/- 6%.",Influence of permanent cannulation of the jugular vein on pharmacokinetics of amoxycillin and antipyrine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488402/),%,54,199156,DB01435,Antipyrine
,1488402,bioavailability,"Rats first dosed by the i.v. route showed an oral bioavailability of 54 +/- 12%, whereas for those first dosed by the oral route the calculated bioavailability was 31 +/- 6%.",Influence of permanent cannulation of the jugular vein on pharmacokinetics of amoxycillin and antipyrine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488402/),%,31,199157,DB01435,Antipyrine
,1488402,clearance,Animals intravenously dosed on the fourth day showed a decreased clearance (1.9 +/- 0.3 ml/min) compared to rats intravenously dosed on the 1st day (2.7 +/- 0.6 ml/min).,Influence of permanent cannulation of the jugular vein on pharmacokinetics of amoxycillin and antipyrine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488402/),[ml] / [min],1.9,199158,DB01435,Antipyrine
,1488402,clearance,Animals intravenously dosed on the fourth day showed a decreased clearance (1.9 +/- 0.3 ml/min) compared to rats intravenously dosed on the 1st day (2.7 +/- 0.6 ml/min).,Influence of permanent cannulation of the jugular vein on pharmacokinetics of amoxycillin and antipyrine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488402/),[ml] / [min],2.7,199159,DB01435,Antipyrine
,1488402,bioavailability,"Antipyrine bioavailability was larger in animals first dosed by the i.v. route than in animals first dosed by the oral route (173 +/- 43 and 74 +/- 15%, respectively).",Influence of permanent cannulation of the jugular vein on pharmacokinetics of amoxycillin and antipyrine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488402/),%,173,199160,DB01435,Antipyrine
,1488402,bioavailability,"Antipyrine bioavailability was larger in animals first dosed by the i.v. route than in animals first dosed by the oral route (173 +/- 43 and 74 +/- 15%, respectively).",Influence of permanent cannulation of the jugular vein on pharmacokinetics of amoxycillin and antipyrine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1488402/),%,74,199161,DB01435,Antipyrine
,16621934,E(H),"Fexofenadine had a low liver extraction (E(H); mean +/- S.E.M.), and the given doses of verapamil did not affect the E(H) (0.13 +/- 0.04, 0.16 +/- 0.03, and 0.12 +/- 0.02 for G1, G2, and G3, respectively) or biliary clearance.",First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621934/),,0.13,200647,DB01435,Antipyrine
,16621934,E(H),"Fexofenadine had a low liver extraction (E(H); mean +/- S.E.M.), and the given doses of verapamil did not affect the E(H) (0.13 +/- 0.04, 0.16 +/- 0.03, and 0.12 +/- 0.02 for G1, G2, and G3, respectively) or biliary clearance.",First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621934/),,0.16,200648,DB01435,Antipyrine
,16621934,E(H),"Fexofenadine had a low liver extraction (E(H); mean +/- S.E.M.), and the given doses of verapamil did not affect the E(H) (0.13 +/- 0.04, 0.16 +/- 0.03, and 0.12 +/- 0.02 for G1, G2, and G3, respectively) or biliary clearance.",First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621934/),,0.12,200649,DB01435,Antipyrine
,2886338,maximum plasma concentration (Cmax),"After the first dose of antipyrine the mean maximum plasma concentration (Cmax) was 78.3 mumol/l (range: 60.3 to 95.8), the mean AUC (0-infinity) was 1330 mumol.h/l (range: 1030 to 2074), the mean apparent terminal disposition rate constant K was 0.0656 h-1 (range: 0.0428 to 0.0769) and the mean residence time (MRT) was 16.7 h on average (range: 14.4 to 24.1).","Temelastine, a novel histamine H1-receptor antagonist, does not induce oxidative hepatic enzyme activity in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886338/),[μM] / [l],78.3,201804,DB01435,Antipyrine
,2886338,AUC (0-infinity),"After the first dose of antipyrine the mean maximum plasma concentration (Cmax) was 78.3 mumol/l (range: 60.3 to 95.8), the mean AUC (0-infinity) was 1330 mumol.h/l (range: 1030 to 2074), the mean apparent terminal disposition rate constant K was 0.0656 h-1 (range: 0.0428 to 0.0769) and the mean residence time (MRT) was 16.7 h on average (range: 14.4 to 24.1).","Temelastine, a novel histamine H1-receptor antagonist, does not induce oxidative hepatic enzyme activity in man. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886338/),[h·μM] / [l],1330,201805,DB01435,Antipyrine
,2886338,apparent terminal disposition rate constant K,"After the first dose of antipyrine the mean maximum plasma concentration (Cmax) was 78.3 mumol/l (range: 60.3 to 95.8), the mean AUC (0-infinity) was 1330 mumol.h/l (range: 1030 to 2074), the mean apparent terminal disposition rate constant K was 0.0656 h-1 (range: 0.0428 to 0.0769) and the mean residence time (MRT) was 16.7 h on average (range: 14.4 to 24.1).","Temelastine, a novel histamine H1-receptor antagonist, does not induce oxidative hepatic enzyme activity in man. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886338/),1/[h],0.0656,201806,DB01435,Antipyrine
,2886338,mean residence time (MRT),"After the first dose of antipyrine the mean maximum plasma concentration (Cmax) was 78.3 mumol/l (range: 60.3 to 95.8), the mean AUC (0-infinity) was 1330 mumol.h/l (range: 1030 to 2074), the mean apparent terminal disposition rate constant K was 0.0656 h-1 (range: 0.0428 to 0.0769) and the mean residence time (MRT) was 16.7 h on average (range: 14.4 to 24.1).","Temelastine, a novel histamine H1-receptor antagonist, does not induce oxidative hepatic enzyme activity in man. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886338/),h,16.7,201807,DB01435,Antipyrine
,6883204,"inhibition constant, Ki","The inhibition constant, Ki, varied between 0.06 to 0.25 mM depending on the substrate used.",Inhibitory effect of phenelzine on oxidative microsomal enzyme systems of rat liver. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883204/),mM,0.06 to 0.25,202239,DB01435,Antipyrine
,6883204,Ks,Phenelzine induced a type II spectral change when combined with oxidized cytochrome P-450 with a Ks value of 0.4 mM.,Inhibitory effect of phenelzine on oxidative microsomal enzyme systems of rat liver. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883204/),mM,0.4,202240,DB01435,Antipyrine
,6883204,serum half-life,"The serum half-life, apparent volume of distribution, and total body clearance of antipyrine were modified to 3.6 h, 294.1 mL X kg-1, and 56.8 mL X h-1 X kg-1, respectively, from 1.5 h, 666.7 mL X kg-1, and 312.5 mL X h-1 X kg-1 when antipyrine was administered alone.",Inhibitory effect of phenelzine on oxidative microsomal enzyme systems of rat liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883204/),h,3.6,202241,DB01435,Antipyrine
,6883204,apparent volume of distribution,"The serum half-life, apparent volume of distribution, and total body clearance of antipyrine were modified to 3.6 h, 294.1 mL X kg-1, and 56.8 mL X h-1 X kg-1, respectively, from 1.5 h, 666.7 mL X kg-1, and 312.5 mL X h-1 X kg-1 when antipyrine was administered alone.",Inhibitory effect of phenelzine on oxidative microsomal enzyme systems of rat liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883204/),[ml] / [kg],294.1,202242,DB01435,Antipyrine
,6883204,apparent volume of distribution,"The serum half-life, apparent volume of distribution, and total body clearance of antipyrine were modified to 3.6 h, 294.1 mL X kg-1, and 56.8 mL X h-1 X kg-1, respectively, from 1.5 h, 666.7 mL X kg-1, and 312.5 mL X h-1 X kg-1 when antipyrine was administered alone.",Inhibitory effect of phenelzine on oxidative microsomal enzyme systems of rat liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883204/),h,1.5,202243,DB01435,Antipyrine
,6883204,apparent volume of distribution,"The serum half-life, apparent volume of distribution, and total body clearance of antipyrine were modified to 3.6 h, 294.1 mL X kg-1, and 56.8 mL X h-1 X kg-1, respectively, from 1.5 h, 666.7 mL X kg-1, and 312.5 mL X h-1 X kg-1 when antipyrine was administered alone.",Inhibitory effect of phenelzine on oxidative microsomal enzyme systems of rat liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883204/),[ml] / [kg],666.7,202244,DB01435,Antipyrine
,6883204,total body clearance,"The serum half-life, apparent volume of distribution, and total body clearance of antipyrine were modified to 3.6 h, 294.1 mL X kg-1, and 56.8 mL X h-1 X kg-1, respectively, from 1.5 h, 666.7 mL X kg-1, and 312.5 mL X h-1 X kg-1 when antipyrine was administered alone.",Inhibitory effect of phenelzine on oxidative microsomal enzyme systems of rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883204/),[ml] / [h·kg],56.8,202245,DB01435,Antipyrine
,6883204,total body clearance,"The serum half-life, apparent volume of distribution, and total body clearance of antipyrine were modified to 3.6 h, 294.1 mL X kg-1, and 56.8 mL X h-1 X kg-1, respectively, from 1.5 h, 666.7 mL X kg-1, and 312.5 mL X h-1 X kg-1 when antipyrine was administered alone.",Inhibitory effect of phenelzine on oxidative microsomal enzyme systems of rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883204/),[ml] / [h·kg],312.5,202246,DB01435,Antipyrine
,1515999,clearance,"In patients with cancer, antipyrine clearance (0.472 +/- 0.177 ml/min/kg) was similar to that in healthy volunteers (0.456 +/- 0.198 ml/min/kg) and significantly higher than in those with cirrhosis (0.259 +/- 0.17 ml/min/kg, P less than 0.001).",Antipyrine metabolism in patients with liver metastases from colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1515999/),[ml] / [kg·min],0.472,205161,DB01435,Antipyrine
,1515999,clearance,"In patients with cancer, antipyrine clearance (0.472 +/- 0.177 ml/min/kg) was similar to that in healthy volunteers (0.456 +/- 0.198 ml/min/kg) and significantly higher than in those with cirrhosis (0.259 +/- 0.17 ml/min/kg, P less than 0.001).",Antipyrine metabolism in patients with liver metastases from colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1515999/),[ml] / [kg·min],0.456,205162,DB01435,Antipyrine
,1515999,clearance,"In patients with cancer, antipyrine clearance (0.472 +/- 0.177 ml/min/kg) was similar to that in healthy volunteers (0.456 +/- 0.198 ml/min/kg) and significantly higher than in those with cirrhosis (0.259 +/- 0.17 ml/min/kg, P less than 0.001).",Antipyrine metabolism in patients with liver metastases from colorectal cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1515999/),[ml] / [kg·min],0.259,205163,DB01435,Antipyrine
,11808861,clearance (CL),"Systemic antipyrine clearance (CL) increased from 31.8 ml/min/kg (controls) by 64% and 42% following repeated exposure to RFM and RBT, respectively.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),[ml] / [kg·min],31.8,207919,DB01435,Antipyrine
,11808861,F,"Estimate of F for antipyrine decreased from 0.97 in controls to 0.58 and 0.82 in animals treated with RFM and RBT, respectively.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),,0.97,207920,DB01435,Antipyrine
,11808861,F,"Estimate of F for antipyrine decreased from 0.97 in controls to 0.58 and 0.82 in animals treated with RFM and RBT, respectively.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),,0.58,207921,DB01435,Antipyrine
,11808861,F,"Estimate of F for antipyrine decreased from 0.97 in controls to 0.58 and 0.82 in animals treated with RFM and RBT, respectively.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),,0.82,207922,DB01435,Antipyrine
,11808861,P450,"The content of P450 (nmol/mg protein) in the liver increased from 0.61 (control) to 1.36 following RFM and 0.82 for RBT, while no significant changes were observed for the GI tract.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),[nM] / [mg],0.61,207923,DB01435,Antipyrine
,11808861,P450,"The content of P450 (nmol/mg protein) in the liver increased from 0.61 (control) to 1.36 following RFM and 0.82 for RBT, while no significant changes were observed for the GI tract.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),[nM] / [mg],1.36,207924,DB01435,Antipyrine
,11808861,P450,"The content of P450 (nmol/mg protein) in the liver increased from 0.61 (control) to 1.36 following RFM and 0.82 for RBT, while no significant changes were observed for the GI tract.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),[nM] / [mg],0.82,207925,DB01435,Antipyrine
,3243660,half-life (t0.5),The mean phenazone half-life (t0.5) was significantly shorter in patients with Hodgkin's disease (8.002 +/- 2.775 h) and in patients with non-Hodgkin's lymphoma (8.775 +/- 2.440 h) than in healthy persons (11.351 +/- 3.706 h).,Phenazone pharmacokinetics as an index of hepatic metabolic efficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243660/),h,8.002,209055,DB01435,Antipyrine
,3243660,half-life (t0.5),The mean phenazone half-life (t0.5) was significantly shorter in patients with Hodgkin's disease (8.002 +/- 2.775 h) and in patients with non-Hodgkin's lymphoma (8.775 +/- 2.440 h) than in healthy persons (11.351 +/- 3.706 h).,Phenazone pharmacokinetics as an index of hepatic metabolic efficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243660/),h,8.775,209056,DB01435,Antipyrine
,3243660,half-life (t0.5),The mean phenazone half-life (t0.5) was significantly shorter in patients with Hodgkin's disease (8.002 +/- 2.775 h) and in patients with non-Hodgkin's lymphoma (8.775 +/- 2.440 h) than in healthy persons (11.351 +/- 3.706 h).,Phenazone pharmacokinetics as an index of hepatic metabolic efficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243660/),h,11.351,209057,DB01435,Antipyrine
,3243660,elimination rate constant (Kel),"In patients with Hodgkin's disease and in patients with non-Hodgkin's lymphoma mean elimination rate constant (Kel) (0.101 +/- 0.050 h-1; 0.086 +/- 0.028 h-1) and mean metabolic clearance rate (MCR) (70.464 +/- 50.347 ml/min; 71.621 +/- 21.448 ml/min) differed statistically significantly from the same parameters in control group, where K was 0.067 +/- 0.021 h-1 and MCR 49.361 +/- 18.167 ml/min.",Phenazone pharmacokinetics as an index of hepatic metabolic efficiency. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243660/),1/[h],0.101,209058,DB01435,Antipyrine
,3243660,elimination rate constant (Kel),"In patients with Hodgkin's disease and in patients with non-Hodgkin's lymphoma mean elimination rate constant (Kel) (0.101 +/- 0.050 h-1; 0.086 +/- 0.028 h-1) and mean metabolic clearance rate (MCR) (70.464 +/- 50.347 ml/min; 71.621 +/- 21.448 ml/min) differed statistically significantly from the same parameters in control group, where K was 0.067 +/- 0.021 h-1 and MCR 49.361 +/- 18.167 ml/min.",Phenazone pharmacokinetics as an index of hepatic metabolic efficiency. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243660/),1/[h],0.086,209059,DB01435,Antipyrine
,3243660,metabolic clearance rate (MCR),"In patients with Hodgkin's disease and in patients with non-Hodgkin's lymphoma mean elimination rate constant (Kel) (0.101 +/- 0.050 h-1; 0.086 +/- 0.028 h-1) and mean metabolic clearance rate (MCR) (70.464 +/- 50.347 ml/min; 71.621 +/- 21.448 ml/min) differed statistically significantly from the same parameters in control group, where K was 0.067 +/- 0.021 h-1 and MCR 49.361 +/- 18.167 ml/min.",Phenazone pharmacokinetics as an index of hepatic metabolic efficiency. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243660/),[ml] / [min],70.464,209060,DB01435,Antipyrine
,3243660,metabolic clearance rate (MCR),"In patients with Hodgkin's disease and in patients with non-Hodgkin's lymphoma mean elimination rate constant (Kel) (0.101 +/- 0.050 h-1; 0.086 +/- 0.028 h-1) and mean metabolic clearance rate (MCR) (70.464 +/- 50.347 ml/min; 71.621 +/- 21.448 ml/min) differed statistically significantly from the same parameters in control group, where K was 0.067 +/- 0.021 h-1 and MCR 49.361 +/- 18.167 ml/min.",Phenazone pharmacokinetics as an index of hepatic metabolic efficiency. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243660/),[ml] / [min],71.621,209061,DB01435,Antipyrine
,3243660,K,"In patients with Hodgkin's disease and in patients with non-Hodgkin's lymphoma mean elimination rate constant (Kel) (0.101 +/- 0.050 h-1; 0.086 +/- 0.028 h-1) and mean metabolic clearance rate (MCR) (70.464 +/- 50.347 ml/min; 71.621 +/- 21.448 ml/min) differed statistically significantly from the same parameters in control group, where K was 0.067 +/- 0.021 h-1 and MCR 49.361 +/- 18.167 ml/min.",Phenazone pharmacokinetics as an index of hepatic metabolic efficiency. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243660/),1/[h],0.067,209062,DB01435,Antipyrine
,3243660,MCR,"In patients with Hodgkin's disease and in patients with non-Hodgkin's lymphoma mean elimination rate constant (Kel) (0.101 +/- 0.050 h-1; 0.086 +/- 0.028 h-1) and mean metabolic clearance rate (MCR) (70.464 +/- 50.347 ml/min; 71.621 +/- 21.448 ml/min) differed statistically significantly from the same parameters in control group, where K was 0.067 +/- 0.021 h-1 and MCR 49.361 +/- 18.167 ml/min.",Phenazone pharmacokinetics as an index of hepatic metabolic efficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243660/),[ml] / [min],49.361,209063,DB01435,Antipyrine
,8530713,systemic bioavailability,Oral estrogens have minimal systemic bioavailability (2% to 10%) due to gut and liver (first-pass) metabolism.,Pharmacokinetic and pharmacologic variation between different estrogen products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530713/),%,2,209255,DB01435,Antipyrine
,8530713,systemic bioavailability,Oral estrogens have minimal systemic bioavailability (2% to 10%) due to gut and liver (first-pass) metabolism.,Pharmacokinetic and pharmacologic variation between different estrogen products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530713/),%,10,209256,DB01435,Antipyrine
,8530713,terminal half lives,The terminal half lives for the different estrogen compounds (after oral or intravenous administration) vary from 1-12 hours.,Pharmacokinetic and pharmacologic variation between different estrogen products. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530713/),h,1-12,209257,DB01435,Antipyrine
,8828783,Total body water,"Total body water as the volume of distribution for antipyrine was 24.8 to 61.5 (mean 44.0 +/- 10.3) L, or 68% of body weight, and tritiated water space 27.0 to 56.6 L (43.6 +/- 7.7), 67% of body weight.",Assessment of total body water in hemodialysis patients by a single oral dose of antipyrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8828783/),l,44.0,210646,DB01435,Antipyrine
,8828783,tritiated water space,"Total body water as the volume of distribution for antipyrine was 24.8 to 61.5 (mean 44.0 +/- 10.3) L, or 68% of body weight, and tritiated water space 27.0 to 56.6 L (43.6 +/- 7.7), 67% of body weight.",Assessment of total body water in hemodialysis patients by a single oral dose of antipyrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8828783/),l,27.0 to 56.6,210647,DB01435,Antipyrine
,8828783,tritiated water space,"Total body water as the volume of distribution for antipyrine was 24.8 to 61.5 (mean 44.0 +/- 10.3) L, or 68% of body weight, and tritiated water space 27.0 to 56.6 L (43.6 +/- 7.7), 67% of body weight.",Assessment of total body water in hemodialysis patients by a single oral dose of antipyrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8828783/),,43.6,210648,DB01435,Antipyrine
,8828783,Fluid excess,"Fluid excess calculated from tritiated water space was between 2.5 and 12.4 (6.0 +/- 4.0) L, and from volume of distribution for antipyrine -0.7 to 13.3 (5.7 +/- 5.1) L (r = 0.80, p = 0.001).",Assessment of total body water in hemodialysis patients by a single oral dose of antipyrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8828783/),l,2.5 and 12.4,210649,DB01435,Antipyrine
,8828783,Fluid excess,"Fluid excess calculated from tritiated water space was between 2.5 and 12.4 (6.0 +/- 4.0) L, and from volume of distribution for antipyrine -0.7 to 13.3 (5.7 +/- 5.1) L (r = 0.80, p = 0.001).",Assessment of total body water in hemodialysis patients by a single oral dose of antipyrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8828783/),l,6.0,210650,DB01435,Antipyrine
,8828783,volume of distribution,"Fluid excess calculated from tritiated water space was between 2.5 and 12.4 (6.0 +/- 4.0) L, and from volume of distribution for antipyrine -0.7 to 13.3 (5.7 +/- 5.1) L (r = 0.80, p = 0.001).",Assessment of total body water in hemodialysis patients by a single oral dose of antipyrine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8828783/),l,5.7,210651,DB01435,Antipyrine
,8031046,clearance,"The clearance associated with maternal-fetal transfer of the drug, CLdf (0.38 +/- 0.21 ml/min/kg), was not significantly different (P > 0.05) from the clearance associated with fetal-maternal transfer of the drug, CLfd (0.56 +/- 0.27 ml/min/kg).",Transplacental pharmacokinetics of dideoxyinosine in pigtailed macaques. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031046/),[ml] / [kg·min],0.38,211245,DB01435,Antipyrine
,8031046,CLdf,"The clearance associated with maternal-fetal transfer of the drug, CLdf (0.38 +/- 0.21 ml/min/kg), was not significantly different (P > 0.05) from the clearance associated with fetal-maternal transfer of the drug, CLfd (0.56 +/- 0.27 ml/min/kg).",Transplacental pharmacokinetics of dideoxyinosine in pigtailed macaques. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031046/),[ml] / [kg·min],0.38,211246,DB01435,Antipyrine
,8031046,CLfd,"The clearance associated with maternal-fetal transfer of the drug, CLdf (0.38 +/- 0.21 ml/min/kg), was not significantly different (P > 0.05) from the clearance associated with fetal-maternal transfer of the drug, CLfd (0.56 +/- 0.27 ml/min/kg).",Transplacental pharmacokinetics of dideoxyinosine in pigtailed macaques. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031046/),[ml] / [kg·min],0.56,211247,DB01435,Antipyrine
,8031046,CLfd,"Also, CLdf was not significantly different (P > 0.05) from CLfd when normalized with respect to the corresponding transplacental clearance of antipyrine (0.07 +/- 0.04 CLdf versus 0.09 +/- 0.04 CLfd).",Transplacental pharmacokinetics of dideoxyinosine in pigtailed macaques. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031046/),,0.09,211248,DB01435,Antipyrine
,20487220,limit of detection,"The limit of detection of puerarin and edaravone was 0.03 and 0.05 microg/ml, respectively.","Pharmacokinetic interaction between puerarin and edaravone, and effect of borneol on the brain distribution kinetics of puerarin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20487220/),[μg] / [ml],0.03,212888,DB01435,Antipyrine
,20487220,limit of detection,"The limit of detection of puerarin and edaravone was 0.03 and 0.05 microg/ml, respectively.","Pharmacokinetic interaction between puerarin and edaravone, and effect of borneol on the brain distribution kinetics of puerarin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20487220/),[μg] / [ml],0.05,212889,DB01435,Antipyrine
>,20487220,recovery,The average recovery of the two compounds from rat plasma was >94%.,"Pharmacokinetic interaction between puerarin and edaravone, and effect of borneol on the brain distribution kinetics of puerarin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20487220/),%,94,212890,DB01435,Antipyrine
exceeded,1622175,volume of distribution,The volume of distribution exceeded 1 liter/kg in healthy controls and was not affected by liver impairment (P greater than 0.05).,Fleroxacin pharmacokinetics in patients with liver cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1622175/),[l] / [kg],1,214595,DB01435,Antipyrine
,8841151,absolute transnasal bioavailability,The absolute transnasal bioavailability of butorphanol was significantly higher (approximately 20%) in patients with hepatic impairment.,The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841151/),%,20,214838,DB01435,Antipyrine
,25452230,bioavailability,"After intravenous and oral administration of ibuprofen and fexofenadine (BCS class II and III), the plasma concentration and pharmacokinetic parameters were evaluated by our method and a terminal blood sampling method, with the result that both methods gave comparable results (ibuprofen: 63.8 ± 4.0% and 64.4%, fexofenadine: 6.5 ± 0.7% and 7.9%, respectively, in bioavailability).",Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25452230/),%,6.5,216135,DB01435,Antipyrine
,25452230,bioavailability,"After intravenous and oral administration of ibuprofen and fexofenadine (BCS class II and III), the plasma concentration and pharmacokinetic parameters were evaluated by our method and a terminal blood sampling method, with the result that both methods gave comparable results (ibuprofen: 63.8 ± 4.0% and 64.4%, fexofenadine: 6.5 ± 0.7% and 7.9%, respectively, in bioavailability).",Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25452230/),%,7.9,216136,DB01435,Antipyrine
,1782837,clearance,The uncorrected antipyrine clearance was significantly lower in the immature group (mean +/- SD 22.65 +/- 6.04 ml/min) than in others (mean +/- SD 41.30 +/- 13.26; p less than 0.01).,"Changes in salivary antipyrine pharmacokinetics during adolescence, correlated with age, hormonal levels and Tanner stage. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782837/),[ml] / [min],22.65,216250,DB01435,Antipyrine
,1782837,clearance,The uncorrected antipyrine clearance was significantly lower in the immature group (mean +/- SD 22.65 +/- 6.04 ml/min) than in others (mean +/- SD 41.30 +/- 13.26; p less than 0.01).,"Changes in salivary antipyrine pharmacokinetics during adolescence, correlated with age, hormonal levels and Tanner stage. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782837/),[ml] / [min],41.30,216251,DB01435,Antipyrine
,31408460,clearance index,"After 3h of recirculating perfusion, the mean (± SD) DTG concentrations in the maternal and in the fetal compartments were respectively 2450 ± 286 ng/mL and 715 ± 369 ng/mL, with a fetal-to-maternal ratio of 34% ± 18% and a clearance index (in comparison with antipyrine transfer) of 79% ± 23%.",Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31408460/),%,79,216708,DB01435,Antipyrine
,31408460,accumulation index,The mean cotyledon accumulation index was 153% ± 25%.,Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31408460/),%,153,216709,DB01435,Antipyrine
,6311786,serum half life,"The serum half life of ketoconazole was 74.8 +/- 13.9 min (mean +/- S.D.) on day 1, and 155.9 +/- 32.7 min on day 5.",Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311786/),min,74.8,217367,DB01435,Antipyrine
,6311786,serum half life,"The serum half life of ketoconazole was 74.8 +/- 13.9 min (mean +/- S.D.) on day 1, and 155.9 +/- 32.7 min on day 5.",Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311786/),min,155.9,217368,DB01435,Antipyrine
,6311786,area under the serum concentration time curve,"On day 1 the area under the serum concentration time curve was 626.9 +/- 230.1 mg/l.min, and 1441 +/- 897.3 mg/l.min on day 5.",Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311786/),[mg] / [l·min],626.9,217369,DB01435,Antipyrine
,6311786,area under the serum concentration time curve,"On day 1 the area under the serum concentration time curve was 626.9 +/- 230.1 mg/l.min, and 1441 +/- 897.3 mg/l.min on day 5.",Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6311786/),[mg] / [l·min],1441,217370,DB01435,Antipyrine
,3392664,total apparent oral clearance,"Mean total apparent oral clearance after a single dose of verapamil was increased after phenobarbital treatment (75.1 +/- 49.2 vs. 376.2 +/- 221.8 ml/min/kg, P less than .05).",Effects of chronic phenobarbital on verapamil disposition in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],75.1,217679,DB01435,Antipyrine
,3392664,total apparent oral clearance,"Mean total apparent oral clearance after a single dose of verapamil was increased after phenobarbital treatment (75.1 +/- 49.2 vs. 376.2 +/- 221.8 ml/min/kg, P less than .05).",Effects of chronic phenobarbital on verapamil disposition in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],376.2,217680,DB01435,Antipyrine
,3392664,systemic clearance,"Mean total verapamil systemic clearance was increased (9.95 +/- 1.3 vs. 18.9 +/- 8.7 ml/min/kg, P less than .05); however free drug clearance was not altered.",Effects of chronic phenobarbital on verapamil disposition in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],9.95,217681,DB01435,Antipyrine
,3392664,systemic clearance,"Mean total verapamil systemic clearance was increased (9.95 +/- 1.3 vs. 18.9 +/- 8.7 ml/min/kg, P less than .05); however free drug clearance was not altered.",Effects of chronic phenobarbital on verapamil disposition in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],18.9,217682,DB01435,Antipyrine
,3392664,apparent oral clearance,"After multiple oral administration, total verapamil apparent oral clearance was increased after phenobarbital pretreatment (21.2 +/- 9.8 vs. 91.2 +/- 28.5 ml/min/kg, P less than .05).",Effects of chronic phenobarbital on verapamil disposition in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],21.2,217683,DB01435,Antipyrine
,3392664,apparent oral clearance,"After multiple oral administration, total verapamil apparent oral clearance was increased after phenobarbital pretreatment (21.2 +/- 9.8 vs. 91.2 +/- 28.5 ml/min/kg, P less than .05).",Effects of chronic phenobarbital on verapamil disposition in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],91.2,217684,DB01435,Antipyrine
,6662064,t50,"group H: t50,2 +/- 11,7 h, Cltot 27 +/- 13,3 ml.",[Determination of hepatic metabolic capacity: antipyrine pharmacokinetics in circulatory liver damage due to cardiac insufficiency]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662064/),h,2,217865,DB01435,Antipyrine
,6662064,Cltot,"group H: t50,2 +/- 11,7 h, Cltot 27 +/- 13,3 ml.",[Determination of hepatic metabolic capacity: antipyrine pharmacokinetics in circulatory liver damage due to cardiac insufficiency]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662064/),ml,27,217866,DB01435,Antipyrine
,6662064,t50,"min-1; group V: t50 19,3 +/- 6,3 h, Cltot 21,9 +/- 8,6 ml. min-1.",[Determination of hepatic metabolic capacity: antipyrine pharmacokinetics in circulatory liver damage due to cardiac insufficiency]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662064/),h,"19,3",217867,DB01435,Antipyrine
,6662064,Cltot,"min-1; group V: t50 19,3 +/- 6,3 h, Cltot 21,9 +/- 8,6 ml. min-1.",[Determination of hepatic metabolic capacity: antipyrine pharmacokinetics in circulatory liver damage due to cardiac insufficiency]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662064/),[ml] / [min],"21,9",217868,DB01435,Antipyrine
,6662064,t50,"Those patients with acute myocardial infarction and normal liver condition had a prolonged half-time as well though the clearance was decreased just insignificantly (t50 12 +/- 4,9 h, Cltot 42,6 +/- 15,8 ml. min-1).",[Determination of hepatic metabolic capacity: antipyrine pharmacokinetics in circulatory liver damage due to cardiac insufficiency]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662064/),h,12,217869,DB01435,Antipyrine
,6662064,Cltot,"Those patients with acute myocardial infarction and normal liver condition had a prolonged half-time as well though the clearance was decreased just insignificantly (t50 12 +/- 4,9 h, Cltot 42,6 +/- 15,8 ml. min-1).",[Determination of hepatic metabolic capacity: antipyrine pharmacokinetics in circulatory liver damage due to cardiac insufficiency]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662064/),[ml] / [min],"42,6",217870,DB01435,Antipyrine
,8573686,elimination half-life,"Before surgery, the mean elimination half-life was about 1.1 h and total clearance averaged 6 L h-1.",Pharmacokinetic parameters of antipyrine in dog after hepatectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573686/),h,1.1,218035,DB01435,Antipyrine
,8573686,total clearance,"Before surgery, the mean elimination half-life was about 1.1 h and total clearance averaged 6 L h-1.",Pharmacokinetic parameters of antipyrine in dog after hepatectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573686/),[l] / [h],6,218036,DB01435,Antipyrine
,1115054,half-life,"The plasma antipyrine half-life and metabolic clearances in the control subjects were 11.7 plus or minus 1.3 hours and 42.5 plus or minus 3.3 ml/min, respectively; in patients with gallstones, 12.3 plus or minus 1.3 hours and 36.0 plus or minus 3.2 ml/min, respectively; and in patients having undergone cholecystectomy, 13.2 plus or minus 1.8 hours and 33.8 plus or minus 4.2 ml/min, respectively.",Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115054/),h,11.7,219211,DB01435,Antipyrine
,1115054,half-life,"The plasma antipyrine half-life and metabolic clearances in the control subjects were 11.7 plus or minus 1.3 hours and 42.5 plus or minus 3.3 ml/min, respectively; in patients with gallstones, 12.3 plus or minus 1.3 hours and 36.0 plus or minus 3.2 ml/min, respectively; and in patients having undergone cholecystectomy, 13.2 plus or minus 1.8 hours and 33.8 plus or minus 4.2 ml/min, respectively.",Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115054/),h,12.3,219212,DB01435,Antipyrine
,1115054,half-life,"The plasma antipyrine half-life and metabolic clearances in the control subjects were 11.7 plus or minus 1.3 hours and 42.5 plus or minus 3.3 ml/min, respectively; in patients with gallstones, 12.3 plus or minus 1.3 hours and 36.0 plus or minus 3.2 ml/min, respectively; and in patients having undergone cholecystectomy, 13.2 plus or minus 1.8 hours and 33.8 plus or minus 4.2 ml/min, respectively.",Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115054/),h,13.2,219213,DB01435,Antipyrine
,1115054,metabolic clearances,"The plasma antipyrine half-life and metabolic clearances in the control subjects were 11.7 plus or minus 1.3 hours and 42.5 plus or minus 3.3 ml/min, respectively; in patients with gallstones, 12.3 plus or minus 1.3 hours and 36.0 plus or minus 3.2 ml/min, respectively; and in patients having undergone cholecystectomy, 13.2 plus or minus 1.8 hours and 33.8 plus or minus 4.2 ml/min, respectively.",Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115054/),[ml] / [min],42.5,219214,DB01435,Antipyrine
,1115054,metabolic clearances,"The plasma antipyrine half-life and metabolic clearances in the control subjects were 11.7 plus or minus 1.3 hours and 42.5 plus or minus 3.3 ml/min, respectively; in patients with gallstones, 12.3 plus or minus 1.3 hours and 36.0 plus or minus 3.2 ml/min, respectively; and in patients having undergone cholecystectomy, 13.2 plus or minus 1.8 hours and 33.8 plus or minus 4.2 ml/min, respectively.",Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115054/),[ml] / [min],36.0,219215,DB01435,Antipyrine
,1115054,metabolic clearances,"The plasma antipyrine half-life and metabolic clearances in the control subjects were 11.7 plus or minus 1.3 hours and 42.5 plus or minus 3.3 ml/min, respectively; in patients with gallstones, 12.3 plus or minus 1.3 hours and 36.0 plus or minus 3.2 ml/min, respectively; and in patients having undergone cholecystectomy, 13.2 plus or minus 1.8 hours and 33.8 plus or minus 4.2 ml/min, respectively.",Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115054/),h,13.2,219216,DB01435,Antipyrine
,1115054,metabolic clearances,"The plasma antipyrine half-life and metabolic clearances in the control subjects were 11.7 plus or minus 1.3 hours and 42.5 plus or minus 3.3 ml/min, respectively; in patients with gallstones, 12.3 plus or minus 1.3 hours and 36.0 plus or minus 3.2 ml/min, respectively; and in patients having undergone cholecystectomy, 13.2 plus or minus 1.8 hours and 33.8 plus or minus 4.2 ml/min, respectively.",Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115054/),[ml] / [min],33.8,219217,DB01435,Antipyrine
,27469324,Systemic plasma clearance,"Systemic plasma clearance for the seven drugs ranged from low (1.1 ml/min/kg, theophylline) to close to liver blood flow (37.4 ml/min/kg, cimetidine).",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[ml] / [kg·min],1.1,220371,DB01435,Antipyrine
,27469324,Systemic plasma clearance,"Systemic plasma clearance for the seven drugs ranged from low (1.1 ml/min/kg, theophylline) to close to liver blood flow (37.4 ml/min/kg, cimetidine).",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[ml] / [kg·min],37.4,220372,DB01435,Antipyrine
,27469324,Volume of distribution,Volume of distribution in minipigs ranged from 0.7 L/kg for antipyrine to 3.2 L/kg for hydrochlorothiazide.,Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[l] / [kg],0.7,220373,DB01435,Antipyrine
,27469324,Volume of distribution,Volume of distribution in minipigs ranged from 0.7 L/kg for antipyrine to 3.2 L/kg for hydrochlorothiazide.,Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[l] / [kg],3.2,220374,DB01435,Antipyrine
,27469324,hepatocellularity,"The hepatocellularity for minipig was determined as 124 Mcells/g liver, similar to the values reported for human.",Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27469324/),[Mcells] / [g],124,220375,DB01435,Antipyrine
,1738110,intra,"The intravesical bioavailability was variable between animals, with an average of 11.6 +/- 6.4% (mean +/- S.D.; range, 4.1-19.2%).",Evidence of significant absorption of antipyrine from urinary bladder of rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1738110/),%,11.6,221669,DB01435,Antipyrine
,1738110,bioavailability,"The intravesical bioavailability was variable between animals, with an average of 11.6 +/- 6.4% (mean +/- S.D.; range, 4.1-19.2%).",Evidence of significant absorption of antipyrine from urinary bladder of rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1738110/),%,11.6,221670,DB01435,Antipyrine
,10839928,minimum alveolar concentration,"The dogs were studied while awake and while anesthetized with 1.7%, 2.6%, and 3.5% isoflurane (1.15, 1.7, and 2.3 minimum alveolar concentration, respectively) in a randomized order determined by a Latin square experimental design.",Isoflurane alters the recirculatory pharmacokinetics of physiologic markers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839928/),,1.15,222019,DB01435,Antipyrine
,10839928,minimum alveolar concentration,"The dogs were studied while awake and while anesthetized with 1.7%, 2.6%, and 3.5% isoflurane (1.15, 1.7, and 2.3 minimum alveolar concentration, respectively) in a randomized order determined by a Latin square experimental design.",Isoflurane alters the recirculatory pharmacokinetics of physiologic markers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839928/),,1.7,222020,DB01435,Antipyrine
,10839928,minimum alveolar concentration,"The dogs were studied while awake and while anesthetized with 1.7%, 2.6%, and 3.5% isoflurane (1.15, 1.7, and 2.3 minimum alveolar concentration, respectively) in a randomized order determined by a Latin square experimental design.",Isoflurane alters the recirculatory pharmacokinetics of physiologic markers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839928/),,2.3,222021,DB01435,Antipyrine
,9421317,steady-state plasma concentration ratio,The fetal:maternal ratio of the area under the simulated zalcitabine plasma concentration-time profile after an i.v. bolus dose (0.58) was close to the earlier observed fetal:maternal steady-state plasma concentration ratio after i.v. infusion of the drug (0.58 +/- 0.05).,"Effect of pregnancy, mode of administration and neonatal age on the pharmacokinetics of zalcitabine (2', 3'-dideoxycytidine) in the pigtailed macaque (Macaca nemestrina). ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421317/),,0.58,222704,DB01435,Antipyrine
,3775212,clearance,When compared to values obtained in 17 normal weight normolipidemic control subjects (41.63 +/- 2.73 ml X min-1) antipyrine clearance determined in the saliva was found to be obviously decreased in the 10 patients with liver cirrhosis (21.88 +/- 0.79) and significantly increased in the 17 subjects with type IV hyperlipoproteinemia (59.91 +/- 4.59).,Increased values of antipyrine clearance in type IV hyperlipoproteinemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3775212/),[ml] / [min],41.63,223135,DB01435,Antipyrine
,3775212,clearance,When compared to values obtained in 17 normal weight normolipidemic control subjects (41.63 +/- 2.73 ml X min-1) antipyrine clearance determined in the saliva was found to be obviously decreased in the 10 patients with liver cirrhosis (21.88 +/- 0.79) and significantly increased in the 17 subjects with type IV hyperlipoproteinemia (59.91 +/- 4.59).,Increased values of antipyrine clearance in type IV hyperlipoproteinemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3775212/),[ml] / [min],21.88,223136,DB01435,Antipyrine
,3775212,clearance,When compared to values obtained in 17 normal weight normolipidemic control subjects (41.63 +/- 2.73 ml X min-1) antipyrine clearance determined in the saliva was found to be obviously decreased in the 10 patients with liver cirrhosis (21.88 +/- 0.79) and significantly increased in the 17 subjects with type IV hyperlipoproteinemia (59.91 +/- 4.59).,Increased values of antipyrine clearance in type IV hyperlipoproteinemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3775212/),,59.91,223137,DB01435,Antipyrine
,6505390,serum half-life,"The mean values +/- SE (range) for the serum half-life, apparent volume of distribution and total body clearance of antipyrine were: 2.5 +/- 0.6 (1.6-4.9) h, 868.7 +/- 203.9 (590-1275) ml/kg and 269.2 +/- 14.7 (165-516) ml/h/kg respectively.",Monthly variations in the clearance of antipyrine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6505390/),h,2.5,224386,DB01435,Antipyrine
,6505390,apparent volume of distribution,"The mean values +/- SE (range) for the serum half-life, apparent volume of distribution and total body clearance of antipyrine were: 2.5 +/- 0.6 (1.6-4.9) h, 868.7 +/- 203.9 (590-1275) ml/kg and 269.2 +/- 14.7 (165-516) ml/h/kg respectively.",Monthly variations in the clearance of antipyrine in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6505390/),[ml] / [kg],868.7,224387,DB01435,Antipyrine
,6505390,total body clearance,"The mean values +/- SE (range) for the serum half-life, apparent volume of distribution and total body clearance of antipyrine were: 2.5 +/- 0.6 (1.6-4.9) h, 868.7 +/- 203.9 (590-1275) ml/kg and 269.2 +/- 14.7 (165-516) ml/h/kg respectively.",Monthly variations in the clearance of antipyrine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6505390/),[ml] / [h·kg],269.2,224388,DB01435,Antipyrine
,17610404,clearance,"However, the clearance of antipyrine (mean = 8.33 mL/min/kg) in Greyhounds was significantly slower than Beagles (13.42 mL/min/kg, P = 0.004).","Comparative disposition of pharmacologic markers for cytochrome P-450 mediated metabolism, glomerular filtration rate, and extracellular and total body fluid volume of Greyhound and Beagle dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610404/),[ml] / [kg·min],8.33,224457,DB01435,Antipyrine
,17610404,clearance,"However, the clearance of antipyrine (mean = 8.33 mL/min/kg) in Greyhounds was significantly slower than Beagles (13.42 mL/min/kg, P = 0.004).","Comparative disposition of pharmacologic markers for cytochrome P-450 mediated metabolism, glomerular filtration rate, and extracellular and total body fluid volume of Greyhound and Beagle dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610404/),[ml] / [kg·min],13.42,224458,DB01435,Antipyrine
,17610404,volume of distribution,"The volume of distribution of antipyrine was significantly larger in Greyhounds (0.789 L/kg) than in Beagles (0.644 L/kg, P = 0.01).","Comparative disposition of pharmacologic markers for cytochrome P-450 mediated metabolism, glomerular filtration rate, and extracellular and total body fluid volume of Greyhound and Beagle dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610404/),[l] / [kg],0.789,224459,DB01435,Antipyrine
,17610404,volume of distribution,"The volume of distribution of antipyrine was significantly larger in Greyhounds (0.789 L/kg) than in Beagles (0.644 L/kg, P = 0.01).","Comparative disposition of pharmacologic markers for cytochrome P-450 mediated metabolism, glomerular filtration rate, and extracellular and total body fluid volume of Greyhound and Beagle dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610404/),[l] / [kg],0.644,224460,DB01435,Antipyrine
,17610404,half-life,"The half-life of antipyrine was significantly longer in Greyhounds (1.09 h) compared with Beagles (0.55 h, P = 0.002).","Comparative disposition of pharmacologic markers for cytochrome P-450 mediated metabolism, glomerular filtration rate, and extracellular and total body fluid volume of Greyhound and Beagle dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610404/),h,1.09,224461,DB01435,Antipyrine
,17610404,half-life,"The half-life of antipyrine was significantly longer in Greyhounds (1.09 h) compared with Beagles (0.55 h, P = 0.002).","Comparative disposition of pharmacologic markers for cytochrome P-450 mediated metabolism, glomerular filtration rate, and extracellular and total body fluid volume of Greyhound and Beagle dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610404/),h,0.55,224462,DB01435,Antipyrine
,17610404,plasma protein binding,"The in vitro plasma protein binding of antipyrine was significantly less in Greyhounds (28%) compared with Beagles (40.3%, P = 0.008).","Comparative disposition of pharmacologic markers for cytochrome P-450 mediated metabolism, glomerular filtration rate, and extracellular and total body fluid volume of Greyhound and Beagle dogs. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610404/),%,28,224463,DB01435,Antipyrine
,17610404,plasma protein binding,"The in vitro plasma protein binding of antipyrine was significantly less in Greyhounds (28%) compared with Beagles (40.3%, P = 0.008).","Comparative disposition of pharmacologic markers for cytochrome P-450 mediated metabolism, glomerular filtration rate, and extracellular and total body fluid volume of Greyhound and Beagle dogs. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610404/),%,40.3,224464,DB01435,Antipyrine
,9342585,plasma protein binding,"The mean plasma protein binding of 3-hydroxyquinine was 46%, which was significantly lower than that of quinine (90.5%) or dihydroquinine (90.5%).",A study of the factors affecting the metabolic clearance of quinine in malaria. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342585/),%,46,227091,DB01435,Antipyrine
,9342585,plasma protein binding,"The mean plasma protein binding of 3-hydroxyquinine was 46%, which was significantly lower than that of quinine (90.5%) or dihydroquinine (90.5%).",A study of the factors affecting the metabolic clearance of quinine in malaria. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342585/),%,90.5,227092,DB01435,Antipyrine
,2762375,elimination half-life,"Among male subjects, elimination half-life was prolonged (20 vs. 8 h, p less than 0.025) and clearance reduced (20 vs. 43 ml/min, p less than 0.05) in elderly as opposed to young volunteers.",Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762375/),h,20,227292,DB01435,Antipyrine
,2762375,elimination half-life,"Among male subjects, elimination half-life was prolonged (20 vs. 8 h, p less than 0.025) and clearance reduced (20 vs. 43 ml/min, p less than 0.05) in elderly as opposed to young volunteers.",Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762375/),h,8,227293,DB01435,Antipyrine
,2762375,clearance,"Among male subjects, elimination half-life was prolonged (20 vs. 8 h, p less than 0.025) and clearance reduced (20 vs. 43 ml/min, p less than 0.05) in elderly as opposed to young volunteers.",Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762375/),[ml] / [min],20,227294,DB01435,Antipyrine
,2762375,clearance,"Among male subjects, elimination half-life was prolonged (20 vs. 8 h, p less than 0.025) and clearance reduced (20 vs. 43 ml/min, p less than 0.05) in elderly as opposed to young volunteers.",Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762375/),[ml] / [min],43,227295,DB01435,Antipyrine
,2762375,elimination half-life,"Among women, there was no significant difference between elderly and young subjects in elimination half-life (12 vs. 13 h) or clearance (29 vs. 22 ml/min).",Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762375/),h,12,227296,DB01435,Antipyrine
,2762375,elimination half-life,"Among women, there was no significant difference between elderly and young subjects in elimination half-life (12 vs. 13 h) or clearance (29 vs. 22 ml/min).",Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762375/),h,13,227297,DB01435,Antipyrine
,2762375,clearance,"Among women, there was no significant difference between elderly and young subjects in elimination half-life (12 vs. 13 h) or clearance (29 vs. 22 ml/min).",Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762375/),[ml] / [min],29,227298,DB01435,Antipyrine
,2762375,clearance,"Among women, there was no significant difference between elderly and young subjects in elimination half-life (12 vs. 13 h) or clearance (29 vs. 22 ml/min).",Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762375/),[ml] / [min],22,227299,DB01435,Antipyrine
less,2762375,Absolute bioavailability,"Absolute bioavailability of oral chlordiazepoxide was not less than 100%, and was unrelated to age or sex.",Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762375/),%,100,227300,DB01435,Antipyrine
,2612536,t1/2,"During all three parts of the study, the pharmacokinetics of antipyrine viz. t1/2 (11.7 h), total plasma (38.5 ml.h-1.kg-1) and renal clearance (1.6 ml.h-1.kg-1), and its clearance rates to metabolites (CLM), eg. CLM for 4-OH-AP (12.3 ml.h-1.kg-1), CLM for 3-OH-CH3-AP (4.2 ml.h-1.kg-1) and CLM for Nor-AP (6.7 ml.h-1.kg-1) did not differ from the control values.","Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612536/),h,11.7,228131,DB01435,Antipyrine
,2612536,total plasma,"During all three parts of the study, the pharmacokinetics of antipyrine viz. t1/2 (11.7 h), total plasma (38.5 ml.h-1.kg-1) and renal clearance (1.6 ml.h-1.kg-1), and its clearance rates to metabolites (CLM), eg. CLM for 4-OH-AP (12.3 ml.h-1.kg-1), CLM for 3-OH-CH3-AP (4.2 ml.h-1.kg-1) and CLM for Nor-AP (6.7 ml.h-1.kg-1) did not differ from the control values.","Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612536/),[ml] / [h·kg],38.5,228132,DB01435,Antipyrine
,2612536,renal clearance,"During all three parts of the study, the pharmacokinetics of antipyrine viz. t1/2 (11.7 h), total plasma (38.5 ml.h-1.kg-1) and renal clearance (1.6 ml.h-1.kg-1), and its clearance rates to metabolites (CLM), eg. CLM for 4-OH-AP (12.3 ml.h-1.kg-1), CLM for 3-OH-CH3-AP (4.2 ml.h-1.kg-1) and CLM for Nor-AP (6.7 ml.h-1.kg-1) did not differ from the control values.","Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612536/),[ml] / [h·kg],1.6,228133,DB01435,Antipyrine
,2612536,clearance rates,"During all three parts of the study, the pharmacokinetics of antipyrine viz. t1/2 (11.7 h), total plasma (38.5 ml.h-1.kg-1) and renal clearance (1.6 ml.h-1.kg-1), and its clearance rates to metabolites (CLM), eg. CLM for 4-OH-AP (12.3 ml.h-1.kg-1), CLM for 3-OH-CH3-AP (4.2 ml.h-1.kg-1) and CLM for Nor-AP (6.7 ml.h-1.kg-1) did not differ from the control values.","Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612536/),[ml] / [h·kg],12.3,228134,DB01435,Antipyrine
,2612536,CLM,"During all three parts of the study, the pharmacokinetics of antipyrine viz. t1/2 (11.7 h), total plasma (38.5 ml.h-1.kg-1) and renal clearance (1.6 ml.h-1.kg-1), and its clearance rates to metabolites (CLM), eg. CLM for 4-OH-AP (12.3 ml.h-1.kg-1), CLM for 3-OH-CH3-AP (4.2 ml.h-1.kg-1) and CLM for Nor-AP (6.7 ml.h-1.kg-1) did not differ from the control values.","Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612536/),[ml] / [h·kg],12.3,228135,DB01435,Antipyrine
,2612536,CLM,"During all three parts of the study, the pharmacokinetics of antipyrine viz. t1/2 (11.7 h), total plasma (38.5 ml.h-1.kg-1) and renal clearance (1.6 ml.h-1.kg-1), and its clearance rates to metabolites (CLM), eg. CLM for 4-OH-AP (12.3 ml.h-1.kg-1), CLM for 3-OH-CH3-AP (4.2 ml.h-1.kg-1) and CLM for Nor-AP (6.7 ml.h-1.kg-1) did not differ from the control values.","Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612536/),[ml] / [h·kg],4.2,228136,DB01435,Antipyrine
,2612536,CLM,"During all three parts of the study, the pharmacokinetics of antipyrine viz. t1/2 (11.7 h), total plasma (38.5 ml.h-1.kg-1) and renal clearance (1.6 ml.h-1.kg-1), and its clearance rates to metabolites (CLM), eg. CLM for 4-OH-AP (12.3 ml.h-1.kg-1), CLM for 3-OH-CH3-AP (4.2 ml.h-1.kg-1) and CLM for Nor-AP (6.7 ml.h-1.kg-1) did not differ from the control values.","Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612536/),[ml] / [h·kg],6.7,228137,DB01435,Antipyrine
,3472701,clearance,"We found an improvement in clearance of antipyrine (0.65 to 0.95 ml/min/kg; P less than 0.01) and lorazepam (0.93 to 1.20 ml/min/kg; P less than 0.05) in 12 of 14 patients, with a mean increase of 67% and 52%, respectively, from before to after remission.",Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3472701/),[ml] / [kg·min],0.65 to 0.95,228150,DB01435,Antipyrine
,3472701,clearance,"We found an improvement in clearance of antipyrine (0.65 to 0.95 ml/min/kg; P less than 0.01) and lorazepam (0.93 to 1.20 ml/min/kg; P less than 0.05) in 12 of 14 patients, with a mean increase of 67% and 52%, respectively, from before to after remission.",Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3472701/),[ml] / [kg·min],0.93 to 1.20,228151,DB01435,Antipyrine
,3472701,clearance,There was no significant difference in mean indocyanine green clearance from before to after induction (14.8 vs. 14.4 ml/min/kg).,Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3472701/),[ml] / [kg·min],14.8,228152,DB01435,Antipyrine
,3472701,clearance,There was no significant difference in mean indocyanine green clearance from before to after induction (14.8 vs. 14.4 ml/min/kg).,Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3472701/),[ml] / [kg·min],14.4,228153,DB01435,Antipyrine
,8046321,elimination capacity,"Galactose elimination capacity decreased from 2.45 (+/- 0.48) mM min-1 to 2.04 (+/- 0.60) mM min-1 after the five planned courses of chemotherapy (P = 0.013, Wilcoxon signed-rank test), without any change in routine liver function tests.",High-dose methotrexate treatment and liver function in patients with osteosarcoma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8046321/),[mM] / [min],2.45,229939,DB01435,Antipyrine
,8046321,elimination capacity,"Galactose elimination capacity decreased from 2.45 (+/- 0.48) mM min-1 to 2.04 (+/- 0.60) mM min-1 after the five planned courses of chemotherapy (P = 0.013, Wilcoxon signed-rank test), without any change in routine liver function tests.",High-dose methotrexate treatment and liver function in patients with osteosarcoma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8046321/),[mM] / [min],2.04,229940,DB01435,Antipyrine
,8429118,Vd,"Mean kinetic variables for antipyrine in controls and primary biliary cirrhosis patients were: Vd, .54 versus .49 L/kg; half-life, 12.0 versus 15.1 hours (P < .07); clearance, .55 versus .41 mL/min/kg (P < .04).",Antipyrine kinetics in patients with primary biliary cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429118/),[l] / [kg],.54,230066,DB01435,Antipyrine
,8429118,Vd,"Mean kinetic variables for antipyrine in controls and primary biliary cirrhosis patients were: Vd, .54 versus .49 L/kg; half-life, 12.0 versus 15.1 hours (P < .07); clearance, .55 versus .41 mL/min/kg (P < .04).",Antipyrine kinetics in patients with primary biliary cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429118/),[l] / [kg],.49,230067,DB01435,Antipyrine
,8429118,half-life,"Mean kinetic variables for antipyrine in controls and primary biliary cirrhosis patients were: Vd, .54 versus .49 L/kg; half-life, 12.0 versus 15.1 hours (P < .07); clearance, .55 versus .41 mL/min/kg (P < .04).",Antipyrine kinetics in patients with primary biliary cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429118/),h,12.0,230068,DB01435,Antipyrine
,8429118,half-life,"Mean kinetic variables for antipyrine in controls and primary biliary cirrhosis patients were: Vd, .54 versus .49 L/kg; half-life, 12.0 versus 15.1 hours (P < .07); clearance, .55 versus .41 mL/min/kg (P < .04).",Antipyrine kinetics in patients with primary biliary cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429118/),h,15.1,230069,DB01435,Antipyrine
,8429118,clearance,"Mean kinetic variables for antipyrine in controls and primary biliary cirrhosis patients were: Vd, .54 versus .49 L/kg; half-life, 12.0 versus 15.1 hours (P < .07); clearance, .55 versus .41 mL/min/kg (P < .04).",Antipyrine kinetics in patients with primary biliary cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429118/),[ml] / [kg·min],.55,230070,DB01435,Antipyrine
,8429118,clearance,"Mean kinetic variables for antipyrine in controls and primary biliary cirrhosis patients were: Vd, .54 versus .49 L/kg; half-life, 12.0 versus 15.1 hours (P < .07); clearance, .55 versus .41 mL/min/kg (P < .04).",Antipyrine kinetics in patients with primary biliary cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429118/),[ml] / [kg·min],.41,230071,DB01435,Antipyrine
,6933259,half-life (t 1/2),"The mean half-life (t 1/2) of antipyrine in group 3 (15.6 +/- 4.8 hr) was significantly longer than that in group 1 (8.1 +/- 0.9 hr, P < 0.01).",Effect of age on antipyrine metabolism in patients with gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6933259/),h,15.6,232250,DB01435,Antipyrine
,6933259,half-life (t 1/2),"The mean half-life (t 1/2) of antipyrine in group 3 (15.6 +/- 4.8 hr) was significantly longer than that in group 1 (8.1 +/- 0.9 hr, P < 0.01).",Effect of age on antipyrine metabolism in patients with gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6933259/),h,8.1,232251,DB01435,Antipyrine
,6933259,metabolic clearance rate (MCR),"Similarly, the mean metabolic clearance rate (MCR) in group 3 (246 +/- 78 ml/hr/kg) was significantly lower than that in group 1 (498 +/- 175 ml/hr/kg, P < 0.02).",Effect of age on antipyrine metabolism in patients with gastric cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6933259/),[ml] / [h·kg],246,232252,DB01435,Antipyrine
,6933259,metabolic clearance rate (MCR),"Similarly, the mean metabolic clearance rate (MCR) in group 3 (246 +/- 78 ml/hr/kg) was significantly lower than that in group 1 (498 +/- 175 ml/hr/kg, P < 0.02).",Effect of age on antipyrine metabolism in patients with gastric cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6933259/),[ml] / [h·kg],498,232253,DB01435,Antipyrine
,991537,halic-life,"Since in man aminopyrine has a biologic halic-life of approximately 2.7 hr, the marked inhibitory effects observed 5 hr after aminopyrine administration may be due to its major metabolite, 4-aminoantipyrine.",Interaction between antipyrine and aminopyrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/991537/),h,2.7,232294,DB01435,Antipyrine
,10552268,half-life,"After 3 months of participation in the exercise program, salivary antipyrine clearance was significantly increased by 17% mean (SEM) 0.42 (0.02) vs 0.36 (0.02) ml/min/kg; P < 0.05) and the half-life of antipyrine was significantly reduced by 18% (17.9 (1.1) vs 22.3 (1.3) h; P < 0.05).",Physical exercise and improvement of liver oxidative metabolism in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10552268/),h,17.9,232915,DB01435,Antipyrine
,10552268,half-life,"After 3 months of participation in the exercise program, salivary antipyrine clearance was significantly increased by 17% mean (SEM) 0.42 (0.02) vs 0.36 (0.02) ml/min/kg; P < 0.05) and the half-life of antipyrine was significantly reduced by 18% (17.9 (1.1) vs 22.3 (1.3) h; P < 0.05).",Physical exercise and improvement of liver oxidative metabolism in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10552268/),h,22.3,232916,DB01435,Antipyrine
,10552268,renal clearance,"No significant change with exercise was observed in the renal clearance of antipyrine or in the norantipyrine formation clearance, but significant increases were found for hydroxymethylantipyrine [42 (5) vs 32 (4) microl/kg/min; P < 0.05; +31%] and 4-hydroxyantipyrine [243 (18) vs 194 (17) microl/kg/min; P < 0.05; +25%] formation clearances.",Physical exercise and improvement of liver oxidative metabolism in the elderly. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10552268/),[μl] / [kg·min],42,232917,DB01435,Antipyrine
,10552268,formation,"No significant change with exercise was observed in the renal clearance of antipyrine or in the norantipyrine formation clearance, but significant increases were found for hydroxymethylantipyrine [42 (5) vs 32 (4) microl/kg/min; P < 0.05; +31%] and 4-hydroxyantipyrine [243 (18) vs 194 (17) microl/kg/min; P < 0.05; +25%] formation clearances.",Physical exercise and improvement of liver oxidative metabolism in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10552268/),[μl] / [kg·min],32,232918,DB01435,Antipyrine
,10552268,formation,"No significant change with exercise was observed in the renal clearance of antipyrine or in the norantipyrine formation clearance, but significant increases were found for hydroxymethylantipyrine [42 (5) vs 32 (4) microl/kg/min; P < 0.05; +31%] and 4-hydroxyantipyrine [243 (18) vs 194 (17) microl/kg/min; P < 0.05; +25%] formation clearances.",Physical exercise and improvement of liver oxidative metabolism in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10552268/),[μl] / [kg·min],243,232919,DB01435,Antipyrine
,7741785,area under the serum concentration-time curves (AUC),The geometric mean of the area under the serum concentration-time curves (AUC) of 4-MAA for the test formulation was 87.61 (57.58-133.30) micrograms.h/ml and was similar to that for the reference formulation (86.83; 53.86-139.92 micrograms.h/ml).,Comparative bioavailability of two oral metamizole formulations. Influence of the acetylation phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741785/),[h·μg] / [ml],87.61,233392,DB01435,Antipyrine
,7741785,area under the serum concentration-time curves (AUC),The geometric mean of the area under the serum concentration-time curves (AUC) of 4-MAA for the test formulation was 87.61 (57.58-133.30) micrograms.h/ml and was similar to that for the reference formulation (86.83; 53.86-139.92 micrograms.h/ml).,Comparative bioavailability of two oral metamizole formulations. Influence of the acetylation phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741785/),[h·μg] / [ml],86.83,233393,DB01435,Antipyrine
,9612607,clearance,The antipyrine clearance was significantly reduced in the group of AIDS patients (43.1 +/- 7.2 ml/min compared to 56.4 +/- 8.7 ml/min).,Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9612607/),[ml] / [min],43.1,235139,DB01435,Antipyrine
,9612607,clearance,The antipyrine clearance was significantly reduced in the group of AIDS patients (43.1 +/- 7.2 ml/min compared to 56.4 +/- 8.7 ml/min).,Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9612607/),[ml] / [min],56.4,235140,DB01435,Antipyrine
,9612607,clearance,"In contrast to these results, we found a significant decrease in IFN-alpha and IFN-gamma (19.8 +/- 3.6 U/ml, 4.6 +/- 1.5 U/ml before; 7.9 +/- 2.6 U/ml, 1.9 +/- 1.3 U/ml after administration of ZDV), a decrease in antipyrine half-life, an elevation of the antipyrine clearance (49.8 +/- 15.7 ml/min, 57.3 +/- 13.7 ml/min) and an elevation of the clearances to metabolite.",Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9612607/),[ml] / [min],49.8,235141,DB01435,Antipyrine
,9612607,clearance,"In contrast to these results, we found a significant decrease in IFN-alpha and IFN-gamma (19.8 +/- 3.6 U/ml, 4.6 +/- 1.5 U/ml before; 7.9 +/- 2.6 U/ml, 1.9 +/- 1.3 U/ml after administration of ZDV), a decrease in antipyrine half-life, an elevation of the antipyrine clearance (49.8 +/- 15.7 ml/min, 57.3 +/- 13.7 ml/min) and an elevation of the clearances to metabolite.",Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9612607/),[ml] / [min],57.3,235142,DB01435,Antipyrine
,8403737,urinary recovery,"However, the summation of the urinary recovery of phenazone and the measured metabolites, expressed as percentage of the phenazone dose, was lower in the healthy elderly (37 +/- 9% vs 74 +/- 15%).",The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403737/),%,37,235590,DB01435,Antipyrine
,8403737,urinary recovery,"However, the summation of the urinary recovery of phenazone and the measured metabolites, expressed as percentage of the phenazone dose, was lower in the healthy elderly (37 +/- 9% vs 74 +/- 15%).",The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403737/),%,74,235591,DB01435,Antipyrine
,6827475,elimination T1/2,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,16.7,235671,DB01435,Antipyrine
,6827475,elimination T1/2,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,10.9,235672,DB01435,Antipyrine
,6827475,total metabolic clearance,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.46,235673,DB01435,Antipyrine
,6827475,total metabolic clearance,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.72,235674,DB01435,Antipyrine
,6827475,T1/2,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,58,235675,DB01435,Antipyrine
,6827475,T1/2,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,39,235676,DB01435,Antipyrine
,6827475,total metabolic clearance,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.42,235677,DB01435,Antipyrine
,6827475,total metabolic clearance,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.30,235678,DB01435,Antipyrine
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,16.8,235679,DB01435,Antipyrine
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,15.3,235680,DB01435,Antipyrine
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],1.03,235681,DB01435,Antipyrine
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],1.07,235682,DB01435,Antipyrine
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,2.66,235683,DB01435,Antipyrine
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,2.60,235684,DB01435,Antipyrine
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],4.8,235685,DB01435,Antipyrine
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],4.5,235686,DB01435,Antipyrine
,6827475,LD50,"In an animal model used to assess the effect of cimetidine on acetaminophen toxicity, the LD50 of acetaminophen alone in Charles River CD-1 mice was 480 mg/kg (95% confidence interval: 436-528 mg/kg).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[mg] / [kg],480,235687,DB01435,Antipyrine
,6510457,CL,"The individual CL values varied within the same study groups, but the mean +/- SD (0.026 +/- 0.004 l/h/kg) in the GS patients did not significantly differ from that in normal nonsmokers (0.025 +/- 0.006 l/h/kg) or in normal mild smokers (0.028 +/- 0.001 l/h/kg).",Antipyrine clearance in patients with Gilbert's syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510457/),[l] / [h·kg],0.026,236691,DB01435,Antipyrine
,6510457,CL,"The individual CL values varied within the same study groups, but the mean +/- SD (0.026 +/- 0.004 l/h/kg) in the GS patients did not significantly differ from that in normal nonsmokers (0.025 +/- 0.006 l/h/kg) or in normal mild smokers (0.028 +/- 0.001 l/h/kg).",Antipyrine clearance in patients with Gilbert's syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510457/),[l] / [h·kg],0.025,236692,DB01435,Antipyrine
,6510457,CL,"The individual CL values varied within the same study groups, but the mean +/- SD (0.026 +/- 0.004 l/h/kg) in the GS patients did not significantly differ from that in normal nonsmokers (0.025 +/- 0.006 l/h/kg) or in normal mild smokers (0.028 +/- 0.001 l/h/kg).",Antipyrine clearance in patients with Gilbert's syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510457/),[l] / [h·kg],0.028,236693,DB01435,Antipyrine
,6510457,CL,"When the 3 patients with GS who smoked were excluded, the mean CL of the group (0.025 l/h/kg) was again comparable to that of the normal nonsmokers and mild smokers.",Antipyrine clearance in patients with Gilbert's syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510457/),[l] / [h·kg],0.025,236694,DB01435,Antipyrine
,6510457,CL,"The mean (+/- SD) CL in normal heavy smokers (0.040 +/- 0.012 l/h/kg) was significantly greater than in normal mild smokers (p less than 0.05), in normal nonsmokers (p less than 0.001) and in patients with GS (p less than 0.001).",Antipyrine clearance in patients with Gilbert's syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510457/),[l] / [h·kg],0.040,236695,DB01435,Antipyrine
,9249209,mean residence times (MRTs),"In culture-positive patients (n = 16), mean residence times (MRTs) and steady-state volumes of distribution (V(d)ss) for i.v. chloramphenicol (mean +/- S.D.; 4.9 +/- 0.9 h and 1.9 +/- 0.8 L/kg; n = 7) were less than after i.m. chloramphenicol (12.3 +/- 7.3 h and 3.7 +/- 2.5 L/kg; n = 9; P < 0.05), with a higher peak plasma concentration after i.v. (16.2 +/- 9.1 versus 7.8 +/- 3.6 mg/L; P < 0.05); plasma clearance (Cl(p)) was similar in the two groups (368 +/- 172 and 310 +/- 224 mL/kg/min after i.v. and i.m. respectively).",Factors affecting the pharmacokinetics of parenteral chloramphenicol in enteric fever. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9249209/),h,4.9,237547,DB01435,Antipyrine
,9249209,mean residence times (MRTs),"In culture-positive patients (n = 16), mean residence times (MRTs) and steady-state volumes of distribution (V(d)ss) for i.v. chloramphenicol (mean +/- S.D.; 4.9 +/- 0.9 h and 1.9 +/- 0.8 L/kg; n = 7) were less than after i.m. chloramphenicol (12.3 +/- 7.3 h and 3.7 +/- 2.5 L/kg; n = 9; P < 0.05), with a higher peak plasma concentration after i.v. (16.2 +/- 9.1 versus 7.8 +/- 3.6 mg/L; P < 0.05); plasma clearance (Cl(p)) was similar in the two groups (368 +/- 172 and 310 +/- 224 mL/kg/min after i.v. and i.m. respectively).",Factors affecting the pharmacokinetics of parenteral chloramphenicol in enteric fever. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9249209/),h,12.3,237548,DB01435,Antipyrine
,9249209,steady-state volumes of distribution (V(d)ss),"In culture-positive patients (n = 16), mean residence times (MRTs) and steady-state volumes of distribution (V(d)ss) for i.v. chloramphenicol (mean +/- S.D.; 4.9 +/- 0.9 h and 1.9 +/- 0.8 L/kg; n = 7) were less than after i.m. chloramphenicol (12.3 +/- 7.3 h and 3.7 +/- 2.5 L/kg; n = 9; P < 0.05), with a higher peak plasma concentration after i.v. (16.2 +/- 9.1 versus 7.8 +/- 3.6 mg/L; P < 0.05); plasma clearance (Cl(p)) was similar in the two groups (368 +/- 172 and 310 +/- 224 mL/kg/min after i.v. and i.m. respectively).",Factors affecting the pharmacokinetics of parenteral chloramphenicol in enteric fever. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9249209/),[l] / [kg],1.9,237549,DB01435,Antipyrine
,9249209,steady-state volumes of distribution (V(d)ss),"In culture-positive patients (n = 16), mean residence times (MRTs) and steady-state volumes of distribution (V(d)ss) for i.v. chloramphenicol (mean +/- S.D.; 4.9 +/- 0.9 h and 1.9 +/- 0.8 L/kg; n = 7) were less than after i.m. chloramphenicol (12.3 +/- 7.3 h and 3.7 +/- 2.5 L/kg; n = 9; P < 0.05), with a higher peak plasma concentration after i.v. (16.2 +/- 9.1 versus 7.8 +/- 3.6 mg/L; P < 0.05); plasma clearance (Cl(p)) was similar in the two groups (368 +/- 172 and 310 +/- 224 mL/kg/min after i.v. and i.m. respectively).",Factors affecting the pharmacokinetics of parenteral chloramphenicol in enteric fever. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9249209/),[l] / [kg],3.7,237550,DB01435,Antipyrine
,9249209,peak plasma concentration,"In culture-positive patients (n = 16), mean residence times (MRTs) and steady-state volumes of distribution (V(d)ss) for i.v. chloramphenicol (mean +/- S.D.; 4.9 +/- 0.9 h and 1.9 +/- 0.8 L/kg; n = 7) were less than after i.m. chloramphenicol (12.3 +/- 7.3 h and 3.7 +/- 2.5 L/kg; n = 9; P < 0.05), with a higher peak plasma concentration after i.v. (16.2 +/- 9.1 versus 7.8 +/- 3.6 mg/L; P < 0.05); plasma clearance (Cl(p)) was similar in the two groups (368 +/- 172 and 310 +/- 224 mL/kg/min after i.v. and i.m. respectively).",Factors affecting the pharmacokinetics of parenteral chloramphenicol in enteric fever. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9249209/),[mg] / [l],16.2,237551,DB01435,Antipyrine
,9249209,peak plasma concentration,"In culture-positive patients (n = 16), mean residence times (MRTs) and steady-state volumes of distribution (V(d)ss) for i.v. chloramphenicol (mean +/- S.D.; 4.9 +/- 0.9 h and 1.9 +/- 0.8 L/kg; n = 7) were less than after i.m. chloramphenicol (12.3 +/- 7.3 h and 3.7 +/- 2.5 L/kg; n = 9; P < 0.05), with a higher peak plasma concentration after i.v. (16.2 +/- 9.1 versus 7.8 +/- 3.6 mg/L; P < 0.05); plasma clearance (Cl(p)) was similar in the two groups (368 +/- 172 and 310 +/- 224 mL/kg/min after i.v. and i.m. respectively).",Factors affecting the pharmacokinetics of parenteral chloramphenicol in enteric fever. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9249209/),[mg] / [l],7.8,237552,DB01435,Antipyrine
,9249209,plasma clearance (Cl(p)),"In culture-positive patients (n = 16), mean residence times (MRTs) and steady-state volumes of distribution (V(d)ss) for i.v. chloramphenicol (mean +/- S.D.; 4.9 +/- 0.9 h and 1.9 +/- 0.8 L/kg; n = 7) were less than after i.m. chloramphenicol (12.3 +/- 7.3 h and 3.7 +/- 2.5 L/kg; n = 9; P < 0.05), with a higher peak plasma concentration after i.v. (16.2 +/- 9.1 versus 7.8 +/- 3.6 mg/L; P < 0.05); plasma clearance (Cl(p)) was similar in the two groups (368 +/- 172 and 310 +/- 224 mL/kg/min after i.v. and i.m. respectively).",Factors affecting the pharmacokinetics of parenteral chloramphenicol in enteric fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9249209/),[ml] / [kg·min],368,237553,DB01435,Antipyrine
,9249209,plasma clearance (Cl(p)),"In culture-positive patients (n = 16), mean residence times (MRTs) and steady-state volumes of distribution (V(d)ss) for i.v. chloramphenicol (mean +/- S.D.; 4.9 +/- 0.9 h and 1.9 +/- 0.8 L/kg; n = 7) were less than after i.m. chloramphenicol (12.3 +/- 7.3 h and 3.7 +/- 2.5 L/kg; n = 9; P < 0.05), with a higher peak plasma concentration after i.v. (16.2 +/- 9.1 versus 7.8 +/- 3.6 mg/L; P < 0.05); plasma clearance (Cl(p)) was similar in the two groups (368 +/- 172 and 310 +/- 224 mL/kg/min after i.v. and i.m. respectively).",Factors affecting the pharmacokinetics of parenteral chloramphenicol in enteric fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9249209/),[ml] / [kg·min],310,237554,DB01435,Antipyrine
>,14570767,IC50,"In the absence of preincubation, the racemate was found to be a weak inhibitor (IC50 > 100 microM) of phenacetin O-deethylation (POD) (CYP1A2), paclitaxel 6alpha-hydroxylation (CYP2C8), diclofenac 4'-hydroxylation (CYP2C9), (S)-mephenytoin 4'-hydroxylation (CYP2C19), bufuralol 1'-hydroxylation (CYP2D6), testosterone 6beta-hydroxylation (CYP3A4), chlorzoxazone 6-hydroxylation (CYP2E1), and bupropion hydroxylation (CYP2B6).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,100,238065,DB01435,Antipyrine
,14570767,kinact,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238066,DB01435,Antipyrine
,14570767,apparent KI,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238067,DB01435,Antipyrine
,14570767,kinact/KIratio,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0003,238068,DB01435,Antipyrine
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.037,238069,DB01435,Antipyrine
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,98.2,238070,DB01435,Antipyrine
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0004,238071,DB01435,Antipyrine
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.012,238072,DB01435,Antipyrine
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,66.6,238073,DB01435,Antipyrine
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0002,238074,DB01435,Antipyrine
,1868674,clearance,"Antipyrine clearance normalized to body weight was significantly greater in children than in adults (0.91 versus 0.59 ml/min/kg; p = 0.012), but was not different when normalized to body surface area.",Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868674/),[ml] / [kg·min],0.91,238623,DB01435,Antipyrine
,1868674,clearance,"Antipyrine clearance normalized to body weight was significantly greater in children than in adults (0.91 versus 0.59 ml/min/kg; p = 0.012), but was not different when normalized to body surface area.",Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868674/),[ml] / [kg·min],0.59,238624,DB01435,Antipyrine
,1868674,CL,"In contrast, lorazepam total clearance (CL) and unbound clearance (CLu) normalized to body weight were not significantly different between children and adults but were smaller in children when normalized to body surface area (CL = 31.9 versus 40.6 ml/min/m2, p = 0.036; CLu = 352 versus 485 ml/min/m2, p = 0.010).",Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868674/),[ml] / [m2·min],31.9,238625,DB01435,Antipyrine
,1868674,CL,"In contrast, lorazepam total clearance (CL) and unbound clearance (CLu) normalized to body weight were not significantly different between children and adults but were smaller in children when normalized to body surface area (CL = 31.9 versus 40.6 ml/min/m2, p = 0.036; CLu = 352 versus 485 ml/min/m2, p = 0.010).",Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868674/),[ml] / [m2·min],40.6,238626,DB01435,Antipyrine
,1868674,CLu,"In contrast, lorazepam total clearance (CL) and unbound clearance (CLu) normalized to body weight were not significantly different between children and adults but were smaller in children when normalized to body surface area (CL = 31.9 versus 40.6 ml/min/m2, p = 0.036; CLu = 352 versus 485 ml/min/m2, p = 0.010).",Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868674/),[ml] / [m2·min],352,238627,DB01435,Antipyrine
,1868674,CLu,"In contrast, lorazepam total clearance (CL) and unbound clearance (CLu) normalized to body weight were not significantly different between children and adults but were smaller in children when normalized to body surface area (CL = 31.9 versus 40.6 ml/min/m2, p = 0.036; CLu = 352 versus 485 ml/min/m2, p = 0.010).",Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868674/),[ml] / [m2·min],485,238628,DB01435,Antipyrine
,1868674,fraction unbound,"The mean lorazepam fraction unbound in children was 0.087, which was not different from adult volunteers (0.084).",Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868674/),,0.087,238629,DB01435,Antipyrine
,1868674,fraction unbound,"The mean lorazepam fraction unbound in children was 0.087, which was not different from adult volunteers (0.084).",Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868674/),,0.084,238630,DB01435,Antipyrine
,6153210,plasma clearance,Sufficient lindane was absorbed to increase the plasma clearance of antipyrine from 0.027 +/- 0.009 to 0.037 +/- 0.011 1/kg/hr (p less than 0.05).,Topical application of lindane cream (Kwell) and antipyrine metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6153210/),[1] / [h·kg],0.027,239740,DB01435,Antipyrine
,6153210,plasma clearance,Sufficient lindane was absorbed to increase the plasma clearance of antipyrine from 0.027 +/- 0.009 to 0.037 +/- 0.011 1/kg/hr (p less than 0.05).,Topical application of lindane cream (Kwell) and antipyrine metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6153210/),[1] / [h·kg],0.037,239741,DB01435,Antipyrine
,8059538,plasma clearance,"2. When both drugs were given at a dose of 5 mg/kg, AP plasma clearance was reduced from 2.22 to 0.96 lh-1 kg-1.",Dose-dependent pharmacokinetic interaction between antipyrine and paracetamol in vivo and in vitro when administered as a cocktail in pig. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059538/),1/[kg·lh],2.22,240144,DB01435,Antipyrine
,8059538,plasma clearance,"2. When both drugs were given at a dose of 5 mg/kg, AP plasma clearance was reduced from 2.22 to 0.96 lh-1 kg-1.",Dose-dependent pharmacokinetic interaction between antipyrine and paracetamol in vivo and in vitro when administered as a cocktail in pig. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059538/),1/[kg·lh],0.96,240145,DB01435,Antipyrine
,8059538,apparent Km,The apparent Km value for PA glucuronidation was 40 mM with a Vmax = 54 nmol min-1 mg protein-1.,Dose-dependent pharmacokinetic interaction between antipyrine and paracetamol in vivo and in vitro when administered as a cocktail in pig. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059538/),mM,40,240146,DB01435,Antipyrine
,8059538,Vmax,The apparent Km value for PA glucuronidation was 40 mM with a Vmax = 54 nmol min-1 mg protein-1.,Dose-dependent pharmacokinetic interaction between antipyrine and paracetamol in vivo and in vitro when administered as a cocktail in pig. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059538/),[-1·mg·nM] / [min],54,240147,DB01435,Antipyrine
,8059538,Ki app,"It appeared that 4-OHA was a competitive inhibitor with a Ki app = 0.07 microM, whereas AP had no effect.",Dose-dependent pharmacokinetic interaction between antipyrine and paracetamol in vivo and in vitro when administered as a cocktail in pig. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8059538/),μM,0.07,240148,DB01435,Antipyrine
,7735209,resolution coefficient,The resolution coefficient between IPA and IPA-3-C2H3-4-(C2H3)2 (IPA-2H-7) was 1.46 at 200 degrees C for column temperature.,Isotopic fractionation of isopropylantipyrine and its deuterated analogues by capillary gas chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735209/),,1.46,240492,DB01435,Antipyrine
,19716867,perfusion pressures,"Similar perfusion pressures (17.6+/-6.71 vs 17.7+/-8.87 cm H(2)O), lung wet/dry ratio (6.14+/-1.16 vs 5.16+/-0.87), physiological spaces, and permeability-surface area products were found for the two perfusates.",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),cm·h(2,17.6,242633,DB01435,Antipyrine
,19716867,perfusion pressures,"Similar perfusion pressures (17.6+/-6.71 vs 17.7+/-8.87 cm H(2)O), lung wet/dry ratio (6.14+/-1.16 vs 5.16+/-0.87), physiological spaces, and permeability-surface area products were found for the two perfusates.",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),cm·h(2,17.7,242634,DB01435,Antipyrine
,19716867,wet/dry ratio,"Similar perfusion pressures (17.6+/-6.71 vs 17.7+/-8.87 cm H(2)O), lung wet/dry ratio (6.14+/-1.16 vs 5.16+/-0.87), physiological spaces, and permeability-surface area products were found for the two perfusates.",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),,6.14,242635,DB01435,Antipyrine
,19716867,wet/dry ratio,"Similar perfusion pressures (17.6+/-6.71 vs 17.7+/-8.87 cm H(2)O), lung wet/dry ratio (6.14+/-1.16 vs 5.16+/-0.87), physiological spaces, and permeability-surface area products were found for the two perfusates.",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),,5.16,242636,DB01435,Antipyrine
,19716867,recovery,"However, the recovery of propranolol using perfusate A (49.3+/-10.1%) was significantly higher than that using perfusate B (38.9+/-9.91%).",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),%,49.3,242637,DB01435,Antipyrine
,19716867,recovery,"However, the recovery of propranolol using perfusate A (49.3+/-10.1%) was significantly higher than that using perfusate B (38.9+/-9.91%).",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),%,38.9,242638,DB01435,Antipyrine
,9421115,total run time,"Chromatographic conditions comprise a C18 column, a mobile phase with 30% methanol and 70% 0.25N sodium acetate buffer (pH 5.0), a total run time of 10 minutes, and ultraviolet absorbance detection at 254 nm.",Determination of antipyrine and metabolites in plasma of a patient with mild renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421115/),min,10,242688,DB01435,Antipyrine
,9421115,CL(CR),The assay shows to be suitable for pharmacokinetics and drug metabolism studies after administration of a single oral dose of 500 mg of antipyrine to a patient with hypertension and chronic renal failure (CL(CR) = 34.17 ml/min(-1); 1.73 m(-2)).,Determination of antipyrine and metabolites in plasma of a patient with mild renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421115/),[ml] / [min],34.17,242689,DB01435,Antipyrine
,9421115,CL(CR),The assay shows to be suitable for pharmacokinetics and drug metabolism studies after administration of a single oral dose of 500 mg of antipyrine to a patient with hypertension and chronic renal failure (CL(CR) = 34.17 ml/min(-1); 1.73 m(-2)).,Determination of antipyrine and metabolites in plasma of a patient with mild renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421115/),1/[(m)^2],1.73,242690,DB01435,Antipyrine
,3383988,half-life,Sulphaphenazole produced a significant increase in the half-life of tolbutamide (7.10 to 21.50 h) and a corresponding decrease in its clearance (0.260 to 0.084 ml.min-1.kg-1).,"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),h,7.10 to 21.50,243330,DB01435,Antipyrine
,3383988,clearance,Sulphaphenazole produced a significant increase in the half-life of tolbutamide (7.10 to 21.50 h) and a corresponding decrease in its clearance (0.260 to 0.084 ml.min-1.kg-1).,"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),[ml] / [kg·min],0.260 to 0.084,243331,DB01435,Antipyrine
,3383988,half lives,"However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively).","Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),h,6.21 to 9.04,243332,DB01435,Antipyrine
,3383988,half lives,"However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively).","Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),h,14.2 to 19.2,243333,DB01435,Antipyrine
,3383988,clearance,"However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively).","Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),[ml] / [kg·min],0.226 to 0.148,243334,DB01435,Antipyrine
,3383988,clearance,"However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively).","Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),[ml] / [kg·min],0.50 to 0.31,243335,DB01435,Antipyrine
,3383988,half-life,A single dose of primaquine had no demonstrable effect on tolbutamide disposition whereas the half-life of antipyrine was increased (12.1 to 15.0 h) and its clearance decreased (0.63 to 0.38 ml.min-1.kg-1).,"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),h,12.1 to 15.0,243336,DB01435,Antipyrine
,3383988,clearance,A single dose of primaquine had no demonstrable effect on tolbutamide disposition whereas the half-life of antipyrine was increased (12.1 to 15.0 h) and its clearance decreased (0.63 to 0.38 ml.min-1.kg-1).,"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),[ml] / [kg·min],0.63 to 0.38,243337,DB01435,Antipyrine
,7768256,V,"Antipyrine apparent volume of distribution (V) and elimination half-life (t1/2) were significantly greater in the obese than in the lean group (V 49.9 vs 34.3 l respectively; t1/2 15.5 vs 12.0 h respectively), but its clearance rate (CL0) values were similar.",Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768256/),l,49.9,243692,DB01435,Antipyrine
,7768256,V,"Antipyrine apparent volume of distribution (V) and elimination half-life (t1/2) were significantly greater in the obese than in the lean group (V 49.9 vs 34.3 l respectively; t1/2 15.5 vs 12.0 h respectively), but its clearance rate (CL0) values were similar.",Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768256/),l,34.3,243693,DB01435,Antipyrine
,7768256,t1/2,"Antipyrine apparent volume of distribution (V) and elimination half-life (t1/2) were significantly greater in the obese than in the lean group (V 49.9 vs 34.3 l respectively; t1/2 15.5 vs 12.0 h respectively), but its clearance rate (CL0) values were similar.",Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768256/),h,15.5,243694,DB01435,Antipyrine
,7768256,t1/2,"Antipyrine apparent volume of distribution (V) and elimination half-life (t1/2) were significantly greater in the obese than in the lean group (V 49.9 vs 34.3 l respectively; t1/2 15.5 vs 12.0 h respectively), but its clearance rate (CL0) values were similar.",Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768256/),h,12.0,243695,DB01435,Antipyrine
,7768256,V,V corrected for total body weight was significantly reduced in group A than in group B (0.45 vs 0.55 l.kg-1 respectively).,Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768256/),[l] / [kg],0.45,243696,DB01435,Antipyrine
,7768256,V,V corrected for total body weight was significantly reduced in group A than in group B (0.45 vs 0.55 l.kg-1 respectively).,Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768256/),[l] / [kg],0.55,243697,DB01435,Antipyrine
,7768256,V,"In group C, weight reduction was associated with a significant decrease in antipyrine V (from 51.8 to 47.5 l) and t1/2 (from 15.1 to 12.7 h), and a non-significant increase in antipyrine CL0.",Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768256/),l,51.8 to 47.5,243698,DB01435,Antipyrine
,7768256,t1/2,"In group C, weight reduction was associated with a significant decrease in antipyrine V (from 51.8 to 47.5 l) and t1/2 (from 15.1 to 12.7 h), and a non-significant increase in antipyrine CL0.",Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768256/),h,15.1 to 12.7,243699,DB01435,Antipyrine
,2183884,half-life,Antipyrine half-life of 10.04 +/- 1.43 h (mean +/- SD) after a week intake of nifedipine (20 mg twice daily) was not significantly different from the control value of 10.64 +/- 2.15 h; nor was that of 10.02 +/- 1.49 h after 2 weeks pretreatment with the calcium channel blocker in eight healthy volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,10.04,244288,DB01435,Antipyrine
,2183884,half-life,Antipyrine half-life of 10.04 +/- 1.43 h (mean +/- SD) after a week intake of nifedipine (20 mg twice daily) was not significantly different from the control value of 10.64 +/- 2.15 h; nor was that of 10.02 +/- 1.49 h after 2 weeks pretreatment with the calcium channel blocker in eight healthy volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,10.64,244289,DB01435,Antipyrine
,2183884,half-life,Antipyrine half-life of 10.04 +/- 1.43 h (mean +/- SD) after a week intake of nifedipine (20 mg twice daily) was not significantly different from the control value of 10.64 +/- 2.15 h; nor was that of 10.02 +/- 1.49 h after 2 weeks pretreatment with the calcium channel blocker in eight healthy volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,10.02,244290,DB01435,Antipyrine
,2183884,clearance,"Control antipyrine clearance (ml min-1) of 44.40 +/- 10.58 was not significantly different from that of 45.66 +/- 9.34 and 46.87 +/- 9.63 after nifedipine pretreatment of 1 and 2 weeks, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],44.40,244291,DB01435,Antipyrine
,2183884,clearance,"Control antipyrine clearance (ml min-1) of 44.40 +/- 10.58 was not significantly different from that of 45.66 +/- 9.34 and 46.87 +/- 9.63 after nifedipine pretreatment of 1 and 2 weeks, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],45.66,244292,DB01435,Antipyrine
,2183884,clearance,"Control antipyrine clearance (ml min-1) of 44.40 +/- 10.58 was not significantly different from that of 45.66 +/- 9.34 and 46.87 +/- 9.63 after nifedipine pretreatment of 1 and 2 weeks, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],46.87,244293,DB01435,Antipyrine
,2183884,volume of distribution,"Similarly volume of distribution was unaltered: 0.601 +/- 0.074, 0.591 +/- 0.078 and 0.602 +/- 0.051 l kg-1, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.601,244294,DB01435,Antipyrine
,2183884,volume of distribution,"Similarly volume of distribution was unaltered: 0.601 +/- 0.074, 0.591 +/- 0.078 and 0.602 +/- 0.051 l kg-1, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.591,244295,DB01435,Antipyrine
,2183884,volume of distribution,"Similarly volume of distribution was unaltered: 0.601 +/- 0.074, 0.591 +/- 0.078 and 0.602 +/- 0.051 l kg-1, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.602,244296,DB01435,Antipyrine
,2183884,half-life,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,7.32,244297,DB01435,Antipyrine
,2183884,half-life,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,7.50,244298,DB01435,Antipyrine
,2183884,clearance,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],42.10,244299,DB01435,Antipyrine
,2183884,clearance,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],43.77,244300,DB01435,Antipyrine
,2183884,volume of distribution,However the change in volume of distribution: 0.451 +/- 0.053 l kg-1 (control) to 0.483 +/- 0.062 l kg-1 was significant (p less than 0.025).,Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.451,244301,DB01435,Antipyrine
,2183884,volume of distribution,However the change in volume of distribution: 0.451 +/- 0.053 l kg-1 (control) to 0.483 +/- 0.062 l kg-1 was significant (p less than 0.025).,Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.483,244302,DB01435,Antipyrine
,6508979,elimination half-life,After rifampicin treatment the elimination half-life of antipyrine had decreased in all patients from 12.9 +/- 5.0 to 8.8 +/- 2.0 h (P less than 0.05).,Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508979/),h,12.9,245332,DB01435,Antipyrine
,6508979,elimination half-life,After rifampicin treatment the elimination half-life of antipyrine had decreased in all patients from 12.9 +/- 5.0 to 8.8 +/- 2.0 h (P less than 0.05).,Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508979/),h,8.8,245333,DB01435,Antipyrine
,6508979,clearance,"Antipyrine clearance had increased from 2.2 +/- 0.9 to 2.9 +/- 0.7 l/h (P less than 0.05), while no change in apparent volume of distribution was observed.",Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508979/),[l] / [h],2.2,245334,DB01435,Antipyrine
,6508979,clearance,"Antipyrine clearance had increased from 2.2 +/- 0.9 to 2.9 +/- 0.7 l/h (P less than 0.05), while no change in apparent volume of distribution was observed.",Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508979/),[l] / [h],2.9,245335,DB01435,Antipyrine
,6508979,rate of formation,The increase in antipyrine clearance was primarily due to a selective increase in the rate of formation of norantipyrine by 80% from 6.9 +/- 3.4 to 12.4 +/- 3.4 ml/min.,Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508979/),[ml] / [min],6.9,245336,DB01435,Antipyrine
,6508979,rate of formation,The increase in antipyrine clearance was primarily due to a selective increase in the rate of formation of norantipyrine by 80% from 6.9 +/- 3.4 to 12.4 +/- 3.4 ml/min.,Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508979/),[ml] / [min],12.4,245337,DB01435,Antipyrine
,891094,plasma half-life,"Antipyrine plasma half-life increased during THC in 5 of 6 subjects--mean, 7.9 hr +/- 3.3 (SD) to 9.6 +/- 3.8.","Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),h,7.9,246096,DB01435,Antipyrine
,891094,plasma half-life,"Antipyrine plasma half-life increased during THC in 5 of 6 subjects--mean, 7.9 hr +/- 3.3 (SD) to 9.6 +/- 3.8.","Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),h,9.6,246097,DB01435,Antipyrine
,891094,half-life,"Pentobarbital half-life increased in 7 of 8 subjects--mean, 16.9 hr +/- 2.0 to 20.8 +/- 4.2.","Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),h,16.9,246098,DB01435,Antipyrine
,891094,half-life,"Pentobarbital half-life increased in 7 of 8 subjects--mean, 16.9 hr +/- 2.0 to 20.8 +/- 4.2.","Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),h,20.8,246099,DB01435,Antipyrine
,891094,Blood ethanol disappearance rate,Blood ethanol disappearance rate decreased in 7 of 8 subjects from a mean of 0.26 mg/100 ml/min +/- 0.05 to 0.23 +/- 0.07.,"Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),[mg] / [100·min·ml],0.26,246100,DB01435,Antipyrine
,891094,Blood ethanol disappearance rate,Blood ethanol disappearance rate decreased in 7 of 8 subjects from a mean of 0.26 mg/100 ml/min +/- 0.05 to 0.23 +/- 0.07.,"Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),[mg] / [100·min·ml],0.23,246101,DB01435,Antipyrine
,10584978,total,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],43.0,247040,DB01435,Antipyrine
,10584978,clearance,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],43.0,247041,DB01435,Antipyrine
,10584978,clearance,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],51.0,247042,DB01435,Antipyrine
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],7.11,247043,DB01435,Antipyrine
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],8.60,247044,DB01435,Antipyrine
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],11.5,247045,DB01435,Antipyrine
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],14.0,247046,DB01435,Antipyrine
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],4.05,247047,DB01435,Antipyrine
,10584978,clearances,"However, in contrast an activation of the CYP450 enzyme system was observed in group B after 28 days of fusidic acid therapy with an increase of total antipyrine clearance (43.0 +/- 7.62 ml/min to 51.0 +/- 9.03 ml/min) as well as clearances to all metabolites (NORA 7.11 +/- 1.75 to 8.60 +/-2.10 ml/min, OHA 11.5 +/- 2.89 to 14.0 +/- 3.97 ml/min, HMA 4.05 +/- 0.99 to 4.94 +/- 1.27 ml/min).",Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),[ml] / [min],4.94,247048,DB01435,Antipyrine
,10584978,half-life,Antipyrine half-life was significantly reduced (12.3 +/- 2.8 h to 9.4 +/- 2.2 h) and some patients developed clinical signs of L-methadone underdosage.,Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),h,12.3,247049,DB01435,Antipyrine
,10584978,half-life,Antipyrine half-life was significantly reduced (12.3 +/- 2.8 h to 9.4 +/- 2.2 h) and some patients developed clinical signs of L-methadone underdosage.,Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584978/),h,9.4,247050,DB01435,Antipyrine
,22168075,T1/2,"It was shown that of 36 patients examined in the 28-patients with ALD (group 2) there was a significant decrease in activity of liver enzymes according to the test with antipyrine (T1/2 = 28.7 +/- 3.4, CL = 17,9 +/- 5.2; p < 0,01 vs normal), whereas in 8 patients (group 1) was noted the typical for alcohol inductive influence on the activity of liver monooxygenases (T1/2 = 7.8 +/- 1.5, CL = 39.1 +/- 6.8; p < 0,05 vs normal).",[Dynamics of antipirin test at patients with alcoholic liver disease on the background of metadoksin drug receiving]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168075/),,28.7,247905,DB01435,Antipyrine
,22168075,CL,"It was shown that of 36 patients examined in the 28-patients with ALD (group 2) there was a significant decrease in activity of liver enzymes according to the test with antipyrine (T1/2 = 28.7 +/- 3.4, CL = 17,9 +/- 5.2; p < 0,01 vs normal), whereas in 8 patients (group 1) was noted the typical for alcohol inductive influence on the activity of liver monooxygenases (T1/2 = 7.8 +/- 1.5, CL = 39.1 +/- 6.8; p < 0,05 vs normal).",[Dynamics of antipirin test at patients with alcoholic liver disease on the background of metadoksin drug receiving]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168075/),,"17,9",247906,DB01435,Antipyrine
,22168075,T1/2,"It was shown that of 36 patients examined in the 28-patients with ALD (group 2) there was a significant decrease in activity of liver enzymes according to the test with antipyrine (T1/2 = 28.7 +/- 3.4, CL = 17,9 +/- 5.2; p < 0,01 vs normal), whereas in 8 patients (group 1) was noted the typical for alcohol inductive influence on the activity of liver monooxygenases (T1/2 = 7.8 +/- 1.5, CL = 39.1 +/- 6.8; p < 0,05 vs normal).",[Dynamics of antipirin test at patients with alcoholic liver disease on the background of metadoksin drug receiving]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168075/),,7.8,247907,DB01435,Antipyrine
,22168075,CL,"It was shown that of 36 patients examined in the 28-patients with ALD (group 2) there was a significant decrease in activity of liver enzymes according to the test with antipyrine (T1/2 = 28.7 +/- 3.4, CL = 17,9 +/- 5.2; p < 0,01 vs normal), whereas in 8 patients (group 1) was noted the typical for alcohol inductive influence on the activity of liver monooxygenases (T1/2 = 7.8 +/- 1.5, CL = 39.1 +/- 6.8; p < 0,05 vs normal).",[Dynamics of antipirin test at patients with alcoholic liver disease on the background of metadoksin drug receiving]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168075/),,39.1,247908,DB01435,Antipyrine
,42427,half-life,"The elimination of diazepam was significantly altered having a half-life of 37 h before and 18 h afterwards combined with a significant increase in total body clearance after the induction period, although the volume of distribution remained unaltered.",The effect of enzyme induction on diazepam metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42427/),h,37,249060,DB01435,Antipyrine
,42427,half-life,"The elimination of diazepam was significantly altered having a half-life of 37 h before and 18 h afterwards combined with a significant increase in total body clearance after the induction period, although the volume of distribution remained unaltered.",The effect of enzyme induction on diazepam metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42427/),h,18,249061,DB01435,Antipyrine
,42427,half-life,"The formation of the main metabolite N-desmethyldiazepam was not changed, but its elimination was increased having a half-life of 139 or 58 h respectively.",The effect of enzyme induction on diazepam metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42427/),h,139,249062,DB01435,Antipyrine
,42427,half-life,"The formation of the main metabolite N-desmethyldiazepam was not changed, but its elimination was increased having a half-life of 139 or 58 h respectively.",The effect of enzyme induction on diazepam metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42427/),h,58,249063,DB01435,Antipyrine
,9522945,plasma clearance,"Median plasma clearance of AP in horses was 6.2 ml/min/kg, of which < 2% could be attributed to renal clearance.",Antipyrine pharmacokinetics and urinary excretion in female horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9522945/),[ml] / [kg·min],6.2,249332,DB01435,Antipyrine
,8165194,steady-state CSF/plasma concentration ratios,"When ZDV and ddI were administered alone, the steady-state CSF/plasma concentration ratios were significantly different from unity (ZDV, 0.20 +/- 0.08; ddI, 0.09 +/- 0.04) and were independent of the plasma concentration (P > 0.05).","Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165194/),,unity,249699,DB01435,Antipyrine
,8165194,steady-state CSF/plasma concentration ratios,"When ZDV and ddI were administered alone, the steady-state CSF/plasma concentration ratios were significantly different from unity (ZDV, 0.20 +/- 0.08; ddI, 0.09 +/- 0.04) and were independent of the plasma concentration (P > 0.05).","Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165194/),,0.20,249700,DB01435,Antipyrine
,8165194,steady-state CSF/plasma concentration ratios,"When ZDV and ddI were administered alone, the steady-state CSF/plasma concentration ratios were significantly different from unity (ZDV, 0.20 +/- 0.08; ddI, 0.09 +/- 0.04) and were independent of the plasma concentration (P > 0.05).","Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165194/),,0.09,249701,DB01435,Antipyrine
,8165194,CSF/plasma concentration ratio,"In contrast, the CSF/plasma concentration ratio of antipyrine (0.82 +/- 0.19) was close but significantly smaller than unity (P > 0.05).","Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165194/),,0.82,249702,DB01435,Antipyrine
,3653225,"area under the plasma concentration-time curve, AUC (0-24),","After chronic oral dosing, the area under the plasma concentration-time curve, AUC (0-24), was 94.5 ng ml-1 h and the plasma clearance CL was 1380.6 ml/min in the healthy controls; in patients with cirrhosis the AUC (0-24) h was significantly greater at 309.4 ng ml-1 h and CL had fallen to 686.6 ml/min.",Bioavailability and elimination of nitrendipine in liver disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653225/),[h·ng] / [ml],94.5,249828,DB01435,Antipyrine
,3653225,plasma clearance CL,"After chronic oral dosing, the area under the plasma concentration-time curve, AUC (0-24), was 94.5 ng ml-1 h and the plasma clearance CL was 1380.6 ml/min in the healthy controls; in patients with cirrhosis the AUC (0-24) h was significantly greater at 309.4 ng ml-1 h and CL had fallen to 686.6 ml/min.",Bioavailability and elimination of nitrendipine in liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653225/),[ml] / [min],1380.6,249829,DB01435,Antipyrine
,3653225,AUC (0-24) h,"After chronic oral dosing, the area under the plasma concentration-time curve, AUC (0-24), was 94.5 ng ml-1 h and the plasma clearance CL was 1380.6 ml/min in the healthy controls; in patients with cirrhosis the AUC (0-24) h was significantly greater at 309.4 ng ml-1 h and CL had fallen to 686.6 ml/min.",Bioavailability and elimination of nitrendipine in liver disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653225/),[h·ng] / [ml],309.4,249830,DB01435,Antipyrine
,3653225,CL,"After chronic oral dosing, the area under the plasma concentration-time curve, AUC (0-24), was 94.5 ng ml-1 h and the plasma clearance CL was 1380.6 ml/min in the healthy controls; in patients with cirrhosis the AUC (0-24) h was significantly greater at 309.4 ng ml-1 h and CL had fallen to 686.6 ml/min.",Bioavailability and elimination of nitrendipine in liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653225/),[ml] / [min],686.6,249831,DB01435,Antipyrine
,8018459,t1/2,"Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were significantly different in cirrhotic patients compared with the healthy subjects (mean +/- s.d.-healthy controls: t1/2 = 13.7 +/- 3.0 h, CL = 30.0 +/- 8.6 ml h-1 kg-1, AUC = 549 +/- 139 mg l-1 h; cirrhotic patients: t1/2 = 32.4 +/- 1.7 h, CL = 12.3 +/- 2.1 ml h-1 kg-1, AUC = 1061 +/- 218 mg l-1 h; P < 0.008).","Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018459/),h,13.7,250705,DB01435,Antipyrine
,8018459,CL,"Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were significantly different in cirrhotic patients compared with the healthy subjects (mean +/- s.d.-healthy controls: t1/2 = 13.7 +/- 3.0 h, CL = 30.0 +/- 8.6 ml h-1 kg-1, AUC = 549 +/- 139 mg l-1 h; cirrhotic patients: t1/2 = 32.4 +/- 1.7 h, CL = 12.3 +/- 2.1 ml h-1 kg-1, AUC = 1061 +/- 218 mg l-1 h; P < 0.008).","Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018459/),[ml] / [h·kg],30.0,250706,DB01435,Antipyrine
,8018459,AUC,"Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were significantly different in cirrhotic patients compared with the healthy subjects (mean +/- s.d.-healthy controls: t1/2 = 13.7 +/- 3.0 h, CL = 30.0 +/- 8.6 ml h-1 kg-1, AUC = 549 +/- 139 mg l-1 h; cirrhotic patients: t1/2 = 32.4 +/- 1.7 h, CL = 12.3 +/- 2.1 ml h-1 kg-1, AUC = 1061 +/- 218 mg l-1 h; P < 0.008).","Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018459/),[h·mg] / [l],549,250707,DB01435,Antipyrine
,8018459,t1/2,"Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were significantly different in cirrhotic patients compared with the healthy subjects (mean +/- s.d.-healthy controls: t1/2 = 13.7 +/- 3.0 h, CL = 30.0 +/- 8.6 ml h-1 kg-1, AUC = 549 +/- 139 mg l-1 h; cirrhotic patients: t1/2 = 32.4 +/- 1.7 h, CL = 12.3 +/- 2.1 ml h-1 kg-1, AUC = 1061 +/- 218 mg l-1 h; P < 0.008).","Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018459/),h,32.4,250708,DB01435,Antipyrine
,8018459,CL,"Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were significantly different in cirrhotic patients compared with the healthy subjects (mean +/- s.d.-healthy controls: t1/2 = 13.7 +/- 3.0 h, CL = 30.0 +/- 8.6 ml h-1 kg-1, AUC = 549 +/- 139 mg l-1 h; cirrhotic patients: t1/2 = 32.4 +/- 1.7 h, CL = 12.3 +/- 2.1 ml h-1 kg-1, AUC = 1061 +/- 218 mg l-1 h; P < 0.008).","Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018459/),[ml] / [h·kg],12.3,250709,DB01435,Antipyrine
,8018459,AUC,"Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were significantly different in cirrhotic patients compared with the healthy subjects (mean +/- s.d.-healthy controls: t1/2 = 13.7 +/- 3.0 h, CL = 30.0 +/- 8.6 ml h-1 kg-1, AUC = 549 +/- 139 mg l-1 h; cirrhotic patients: t1/2 = 32.4 +/- 1.7 h, CL = 12.3 +/- 2.1 ml h-1 kg-1, AUC = 1061 +/- 218 mg l-1 h; P < 0.008).","Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018459/),[h·mg] / [l],1061,250710,DB01435,Antipyrine
,8018459,t1/2,"Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were not significantly different in hepatitis patients compared with the healthy subjects (hepatitis patients: t1/2 = 14.3 +/- 3.7 h, CL = 29.3 +/- 8.5 ml h-1 kg-1, AUC = 498 +/- 142 mg l-1 h).","Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018459/),h,14.3,250711,DB01435,Antipyrine
,8018459,CL,"Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were not significantly different in hepatitis patients compared with the healthy subjects (hepatitis patients: t1/2 = 14.3 +/- 3.7 h, CL = 29.3 +/- 8.5 ml h-1 kg-1, AUC = 498 +/- 142 mg l-1 h).","Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018459/),[ml] / [h·kg],29.3,250712,DB01435,Antipyrine
,8018459,AUC,"Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were not significantly different in hepatitis patients compared with the healthy subjects (hepatitis patients: t1/2 = 14.3 +/- 3.7 h, CL = 29.3 +/- 8.5 ml h-1 kg-1, AUC = 498 +/- 142 mg l-1 h).","Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018459/),[h·mg] / [l],498,250713,DB01435,Antipyrine
,8793599,absolute bioavailability,Its absolute bioavailability is 77% and does not change upon multiple dosing.,Pharmacokinetics of pantoprazole in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),%,77,251776,DB01435,Antipyrine
,8793599,Cmax,"Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h.",Pharmacokinetics of pantoprazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),[mg] / [l],2.5,251777,DB01435,Antipyrine
,8793599,tmax,"Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h.",Pharmacokinetics of pantoprazole in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),h,2-3,251778,DB01435,Antipyrine
,8793599,AUC(0,"The AUC(0,inf.) is approximately 5 mgxh/l.",Pharmacokinetics of pantoprazole in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),[h·mg] / [l],5,251779,DB01435,Antipyrine
,8793599,total serum clearance,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination half-life of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),[l] / [h·kg],0.1,251780,DB01435,Antipyrine
,8793599,serum elimination half-life,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination half-life of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),h,1.1,251781,DB01435,Antipyrine
,8793599,apparent volume of distribution,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination half-life of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),[l] / [kg],0.15,251782,DB01435,Antipyrine
,8793599,half-life,"In patients with severe liver cirrhosis, the decreased rate of metabolism results in a half-life of 7-9 h.",Pharmacokinetics of pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),h,7-9,251783,DB01435,Antipyrine
,8793599,half-life,"The clearance of pantoprazole is only slightly affected by age, its half-life being approximately 1.25 h in the elderly.",Pharmacokinetics of pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),h,1.25,251784,DB01435,Antipyrine
,30056192,absolute bioavailability,"While the aqueous solubility of edaravone widely varied depending on the vehicle used, the oral bioavailability of the drug was not low when it was adequately solubilized, as evidenced by the fact that the oral exposure was high (in terms of the absolute bioavailability of 50-90%) at all dose ranges (i.e., 0.5-27 mg/kg) under solubilized conditions in rats.",Identification of the primary determining factor(s) governing the oral absorption of edaravone in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30056192/),%,50-90,252765,DB01435,Antipyrine
,30056192,clearance,"The sum of the in vitro clearance values for edaravone, 12.7 mL/(min × kg), obtained from metabolic stability studies with tissue-homogenates from the rat liver, kidney, intestine, and with the rat plasma, was found to be virtually identical to the systemic clearance of the drug in rats.",Identification of the primary determining factor(s) governing the oral absorption of edaravone in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30056192/),[ml] / [kg·min],12.7,252766,DB01435,Antipyrine
,30056192,hepatic extraction ratio,"It was noted that the liver represented over 83.9% of the total elimination with a hepatic extraction ratio of approximately 0.137, indicative of the minor role of hepatic first pass metabolism in the systemic absorption of edaravone after its oral administration.",Identification of the primary determining factor(s) governing the oral absorption of edaravone in rats. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30056192/),,0.137,252767,DB01435,Antipyrine
over,30056192,Papp,"In studies with Ussing chamber with rat intestinal segments and Madin-Darby canine kidney (MDCKII) cells, edaravone was found to be highly permeable (i.e., Papp over 10 × 10-6 cm/s), and appeared to be a substrate for rat P-glycoprotein (P-gp; estimated Km of 421 μM).",Identification of the primary determining factor(s) governing the oral absorption of edaravone in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30056192/),[cm] / [s],10 × 10-6,252768,DB01435,Antipyrine
,30056192,Km,"In studies with Ussing chamber with rat intestinal segments and Madin-Darby canine kidney (MDCKII) cells, edaravone was found to be highly permeable (i.e., Papp over 10 × 10-6 cm/s), and appeared to be a substrate for rat P-glycoprotein (P-gp; estimated Km of 421 μM).",Identification of the primary determining factor(s) governing the oral absorption of edaravone in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30056192/),μM,421,252769,DB01435,Antipyrine
,22010358,entrapped efficiency,"The entrapped efficiency of rivastigmine liposome was (33.41 +/- 6.58) %, with the mean diameter of 154-236 nm and zeta potential of (-10.47 +/- 2.41) mV.",[Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010358/),%,33.41,254059,DB01435,Antipyrine
,22010358,zeta potential,"The entrapped efficiency of rivastigmine liposome was (33.41 +/- 6.58) %, with the mean diameter of 154-236 nm and zeta potential of (-10.47 +/- 2.41) mV.",[Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010358/),mv,-,254060,DB01435,Antipyrine
,22010358,zeta potential,"The entrapped efficiency of rivastigmine liposome was (33.41 +/- 6.58) %, with the mean diameter of 154-236 nm and zeta potential of (-10.47 +/- 2.41) mV.",[Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010358/),mv,10.47,254061,DB01435,Antipyrine
,22010358,C(max),"The pharmacokinetic studies indicated that the C(max), T(max) and AUC(0-infinity), of rivastigmine liposome were (1.50 +/- 0.15) mg x L(-1), 15 min and (89.06 +/- 8.30) mg x L(-') x min, respectively.",[Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010358/),[mg] / [l],1.50,254062,DB01435,Antipyrine
,22010358,T(max),"The pharmacokinetic studies indicated that the C(max), T(max) and AUC(0-infinity), of rivastigmine liposome were (1.50 +/- 0.15) mg x L(-1), 15 min and (89.06 +/- 8.30) mg x L(-') x min, respectively.",[Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010358/),min,15,254063,DB01435,Antipyrine
,22010358,AUC(0-infinity),"The pharmacokinetic studies indicated that the C(max), T(max) and AUC(0-infinity), of rivastigmine liposome were (1.50 +/- 0.15) mg x L(-1), 15 min and (89.06 +/- 8.30) mg x L(-') x min, respectively.",[Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010358/),l(-')·mg·min,89.06,254064,DB01435,Antipyrine
less,2741499,t50,"Therefore our patients were subdivided into groups of so-called fast, intermediate and slow metabolisers (fast: t50 less than 7.6 h and slow: t50 greater than 14.9 h).",[The antipyrine test in occupational medicine research--evaluation of individual reproducibility and frequency distribution of half-life]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741499/),h,7.6,254485,DB01435,Antipyrine
greater,2741499,t50,"Therefore our patients were subdivided into groups of so-called fast, intermediate and slow metabolisers (fast: t50 less than 7.6 h and slow: t50 greater than 14.9 h).",[The antipyrine test in occupational medicine research--evaluation of individual reproducibility and frequency distribution of half-life]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741499/),h,14.9,254486,DB01435,Antipyrine
,22762844,area under the plasma concentration-time curve during a dosage interval (AUC(τ)),"The area under the plasma concentration-time curve during a dosage interval (AUC(τ)) values of the single dose in the 20, 30, and 60 mg dose groups were 3.64 ± 1.37, 5.17 ± 0.93, and 11.25 ± 3.42 mg · h/L, respectively, while in the group receiving repeated dosing of 30 mg, the mean AUC(τ) value was 5.06 ± 0.89 mg · h/L.",Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762844/),[h·mg] / [l],3.64,254927,DB01435,Antipyrine
,22762844,area under the plasma concentration-time curve during a dosage interval (AUC(τ)),"The area under the plasma concentration-time curve during a dosage interval (AUC(τ)) values of the single dose in the 20, 30, and 60 mg dose groups were 3.64 ± 1.37, 5.17 ± 0.93, and 11.25 ± 3.42 mg · h/L, respectively, while in the group receiving repeated dosing of 30 mg, the mean AUC(τ) value was 5.06 ± 0.89 mg · h/L.",Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762844/),[h·mg] / [l],5.17,254928,DB01435,Antipyrine
,22762844,area under the plasma concentration-time curve during a dosage interval (AUC(τ)),"The area under the plasma concentration-time curve during a dosage interval (AUC(τ)) values of the single dose in the 20, 30, and 60 mg dose groups were 3.64 ± 1.37, 5.17 ± 0.93, and 11.25 ± 3.42 mg · h/L, respectively, while in the group receiving repeated dosing of 30 mg, the mean AUC(τ) value was 5.06 ± 0.89 mg · h/L.",Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762844/),[h·mg] / [l],11.25,254929,DB01435,Antipyrine
,22762844,AUC(τ),"The area under the plasma concentration-time curve during a dosage interval (AUC(τ)) values of the single dose in the 20, 30, and 60 mg dose groups were 3.64 ± 1.37, 5.17 ± 0.93, and 11.25 ± 3.42 mg · h/L, respectively, while in the group receiving repeated dosing of 30 mg, the mean AUC(τ) value was 5.06 ± 0.89 mg · h/L.",Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762844/),[h·mg] / [l],5.06,254930,DB01435,Antipyrine
,22762844,maximum plasma drug concentration (C(max)),"The corresponding maximum plasma drug concentration (C(max)) values were 1599.0 ± 382.6, 2378.7 ± 316.7, and 4540.1 ± 901.1 ng/mL, respectively, in the single-dose groups, and 2479.1 ± 477.9 ng/mL in the 30 mg repeated-dose group.",Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762844/),[ng] / [ml],1599.0,254931,DB01435,Antipyrine
,22762844,maximum plasma drug concentration (C(max)),"The corresponding maximum plasma drug concentration (C(max)) values were 1599.0 ± 382.6, 2378.7 ± 316.7, and 4540.1 ± 901.1 ng/mL, respectively, in the single-dose groups, and 2479.1 ± 477.9 ng/mL in the 30 mg repeated-dose group.",Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762844/),[ng] / [ml],2378.7,254932,DB01435,Antipyrine
,22762844,maximum plasma drug concentration (C(max)),"The corresponding maximum plasma drug concentration (C(max)) values were 1599.0 ± 382.6, 2378.7 ± 316.7, and 4540.1 ± 901.1 ng/mL, respectively, in the single-dose groups, and 2479.1 ± 477.9 ng/mL in the 30 mg repeated-dose group.",Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762844/),[ng] / [ml],4540.1,254933,DB01435,Antipyrine
,22762844,maximum plasma drug concentration (C(max)),"The corresponding maximum plasma drug concentration (C(max)) values were 1599.0 ± 382.6, 2378.7 ± 316.7, and 4540.1 ± 901.1 ng/mL, respectively, in the single-dose groups, and 2479.1 ± 477.9 ng/mL in the 30 mg repeated-dose group.",Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762844/),[ng] / [ml],2479.1,254934,DB01435,Antipyrine
,5389794,half-life,The mean half-life of antipyrine in the plasma of four sets of identical and four sets of fraternal twins after a single oral dose of 16 mg/kg of antipyrine was 12.7 +/-(SD) 3.3 hr.,Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5389794/),h,12.7,255207,DB01435,Antipyrine
,5389794,half-life,After 2 wk on sodium phenobarbital (2 mg/kg daily) the half-life of antipyrine in the plasma of these twins was reduced to 8.0 +/-(SD) 1.5 hr.,Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5389794/),h,8.0,255208,DB01435,Antipyrine
,7333060,half-life,"The half-life of antipyrine was significantly longer in the elderly than in the younger group, 756 +/- 318 and 465 +/- 110 minutes, respectively, and the MCR was correspondingly lower in the elderly even when calculated per litre of live volume, 22.8 +/- 7.8 and 36.3 +/- 8.9ml/minute/L liver volume, respectively.",Disposition of antipyrine and phenytoin correlated with age and liver volume in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333060/),min,756,255992,DB01435,Antipyrine
,7333060,half-life,"The half-life of antipyrine was significantly longer in the elderly than in the younger group, 756 +/- 318 and 465 +/- 110 minutes, respectively, and the MCR was correspondingly lower in the elderly even when calculated per litre of live volume, 22.8 +/- 7.8 and 36.3 +/- 8.9ml/minute/L liver volume, respectively.",Disposition of antipyrine and phenytoin correlated with age and liver volume in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333060/),min,465,255993,DB01435,Antipyrine
,7333060,MCR,"The half-life of antipyrine was significantly longer in the elderly than in the younger group, 756 +/- 318 and 465 +/- 110 minutes, respectively, and the MCR was correspondingly lower in the elderly even when calculated per litre of live volume, 22.8 +/- 7.8 and 36.3 +/- 8.9ml/minute/L liver volume, respectively.",Disposition of antipyrine and phenytoin correlated with age and liver volume in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333060/),[ml] / [l·min],22.8,255994,DB01435,Antipyrine
,7333060,MCR,"The half-life of antipyrine was significantly longer in the elderly than in the younger group, 756 +/- 318 and 465 +/- 110 minutes, respectively, and the MCR was correspondingly lower in the elderly even when calculated per litre of live volume, 22.8 +/- 7.8 and 36.3 +/- 8.9ml/minute/L liver volume, respectively.",Disposition of antipyrine and phenytoin correlated with age and liver volume in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333060/),[ml] / [l·min],36.3,255995,DB01435,Antipyrine
,7333060,clearance,"No significant differences in the 2 age groups were found in half-life and total clearance of phenytoin, but a reduced free phenytoin clearance was demonstrated in the elderly (240 +/- 92ml/minute/L liver volume) compared with the younger (325 +/- 81ml/minute/L liver volume) group.",Disposition of antipyrine and phenytoin correlated with age and liver volume in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333060/),[ml] / [l·liver·min·volume],240,255996,DB01435,Antipyrine
,7333060,clearance,"No significant differences in the 2 age groups were found in half-life and total clearance of phenytoin, but a reduced free phenytoin clearance was demonstrated in the elderly (240 +/- 92ml/minute/L liver volume) compared with the younger (325 +/- 81ml/minute/L liver volume) group.",Disposition of antipyrine and phenytoin correlated with age and liver volume in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333060/),[ml] / [l·min],325,255997,DB01435,Antipyrine
,6815599,clearance,"The antipyrine clearance at term (0.53 +/- 0.11 ml/min/kg, mean +/- SD) was lower than it was early during puerperium (0.70 +/- 0.14 ml/min/kg, P less than .05) and approximately 3 months after delivery (1.14 +/- 0.26 ml/min/kg, P less than .01).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],0.53,256724,DB01435,Antipyrine
,6815599,clearance,"The antipyrine clearance at term (0.53 +/- 0.11 ml/min/kg, mean +/- SD) was lower than it was early during puerperium (0.70 +/- 0.14 ml/min/kg, P less than .05) and approximately 3 months after delivery (1.14 +/- 0.26 ml/min/kg, P less than .01).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],0.70,256725,DB01435,Antipyrine
,6815599,clearance,"The antipyrine clearance at term (0.53 +/- 0.11 ml/min/kg, mean +/- SD) was lower than it was early during puerperium (0.70 +/- 0.14 ml/min/kg, P less than .05) and approximately 3 months after delivery (1.14 +/- 0.26 ml/min/kg, P less than .01).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],1.14,256726,DB01435,Antipyrine
,6815599,clearance,"The antipyrine clearance in nonpregnant epileptics (1.17 +/- 0.44 ml/min/kg) was comparable to that found 3 months after delivery, whereas it was significantly (P less than .01) higher than that found in healthy women (0.47 +/- 0.02 ml/min/kg).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],1.17,256727,DB01435,Antipyrine
,6815599,clearance,"The antipyrine clearance in nonpregnant epileptics (1.17 +/- 0.44 ml/min/kg) was comparable to that found 3 months after delivery, whereas it was significantly (P less than .01) higher than that found in healthy women (0.47 +/- 0.02 ml/min/kg).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],0.47,256728,DB01435,Antipyrine
,30241688,Cmax,"Amean (SD) Cmax of 2030.2 (517.2) ng/mL was reached within a median Tmax of 0.875hour, which was statistically significantly longer than the median Tmax with IV administration (0.5 hour).",Bioavailability of Edaravone Sublingual Tablet Versus Intravenous Infusion in Healthy Male Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30241688/),[ng] / [ml],2030.2,257465,DB01435,Antipyrine
,30241688,Tmax,"Amean (SD) Cmax of 2030.2 (517.2) ng/mL was reached within a median Tmax of 0.875hour, which was statistically significantly longer than the median Tmax with IV administration (0.5 hour).",Bioavailability of Edaravone Sublingual Tablet Versus Intravenous Infusion in Healthy Male Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30241688/),h,0.875,257466,DB01435,Antipyrine
,30241688,Tmax,"Amean (SD) Cmax of 2030.2 (517.2) ng/mL was reached within a median Tmax of 0.875hour, which was statistically significantly longer than the median Tmax with IV administration (0.5 hour).",Bioavailability of Edaravone Sublingual Tablet Versus Intravenous Infusion in Healthy Male Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30241688/),h,0.5,257467,DB01435,Antipyrine
,30241688,Cmax,"The Cmax with SL administration corresponded to 83.92% (90% CI, 73.22%-96.18%) of the Cmax with the start of IV infusion (2354.0 [336.6] ng/mL).",Bioavailability of Edaravone Sublingual Tablet Versus Intravenous Infusion in Healthy Male Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30241688/),[ng] / [ml],2354.0,257468,DB01435,Antipyrine
,30241688,AUC0-t,"The mean AUC0-t with SL dosing was 5420.07 (1429.75) h · ng/mL, which corresponded to 91.94% (90% CI, 86.81%-97.39%) of the AUC0-t with IV administration (5824.42 [1338.48] h · ng/mL).",Bioavailability of Edaravone Sublingual Tablet Versus Intravenous Infusion in Healthy Male Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30241688/),[h·ng] / [ml],5420.07,257469,DB01435,Antipyrine
,30241688,AUC0-t,"The mean AUC0-t with SL dosing was 5420.07 (1429.75) h · ng/mL, which corresponded to 91.94% (90% CI, 86.81%-97.39%) of the AUC0-t with IV administration (5824.42 [1338.48] h · ng/mL).",Bioavailability of Edaravone Sublingual Tablet Versus Intravenous Infusion in Healthy Male Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30241688/),[h·ng] / [ml],5824.42,257470,DB01435,Antipyrine
,30241688,bioavailability,The bioavailability of the SL tablet of edaravone was 91.94%.,Bioavailability of Edaravone Sublingual Tablet Versus Intravenous Infusion in Healthy Male Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30241688/),%,91.94,257471,DB01435,Antipyrine
,2110459,Elimination half-lives,"Elimination half-lives were 57.92 +/- 14.10 and 72.72 +/- 4.14 min 8 and 12 weeks after infection, respectively, compared to 19.29 +/- 3.30 and 26.14 +/- 5.31 min in corresponding controls.",Effect of schistosomiasis infection on the clearance of phenazone in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2110459/),min,57.92,257897,DB01435,Antipyrine
,2110459,Elimination half-lives,"Elimination half-lives were 57.92 +/- 14.10 and 72.72 +/- 4.14 min 8 and 12 weeks after infection, respectively, compared to 19.29 +/- 3.30 and 26.14 +/- 5.31 min in corresponding controls.",Effect of schistosomiasis infection on the clearance of phenazone in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2110459/),min,72.72,257898,DB01435,Antipyrine
,2110459,Elimination half-lives,"Elimination half-lives were 57.92 +/- 14.10 and 72.72 +/- 4.14 min 8 and 12 weeks after infection, respectively, compared to 19.29 +/- 3.30 and 26.14 +/- 5.31 min in corresponding controls.",Effect of schistosomiasis infection on the clearance of phenazone in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2110459/),min,19.29,257899,DB01435,Antipyrine
,2110459,Elimination half-lives,"Elimination half-lives were 57.92 +/- 14.10 and 72.72 +/- 4.14 min 8 and 12 weeks after infection, respectively, compared to 19.29 +/- 3.30 and 26.14 +/- 5.31 min in corresponding controls.",Effect of schistosomiasis infection on the clearance of phenazone in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2110459/),min,26.14,257900,DB01435,Antipyrine
,2619775,detection limit,The detection limit for all four metabolites is 0.1 microgram/ml in plasma and 2 micrograms/ml in urine.,Simultaneous determination of the main metabolites of dipyrone by high-pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619775/),[μg] / [ml],0.1,258277,DB01435,Antipyrine
,2619775,detection limit,The detection limit for all four metabolites is 0.1 microgram/ml in plasma and 2 micrograms/ml in urine.,Simultaneous determination of the main metabolites of dipyrone by high-pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2619775/),[μg] / [ml],2,258278,DB01435,Antipyrine
,6489432,half-life,In hyperthyroidism the half-life of antipyrine was significantly shorter (p less than 0.05) than after recovery (9.3 +/- 1.0 versus 10.6 +/- 0.9 h).,Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489432/),h,9.3,258926,DB01435,Antipyrine
,6489432,half-life,In hyperthyroidism the half-life of antipyrine was significantly shorter (p less than 0.05) than after recovery (9.3 +/- 1.0 versus 10.6 +/- 0.9 h).,Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489432/),h,10.6,258927,DB01435,Antipyrine
,6489432,elimination half-life,Hypothyroid patients showed a significantly longer elimination half-life before treatment than after recovery (12.7 +/- 2.6 versus 10.3 +/- 2.6 h).,Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489432/),h,12.7,258928,DB01435,Antipyrine
,6489432,elimination half-life,Hypothyroid patients showed a significantly longer elimination half-life before treatment than after recovery (12.7 +/- 2.6 versus 10.3 +/- 2.6 h).,Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489432/),h,10.3,258929,DB01435,Antipyrine
,6489432,clearance,"Antipyrine clearance in hyperthyroid patients was decreased after treatment from 2.7 +/- 0.3 to 2.4 +/- 0.3 l/h, and it was increased in hypothyroid patients from 2.1 +/- 0.4 to 2.5 +/- 0.5 l/h (p less than 0.05).",Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489432/),[l] / [h],2.7,258930,DB01435,Antipyrine
,6489432,clearance,"Antipyrine clearance in hyperthyroid patients was decreased after treatment from 2.7 +/- 0.3 to 2.4 +/- 0.3 l/h, and it was increased in hypothyroid patients from 2.1 +/- 0.4 to 2.5 +/- 0.5 l/h (p less than 0.05).",Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489432/),[l] / [h],2.4,258931,DB01435,Antipyrine
,6489432,clearance,"Antipyrine clearance in hyperthyroid patients was decreased after treatment from 2.7 +/- 0.3 to 2.4 +/- 0.3 l/h, and it was increased in hypothyroid patients from 2.1 +/- 0.4 to 2.5 +/- 0.5 l/h (p less than 0.05).",Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489432/),[l] / [h],2.1,258932,DB01435,Antipyrine
,6489432,clearance,"Antipyrine clearance in hyperthyroid patients was decreased after treatment from 2.7 +/- 0.3 to 2.4 +/- 0.3 l/h, and it was increased in hypothyroid patients from 2.1 +/- 0.4 to 2.5 +/- 0.5 l/h (p less than 0.05).",Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489432/),[l] / [h],2.5,258933,DB01435,Antipyrine
,6639836,half-life,"Primaquine (45 mg) given 2 h before antipyrine (300 mg orally), increased antipyrine half-life (calculated from 0-24 h) from 12.7 +/- 3.2 (mean +/- s.d.) to 25.3 +/- 3.9 h and decreased clearance from 3.01 +/- 0.67 to 1.32 +/- 0.32 1 h-1.",Effect of chloroquine and primaquine on antipyrine metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639836/),h,12.7,259538,DB01435,Antipyrine
,6639836,half-life,"Primaquine (45 mg) given 2 h before antipyrine (300 mg orally), increased antipyrine half-life (calculated from 0-24 h) from 12.7 +/- 3.2 (mean +/- s.d.) to 25.3 +/- 3.9 h and decreased clearance from 3.01 +/- 0.67 to 1.32 +/- 0.32 1 h-1.",Effect of chloroquine and primaquine on antipyrine metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639836/),h,25.3,259539,DB01435,Antipyrine
,6639836,clearance,"Primaquine (45 mg) given 2 h before antipyrine (300 mg orally), increased antipyrine half-life (calculated from 0-24 h) from 12.7 +/- 3.2 (mean +/- s.d.) to 25.3 +/- 3.9 h and decreased clearance from 3.01 +/- 0.67 to 1.32 +/- 0.32 1 h-1.",Effect of chloroquine and primaquine on antipyrine metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639836/),[1] / [h],3.01,259540,DB01435,Antipyrine
,6639836,clearance,"Primaquine (45 mg) given 2 h before antipyrine (300 mg orally), increased antipyrine half-life (calculated from 0-24 h) from 12.7 +/- 3.2 (mean +/- s.d.) to 25.3 +/- 3.9 h and decreased clearance from 3.01 +/- 0.67 to 1.32 +/- 0.32 1 h-1.",Effect of chloroquine and primaquine on antipyrine metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639836/),[1] / [h],1.32,259541,DB01435,Antipyrine
,7002187,Maximum plasma concentrations,Maximum plasma concentrations between 1.5 microgram/ml and 3.5 micrograms/ml were found 30 min later.,"Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7002187/),[μg] / [ml],1.5,260374,DB01435,Antipyrine
,7002187,Maximum plasma concentrations,Maximum plasma concentrations between 1.5 microgram/ml and 3.5 micrograms/ml were found 30 min later.,"Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7002187/),[μg] / [ml],3.5,260375,DB01435,Antipyrine
,7002187,distribution volumes,The distribution volumes were 2 l/kg.,"Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7002187/),[l] / [kg],2,260376,DB01435,Antipyrine
,7002187,Maximum plasma concentrations,Maximum plasma concentrations of 10 microgram/ml are reached 1.5 h after a 500 mg dose.,"Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7002187/),[μg] / [ml],10,260377,DB01435,Antipyrine
,7002187,biological half-life,"The biological half-life is 2-3 h, the relative distribution volume 60% on average, and binding to plasma proteins approximately 15%.","Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7002187/),h,2-3,260378,DB01435,Antipyrine
,7002187,maximum serum concentration,5 After oral administration of [14C]-dipyrone 480 mg the maximum serum concentration of 13.4 +/- 0.8 microgram/ml occurred at 1-1.5 hours.,"Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7002187/),[μg] / [ml],13.4,260379,DB01435,Antipyrine
,28335025,m,"The analyte detection was performed on a triple quadrupole tandem mass spectrometer equipped with positive-ion electrospray ionization by multiple reaction ion monitoring mode of the transitions at m/z [M + H]+ 175.1 → 77.1 for edaravone, and m/z [M + H]+ 180.2 → 110.0 for phenacetin.","A Novel LC-MS-MS Method With an Effective Antioxidant for the Determination of Edaravone, a Free-Radical Scavenger in Dog Plasma and its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28335025/),,77,260639,DB01435,Antipyrine
,28335025,m/,"The analyte detection was performed on a triple quadrupole tandem mass spectrometer equipped with positive-ion electrospray ionization by multiple reaction ion monitoring mode of the transitions at m/z [M + H]+ 175.1 → 77.1 for edaravone, and m/z [M + H]+ 180.2 → 110.0 for phenacetin.","A Novel LC-MS-MS Method With an Effective Antioxidant for the Determination of Edaravone, a Free-Radical Scavenger in Dog Plasma and its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28335025/),,180.,260640,DB01435,Antipyrine
,28335025,m/,"The analyte detection was performed on a triple quadrupole tandem mass spectrometer equipped with positive-ion electrospray ionization by multiple reaction ion monitoring mode of the transitions at m/z [M + H]+ 175.1 → 77.1 for edaravone, and m/z [M + H]+ 180.2 → 110.0 for phenacetin.","A Novel LC-MS-MS Method With an Effective Antioxidant for the Determination of Edaravone, a Free-Radical Scavenger in Dog Plasma and its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28335025/),,110.0,260641,DB01435,Antipyrine
,9923582,clearance,The serum concentration-time curves of propiverine and its main metabolite propiverine-N-oxide were investigated in 12 patients with mild to moderate impairment of liver function (mean antipyrine clearance 26.0 ml x min(-1)) and in 12 controls (antipyrine clearance 42.8 ml x min(-1)).,Pharmacokinetics and safety of propiverine in patients with fatty liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923582/),[ml] / [min],26.0,263623,DB01435,Antipyrine
,9923582,clearance,The serum concentration-time curves of propiverine and its main metabolite propiverine-N-oxide were investigated in 12 patients with mild to moderate impairment of liver function (mean antipyrine clearance 26.0 ml x min(-1)) and in 12 controls (antipyrine clearance 42.8 ml x min(-1)).,Pharmacokinetics and safety of propiverine in patients with fatty liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923582/),[ml] / [min],42.8,263624,DB01435,Antipyrine
,7555975,half-life (t1/2),"The drug was rapidly absorbed, and half-life (t1/2) averaged 5-8 h.","Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555975/),h,5-8,264447,DB01435,Antipyrine
<,7555975,accumulation ratio,The accumulation ratio was fairly low: < 1.4 in most subjects.,"Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7555975/),,1.4,264448,DB01435,Antipyrine
,34431528,AUCIM /AUCIV ratio,"The AUCIM /AUCIV ratio in female and male horses for MAA was 1.19 and 1.13, respectively.",Pharmacokinetic Profiles of Metamizole Metabolites after Intramuscular and Intravenous Administration in Healthy Arabian Horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34431528/),,1.19,264619,DB01435,Antipyrine
,34431528,AUCIM /AUCIV ratio,"The AUCIM /AUCIV ratio in female and male horses for MAA was 1.19 and 1.13, respectively.",Pharmacokinetic Profiles of Metamizole Metabolites after Intramuscular and Intravenous Administration in Healthy Arabian Horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34431528/),,1.13,264620,DB01435,Antipyrine
,33333142,bioavailability,"Current in vivo study in pigs showed: (1) steady plateau levels of apomorphine in plasma were obtained 30 min following administration and remained constant for 8 h until a delivery device was removed, (2) bioavailability of apomorphine was 55%-80% as opposed to <2% peroral and (3) simulation of the pharmacokinetic profile obtained in pigs predicted therapeutically relevant levels of apomorphine in human.","Prolonged Delivery of Apomorphine Through the Buccal Mucosa, Towards a Noninvasive Sustained Administration Method in Parkinson's Disease: In Vivo Investigations in Pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33333142/),%,55,265212,DB01435,Antipyrine
<,33333142,bioavailability,"Current in vivo study in pigs showed: (1) steady plateau levels of apomorphine in plasma were obtained 30 min following administration and remained constant for 8 h until a delivery device was removed, (2) bioavailability of apomorphine was 55%-80% as opposed to <2% peroral and (3) simulation of the pharmacokinetic profile obtained in pigs predicted therapeutically relevant levels of apomorphine in human.","Prolonged Delivery of Apomorphine Through the Buccal Mucosa, Towards a Noninvasive Sustained Administration Method in Parkinson's Disease: In Vivo Investigations in Pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33333142/),%·peroral,2,265213,DB01435,Antipyrine
,24706508,m/,"The mass transitions monitored were m/z [M + H](+) 175.1 → 133.0 and [M + H](+) 189.2 → 147.0 for edaravone and its IS, m/z [M - H](-) 124.1 → 80.0 and [M - H](-) 172.0 → 80.0 for taurine and its IS, respectively.",LC-MS/MS methods for the determination of edaravone and/or taurine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24706508/),,175.1,265240,DB01435,Antipyrine
,24706508,m/,"The mass transitions monitored were m/z [M + H](+) 175.1 → 133.0 and [M + H](+) 189.2 → 147.0 for edaravone and its IS, m/z [M - H](-) 124.1 → 80.0 and [M - H](-) 172.0 → 80.0 for taurine and its IS, respectively.",LC-MS/MS methods for the determination of edaravone and/or taurine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24706508/),,133.0,265241,DB01435,Antipyrine
,24706508,m/,"The mass transitions monitored were m/z [M + H](+) 175.1 → 133.0 and [M + H](+) 189.2 → 147.0 for edaravone and its IS, m/z [M - H](-) 124.1 → 80.0 and [M - H](-) 172.0 → 80.0 for taurine and its IS, respectively.",LC-MS/MS methods for the determination of edaravone and/or taurine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24706508/),,189.2,265242,DB01435,Antipyrine
,24706508,m/,"The mass transitions monitored were m/z [M + H](+) 175.1 → 133.0 and [M + H](+) 189.2 → 147.0 for edaravone and its IS, m/z [M - H](-) 124.1 → 80.0 and [M - H](-) 172.0 → 80.0 for taurine and its IS, respectively.",LC-MS/MS methods for the determination of edaravone and/or taurine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24706508/),,147.0,265243,DB01435,Antipyrine
,24706508,m/z,"The mass transitions monitored were m/z [M + H](+) 175.1 → 133.0 and [M + H](+) 189.2 → 147.0 for edaravone and its IS, m/z [M - H](-) 124.1 → 80.0 and [M - H](-) 172.0 → 80.0 for taurine and its IS, respectively.",LC-MS/MS methods for the determination of edaravone and/or taurine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24706508/),,124.1,265244,DB01435,Antipyrine
,24706508,m/z,"The mass transitions monitored were m/z [M + H](+) 175.1 → 133.0 and [M + H](+) 189.2 → 147.0 for edaravone and its IS, m/z [M - H](-) 124.1 → 80.0 and [M - H](-) 172.0 → 80.0 for taurine and its IS, respectively.",LC-MS/MS methods for the determination of edaravone and/or taurine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24706508/),,80.0,265245,DB01435,Antipyrine
,24706508,m/z,"The mass transitions monitored were m/z [M + H](+) 175.1 → 133.0 and [M + H](+) 189.2 → 147.0 for edaravone and its IS, m/z [M - H](-) 124.1 → 80.0 and [M - H](-) 172.0 → 80.0 for taurine and its IS, respectively.",LC-MS/MS methods for the determination of edaravone and/or taurine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24706508/),,172.0,265246,DB01435,Antipyrine
,2900404,oral bioavailability,"Felodipine is a dihydropyridine calcium antagonist, structurally related to nifedipine, which undergoes extensive first-pass hepatic metabolism and normally has an oral bioavailability of 15%.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),%,15,266162,DB01435,Antipyrine
,2900404,peak concentration,"Plasma felodipine concentrations after a 5 mg oral dose were grossly reduced in the epileptic patients: the mean peak concentration was 1.6 (vs 8.9) nmol/l, and the area under the curve was only 2.0 (vs 30.0) nmol.h/l.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),[nM] / [l],1.6,266163,DB01435,Antipyrine
,2900404,peak concentration,"Plasma felodipine concentrations after a 5 mg oral dose were grossly reduced in the epileptic patients: the mean peak concentration was 1.6 (vs 8.9) nmol/l, and the area under the curve was only 2.0 (vs 30.0) nmol.h/l.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),[nM] / [l],8.9,266164,DB01435,Antipyrine
,2900404,area under the curve,"Plasma felodipine concentrations after a 5 mg oral dose were grossly reduced in the epileptic patients: the mean peak concentration was 1.6 (vs 8.9) nmol/l, and the area under the curve was only 2.0 (vs 30.0) nmol.h/l.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),[h·nM] / [l],2.0,266165,DB01435,Antipyrine
,2900404,area under the curve,"Plasma felodipine concentrations after a 5 mg oral dose were grossly reduced in the epileptic patients: the mean peak concentration was 1.6 (vs 8.9) nmol/l, and the area under the curve was only 2.0 (vs 30.0) nmol.h/l.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),[h·nM] / [l],30.0,266166,DB01435,Antipyrine
,2900404,relative bioavailability,"The relative bioavailability of felodipine in the epileptic patients was thus only 6.6% of that in the normal subjects, and less than 1% of the oral dose was systemically available.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),%,6.6,266167,DB01435,Antipyrine
less,2900404,relative bioavailability,"The relative bioavailability of felodipine in the epileptic patients was thus only 6.6% of that in the normal subjects, and less than 1% of the oral dose was systemically available.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),%,1,266168,DB01435,Antipyrine
,3575876,extraction ratios,"The drugs, antipyrine, phenytoin, indocyanine green, and d-propranolol, have extraction ratios from 0.01 to 0.99 in the rat.",Effect of Fluosol-DA hemodilution on the kinetics of hepatically eliminated drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3575876/),,0,268182,DB01435,Antipyrine
,506967,T 1/2,"Microsomal oxidation as measured by antipyrine half-life and clearance was shown to be depressed in the acute phase of malnutrition (T 1/2 = 7.9 +/- 5.0 hr, clearance = 8.4 +/- 5.1 ml/min) improving with nutritional rehabilitation (T 1/2 = 4.3 +/- 2.3 hr, clearance = 15.5 +/- 8.7 ml/min).",Antipyrine pharmacokinetics and D-glucaric excretion in kwashiorkor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/506967/),h,7.9,269352,DB01435,Antipyrine
,506967,clearance,"Microsomal oxidation as measured by antipyrine half-life and clearance was shown to be depressed in the acute phase of malnutrition (T 1/2 = 7.9 +/- 5.0 hr, clearance = 8.4 +/- 5.1 ml/min) improving with nutritional rehabilitation (T 1/2 = 4.3 +/- 2.3 hr, clearance = 15.5 +/- 8.7 ml/min).",Antipyrine pharmacokinetics and D-glucaric excretion in kwashiorkor. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/506967/),[ml] / [min],8.4,269353,DB01435,Antipyrine
,506967,T 1/2,"Microsomal oxidation as measured by antipyrine half-life and clearance was shown to be depressed in the acute phase of malnutrition (T 1/2 = 7.9 +/- 5.0 hr, clearance = 8.4 +/- 5.1 ml/min) improving with nutritional rehabilitation (T 1/2 = 4.3 +/- 2.3 hr, clearance = 15.5 +/- 8.7 ml/min).",Antipyrine pharmacokinetics and D-glucaric excretion in kwashiorkor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/506967/),h,4.3,269354,DB01435,Antipyrine
,506967,clearance,"Microsomal oxidation as measured by antipyrine half-life and clearance was shown to be depressed in the acute phase of malnutrition (T 1/2 = 7.9 +/- 5.0 hr, clearance = 8.4 +/- 5.1 ml/min) improving with nutritional rehabilitation (T 1/2 = 4.3 +/- 2.3 hr, clearance = 15.5 +/- 8.7 ml/min).",Antipyrine pharmacokinetics and D-glucaric excretion in kwashiorkor. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/506967/),[ml] / [min],15.5,269355,DB01435,Antipyrine
,506967,excretion,Urinary D-glucaric acid excretion increased from 60.6 +/- 42.2 mumoles/24 hr to 121.8 +/- 105.0 mumoles/24 hr over the same time period.,Antipyrine pharmacokinetics and D-glucaric excretion in kwashiorkor. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/506967/),[mumoles] / [24·h],60.6,269356,DB01435,Antipyrine
,506967,excretion,Urinary D-glucaric acid excretion increased from 60.6 +/- 42.2 mumoles/24 hr to 121.8 +/- 105.0 mumoles/24 hr over the same time period.,Antipyrine pharmacokinetics and D-glucaric excretion in kwashiorkor. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/506967/),[mumoles] / [24·h],121.8,269357,DB01435,Antipyrine
,9024170,systemic clearance,The systemic clearance of nalmefene was reduced by 32% (0.61 +/- 0.21 versus 0.90 +/- 0.27 L/hr/kg [mean +/- SD]) and the terminal elimination half-life was increased by 31% (10.5 +/- 1.9 versus 8.0 +/- 2.2 hours) in the patients with liver disease.,Effects of liver disease on the disposition of the opioid antagonist nalmefene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024170/),[l] / [h·kg],0.61,269910,DB01435,Antipyrine
,9024170,systemic clearance,The systemic clearance of nalmefene was reduced by 32% (0.61 +/- 0.21 versus 0.90 +/- 0.27 L/hr/kg [mean +/- SD]) and the terminal elimination half-life was increased by 31% (10.5 +/- 1.9 versus 8.0 +/- 2.2 hours) in the patients with liver disease.,Effects of liver disease on the disposition of the opioid antagonist nalmefene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024170/),[l] / [h·kg],0.90,269911,DB01435,Antipyrine
,9024170,terminal elimination half-life,The systemic clearance of nalmefene was reduced by 32% (0.61 +/- 0.21 versus 0.90 +/- 0.27 L/hr/kg [mean +/- SD]) and the terminal elimination half-life was increased by 31% (10.5 +/- 1.9 versus 8.0 +/- 2.2 hours) in the patients with liver disease.,Effects of liver disease on the disposition of the opioid antagonist nalmefene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024170/),h,10.5,269912,DB01435,Antipyrine
,9024170,terminal elimination half-life,The systemic clearance of nalmefene was reduced by 32% (0.61 +/- 0.21 versus 0.90 +/- 0.27 L/hr/kg [mean +/- SD]) and the terminal elimination half-life was increased by 31% (10.5 +/- 1.9 versus 8.0 +/- 2.2 hours) in the patients with liver disease.,Effects of liver disease on the disposition of the opioid antagonist nalmefene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024170/),h,8.0,269913,DB01435,Antipyrine
,4041330,half-life,"In the anticonvulsant-treated group, the half-life of cortisol in plasma (73 +/- 5 min, mean +/- s.e. mean) and saliva (83 +/- 5 min, mean +/- s.e. mean) was reduced significantly (P less than 0.01 plasma, P less than 0.05 saliva) from that observed in healthy volunteers.",Anticonvulsant therapy and cortisol elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041330/),min,73,269970,DB01435,Antipyrine
,4041330,half-life,"In the anticonvulsant-treated group, the half-life of cortisol in plasma (73 +/- 5 min, mean +/- s.e. mean) and saliva (83 +/- 5 min, mean +/- s.e. mean) was reduced significantly (P less than 0.01 plasma, P less than 0.05 saliva) from that observed in healthy volunteers.",Anticonvulsant therapy and cortisol elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041330/),min,83,269971,DB01435,Antipyrine
,10598617,Plasma elimination clearance,"Plasma elimination clearance of the S-(+)-ketamine enantiomer, 29.9 ml x min(-1) x kg(-1), was higher than that of the R-(-)-enantiomer, 22.2 ml x min(-1) x kg(-1).",Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598617/),[ml] / [kg·min],29.9,270156,DB01435,Antipyrine
,10598617,Plasma elimination clearance,"Plasma elimination clearance of the S-(+)-ketamine enantiomer, 29.9 ml x min(-1) x kg(-1), was higher than that of the R-(-)-enantiomer, 22.2 ml x min(-1) x kg(-1).",Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598617/),[ml] / [kg·min],22.2,270157,DB01435,Antipyrine
,10598617,apparent pulmonary tissue volumes,The apparent pulmonary tissue volumes of the ketamine S-(+) and R-(-)-enantiomers (0.31 l) did not differ and was approximately twice that of antipyrine (0.16 l).,Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598617/),l,0.31,270158,DB01435,Antipyrine
,10598617,apparent pulmonary tissue volumes,The apparent pulmonary tissue volumes of the ketamine S-(+) and R-(-)-enantiomers (0.31 l) did not differ and was approximately twice that of antipyrine (0.16 l).,Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598617/),l,0.16,270159,DB01435,Antipyrine
,10598617,total volume of distribution,The peripheral tissue distribution volumes and clearances and the total volume of distribution (2.1 l/kg) were the same for both stereoisomers when elimination clearances were modeled from the rapidly equilibrating peripheral compartment.,Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598617/),[l] / [kg],2.1,270160,DB01435,Antipyrine
,119355,half-life,"2. Treatment with phenobarbital decreased the antipyrine half-life from 65 to 30 min, but did not significantly change the urinary metabolite profile.",Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/119355/),min,65,270570,DB01435,Antipyrine
,119355,half-life,"2. Treatment with phenobarbital decreased the antipyrine half-life from 65 to 30 min, but did not significantly change the urinary metabolite profile.",Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/119355/),min,30,270571,DB01435,Antipyrine
,119355,half-life,3. 3-Methylcholanthrene treatment resulted in a decrease of antipyrine half-life from 72 to 37 min.,Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/119355/),min,72,270572,DB01435,Antipyrine
,119355,half-life,3. 3-Methylcholanthrene treatment resulted in a decrease of antipyrine half-life from 72 to 37 min.,Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/119355/),min,37,270573,DB01435,Antipyrine
,8787905,clearance associated with maternal-fetal transfer of the drug (CLdf),"The clearance associated with maternal-fetal transfer of the drug (CLdf) (0.54 +/- 0.08 ml/min/kg) was not significantly different (P > 0.05) from the clearance associated with fetal-maternal transfer of the drug, CLfd (0.66 +/- 0.11 ml/min/kg).","In vivo maternal-fetal pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) in pigtailed macaques (Macaca nemestrina). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787905/),[ml] / [kg·min],0.54,270801,DB01435,Antipyrine
,8787905,CLfd,"The clearance associated with maternal-fetal transfer of the drug (CLdf) (0.54 +/- 0.08 ml/min/kg) was not significantly different (P > 0.05) from the clearance associated with fetal-maternal transfer of the drug, CLfd (0.66 +/- 0.11 ml/min/kg).","In vivo maternal-fetal pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) in pigtailed macaques (Macaca nemestrina). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787905/),[ml] / [kg·min],0.66,270802,DB01435,Antipyrine
below,2959359,platelet nadirs,"Three patients developed platelet nadirs below 100,000/microliters.",Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959359/),,100,271757,DB01435,Antipyrine
,8742233,steady-state plasma concentrations,"To make a valid comparison, differences in pharmacokinetic properties between the azoles were accounted for by using an infusion approach to maintain steady-state plasma concentrations over a range of 1-48 mg/liter.",Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742233/),[mg] / [l],1-48,272847,DB01435,Antipyrine
,8742233,Ki,"Analysis of these data provided Ki values of 3 and 10 microM, for ketoconazole and fluconazole, respectively, based on plasma concentration of azole.",Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742233/),μM,3,272848,DB01435,Antipyrine
,8742233,Ki,"Analysis of these data provided Ki values of 3 and 10 microM, for ketoconazole and fluconazole, respectively, based on plasma concentration of azole.",Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742233/),μM,10,272849,DB01435,Antipyrine
,8742233,Ki,"Ki values based on unbound drug concentration are 0.07 and 8.7 microM for ketoconazole and fluconazole, respectively.",Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742233/),μM,0.07,272850,DB01435,Antipyrine
,8742233,Ki,"Ki values based on unbound drug concentration are 0.07 and 8.7 microM for ketoconazole and fluconazole, respectively.",Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742233/),μM,8.7,272851,DB01435,Antipyrine
,8923333,total,"For the phenobarbital group, a significant increase for antipyrine total (36 versus 45 mL/h/kg) and nonrenal (35 versus 44 mL/h/kg) clearances and 6 beta-hydroxycortisol excretion (338 versus 529 micrograms) and a significant decrease in the terminal exponential half-life (11 versus 9 h) of antipyrine were observed.",Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8923333/),[ml] / [h·kg],36,273424,DB01435,Antipyrine
,8923333,total,"For the phenobarbital group, a significant increase for antipyrine total (36 versus 45 mL/h/kg) and nonrenal (35 versus 44 mL/h/kg) clearances and 6 beta-hydroxycortisol excretion (338 versus 529 micrograms) and a significant decrease in the terminal exponential half-life (11 versus 9 h) of antipyrine were observed.",Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8923333/),[ml] / [h·kg],45,273425,DB01435,Antipyrine
,8923333,excretion,"For the phenobarbital group, a significant increase for antipyrine total (36 versus 45 mL/h/kg) and nonrenal (35 versus 44 mL/h/kg) clearances and 6 beta-hydroxycortisol excretion (338 versus 529 micrograms) and a significant decrease in the terminal exponential half-life (11 versus 9 h) of antipyrine were observed.",Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8923333/),μg,338,273426,DB01435,Antipyrine
,8923333,excretion,"For the phenobarbital group, a significant increase for antipyrine total (36 versus 45 mL/h/kg) and nonrenal (35 versus 44 mL/h/kg) clearances and 6 beta-hydroxycortisol excretion (338 versus 529 micrograms) and a significant decrease in the terminal exponential half-life (11 versus 9 h) of antipyrine were observed.",Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8923333/),μg,529,273427,DB01435,Antipyrine
,8923333,terminal exponential half-life,"For the phenobarbital group, a significant increase for antipyrine total (36 versus 45 mL/h/kg) and nonrenal (35 versus 44 mL/h/kg) clearances and 6 beta-hydroxycortisol excretion (338 versus 529 micrograms) and a significant decrease in the terminal exponential half-life (11 versus 9 h) of antipyrine were observed.",Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8923333/),h,11,273428,DB01435,Antipyrine
,8923333,terminal exponential half-life,"For the phenobarbital group, a significant increase for antipyrine total (36 versus 45 mL/h/kg) and nonrenal (35 versus 44 mL/h/kg) clearances and 6 beta-hydroxycortisol excretion (338 versus 529 micrograms) and a significant decrease in the terminal exponential half-life (11 versus 9 h) of antipyrine were observed.",Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8923333/),h,9,273429,DB01435,Antipyrine
,3656064,bioavailability,"The bioavailability of oleaginous base and water-soluble base (polyethylene glycol 4000) were 44.3% and 82.6%, respectively.","Biopharmaceutical characteristics of a suppository base containing poly (oxyethylene)-poly (oxypropylene) copolymer, Unilube. I. Effects of a suppository base containing Unilube 70DP-950B on release and rectal absorption of aminopyrine in rabbit. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3656064/),%,44.3,273683,DB01435,Antipyrine
,3656064,bioavailability,"The bioavailability of oleaginous base and water-soluble base (polyethylene glycol 4000) were 44.3% and 82.6%, respectively.","Biopharmaceutical characteristics of a suppository base containing poly (oxyethylene)-poly (oxypropylene) copolymer, Unilube. I. Effects of a suppository base containing Unilube 70DP-950B on release and rectal absorption of aminopyrine in rabbit. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3656064/),%,82.6,273684,DB01435,Antipyrine
,3656064,time to reach maximum plasma concentration (Tmax),"The time to reach maximum plasma concentration (Tmax) of the oleaginous and the water-soluble bases were 21.0 +/- 8.2 min and 33.0 +/- 16.4 min, respectively.","Biopharmaceutical characteristics of a suppository base containing poly (oxyethylene)-poly (oxypropylene) copolymer, Unilube. I. Effects of a suppository base containing Unilube 70DP-950B on release and rectal absorption of aminopyrine in rabbit. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3656064/),min,21.0,273685,DB01435,Antipyrine
,3656064,time to reach maximum plasma concentration (Tmax),"The time to reach maximum plasma concentration (Tmax) of the oleaginous and the water-soluble bases were 21.0 +/- 8.2 min and 33.0 +/- 16.4 min, respectively.","Biopharmaceutical characteristics of a suppository base containing poly (oxyethylene)-poly (oxypropylene) copolymer, Unilube. I. Effects of a suppository base containing Unilube 70DP-950B on release and rectal absorption of aminopyrine in rabbit. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3656064/),min,33.0,273686,DB01435,Antipyrine
,3656064,Tmax,"When TCS was used, its Tmax was 30 min and increasing the amount of Unilube in the base from 5% (w/w) to 20% (w/w) decreased the bioavailability from 100.4% to 47.2%.","Biopharmaceutical characteristics of a suppository base containing poly (oxyethylene)-poly (oxypropylene) copolymer, Unilube. I. Effects of a suppository base containing Unilube 70DP-950B on release and rectal absorption of aminopyrine in rabbit. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3656064/),min,30,273687,DB01435,Antipyrine
,3656064,bioavailability,"When TCS was used, its Tmax was 30 min and increasing the amount of Unilube in the base from 5% (w/w) to 20% (w/w) decreased the bioavailability from 100.4% to 47.2%.","Biopharmaceutical characteristics of a suppository base containing poly (oxyethylene)-poly (oxypropylene) copolymer, Unilube. I. Effects of a suppository base containing Unilube 70DP-950B on release and rectal absorption of aminopyrine in rabbit. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3656064/),%,100.4,273688,DB01435,Antipyrine
,3656064,bioavailability,"When TCS was used, its Tmax was 30 min and increasing the amount of Unilube in the base from 5% (w/w) to 20% (w/w) decreased the bioavailability from 100.4% to 47.2%.","Biopharmaceutical characteristics of a suppository base containing poly (oxyethylene)-poly (oxypropylene) copolymer, Unilube. I. Effects of a suppository base containing Unilube 70DP-950B on release and rectal absorption of aminopyrine in rabbit. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3656064/),%,47.2,273689,DB01435,Antipyrine
,3656064,softening temperature,The softening temperature of TCS was 55-57 degrees C.,"Biopharmaceutical characteristics of a suppository base containing poly (oxyethylene)-poly (oxypropylene) copolymer, Unilube. I. Effects of a suppository base containing Unilube 70DP-950B on release and rectal absorption of aminopyrine in rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3656064/),c·degrees,55-57,273690,DB01435,Antipyrine
,8895071,clearance,"Mean antipyrine clearance for the one-sample study (19.72 +/- 1.51) was almost identical to that obtained with the multiple-sample approach (20.73 +/- 1.57), and the two methods were very well correlated (r = 0.989).",Accuracy of the one-sample method for determination of antipyrine clearance in elderly subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895071/),,19.72,273751,DB01435,Antipyrine
,8895071,clearance,"Mean antipyrine clearance for the one-sample study (19.72 +/- 1.51) was almost identical to that obtained with the multiple-sample approach (20.73 +/- 1.57), and the two methods were very well correlated (r = 0.989).",Accuracy of the one-sample method for determination of antipyrine clearance in elderly subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895071/),,20.73,273752,DB01435,Antipyrine
,8895071,elimination half-life,"Values of elimination half-life were likewise very similar for the abbreviated (17.41 +/- 1.21) and complete (17.99 +/- 1.09) methods, with a significant correlation (r = 0.857).",Accuracy of the one-sample method for determination of antipyrine clearance in elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895071/),,17.41,273753,DB01435,Antipyrine
,8895071,elimination half-life,"Values of elimination half-life were likewise very similar for the abbreviated (17.41 +/- 1.21) and complete (17.99 +/- 1.09) methods, with a significant correlation (r = 0.857).",Accuracy of the one-sample method for determination of antipyrine clearance in elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895071/),,17.99,273754,DB01435,Antipyrine
